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Summary	  
	  
Bacterial	  diarrhoeal	  diseases	  have	  significant	  influence	  on	  global	  human	  health,	  and	  are	  a	  
leading	   cause	   of	   preventable	   death	   in	   the	   developing	   world.	   Enterohaemorrhagic	  
Escherichia	  coli	   (EHEC),	  pathogenic	   strains	  of	  E.	  coli	   that	  carry	  potent	   toxins,	  have	  been	  
associated	  with	  a	  high	  number	  of	  large-­‐scale	  outbreaks	  caused	  by	  contaminated	  food	  and	  
water	   sources.	   This	   pathotype	   produces	   diarrhoea	   and	   haemorrhagic	   colitis	   in	   infected	  
humans,	  and	  in	  some	  patients	  leads	  to	  the	  development	  of	  haemolytic	  uremic	  syndrome	  
(HUS),	  which	  can	  result	   in	  mortality	  and	  chronic	  kidney	  disease.	  A	  major	  obstacle	  to	  the	  
treatment	  of	  EHEC	  infections	  is	  the	  increased	  risk	  of	  HUS	  development	  that	  is	  associated	  
with	  antibiotic	  treatment,	  and	  rehydration	  and	  renal	  support	  are	  often	  the	  only	  options	  
available.	   New	   treatments	   designed	   to	   prevent	   or	   clear	   E.	   coli	   infections	   and	   reduce	  
symptoms	  of	  illness	  would	  therefore	  have	  large	  public	  health	  and	  economic	  impacts.	  	  
	  
The	   three	   main	   aims	   of	   this	   thesis	   were:	   to	   explore	   mouse	   models	   for	   pre-­‐clinical	  
evaluation	   in	   vivo	   of	   small	   compounds	   that	   inhibit	   a	  major	  EHEC	  colonisation	   factor,	   to	  
assess	   the	   production	   and	   role	   of	   two	   proteins	   considered	   promising	   candidates	   for	   a	  
broad-­‐spectrum	  vaccine	  against	  pathogenic	  E.	  coli,	  and	  to	  investigate	  a	  novel	  compound	  
that	  has	  recently	  been	  identified	  as	  a	  potential	  inhibitor	  of	  EHEC	  toxin	  production.	  
	  
As	   EHEC	   cannot	   be	   safely	   tested	   in	   humans	   due	   to	   the	   risk	   of	   HUS	   development,	  
appropriate	  small	  animal	  models	  are	  required	  for	  in	  vivo	  testing	  of	  new	  drugs.	  A	  number	  
of	  different	  mouse	  models	  have	  been	  developed	  to	  replicate	  different	   features	  of	  EHEC	  
pathogenesis,	  several	  of	  which	  we	  investigated	  with	  a	  focus	  on	  colonisation	  mediated	  by	  
the	   Type	   III	   Secretion	   System	   (T3SS),	   a	   needle-­‐like	   structure	   that	   translocates	   bacterial	  
proteins	  into	  host	  cells,	  resulting	  in	  a	  tight,	   intimate	  attachment	  between	  pathogen	  and	  
host,	  aiding	  colonisation	  of	  the	  gastrointestinal	  tract.	  As	  E.	  coli	  models	  were	  found	  not	  to	  
depend	   significantly	   on	   the	   T3SS	   for	   colonisation,	   the	   Citrobacter	   rodentium	   model,	   a	  
natural	  mouse	  pathogen	  closely	  related	  to	  E.	  coli,	  was	  deemed	  the	  most	  suitable	  mouse	  
model	  currently	  available	  for	  in	  vivo	  testing	  of	  T3SS-­‐targeting	  compounds.	  
	  
Two	  bacterial	  proteins,	  EaeH	  (an	  outer	  membrane	  adhesin)	  and	  YghJ	  (a	  putative	  secreted	  
lipoprotein),	   highly	   conserved	   surface-­‐associated	   proteins	   recently	   identified	   as	  
	   IV	  
protective	  antigens	  against	  E.	  coli	  infection	  of	  mice,	  were	  explored	  in	  order	  to	  determine	  
their	  suitability	  as	  candidates	  for	  a	  human	  vaccine	  against	  pathogenic	  E.	  coli.	  We	  focused	  
on	  the	  expression	  and	  function	  of	  these	  proteins	  in	  the	  EHEC	  O157:H7	  EDL933	  strain	  and	  
the	  adherent-­‐invasive	  E.	  coli	  (AIEC)	  LF82	  strain.	  Although	  expression	  of	  EaeH	  by	  other	  E.	  
coli	   pathotypes	   has	   recently	   been	   shown	   to	   be	   upregulated	   upon	   contact	   with	   host	  
intestinal	   cells,	   no	   evidence	   of	   this	   upregulation	   could	   be	   demonstrated	   in	   our	   strains.	  
Additionally,	  while	  YghJ	  was	  produced	  by	  the	  AIEC	  strain,	  it	  was	  not	  secreted	  by	  bacteria	  
under	  conditions	  that	  other	  YghJ-­‐expressing	  E.	  coli	  pathotypes	  do,	  despite	  the	  AIEC	  strain	  
carrying	  all	  the	  genes	  required	  to	  encode	  the	  secretion	  system	  it	  is	  associated	  with.	  While	  
our	  findings	  indicate	  that	  a	  vaccine	  that	  raises	  antibodies	  against	  EaeH	  and	  YghJ	  may	  have	  
limited	  effect	  on	  the	  EHEC	  and	  AIEC	  strains	  we	  used,	  recent	  studies	  into	  these	  proteins	  in	  
different	  E.	  coli	  pathogens	  have	  suggested	  they	  are	  still	  excellent	  candidates	  for	  a	  broadly	  
effective	  vaccine	  against	  E.	  coli.	  
	  
Finally,	  we	  characterised	  a	  small	  lead	  compound,	  identified	  by	  high-­‐throughput	  screening	  
as	  a	  possible	   inhibitor	  of	  Shiga	  toxin	  expression.	  Shiga	  toxin	  production	  causes	  both	  the	  
symptoms	   of	   illness	   and	   development	   of	   HUS,	   and	   thus	   reduction	   of	   toxin	   production,	  
release,	   or	   binding	   to	   host	   receptors	   could	   therefore	   be	   an	   effective	   way	   to	   treat	  
infections	   and	   decrease	   the	   risk	   of	   HUS.	   Inhibition	   of	   Shiga	   toxin	   production	   by	   this	  
compound	   was	   confirmed,	   and	   was	   shown	   to	   be	   caused	   by	   an	   inhibitory	   effect	   on	  
activation	  of	  the	  bacterial	  SOS	  response	  rather	  than	  on	  the	  Shiga	  toxin	  genes	  themselves.	  
The	  bacterial	   target	  of	   this	   compound	  was	   identified	   as	  RecA,	   a	  major	   regulator	  of	   the	  
SOS	   response,	   and	   we	   hypothesise	   that	   the	   compound	   binds	   covalently	   to	   its	   target,	  
preventing	  oligomerisation	  of	  RecA	  into	  an	  activated	  filament.	  
	  
Altogether,	   the	   results	   presented	   here	   provide	   an	   improved	   understanding	   of	   these	  
different	  approaches	  to	  combating	  EHEC	  infection,	  which	  will	  aid	  the	  development	  of	  safe	  
and	  effective	  vaccines	  and	  anti-­‐virulence	  treatments	  against	  EHEC.	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1.1	  Pathogenic	  Escherichia	  coli	  
	  
Escherichia	  coli	  are	  Gram-­‐negative,	  facultative	  anaerobic	  bacteria	  commonly	  found	  in	  the	  
lower	  intestine	  of	  warm-­‐blooded	  organisms,	  including	  humans	  who	  are	  colonised	  shortly	  
after	  birth.	  Strains	  can	  be	  classed	  into	  a	  number	  of	  phylogenetically	  distinct	  groups,	  with	  
up	  to	  7	  phylogroups	  proposed	  (A,	  B1,	  B2,	  C,	  D,	  E,	  and	  F),	  with	  the	  closely	  related	  Shigella	  
species	   forming	  an	  accessory	  group	   (Clermont	  et	  al.,	   2013).	   The	  vast	  majority	  of	  E.	   coli	  
strains	   coexist	   in	   a	   mutually	   beneficial	   symbiotic	   relationship	   with	   their	   human	   host,	  
rarely	   causing	   disease	   except	   in	   immunocompromised	   hosts	   or	   where	   normal	  
gastrointestinal	  barriers	  are	  breached.	  E.	  coli	  strains	  are	  also	  extensively	  used	  as	  a	  model	  
organism	  in	  the	  laboratory,	  due	  to	  its	  fast	  growth	  and	  ease	  of	  genetic	  manipulation.	  
	  
1.1.1	  E.	  coli	  pathotypes,	  classification	  and	  identification	  
	  
Pathogenic	   strains	   of	   E.	   coli	   are	   capable	   of	   causing	   a	   range	   of	   diverse	   intestinal	   and	  
extraintestinal	   diseases,	   which	   result	   in	   three	   distinct	   clinical	   syndromes:	  
sepsis/meningitis,	  urinary	  tract	   infection,	  and	  enteric/diarrhoeal	  disease.	  Diarrhoeagenic	  
E.	  coli	   isolates	  can	  be	  classed	   into	  distinct	  clinical	  subcategories:	  enterohaemorrhagic	  E.	  
coli	   (EHEC),	   which	   are	   the	   main	   focus	   of	   this	   thesis,	   enteropathogenic	   E.	   coli	   (EPEC),	  
enterotoxigenic	   E.	   coli	   (ETEC),	   enteroinvasive	   E.	   coli	   (EIEC),	   enteroaggregative	   E.	   coli	  
(EAEC),	  adherent-­‐invasive	  E.	  coli	  (AIEC),	  and	  diffusely	  adherent	  E.	  coli	  (DAEC).	  Pathotypes	  
do	   not	   always	   group	   together	   in	   the	   same	   phylogroup;	   for	   example,	   EHEC	   strains	   are	  
found	  in	  both	  phylogroups	  B1	  and	  E	  (Figure	  1-­‐1).	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Figure	   1-­‐1:	   Phylogenic	   tree	   of	   intestinal	   pathogenic	   E.	   coli.	   The	   5	   main	   E.	   coli	   phylogenic	   groups	   are	  
indicated	  by	  branch	   colour	   coding	  as	   follows:	  Phylogroup	  B1	  =	  blue;	  Phylogroup	  A	  =	   red;	  Phylogroup	  E	  =	  
green;	  Phylogroup	  D	  =	  yellow;	  Phylogroup	  B2	  =	  pink.	  Strains	  with	   the	  enterohaemorrhagic	  pathotype	  are	  
denoted	  by	  a	  black	  circle.	  Adapted	  from	  Hao	  et	  al.	  (2012),	  which	  was	  published	  under	  a	  Creative	  Commons	  
licence.	  
	  
Classification	  of	  pathogenic	  E.	  coli	   strains	   into	   serotypes	   is	   based	  on	  particular	   surface-­‐
exposed	   antigens	   they	   express:	   the	   O	   antigen,	   a	   polymer	   present	   in	   the	  
lipopolysaccharide	  layer,	  and	  the	  H	  antigen,	  a	  major	  component	  of	  flagella.	  Some	  strains	  
can	   also	   be	   classified	   by	   their	   K	   antigen,	   which	   denotes	   their	   capsular	   polysaccharide	  
group.	   Laboratory	   identification	   of	   E.	   coli	   often	   utilises	   selective	   growth	   media,	   with	  
MacConkey	  and	  eosin	  methylene	  blue	  agar,	  which	  select	  for	  Gram-­‐negative	  bacteria	  and	  
lactose	   fermentation,	   commonly	   used	   for	   initial	   identification.	   E.	   coli	   strains	   are	   also	  
oxidase	   negative,	   produce	   indole,	   do	   not	   ferment	   citrate,	   and	   demonstrate	   a	   negative	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Voges-­‐Proskauer	  reaction.	  Additional	  determination	  of	  particular	   isolates	  from	  the	  array	  
of	   virulence	   genes	   they	   carry	   can	   be	   performed	   by	   a	   number	   of	   molecular	   methods,	  
including	   pulsed	   field	   gel	   electrophoresis	   (currently	   considered	   the	   gold	   standard	   for	  
typing	   of	   E.	   coli	   during	   outbreak	   investigations),	   DNA-­‐DNA	   hybridisation,	   PCR	   and	  
multiplex	  PCR,	  and	  microarray	  technology.	  
	  
1.1.2	  Diarrhoeagenic	  E.	  coli	  pathotypes	  
	  
The	   first	   type	  of	  E.	   coli	   to	  be	   associated	  with	  human	  disease,	   EPEC	   is	   a	  major	   cause	  of	  
infantile	   diarrhoea	   and	   infant	   mortality	   in	   developing	   countries.	   Transmission	   of	   EPEC	  
occurs	   through	   the	   faecal-­‐oral	   route,	   with	   its	   reservoir	   believed	   to	   be	   symptomatic	   or	  
asymptomatic	   children	   and	   asymptomatic	   adult	   carriers.	   The	   defining	   characteristic	   of	  
EPEC	   is	   the	   ability	   to	   produce	   an	   attaching/effacing	   (A/E)	   lesion	   at	   the	   site	   of	   bacterial	  
attachment	  to	  host	  cells,	  which	  involves	  major	  host	  cytoskeletal	  changes	  directly	  beneath	  
the	   attached	   bacteria.	   Symptomatic	   infection	   by	   EPEC	   produces	   watery	   or	   bloody	  
diarrhoea,	  which	   is	  achieved	  without	  the	  production	  of	  enterotoxins	  or	   invasion	  of	  host	  
cells.	   Although	   there	   are	   many	   EPEC	   strains	   that	   produce	   disease	   in	   animals	   such	   as	  
rabbits,	  dogs	  and	  pigs,	  these	  strains	  are	  not	  usually	  associated	  with	  human	  disease.	  
	  
Members	  of	   the	  EHEC	  group	  are	   classified	  by	   their	  production	  of	   Shiga	   toxin	   (Stx),	   also	  
known	   as	   Verotoxin,	   which	   inhibits	   protein	   synthesis	   in	   mammalian	   cells.	   EHEC	   are	  
associated	   with	   a	   broad	   spectrum	   of	   disease,	   ranging	   from	   mild	   diarrhoea	   to	   severe	  
haemorrhagic	   colitis	   and	   haemolytic	   uraemic	   syndrome	   (HUS),	   a	   serious	   and	   life-­‐
threatening	   illness	   characterised	   by	   haemolytic	   anaemia,	   acute	   kidney	   failure	   and	  
thrombocytopenia.	   Cattle,	   not	   humans,	   are	   the	   main	   reservoir	   of	   EHEC,	   with	   sporadic	  
outbreaks	  of	  human	  disease	  occurring	  through	  contaminated	  beef	  and	  dairy	  products,	  as	  
well	   as	   through	   fruits	   and	   vegetables	   that	   have	   come	   into	   contact	   with	   contaminated	  
animal	   faeces.	  Despite	   the	   isolation	  of	  over	  380	  different	  EHEC	  serotypes	   from	  humans	  
and	  animals,	  only	  a	  small	  number	  of	  these	  have	  been	  shown	  to	  be	  responsible	  for	  clinical	  
disease	  (Nguyen	  &	  Sperandio,	  2012).	  The	  most	   important	  of	  these	   in	  relation	  to	  human	  
health	  is	  O157:H7,	  although	  other	  serotypes	  have	  been	  involved	  in	  major	  outbreaks.	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ETEC	   strains	  are	   classified	  by	   their	   ability	   to	  produce	  at	   least	  one	  member	  of	   the	  heat-­‐
labile	   (LT)	   or	   heat-­‐stable	   (ST)	   groups	   of	   enterotoxins,	   and	   the	   presence	   of	   fimbriae	   for	  
attachment	  to	  intestinal	  host	  cells.	   Infection	  produces	  watery	  diarrhea	  with	  no	  blood	  or	  
abdominal	   cramping,	   although,	   like	   EPEC,	   strains	   can	   also	   be	   carried	   asymptomatically.	  
ETEC	   infections	   are	   a	   major	   concern	   in	   developing	   countries,	   with	   840	   million	   cases	  
estimated	   to	   occur	   annually,	   280	   million	   of	   these	   in	   children	   under	   the	   age	   of	   four	  
(Wennerås	  &	  Erling,	  2004),	  and	  are	  also	  the	  leading	  cause	  of	  traveler’s	  diarrhoea.	  Illness	  
caused	  by	  ETEC	  infection	  of	  young	  children	  in	  developing	  countries	  also	  has	  been	  linked	  
to	   later	   poor	   growth	   and	   malnourishment,	   and	   ETEC	   have	   also	   been	   implicated	   in	   an	  
increased	  risk	  of	  developing	  post-­‐infectious	  irritable	  bowel	  syndrome	  following	  traveler’s	  
diarrhoea	  (reviewed	  by	  Croxen	  et	  al.,	  2013).	  
	  
Infection	   by	   EIEC	   strains	   produces	   shigellosis,	   an	   illness	   ranging	   from	   mild	   abdominal	  
discomfort	  to	  severe	  dysentery,	  which	  is	  also	  caused	  by	  Shigella	  species,	  with	  whom	  EIEC	  
shares	  many	   genetic	   and	  pathogenic	   features.	   EIEC	   are	  highly	   invasive,	   penetrating	   the	  
epithelial	   barrier	   of	   intestinal	   cells	   by	   transcytosis,	   and	   subvert	   host	   cell	   signalling	  
pathways	  to	  enable	  their	  survival	  and	  replication.	  Although	  reported	  EIEC	   infections	  are	  
rare	  compared	  to	  other	  pathotypes,	  this	  is	  likely	  to	  be	  influenced	  by	  the	  lower	  severity	  of	  
its	  clinical	  manifestations	  and	  possible	  misclassification	  of	  EIEC	  infections	  as	  Shigella.	  
	  
EAEC	   strains	   are	   defined	   by	   their	   adherence	   phenotype,	   a	   “stacked	   brick”	   adhesion	  
pattern	   on	   Hep-­‐2	   human	   epithelial	   cells,	   with	   the	   genes	   encoding	   this	   phenotype	  
contained	  in	  the	  pAA	  plasmid,	  and	  a	  lack	  of	  LT/ST	  enterotoxin	  secretion.	  This	  pathotype	  is	  
increasingly	   recognised	   as	   an	   emerging	   enteric	   pathogen	   since	   it	  was	   first	   described	   in	  
1987,	   and	   causes	   persistent	   diarrhea	   in	   children	   and	   human	   immunodeficiency	   virus	  
(HIV)-­‐infected	   patients.	   In	   a	   large-­‐scale	   study	   of	   bacterial	   diarrhea	   of	   two	   large	   US	  
hospitals,	  EAEC	  was	  found	  to	  be	  the	  most	  common	  pathogen	  in	  diarrhoeal	  stool	  samples	  
(Nataro	  et	  al.,	  2006).	  In	  2011,	  the	  causative	  agent	  of	  a	  major	  E.	  coli	  outbreak	  in	  Germany	  
that	  resulted	  in	  particularly	  high	  levels	  of	  HUS	  was	  identified	  as	  an	  EAEC	  strain	  that	  had	  
acquired	  genes	  encoding	  an	  EHEC	  toxin;	  as	  several	  EAEC	  has	  previously	  been	  reported	  to	  
acquire	  these	  genes	  by	  multiple	  separate	  studies	  (reviewed	  by	  Croxen	  et	  al.,	  2013),	   it	   is	  
likely	  that	  similar	  outbreaks	  may	  occur	  in	  the	  future.	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E.	  coli	   strains	  belonging	   to	   the	  AIEC	  group	  have	  been	   implicated	   in	   the	  development	  of	  
Crohn’s	  disease	  (CD),	  a	  chronic	  inflammatory	  disorder	  of	  the	  intestine	  that	  occurs	  due	  to	  
an	   aberrant	   immune	   response	   to	   intestinal	   bacteria	   in	   susceptible	   hosts.	   CD	   causes	  
symptoms	  such	  as	  bloody	  diarrhoea,	  abdominal	  pain,	  fatigue	  and	  weight	  loss,	  and	  recent	  
epidemiological	  studies	  have	  shown	  a	  rising	  prevalence	  in	  developed	  countries,	  with	  1.4	  
million	  people	   in	  the	  USA	  and	  2.2	  million	  people	   in	  Europe	  estimated	  to	  suffer	  from	  CD	  
(Loftus,	   2004).	   No	   single	   causative	   agent	   of	   CD	   has	   been	   identified,	   and	   it	   is	   currently	  
believed	   that	   a	   combination	   of	   genetic,	   environmental,	   and	   microbiological	   factors	  
contribute	   to	   disease.	   AIEC	   bacteria	   bind	   host	   carcinoembryonic	   antigen-­‐related	   cell	  
adhesion	   molecule	   6	   (CEACAM6)	   receptors,	   antigens	   upregulated	   by	   inflammatory	  
cytokines	  and	  possibly	  AIEC	  itself,	  present	  on	  M	  cells	  overlying	  Peyer’s	  patches,	  lymphatic	  
tissue	   present	   in	   the	   ileum	   involved	   in	   detection	   of	   bacterial	   pathogens	   and	  
immunological	  responses.	   Invasion	  of	  bacteria	   into	  Peyer’s	  patches	   is	  then	  facilitated	  by	  
bacterial	   long	   polar	   fimbriae,	   where	   they	   can	   induce	   immune	   responses	   of	   patch	  
macrophages,	  further	  aggravating	  inflammation	  (reviewed	  by	  Strober,	  2011).	  	  
	  
Diarrhoeagenic	  DAEC	   strains	  are	  an	  unique	  group	  of	  E.	   coli	   that	  adhere	   to	   cells	   in	  non-­‐
classical	   patterns	   of	   attachment	   (such	   as	   attaching	   and	   effacing	   or	   localised),	   instead	  
binding	   diffusely	   over	   the	   entire	   surface	   of	   the	   host	   cell	   in	   a	   scattered	   pattern.	   This	  
adhesion	  phenotype	   is	  mediated	  by	   surface	   fimbriae,	   the	  genes	   for	  which	  are	  encoded	  
either	  on	  the	  bacterial	  chromosome	  or	  on	  a	  plasmid.	  The	  epidemiology	  of	  DAEC	  is	  difficult	  
to	  assess,	  due	   to	  a	   lack	  of	  a	  universal	  method	  of	   identifying	   strains	   in	  a	  clinical	   setting.	  
However,	   some	   studies	   have	   identified	   DAEC	   isolates	   from	   both	   healthy	   patients	   and	  
those	   with	   diarrhoea,	   and	   have	   suggested	   that	   younger	   children	   have	   a	   higher	   risk	   of	  
DAEC-­‐associated	  diarrhoea	  (Levine	  et	  al.,	  1993).	  
	  
1.1.3	  Uropathogenic	  and	  neonatal	  meningitis-­‐causing	  E.	  coli	  
	  
Urinary	   tract	   infections	   (UTIs)	   are	   primarily	   caused	   by	   upropathogenic	   E.	   coli	   (UPEC)	  
strains,	   which	   are	   responsible	   for	   70-­‐95%	   of	   community-­‐acquired	   UTIs	   and	   50%	   of	  
nosocomial	  UTIs	  (Foxman,	  2003).	  UTIs	  are	  one	  of	  the	  most	  common	  infectious	  diseases	  of	  
humans	  with	  approximately	  150	  million	  annual	  cases	  worldwide,	  while	  it	  is	  estimated	  that	  
40-­‐50%	  of	  women	  and	  5%	  of	  men	  will	  develop	  a	  UTI	  in	  their	  lifetime	  (reviewed	  by	  Totsika	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et	   al.,	   2012).	   UPEC	   are	   opportunistic	   pathogens	  whose	   reservoir	   is	   often	   the	   intestinal	  
tract;	   isolates	   identified	   as	   the	   cause	   of	   an	   UTI	   often	   match	   faecal	   isolates	   from	   the	  
patient	   or	   their	   sexual	   partners	   (Russo	   et	   al.,	   1995;	   Foxman	   et	   al.,	   2002).	   Following	  
infiltration	  of	  the	  urinary	  tract,	  UPEC	  preferentially	  colonise	  the	  bladder,	  causing	  cystitis,	  
but	   can	   also	   ascend	   via	   the	   ureters	   to	   reach	   the	   kidneys	   where	   they	   can	   cause	  
pyelonephritis,	  a	  potentially	  serious	  and	  life-­‐threatening	  inflammation	  of	  kidney	  tissue.	  A	  
wide	   array	   of	   virulence	   factors	   facilitate	   UPEC	   infection,	   including	   adhesive	   pili	   that	  
enable	  attachment	  and	   invasion	  of	  epithelial	   cells	   in	   the	  urinary	   tract,	   toxins	   that	  allow	  
bacterial	  dissemination	  and	  modulation	  of	  host	  signalling	  pathways,	  and	  siderophores	  to	  
acquire	  host	  iron	  supplies	  (reviewed	  by	  Wiles	  et	  al.,	  2009).	  
	  
Neonatal	  meningitis	  E.	   coli	   (NMEC),	  which	  belong	  mainly	   to	   the	  B2	  phylogenetic	  group,	  
are	  one	  of	   the	  most	   common	  causes	  of	   	  bacterial	  neonatal	  meningitis,	   inflammation	  of	  
the	  meninges	   caused	  by	  bacterial	   infection	  of	   the	  blood,	  which	   carries	  a	  high	  mortality	  
and	  morbidity	  rate	  as	  well	  as	  severe	  neurological	  defects	  in	  many	  survivors.	  Many	  NMEC	  
strains	   produce	   the	   K1	   capsular	   polysaccharide	   which	   contains	   sialic	   acid,	   a	  
monosaccharide	  widely	   distributed	   in	   human	   tissues	   and	   not	   recognised	   by	   the	   innate	  
immune	   system,	   thus	   protecting	   the	   bacteria	   from	   host	   responses.	   This	   capsule	   also	  
enables	  bacteria	  to	  breach	  the	  blood-­‐brain	  barrier	  in	  order	  to	  reach	  the	  meninges.	  
	  
1.1.4	  Pathogenic	  animal	  E.	  coli	  
	  
Although	   some	   pathotypes	   of	   E.	   coli	   have	   only	   been	   identified	   in	   humans,	   pathogenic	  
EHEC,	  EPEC	  and	  ETEC	  are	   responsible	   for	  a	  wide	   range	  of	  diseases	   in	  animals,	   including	  
many	  domesticated	  species	  such	  as	  cattle,	  pigs,	  goats,	  and	  dogs.	  An	  additional	  pathotype,	  
avian	  pathogenic	  E.	  coli	  (APEC),	  can	  cause	  extraintestinal	  infections	  exclusively	  in	  poultry,	  
producing	   respiratory	   infection,	   pericarditis,	   and	   septicaemia.	   Many	   APEC	   strains	   are	  
present	  in	  the	  intestinal	  microbiota	  of	  healthy	  animals,	  and	  diseases	  associated	  with	  them	  
are	   considered	   secondary	   to	  environmental	   and	  host	  predisposing	   factors	   (reviewed	  by	  
Dho-­‐Moulin	  &	  Fairborther,	  1999).	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1.2	  Enterohaemorrhagic	  O157:H7	  E.	  coli	  
	  
The	   first	   recognition	   of	   an	   EHEC	   strain	   as	   a	   foodborne	   pathogen	   occurred	   in	   1982	   in	  
Oregon	   and	   Michigan,	   USA,	   during	   an	   investigation	   into	   customers	   of	   a	   fast-­‐food	  
restaurant	  chain	  who	  were	  exhibiting	  bloody	  diarrhoea	  and	  severe	  abdominal	  cramping	  
with	  no	  fever.	  The	  E.	  coli	  strain	  O157:H7,	  which	  had	  not	  previously	  been	  associated	  with	  
human	   disease,	   was	   isolated	   from	   infected	   individuals	   and	   traced	   to	   contaminated	  
hamburger	   meat	   (Riley	   et	   al.,	   1983).	   Shortly	   thereafter,	   O157:H7	   was	   linked	   to	   the	  
development	   of	   HUS	   (Karmali	   et	   al.,	   1983),	   a	   disease	   predominantly	   affecting	   children	  
and	   carrying	   a	   5-­‐10%	   mortality	   rate.	   Since	   then,	   EHEC	   have	   been	   recognized	   as	  
responsible	   for	   hundreds	   of	   food	   and	   waterborne	   outbreaks,	   with	   O157:H7	   being	   the	  
most	  prevalent	  serotype	  and	  the	   leading	  cause	  of	  HUS	   in	  Europe	  and	  the	  United	  States	  
(Tarr	  et	  al.,	  2005).	  
	  
1.2.1	  Sources	  and	  transmission	  of	  O157:H7	  
	  
The	  natural	  reservoir	  of	  O157:H7	  is	  the	  gut	  of	  ruminants,	  particularly	  domesticated	  cattle.	  
O157:H7	   colonises	   the	   recto-­‐anal	   junction	   of	   cattle	   (Naylor,	   2005),	   in	   contrast	   to	   the	  
colon	  of	  humans,	  and	  is	  excreted	  into	  the	  environment.	  O157:H7	  are	  non-­‐pathogenic	   in	  
cattle,	   as	   the	   globotriaoslyceramide	   (Gb3)	   receptor	   for	   the	   Shiga	   toxin	   associated	  with	  
HUS	   is	  not	  present	   in	   the	  bovine	  gastrointestinal	   tract.	  While	  Gb3	   receptors	  have	  been	  
identified	   in	   the	   kidney	   and	   brain	   of	   cattle,	   lack	   of	   vascular	   Gb3	   expression	   in	   the	   gut	  
prevents	   the	   toxin	   from	  being	   transported	   through	   the	   endothelium	   into	  blood	   vessels	  
and	  delivered	  to	  those	  organs	  (Pruimboom-­‐Brees	  et	  al.,	  2000).	  
	  
Carriage	  studies	  in	  cattle	  have	  shown	  large	  variations	  in	  the	  quantity	  of	  O157:H7	  shed	  in	  
faeces.	  Prevalence	  of	  colonisation	  in	  dairy	  cattle	  as	  measured	  by	  faecal	  shedding	  ranges	  
from	  0.2-­‐48.8%,	  with	  carriage	  by	  calves	  with	  a	  functioning	  rumen	  higher	  than	  adult	  cows,	  
and	  a	  higher	  level	  of	  prevalence	  observed	  in	  warmer	  months	  compared	  to	  colder	  months	  
(reviewed	   by	   Pennington,	   2010).	   Carriage	   between	   animals	   within	   herds	   is	   also	   highly	  
variable	   with	   some	   individual	   animals,	   termed	   supershedders,	   responsible	   for	   large	  
numbers	  of	   excreted	  O157:H7	   compared	   to	   the	   rest	  of	   the	  population.	   Fitting	  dynamic	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epidemiological	   models	   to	   prevalence	   data	   from	   a	   survey	   of	   cattle	   farms	   in	   Scotland	  
found	  that	  80%	  of	  transmission	  arises	  from	  just	  20%	  of	  animals	  that	  are	  most	  infectious	  
(Matthews	  et	  al.,	  2006).	  These	  supershedders,	  which	  excrete	  O157:H7	  at	  a	  high	  rate	  and	  
for	  a	  longer	  period,	  are	  associated	  with	  bacterial	  colonisation	  of	  a	  lymphoid	  follicle-­‐dense	  
mucosal	   region	  proximal	   to	   the	   recto-­‐anal	   junction	   (Cobbold	  et	  al.,	  2007).	  However,	  no	  
genetic	  marker	  for	  supershedders	  has	  yet	  been	  identified.	  
	  
The	  most	  frequent	  mode	  of	  O157:H7	  transmission	  to	  humans	  is	  through	  consumption	  of	  
contaminated	  food	  and	  water	  (Figure	  1-­‐2),	  a	  method	  that	  is	  substantially	  facilitated	  by	  its	  
low	   infectious	   dose,	   which	   has	   been	   calculated	   to	   between	   tens	   to	   hundreds	   of	  
microorganisms	   based	   on	   data	   from	  outbreaks.	   Analysis	   of	   the	   causes	   of	   90	   outbreaks	  
from	  the	  USA,	  Japan,	  and	  several	  European	  countries	  between	  1982	  and	  2006	  found	  that	  
contaminated	   food	   was	   the	   most	   common	   source	   of	   infection,	   with	   non-­‐dairy	   food	  
responsible	   for	   42.2%	  of	  outbreaks,	   dairy	  products	   for	   12.2%,	  direct	   animal	   contact	   for	  
7.8%,	  water	  for	  6.7%,	  and	  environmental	  for	  2.2%	  (Snedeker	  et	  al.,	  2009).	  Although	  cattle	  
are	   considered	   the	   major	   reservoir	   of	   O157:H7	   and	   other	   EHEC,	   sheep	   may	   also	   be	  
significant	   carriers	   of	   EHEC;	   faecal	   shedding	   studies	   claim	   that	   high	   numbers	   of	   these	  
animals	  (65-­‐87%)	  contained	  Stx-­‐positive	  microbes	  (Cookson	  et	  al.,	  2006;	  Heuvelink	  et	  al.,	  
1998).	   Stx-­‐carrying	   E.	   coli	   have	   also	   been	   identified	   in	   many	   other	   animal	   species,	  
including	  goats,	  pigs,	  deer,	  and	  wild	  birds.	  The	  use	  of	  cattle	  waste	  as	  a	  fertiliser	  for	  crop	  
production	   can	   also	   cause	   O157:H7	   contamination	   of	   human	   food,	   with	   many	   O157	  
outbreaks	   associated	   with	   produce	   such	   as	   spinach,	   apple	   juice,	   lettuce,	   and	   radishes.	  
Other	  non-­‐fruit/vegetable	  foods	  have	  also	  been	  implicated	  in	  outbreaks,	  such	  as	  the	  2009	  
outbreak	   caused	   by	   consumption	   of	   uncooked	   cookie	   dough	   (Neil	   et	   al.,	   2012).	   The	  
globalisation	  of	  food	  distribution	  has	  helped	  to	  facilitate	  the	  easy	  spread	  of	  contaminated	  
food	  and	  has	  increased	  the	  complexity	  of	  identifying	  the	  source	  of	  an	  outbreak.	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Figure	   1-­‐2:	   Transmission	   routes	   of	   O157:H7.	   Cattle	   are	   the	  major	   source	   of	   O157:H7,	   although	   its	   high	  
prevalence	  in	  other	  farm	  animals	  has	  been	  reported.	  Direct	  transmission	  from	  animals	  to	  humans	  can	  occur	  
by	   contact	   (farms,	   petting	   zoos),	   although	   the	   majority	   of	   outbreaks	   have	   been	   caused	   by	   ingestion	   of	  
O157:H7-­‐contaminated	   food,	   such	   as	  meat,	   dairy	   products,	   fruit	   and	   vegetables.	   Contamination	   of	   crops	  
occurs	  through	  faecal	  contamination	  from	  animals,	  such	  as	  the	  use	  of	  manure	  in	  fertiliser.	  
	  
Human	  and	  animal	  wastewater	  is	  thought	  to	  be	  responsible	  for	  contamination	  of	  aquatic	  
environments,	  including	  drinking	  and	  recreational	  water.	  Detection	  rates	  have	  estimated	  
that	  one	   in	  a	   thousand	   faecal	  coliforms	   in	  human	  sewage	  carries	   the	  stx	  gene,	   rising	   to	  
one	   in	   a	   hundred	   in	   agricultural	   animal	   sewage,	   and	   even	   higher	   in	   wastewater	   from	  
sources	  such	  as	  slaughterhouses	  and	  agricultural	  waste	  disposal	  sites	  (reviewed	  by	  Mauro	  
&	  Koudelka,	  2011).	  
	  
1.2.2	  O157:H7	  and	  human	  disease	  
	  
Infection	  by	  O157:H7	  can	  result	  in	  a	  wide	  range	  of	  effects,	  from	  asymptomatic	  to	  watery	  
diarrhoea,	   HUS,	   and	   thrombotic	   thrombocytopenic	   purpura	   (TTP).	   In	   the	   majority	   of	  
clinical	   manifestations	   of	   O157:H7	   infection,	   disease	   is	   mild	   with	   abdominal	   pain	   and	  
watery	   diarrhoea	  occurring	   3-­‐4	   days	   after	   infection.	   In	   patients	  with	   severe	   symptoms,	  
major	  transmission	  route	  
minor	  transmission	  route	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blood	   in	   the	   faeces	   can	   vary	   from	   streaked	   stools	   to	   pure	   (100%)	   blood,	   with	   this	  
symptom	  more	  commonly	  observed	  in	  O157:H7	  than	  other	  EHEC	  infections.	  Illness	  is	  not	  
accompanied	   by	   fever,	   and	   usually	   resolves	   within	   a	   week.	   Approximately	   2-­‐15%	   of	  
people	  infected	  with	  O157:H7	  go	  on	  to	  develop	  HUS,	  and	  children	  are	  particularly	  at	  risk	  
of	   this	   disease,	  with	   15%	  of	   children	   under	   10	   years	   of	   age	  with	   an	  O157:H7	   infection	  
developing	  HUS	  (Tarr	  et	  al.,	  2005).	  O157:H7	  is	  the	  most	  common	  cause	  of	  HUS,	  and	  this	  
disease	   is	   responsible	   for	   the	  majority	  of	   acute	   renal	   failure	   in	   children	   in	   the	  Western	  
world	  (Noris	  &	  Remuzzi,	  2005).	  EHEC-­‐associated	  HUS	  is	  caused	  by	  bacterial	  production	  of	  
the	   Shiga	   toxin,	   which	   produces	   widespread	   thrombotic	   microvascular	   lesions	   in	   the	  
kidney	  with	  subsequent	   red	  blood	  cell	  destruction	  and	  prevention	  of	  blood	  and	  oxygen	  
supply,	  eventually	  resulting	  in	  loss	  of	  tissue	  function	  and	  organ	  failure.	  	  
	  
The	   severity	   of	   disease	   varies	   between	   O157:H7	   outbreaks,	   due	   to	   differences	   in	   the	  
virulence	   of	   the	   strains	   involved.	   Some	   particularly	   severe	   outbreaks	   include	   the	   1996	  
Sakai	   outbreak	   in	   Japan,	   caused	   by	   contamination	   of	   radish	   sprouts	   which	   caused	   12	  
deaths	  and	  left	  thousands	  ill	  (Michino	  et	  al.,	  1999),	  and	  the	  2006	  North	  American	  spinach	  
outbreak	   which	   resulted	   in	   3	   deaths	   and	   hospitalisation	   of	   half	   of	   the	   people	   who	  
reported	   symptoms	   (Grant	  et	   al.,	   2008).	   There	   is	   a	   high	   economic	   cost	   associated	  with	  
O157:H7	   disease;	   the	   annual	   cost	   in	   the	   USA	   is	   estimated	   to	   be	   $405	   million,	   which	  
includes	  medical	  care,	  lost	  productivity,	  and	  premature	  deaths	  (Frenzen	  et	  al.,	  2005).	  The	  
cost	   of	   individual	   outbreaks	   varies	   greatly	   by	   size,	   severity,	   and	   incidence	   of	   HUS.	   The	  
1994	  West	  Lothian	  outbreak	  in	  Scotland	  cost	  approximately	  £3	  million	  at	  the	  time	  of	  the	  
outbreak,	   but	   its	   projected	   cost	   as	   a	   consequence	   of	   long	   term	   damage	   to	   health	  was	  
predicted	  to	  be	  over	  £11	  million	  over	  the	  next	  30	  years	  (Roberts	  et	  al.,	  2000).	  Although	  
the	  yearly	  number	  of	  reported	  O157:H7	  infections	  is	  significantly	  lower	  than	  that	  of	  other	  
enteric	  pathogens	  such	  as	  Salmonella	  or	  Campylobacter	  (Figure	  1-­‐3),	  O157:H7	  is	  treated	  
as	  a	  major	  health	  concern	  due	  to	  its	  higher	  hospitalisation,	  HUS	  risk,	  and	  mortality	  rate.	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Figure	   1-­‐3:	   Annual	   reported	   O157:H7,	   Campylobacter	   and	   Salmonella	   cases	   in	   England,	   Scotland,	   and	  
Wales.	   The	   average	   annual	   reported	   cases	   between	   2008-­‐2012	   were	   1,186	   for	   O157:H7,	   66,165	   for	  
Campylobacter,	   and	   9,882	   for	   Salmonella.	   Data	   was	   obtained	   from	   Public	   Health	   England	  
(https://www.gov.uk/government/organisations/public-­‐health-­‐england)	   and	   Health	   Protection	   Scotland	  
(http://www.hps.scot.nhs.uk/).	  
	  
1.2.3	  O157:H7	  virulence	  factors	  
	  
Pathogenic	  E.	  coli	  carry	  a	  range	  of	  virulence	  factors	  that	  allow	  them	  to	  colonise,	  survive,	  
and	   cause	   disease	   in	   their	   human	   host.	   The	   genes	   encoding	   many	   of	   these	   can	   be	  
transferred	   horizontally	   between	   different	   strains	   of	   E.	   coli,	   enabling	   dissemination	   of	  
virulence	  factors	  between	  different	  phylogroups.	  This	  can	  result	  in	  the	  acquisition	  of	  new	  
virulence	  properties,	  potentially	  leading	  to	  the	  emergence	  of	  novel	  E.	  coli	  pathotypes,	  as	  
seen	  by	  the	  O104:H4	  strain	  responsible	  for	  the	  recent	  2011	  outbreak	  in	  Germany.	  
	  
As	  in	  other	  EHEC	  strains,	  the	  production	  of	  Shiga	  toxin	  in	  O157:H7	  is	  associated	  with	  the	  
development	  of	  HUS.	  The	  Type	  3	  Secretion	  System	  (T3SS)	  is	  another	  important	  virulence	  
factor	   that	  mediates	   intimate	  attachment	  of	  bacteria	   to	  enterocytes,	   and	   is	   carried	  not	  
only	  by	  EHEC	  strains	  but	  also	  by	  EPEC,	  Shigella,	  Salmonella,	   and	  Yersinia	   species.	  Other	  
virulence	   factors	   expressed	   by	   O157:H7	   include	   the	   flagella,	   long	   extracellular	  
appendages	  that	  provide	  motility	  but	  also	  have	  sensory	  and	  adherence	  functions	  (Girón	  
et	   al.,	   2002),	   and	   the	   putative	   virulence	   plasmid	   pO157,	   carried	   by	   all	   clinical	   isolates,	  
which	   contains	   many	   different	   mobile	   genetic	   elements	   such	   as	   prophages	   and	  
transposons.	   The	   focus	   of	   this	   thesis,	   however,	   will	   be	   centered	   on	   just	   two	   of	   these	  
virulence	  factors:	  the	  Shiga	  toxin	  and	  the	  Type	  3	  Secretion	  System.	  






















	   13	  
1.3	  Shiga	  toxin	  
	  
The	   pathogenesis	   of	   haemorrhagic	   colitis	   and	   HUS	   is	   dependent	   on	   the	   production	   of	  
Shiga	  toxin,	  a	  family	  of	  related	  toxins	  essential,	  though	  not	  solely	  responsible	  for	  disease.	  
Stx	   from	   Shigella	   dysenteriae	  was	   first	   identified	   over	   a	   hundred	   years	   ago	   by	   Kiyoshi	  
Shiga,	   and	   subsequently	   found	   to	  be	  expressed	  by	  EHEC	   strains	   in	  1983	   (O’Brien	  et	  al.,	  
1983).	  	  
	  
1.3.1	  Stx	  structure	  and	  mechanism	  of	  action	  
	  
Stx	   belongs	   to	   the	   AB	   family	   of	   toxins,	   in	   which	   one	   A	   subunit	   and	   five	   B	   subunits	  
associate	  to	  form	  an	  active	  toxin.	  Within	  the	  AB5	  holotoxin	  structure,	  enzymatic	  activity	  is	  
located	   in	   the	   single	   A	   subunit,	   while	   the	   binding	   activity	   is	   associated	   with	   the	  
pentameric	  B	  domain.	  This	  structure	  binds	  to	  the	  Gb3	  receptor,	  expressed	  by	  Paneth	  cells	  
in	   the	   intestinal	   mucosa	   and	   by	   kidney	   epithelial	   cells,	   allowing	   clathrin-­‐dependent	  
endocytosis	   of	   the	  A	   subunit.	   The	   internalised	  A	   subunit	   is	   then	  proteolytically	   cleaved	  
into	  two	  parts,	  A1	  (27.5	  kDA)	  and	  A2	  (4.5	  kDA),	  which	  remain	  covalently	  associated	  by	  a	  
disulphide	   bond	   until	   the	   two	   cysteine	   residues	   are	   reduced	   (Olsnes	   et	   al.,	   1981).	   N-­‐
glycosidase	  activity	  within	  the	  A1	  subunit	  enables	  it	  to	  cleave	  a	  single	  adenosine	  from	  the	  
28S	  ribosomal	  RNA	  of	   the	  60S	  ribosomal	  subunit,	  an	  enzymatic	  activity	  shared	  with	   the	  
plant	   lectin	   ricin	   (Endo	   et	   al.,	   1988),	   preventing	   binding	   of	   elongation	   factor	   to	   the	  
ribosome	  and	  thus	  inhibiting	  protein	  synthesis,	  resulting	  in	  cell	  death	  by	  apoptosis	  (Figure	  
1-­‐4).	  Stx	  is	  also	  capable	  of	  interacting	  with	  other	  non-­‐epithelial	  cells,	  and	  can	  affect	  renal	  
tubular	  cells,	  mesangial	  cells,	  monocytes	  and	  platelets.	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Figure	   1-­‐4:	  Mechanism	  of	   action	   of	   Stx.	  The	  B	  subunits	  of	  Stx	  bind	   to	   the	  host	   receptor	  Gb3	  on	   the	  cell	  
surface,	  allowing	  the	  A	  subunit	  of	  Stx	  to	  be	  internalised.	  Inside	  the	  host	  cell,	  the	  A	  subunit	   is	  cleaved	  into	  
two	  parts,	  and	  the	  A1	  component	  cleaves	  a	  specific	  adenine	  residue	  from	  the	  ribosome,	  disrupting	  protein	  
synthesis	  and	  thus	  leading	  to	  cell	  death.	  
	  
1.3.2	  Stx	  variants	  
	  
Stx	  produced	  by	  EHEC	  strains	  are	  differentiated	  into	  two	  types	  that	  share	  55%	  sequence	  
homology	   (Fraser	   et	   al.,	   2004):	   Stx1,	   which	   shares	   very	   high	   homology	   with	   Shigella	  
dysenteriae,	   and	   Stx2,	   which	   is	   structurally	   similar	   to	   Stx1,	   but	   antigenically	   distinct.	  
O157:H7	   can	   carry	   genes	   encoding	   both	   forms	   of	   the	   toxin,	   although	   it	   is	   Stx2	   whose	  
expression	   is	   more	   strongly	   associated	   with	   the	   production	   of	   bloody	   diarrhoea	   and	  
higher	  risk	  of	  HUS.	  Within	  each	  group,	  Stx	   is	  classed	   into	  variants	   (Table	  1-­‐1)	  that	  differ	  
from	  each	  other	  in	  biological	  and	  immunological	  reactivity,	  with	  the	  Stx2	  group	  displaying	  
a	   higher	   level	   of	   heterogeneity	   compared	   to	   the	   Stx1	   group.	  Only	   the	   genes	   for	   Stx1a,	  
Stx1d,	  Stx2a,	  and	  Stx2c	  have	  been	  identified	  in	  O157:H7	  isolates.	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Table	  1-­‐1:	  Stx	  types	  and	  variants.	  Stx	  variants	  found	  in	  O157:H7	  are	  underlined.	  Adapted	  from	  Pacheco	  and	  
Sperandio	  (2012)	  and	  Scheutz	  et	  al.	  (2012).	  
Stx	  type	   Variants	  
Stx1	   Stx1a,	  Stx1c,	  Stx1d	  
Stx2	   Stx2a,	  Stx2c,	  Stx2d,	  Stx2dact,	  Stx2e,	  Stx2f,	  Stx2g	  
	  
	  
The	  most	  virulent	  Stx2	  variants	  are	  Stx2c	  and	  Stx2dact.	  Two	  amino	  acid	  changes	  in	  the	  B	  
subunit	   of	   Stx2c	   reduces	   its	   potential	   to	   generate	   a	   significant	   neutralising	   antibody	  
response	  in	  mice	  compared	  to	  the	  other	  Stx2	  variants,	  although	  it	  displays	  equal	  toxicity	  
(Lindgren	  et	  al.,	  1994).	  The	  Stx2dact	  variant	  also	  shows	  these	  alterations	  in	  the	  B	  subunit,	  
along	  with	  a	   further	   two	  amino	  acid	  changes	   in	   the	  A	  subunit	   that	  allows	  an	  additional	  
proteolytic	  cleavage	  event	  by	  elastase	  to	  occur	  (Kokai-­‐Kun,	  2000).	  This	  results	  in	  a	  greater	  
capacity	  for	  Gb3	  binding	  and	  thus	  an	  enhanced	  increase	  in	  toxicity	  (Bunger	  et	  al.,	  2013).	  
Consequently,	   bacteria	   carrying	   these	   toxins	   are	   more	   virulent	   than	   any	   other	   Stx2-­‐
expressing	   strain	   in	   the	  mouse	  model	   of	   disease	   (Melton-­‐Celsa	   et	   al.,	   1996).	   Although	  
Stx2dact	   has	   been	   associated	   with	   a	   severe	   clinical	   outcome	   and	   high	   risk	   of	   HUS	  
development	  (Bielaszewska	  et	  al.,	  2006),	  it	  has	  not	  yet	  been	  found	  in	  an	  O157:H7	  strain.	  
	  
1.3.3	  Shiga	  toxin-­‐encoding	  bacteriophages	  
	  
The	  genes	  for	  Shiga	  toxins	  in	  E.	  coli	  are	  exclusively	  located	  on	  temperate	  lysogenic	  phages	  
that	  integrate	  into	  the	  genome	  of	  their	  host	  bacterium.	  The	  Stx1	  bacteriophage	  genes	  are	  
integrated	  into	  yehV	  (Yokoyama	  et	  al.,	  2000),	  a	  gene	  encoding	  a	  positive	  regulator	  of	  curli	  
expression.	  The	  Stx2	  bacteriophage	  genes	  are	  integrated	  into	  the	  locus	  for	  wrbA	  (Makino	  
et	   al.,	   1999),	  which	   encodes	   a	  NAD(P)H:quinone	  oxidoreductase,	  with	   the	   exception	   of	  
the	   Stx2c	   variant	   which	   is	   found	   next	   to	   sbcB,	   a	   gene	   encoding	   the	   exonuclease	   Exol	  
involved	   in	  genetic	  stability	   (Eppinger	  et	  al.,	  2011).	   In	   the	   lysogenic	  state,	  Stx	  genes	  are	  
replicated	   as	   an	   integral	   part	   of	   the	   bacterial	   genome.	   Expression	   of	   the	   phage	   genes	  
occurs	   when	   the	   phage	   lytic	   cycle	   is	   activated,	   allowing	   the	   genes	   encoding	   Stx	   to	   be	  
packaged	  in	  phage	  particles,	  which	  are	  assembled	  and	  released	  through	  lysis	  of	  the	  cell.	  
The	  released	  Stx	  bacteriophages	  are	  then	  able	  to	  infect	  other	  non-­‐stx	  E.	  coli,	  potentially	  
leading	   to	   integration	  of	   the	  Stx	  genes	   into	   the	  chromosome	  of	   the	  new	  host	  and	   thus	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dissemination	   of	   this	   virulence	   phenotype.	   Lysis	   of	   bacteria	   also	   allows	   release	   of	  
translated	  Stx	  protein	  into	  the	  local	  environment.	  
	  
1.3.4	  Horizontal	  gene	  transfer	  of	  stx	  and	  its	  contribution	  to	  new	  EHEC	  outbreak	  strains	  
	  
Infection	  of	  bacteria	  by	  bacteriophages	  can	  result	  in	  integration	  of	  the	  phage	  genes	  into	  
the	   bacterial	   chromosome	   as	   the	   phage	   undergoes	   lysogeny	   (Figure	   1-­‐5).	   This	   type	   of	  
horizontal	   gene	   transfer	  by	  phage	  has	  been	  associated	  with	  acquisition	  of	   a	  number	  of	  
major	  virulence	  factors,	  such	  as	  diphtheria	  toxin	  of	  Corynebacteria	  diptheria,	  cholera	  toxin	  
from	   Vibrio	   cholerae,	   and	   enterotoxin	   A	   of	   Staphylococcus	   aureus.	   Together,	   these	  
examples	   highlight	   the	   contribution	   that	   phages	   have	   played	   in	   the	   evolution	   of	   novel	  
pathogens.	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Figure	   1-­‐5:	   The	   lytic	   and	   lysogenic	   cycles	   of	   bacteriophages.	  When	  phage	  DNA	   is	   injected	   into	  bacterial	  
cells	  it	  can	  enter	  one	  of	  two	  cycles	  of	  reproduction.	  In	  the	  lytic	  cycle	  (left)	  the	  phage	  DNA	  hijacks	  the	  cell’s	  
replication	  and	  translation	  mechanisms,	  using	  them	  to	  produce	  more	  phage	  DNA	  and	  proteins.	  Eventually,	  
the	  assembled	  phages	  cause	   lysis	  of	   their	  host	  bacterium,	   releasing	  progeny	  phages	   into	   the	  surrounding	  
environment	  where	  they	  can	  go	  on	  to	  infect	  other	  bacteria.	  In	  the	  lysogenic	  cycle	  (right)	  the	  phage	  DNA	  is	  
integrated	  into	  the	  bacterial	  chromosome,	  becoming	  a	  prophage.	  The	  phage	  DNA	  continues	  to	  reproduce	  
during	  cell	  division	  and	  is	  transmitted	  to	  daughter	  cells.	  Certain	  conditions	  can	  release	  the	  prophage	  from	  
the	  chromosome,	  causing	  it	  to	  enter	  the	  lytic	  cycle	  and	  produce	  phages.	  
	  
A	  recent	  and	  significant	  example	  of	  how	  Stx	  acquisition	  can	  result	  in	  the	  emergence	  of	  a	  
new	  outbreak	  strain	  is	  provided	  by	  the	  E.	  coli	  O104:H4	  outbreak	  in	  Germany	  in	  2011.	  This	  
incident	  resulted	  in	  over	  four	  thousand	  cases	  of	  infection	  and	  852	  cases	  of	  HUS.	  This	  was	  
a	  much	  higher	  rate	  of	  HUS	  (approximately	  29%	  of	  cases)	  compared	  to	  many	  other	  EHEC	  
outbreaks	   (Buchholz	   et	   al.,	   2011).	   Although	   symptoms	   indicated	   the	   infection	   to	   be	  
caused	   by	   an	   EHEC	   strain	   such	   as	   O157	   or	   O111,	   the	   actual	   organism	   responsible	  was	  
eventually	  identified	  as	  an	  EAEC	  strain	  which	  had	  acquired	  the	  stx	  gene.	  The	  combination	  
of	   Stx	   expression,	   capacity	   to	   adhere	   using	   the	   enteroaggregative	   phenotype,	   and	   the	  
ability	   to	   generate	   biofilms	   was	   thought	   to	   contribute	   to	   the	   high	   level	   of	   virulence	  
observed	  in	  this	  outbreak	  (Scheutz	  et	  al.,	  2011).	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1.3.5	  Regulation,	  activation	  and	  expression	  of	  the	  bacterial	  SOS	  response	  
	  
The	  switch	  from	  a	  lysogenic	  lifestyle	  to	  a	  lytic	  cycle	  by	  bacteriophages	  is	  controlled	  by	  the	  
SOS	   response,	   a	   high-­‐activity	   repair	   response	   to	   damage	   of	   DNA.	   When	   the	   cell	  
undergoes	   stress	   that	   results	   in	   DNA	   damage,	   such	   as	   exposure	   to	   UV	   light	   or	   certain	  
antibiotics,	  the	  SOS	  response	  is	  activated	  and	  allows	  Stx	  bacteriophage	  to	  escape	  into	  the	  
surrounding	   environment,	   where	   it	   may	   infect	   other	   bacteria	   and	   enter	   the	   lysogenic	  
cycle	  once	  more.	  
	  
At	  least	  43	  genes	  in	  E.	  coli	  are	  activated	  by	  the	  SOS	  response	  (Courcelle	  et	  al.,	  2001),	  and	  
the	   proteins	   they	   encode	   include	   those	   involved	   in	   DNA	   repair,	   protection	   of	   single-­‐
stranded	  DNA	   (ssDNA)	   from	  destruction,	  DNA	  mutagenesis,	  and	  arrest	  of	   the	  cell	   cycle.	  
The	   interplay	   of	   two	   major	   proteins,	   RecA	   (recombinase	   A)	   and	   LexA	   (locus	   for	   X-­‐ray	  
sensitivity	  A),	   regulates	   the	   SOS	   response.	   RecA,	   a	   38	   kDa	  ATP-­‐dependent	   protein	  with	  
DNA-­‐binding	   abilities,	   is	   highly	   conserved	   in	   bacteria,	   with	   structural	   and	   functional	  
homologues	  present	   in	  all	  organisms,	   including	  humans	   in	  which	   it	   is	   known	  as	  RAD51.	  
LexA	   is	   a	   27	   kDa	   protein	  which	   represses	   the	   expression	   of	   genes	   involved	   in	   the	   SOS	  
response,	  including	  that	  of	  recA	  and	  lexA.	  
	  
Under	  non-­‐stressed	  conditions,	  LexA	  binds	  as	  a	  dimer	  to	   its	  cognate	  LexA	  box	  sequence	  
within	  the	  promoter	  for	  those	  genes	  expressed	  by	  the	  SOS	  regulon,	  thus	  inhibiting	  their	  
production	  (Thliveris	  et	  al.,	  1991).	  As	  a	  consequence,	  SOS	  gene	  expression	  is	  dependent	  
on	  the	  affinity	  of	  LexA	  for	  each	  promoter.	  When	  DNA	  damage	  occurs,	  RecA	  is	  recruited	  to	  
ssDNA	  by	  the	  RecFOR	  complex,	  whereupon	  it	  oligomerises	  to	  form	  a	  right-­‐handed	  helical	  
nucleofilament,	  with	  one	  RecA	  monomer	  bound	  per	  three	  base	  pairs	  of	  DNA	  and	  a	  total	  
of	   six	   monomers	   per	   helical	   turn.	   RecA	   can	   also	   form	   filaments	   on	   double-­‐stranded	  
(dsDNA)	  when	   recruited	  by	   the	  RecBCD	  complex,	  albeit	  much	  weaker	  ones	   (Arenson	  et	  
al.,	   1999).	   The	  assembled	  RecA	   filaments,	   known	  as	  RecA*,	  have	   the	  ability	   to	   catalyse	  
strand	  exchange	  and	  enable	  homologous	  recombination	  to	  repair	  DNA.	  In	  addition,	  they	  
have	   protease	   activity	   which	   allows	   the	   facilitation	   of	   LexA	   autocleavage,	   removing	   it	  
from	  the	  promoter	  sequence	  of	  the	  SOS	  genes	  and	  allowing	  their	  transcription	  (Figure	  1-­‐
6).	  Studies	  using	  UV	  light	  to	  damage	  DNA	  have	  shown	  that	  after	  irradiation,	  the	  amount	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of	  intact	  LexA	  within	  the	  cell	  severely	  decreases	  within	  a	  matter	  of	  minutes	  (Sassanfar	  &	  
Roberts,	  1990).	  	  
	  
	  
Figure	  1-­‐6:	  Activation	  of	  the	  SOS	  response.	  RecA	  monomers	  (red)	  recognise	  and	  bind	  to	  damaged	  ssDNA,	  
forming	  filaments	  that	  enable	  autocleavage	  of	   the	  LexA	  repressor	   (purple).	  Cleavage	  of	  LexA	  results	   in	   its	  
removal	   from	   promoter	   regions	   upstream	   of	   genes	   encoding	   proteins	   involved	   in	   the	   SOS	   response,	  
including	  those	  that	  encode	  for	  RecA	  and	  LexA.	  
	  
The	  first	  SOS	  genes	  to	  be	  expressed	  are	  urvA,	  urvB,	  and	  urvD,	  which	  catalyse	  nucleotide	  
excision	  repair,	  removing	  damaged	  nucleotides	  from	  DNA.	  This	  is	  followed	  by	  expression	  
of	   recA	   and	   homologous	   recombination	   functions,	   which	   result	   in	   repair	   of	   lesions	   at	  
replication	  forks.	  Cell	  division	   is	  also	  halted	  by	  the	  production	  of	  the	   inhibitor	  SfiA.	  Late	  
expression	  of	  umuC	  and	  umuD,	  approximately	  40	  minutes	  after	  DNA	  damage,	  produces	  
the	  mutagenic	  DNA	   repair	   polymerase	   Pol	   V.	   This	   is	   an	   error-­‐prone	  polymerase	   strictly	  
regulated	   by	   the	   cell	   and	   only	   generated	  when	   the	   SOS	   response	   is	   active.	   As	   the	   SOS	  
response	  risks	  the	  introduction	  of	  lethal	  mutations	  into	  the	  genome,	  strong	  regulation	  is	  
required	  to	  ensure	  that	  these	  genes	  are	  repressed	  when	  no	  longer	  required.	  Constitutive	  
expression	  of	  lexA,	  allowing	  LexA	  re-­‐accumulation	  as	  DNA	  is	  repaired,	  results	  in	  eventual	  
repression	  of	  the	  SOS	  response	  once	  more.	  
	  
The	   SOS	   response	   is	   not	   considered	   to	   be	   relative	   to	   the	   amount	   of	   DNA	   damage	  
accumulated.	  Rather,	  studies	  investigating	  the	  promoter	  activity	  of	  the	  SOS	  genes	  suggest	  
that	   the	   SOS	   response	   is	   induced	   to	   a	   level	   that	   repairs	   damage	   but	   allows	   the	   cell	   to	  
survive,	   irrespective	  of	  the	  extent	  of	  DNA	  damage.	   If	   this	   is	   insufficient	  to	  complete	  the	  
repair,	   further	   rounds	   of	   SOS	   induction	   are	   initiated.	   This	   demonstrates	   that	   the	   SOS	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response	  is	  highly	  structured,	  with	  precise	  temporal	  modulation	  of	  gene	  expression	  levels	  
(Friedman	  et	  al.,	  2005).	  
	  
1.3.6	  Regulation	  of	  Stx	  expression	  
	  
Expression	   of	   stx	   and	   the	   other	   Stx	   prophage	   genes	   are	   under	   the	   control	   of	   the	   λ	   cI	  
repressor,	   which	   prevents	   the	   phage	   from	   entering	   the	   lytic	   cycle	   when	   bacteria	   are	  
growing	  and	  persisting	  without	  exposure	   to	  external	   stress.	   The	   cI	   repressor,	   like	  other	  
phage	   repressors	   such	   as	   the	   c2	   repressor	   of	   P22	   and	   the	   cI	   repressor	   of	   ϕ80,	   is	   a	  
functional	  homologue	  of	  LexA	  and	  is	  able	  to	  undergo	  RecA	  nucleofilament-­‐mediated	  self-­‐
cleavage	   (Sauer	   et	   al.,	   1982).	   Therefore	   when	   the	   SOS	   response	   is	   activated,	   the	   cI	  
repressor	   is	   removed	  from	  the	  prophage	  promoter	   region,	  allowing	  expression	  of	   these	  
genes	  and	  a	  shift	  from	  lysogenic	  to	  lytic	  growth.	  The	  stx	  genes	  are	  located	  downstream	  of	  
PR,	  a	  promoter	  which	  is	  only	  active	  when	  the	  lytic	  cycle	  has	  been	  initiated.	  This	  results	  in	  
the	  expression	  of	  genes	  involved	  in	  late	  phage	  function	  (Roberts	  et	  al.,	  1998).	  
	  
Agents	  that	  interfere	  with	  the	  SOS	  response	  further	  control	  regulation	  of	  Stx	  expression.	  
These	  include	  the	  nitric	  oxide	  (NO)	  donor	  NOR4,	  which	  significantly	  decreases	  expression	  
of	   stx2	   and	   inhibits	   production	   of	   phage	   particles	   through	   its	   capacity	   to	   reduce	   the	  
expression	  of	  recA,	  thus	  preventing	  activation	  of	  the	  SOS	  response	  (Vareille	  et	  al.,	  2007).	  
In	  contrast,	  hydrogen	  peroxide,	  produced	  by	  human	  neutrophils,	  results	  in	  increased	  Stx	  
and	   phage	   production	   due	   to	   its	   upregulation	   of	   recA,	   suggesting	   that	   oxidative	   stress	  
may	   stimulate	   pathogenicity	   determinants	   of	   EHEC	   (Imlay	  &	   Linn,	   1987).	   Expression	   of	  
stx1	  is	  also	  repressed	  in	  a	  non-­‐SOS-­‐dependent	  manner	  by	  iron,	  as	  Stx1	  is	  controlled	  by	  the	  
iron-­‐sensitive	  repressor	  Fur	  (Calderwood	  &	  Mekalanos,	  1987).	  The	  promoter	  sequence	  to	  
which	   Fur	   binds	   is	   not	   found	   in	   the	   Stx2	   promoter	   region	   and	   thus	   its	   expression	   is	  
unaffected	  by	  the	  presence	  of	  iron.	  
	  
1.3.7	  The	  role	  of	  Stx	  in	  bacterial	  colonisation	  and	  the	  immune	  response	  
	  
Shiga	   toxin	  may	  also	  have	  a	   function	   in	   the	  Type	  3-­‐mediated	  attachment	  of	  bacteria	   to	  
human	  epithelial	  cells.	  In	  order	  to	  colonise	  the	  intestine,	  the	  T3SS	  facilitates	  attachment	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to	  enterocytes	  and	  the	  formation	  of	  an	  attaching/effacing	   lesion	  by	  translocation	  of	  the	  
protein	  Tir	  (translocated	  intimin	  receptor)	  into	  the	  host	  cell	  membrane,	  where	  it	  acts	  as	  a	  
receptor	   for	   the	   bacterial	   adhesin	   intimin.	   Intimin	   can	   also	   recognise	   nucleolin,	   a	  
eukaryotic	   protein	   which,	   despite	   being	   involved	   in	   the	   synthesis	   and	   maturation	   of	  
ribosomes,	  can	  also	  be	  found	  on	  the	  cell	  surface	  of	  many	  cell	  types	  (Ginisty	  et	  al.,	  1999).	  
In	  vitro	  infection	  studies	  of	  nucleolin-­‐expressing	  human	  epithelial	  cells	  with	  O157:H7	  have	  
shown	   that	  microcolonies	  of	   the	  organisms	  associate	  with	   regions	  of	   surface-­‐expressed	  
nucleolin,	   and	   that	   treatment	   with	   anti-­‐nucleolin	   serum	   reduces	   bacterial	   adherence	  
(Sinclair	   &	   O’Brien,	   2002).	   Further	   work	   by	   Robinson	   et	   al.	   (2006)	   observed	   increased	  
surface	   expression	   of	   nucleolin	   by	   epithelial	   cells	   following	   exposure	   to	   enzymatically	  
active	  purified	  Stx2.	   Stx2	  also	   significantly	  enhanced	   the	  adherence	  of	  O157:H7	   to	  host	  
cells,	  with	  the	  Stx2-­‐expressing	  wild	  type	  strain	  binding	  more	  effectively	  to	  epithelial	  cells	  
in	  tissue	  culture	  than	  the	  isogenic	  stx2	  deletion	  mutant,	  and	  showing	  higher	  colonisation	  
of	  BALB/c	  mice	  (Robinson	  et	  al.,	  2006).	  
	  
The	  link	  between	  the	  Type	  3	  Secretion	  System	  and	  Stx	  is	  likely	  to	  be	  a	  complex	  one.	  There	  
is	   evidence	   that	   the	   presence	   of	   Stx	   phages	   may	   cause	   repression	   of	   the	   T3SS	   at	   the	  
transcriptional	   level.	   In	   particular,	   O157:H7	   phage	   type	   p21/28,	   which	   is	   the	   most	  
prevalent	  strain	  linked	  with	  human	  EHEC	  infections	  in	  the	  UK,	  has	  high	  carriage	  rates	  of	  
both	  Stx2a	  and	  Stx2c	  (90%),	  and	  yet	  lower	  median	  levels	  of	  Type	  3	  secretion	  compared	  to	  
O157:H7	   strains	   in	   which	   carriage	   of	   these	   phages	   is	   lower	   (28%).	   Strains	   that	   were	  
genetically	  manipulated	  to	  delete	  Stx2	  phages	  increased	  Type	  3	  secretion,	  and	  addition	  of	  
the	  Stx2	  phage	  to	  strains	  that	  naturally	  lack	  this	  phage	  resulted	  in	  decreased	  secretion	  (Xu	  
et	  al.,	  2012).	  This	  was	  further	  confirmed	  by	  Xu	  et	  al.	  (2012)	  in	  an	  Stx-­‐negative	  K-­‐12	  E.	  coli	  
strain	   in	  which	   the	   presence	   of	   a	   genome-­‐integrated	   Stx2	   phage	  was	   demonstrated	   to	  
repress	   induction	   of	   Type	   3	   gene	   expression.	   A	   promoter	   fusion	   reporter	   whose	  
expression	   of	   fluorescence	   was	   controlled	   by	   Ler,	   the	   major	   regulator	   of	   Type	   3	  
expression,	  was	  transformed	  into	  the	  K12	  strains	  and	  used	  to	  measure	  Type	  3	  secretion.	  
Ler	  was	   expressed	   from	  an	   IPTG-­‐inducible	  plasmid,	   as	   K12	  does	  not	  naturally	   carry	   the	  
gene	  encoding	  this	  protein.	  The	  K12	  strain	  containing	  the	  Stx2	  phage	  showed	  lower	  levels	  
of	   fluorescence	   production,	   implying	   that	   the	   phage	   represses	   Ler-­‐mediated	   promoter	  
activation.	  This	  repression	  involved	  the	  cII	  phage	  regulator	  and	  reduced	  expression	  of	  the	  
cI	   repressor,	   which	   had	   no	   direct	   impact	   on	   Type	   3	   secretion	   in	   the	   absence	   of	   an	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integrated	  Stx	  prophage.	  A	  model	  based	  on	  these	  findings	  proposes	  that	  colonisation	  of	  
epithelial	   cells	   via	   regulation	   of	   the	   T3SS	   is	   coordinated	   in	   part	   by	   Stx2-­‐encoding	  
bacteriophages.	  This	  regulation	  could	  select	  for	  co-­‐acquisition	  of	  other	  genes	  that	  encode	  
Type	   3-­‐secreted	   proteins	   and	   regulators	   that	   can	   overcome	   this	   Stx	   phage-­‐mediated	  
control	  (Xu	  et	  al.,	  2012).	  
	  
There	   is	   strong	   evidence	   that	   the	   Stx	   proteins	   are	   involved	   in	   the	   activation	   of	  
inflammation	   in	   the	   host.	   This	   response,	   which	   is	   fundamental	   to	   the	   elimination	   of	  
invading	  pathogens,	   involves	   the	   synthesis	  and	   release	  of	   cytokines	  and	  chemokines	  by	  
immune	  cells.	  Studies	  have	  reported	  that	  interleukin	  8	  (IL-­‐8),	  a	  chemokine	  and	  important	  
mediator	  of	  the	  innate	  immune	  system	  response,	  is	  upregulated	  by	  the	  presence	  of	  Stx.	  
Stx	  has	  been	  proposed	  to	  work	  synergistically	  with	  flagellin,	   the	  principal	  component	  of	  
the	   bacterial	   flagella,	   to	   produce	   superinduction	   of	   IL-­‐8	   that	   leads	   to	   absorption	   of	   Stx	  
into	  systemic	  circulation	  (Jandhyala	  et	  al.,	  2010).	  Other	  components	  of	  the	  inflammatory	  
response,	   including	   interleukin	  6	   (IL-­‐6),	  macrophage	  chemoattractant	  protein	  1	   (MCP-­‐1)	  
and	  macrophage	  inflammatory	  protein	  1α/ß,	  have	  been	  implicated	  in	  the	  response	  to	  Stx	  
(reviewed	  by	  Lee	  et	  al.,	  2013).	  The	  elicitation	  of	  these	  responses	  is	  achieved	  through	  the	  
activation	  of	  multiple	  cell	  signalling	  pathways,	  including	  those	  initiated	  through	  ribosomal	  
stress.	   This	   occurs	   during	   Stx-­‐mediated	   depurination	   of	   the	   ribosome,	   resulting	   in	  
activation	  of	  multiple	  mitogen-­‐activated	  protein	  kinase	  signalling	  pathways	  (Smith	  et	  al.,	  
2003).	   Stx	   can	   also	   stimulate	   circulating	   proinflammatory	   cytokines	   such	   as	   tumour	  
necrosis	   factor-­‐α	   (TNF-­‐α)	   and	   interleukin	   1ß	   (IL-­‐1ß)	   by	   directly	   acting	   on	   monocytes,	  
which	  results	  in	  the	  further	  production	  of	  the	  Gb3	  receptor,	  further	  sensitising	  epithelial	  
cells	  to	  the	  effects	  of	  Stx	  (van	  de	  Kar	  et	  al.,	  1992).	  However,	  there	   is	  also	  evidence	  that	  
EHEC	   produce	   an	   anti-­‐inflammatory	   molecule	   that	   attenuates	   the	   inflammatory	  
responses	  to	   its	  own	  Stx,	  possibly	  to	   limit	  the	  host	   immune	  response	  when	  bacteria	  are	  
present.	   In	   contrast,	   Stx	   that	   have	   been	   translocated	   across	   the	   epithelium	   and	   away	  
from	  EHEC	  can	  produce	  unimpaired	   toxin-­‐mediated	   inflammatory	   responses	   (Bellmeyer	  
et	  al.,	  2009).	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1.3.8	  The	  significance	  of	  Stx	  outside	  of	  the	  human	  host	  
	  
Humans	   are	   considered	   an	   incidental	   host	   for	   O157:H7	   as,	   while	   human-­‐to-­‐human	  
transmission	   is	   possible,	   spread	   is	   frequently	   limited	   to	   outbreak	   situations	   and	   thus	  
humans	  are	  considered	  insufficient	  hosts	  for	  sustainability.	  In	  contrast,	  ruminant	  animals	  
are	   the	   primary	   host	   of	   O157:H7	   and	   other	   EHEC	   members.	   Despite	   long-­‐term	  
persistence,	   infection	   is	   asymptomatic	   in	   ruminants,	   which	   is	   associated	  with	   a	   lack	   of	  
host	  Gb3	  receptors	  at	  sites	  of	  bacterial	  colonisation.	  This	  raises	  a	  question	  regarding	  the	  
function	  of	  Stx	  in	  O157:H7	  given	  that	  humans	  are	  not	  considered	  the	  intended	  biological	  
target,	   especially	   as	   Stx	   phages	   are	   found	   in	   the	   genomes	   of	   EHEC	   at	   high	   frequency.	  
These	  phages	  are	   lysogenic	  and	  their	  reproduction	  results	   in	  killing	  of	  the	  bacterial	  host	  
so,	  while	  expression	  of	  their	  genes	  is	  usually	  inhibited,	  their	  presence	  in	  bacteria	  carries	  
the	  risk	  of	  bacteriophage	  production	  and	  subsequent	  cell	  lysis.	  Therefore,	  there	  must	  be	  
an	  evolutionary	  advantage	  for	  bacterial	  carriage	  of	  Stx	  phage	  in	  many	  EHEC	  strains.	  
	  
One	   hypothesis	   is	   that	   the	   purpose	   of	   Stx	   is	   to	   defend	   bacterial	   populations	   from	  
unicellular	  eukaryotic	  predators.	  This	   is	  supported	  by	  coinfection	  studies	  that	  mixed	  the	  
grazing	  protazoa	  Tetrahymena	  pyriformis	  with	  O157:H7	  strains	  positive	  and	  negative	  for	  
Stx	  phages.	  The	  presence	  of	  Stx-­‐encoding	  prophages	  was	   found	  to	  be	  advantageous	   for	  
the	  bacteria,	  as	   it	   increased	  the	  survival	   rate	  of	  O157:H7	  following	   ingestion	   into	  the	  T.	  
pyriformis	   food	   vacuole	   (Steinberg	  &	   Levin,	   2007).	   Stx	   has	   also	   been	   shown	   to	   provide	  
protection	   against	   killing	   by	   another	   protozoan	  bacterivore,	  Tetrahymena	   thermophilia.	  
Studies	  by	  Lainhart	  et	  al.	  (2009)	  found	  that	  T.	  thermophilia	  was	  killed	  in	  the	  presence	  of	  
both	   Stx-­‐producing	   bacteria	   and	   purified	   Stx,	   while	   Stx-­‐producing	   bacterial	   strains	   also	  
displayed	  a	   growth	  advantage	  over	   Stx-­‐negative	   strains.	   This	   production	   and	   release	  of	  
Stx	   in	   response	   to	   T.	   thermophilia	   is	   thought	   to	   be	   triggered	   by	   bacterial	   detection	   of	  
reactive	   oxygen	   species	   released	   by	   the	   predator.	   This	   activates	   the	   SOS	   response,	  
resulting	   in	   production	   of	   Stx	   which	   is	   released	   into	   the	   surrounding	   environment	  
following	  bacterial	  lysis	  (Lainhart	  et	  al.,	  2009).	  
	  
Stx	   has	   also	   shown	   antiviral	   activity,	   with	   the	   A	   subunit	   of	   Stx1	   found	   to	   reduce	   the	  
production	   of	   bovine	   leukemia	   virus	   (BLV)	   particles	   in	   vitro	   (Ferens	   et	   al.,	   2004).	  
Furthermore,	   rates	   of	   BLV	   viraemia,	   as	   assessed	   by	   spontaneous	   lymphocyte	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proliferation,	  was	  significantly	  lower	  in	  sheep	  given	  wild	  type	  O157:H7	  than	  those	  treated	  
with	  an	  Stx-­‐negative	  mutant	  (Ferens	  et	  al.,	  2006).	  This	  has	  been	  further	  corroborated	  by	  a	  
year-­‐long	   study	   assessing	   animal	   health	   and	   the	   prevalence	   of	   Stx-­‐producing	   E.	   coli	   in	  
BLV-­‐infected	   sheep,	   which	   showed	   a	   convincing	   correlation	   between	   animals	   in	   good	  
health	   and	   high	   levels	   of	   Stx-­‐producing	   E.	   coli.	   In	   contrast,	   poor	   health	   and	   tumour	  
development	  only	  occurred	  in	  animals	  with	  low	  levels	  of	  Stx-­‐producing	  E.	  coli	  (Ferens	  et	  
al.,	  2008).	  
	  
These	   findings	   may	   explain	   the	   tolerance	   of	   EHEC	   for	   the	   carriage	   of	   a	   toxin	   whose	  
production	   is	   strongly	   associated	   with	   cell	   death,	   especially	   if	   this	   strategy	   enables	  
survival	   of	   a	   bacterial	   population	   rather	   than	   that	   of	   individual	   organisms.	   If	   lysis	   of	   a	  
small	   percentage	   of	   the	   bacterial	   population	   results	   in	   the	   release	   of	   sufficient	   Stx	   to	  
ensure	  the	  survival	  of	  daughter	  cells,	  this	  may	  be	  a	  cost-­‐effective	  defense	  strategy	  for	  the	  
population.	  One	  argument	  against	  this	  altruism	  hypothesis	  (reviewed	  in	  further	  detail	  by	  
Loś	  et	  al.,	  2012)	  is	  that	  a	  spontaneous	  induction	  rate	  (phages	  produced	  in	  the	  absence	  of	  
any	  inducing	  agents)	  of	  0.005%	  cells	  per	  generation	  for	  Stx	  prophages,	  while	  considered	  
low,	   is	   significantly	  more	   frequent	   than	   any	   other	   lambdoid	   phage	   (Livny	   &	   Friedman,	  
2004;	   Shimizu	   et	   al.,	   2009).	   Similarly,	   the	   observation	   that	   Stx	   production	   and	  
accompanying	   bacterial	   lysis	   occurs	   in	   many	   other	   situations	   where	   the	   toxin	   has	   no	  
discernible	  purpose,	  such	  as	  induction	  by	  high	  hydrostatic	  pressure	  and	  UV	  light,	  rejects	  
this	  theory.	  However,	  current	  research	  supports	  the	  suggested	  model	  of	  altruism	  (Loś	  et	  
al.,	  2012)	  and	  overall,	  there	  is	  a	  substantial	  amount	  of	  evidence	  that	  the	  Stx	  toxin	  has	  a	  
far	  broader	  function	  than	  merely	  causing	  human	  disease.	  
	  
1.4	  The	  Type	  3	  Secretion	  System	  and	  the	  attaching/effacing	  lesion	  
	  
E.	  coli	  contains	  several	  virulence	  factors	  that	  facilitate	  the	  attachment	  of	  bacteria	  to	  host	  
cells.	  The	  most	  important	  one	  of	  these,	  the	  function	  of	  which	  is	  central	  to	  pathogenesis	  of	  
EHEC	   and	   EPEC,	   is	   the	   Type	   3	   Secretion	   System,	   encoded	   by	   the	   locus	   of	   enterocyte	  
effacement	   (LEE)	   pathogenicity	   island.	   In	   EHEC,	   the	   LEE	   consists	   of	   five	  major	   operons	  
containing	  a	  total	  of	  41	  genes	  encoding	  structural	  proteins,	  regulators,	  effector	  proteins,	  
and	  chaperone	  proteins.	  The	  major	  regulator	  of	  the	  LEE	  is	  Ler,	  a	  transcriptional	  activator	  
1.	  INTRODUCTION	  
	   25	  
essential	  for	  the	  expression	  of	  LEE-­‐encoded	  genes	  and	  therefore	  attaching/effacing	  (A/E)	  
lesion	  formation	  (Elliott	  et	  al.,	  2000).	  
	  
The	  T3SS	  is	  a	  multi-­‐protein	  complex	  that	  spans	  the	  inner	  and	  outer	  bacterial	  membrane	  
of	   Gram-­‐negative	   organisms,	   with	   a	   thin	   needle-­‐like	   structure	   protruding	   outside	   the	  
bacterium	  where	   it	   can	   interact	   with	   the	   eukaryotic	   cell	  membrane.	   Bacterial	   proteins	  
known	  as	  effectors	  are	  secreted	  directly	  by	  the	  T3SS	  into	  the	  cytoplasm	  of	  eukaryotic	  cells	  
where	  they	  can	  hijack	  host	  signalling	  pathways,	  and	  aid	  bacterial	  survival	  by	  mechanisms	  
such	  as	  promotion	  of	  attachment	  and	  invasion,	   immune	  system	  subversion,	  and	  cellular	  
trafficking	  interference.	  	  
	  
1.4.1	  Structure	  of	  the	  T3SS	  
	  
The	  T3SS	  is	  composed	  of	  three	  main	  structures:	  the	  needle	  complex,	  the	  translocon,	  and	  
the	  basal	  body	   (Figure	  1-­‐7).	  The	  needle	  complex	   is	  a	  cylindrical	   structure,	  similar	   to	   the	  
flagellar	  basal	  body,	  and	  is	  composed	  of	  the	  protein	  EscF	  which	  forms	  a	  helical	  structure.	  
The	  needle	  complex	  extends	  to	  approximately	  80	  nm,	  although	  this	  can	  vary	  substantially	  
between	  bacterial	  species.	  At	  the	  tip	  of	  the	  needle	  complex,	  the	  hydrophobic	  membrane-­‐
spanning	   proteins	   EspB	   and	   EspD	   form	   the	   translocon,	   a	   proteinaceous	   pore	   that	   is	  
inserted	  directly	   into	  the	  host	  cellular	  membrane.	  Unique	  to	  the	  EHEC	  and	  EPEC	  T3SS	   is	  
the	  tip	  protein	  EspA,	  which	  forms	  a	  highly	  extended	  filament	  at	  the	  end	  of	  the	  needle,	  an	  
adaption	  thought	  to	  be	  important	  for	  attachment	  to	  intestinal	  cells	  (Yip	  et	  al.,	  2005).	  The	  
basal	   body	   of	   the	   T3SS	   is	  made	   up	   of	   a	   number	   of	   different	   structural	   proteins,	  which	  
form	  ring	  structures	  in	  both	  bacterial	  membranes.	  The	  inner	  membrane	  ring	  of	  the	  basal	  
body	   is	  composed	  of	   the	  proteins	  EscD,	  EscQ,	  EscR,	  EscS,	  EscT,	  EscU	  and	  EscV,	  with	  the	  
ATPase	   EscN	   facilitating	   transport	   of	   proteins	   through	   the	   complex,	   while	   the	   outer	  
membrane	  ring	   is	  made	  up	  of	  EscC	  subunits.	   In	  the	  periplasmic	  space	  of	  the	  membrane	  
and	  connecting	  these	  two	  rings	  is	  EscJ,	  a	  protein	  that	  shares	  sequence	  similarity	  with	  the	  
central	   pore-­‐forming	   flagellar	   protein	   FliF	   and	   is	   one	   of	   the	   first	   structural	   proteins	  
involved	  in	  assembly	  of	  the	  T3SS,	  acting	  as	  a	  platform	  for	  the	  rest	  of	  the	  basal	  apparatus	  
(Yip	  &	  Strynadka,	  2006).	  A	  large	  number	  of	  chaperone	  proteins	  are	  also	  involved	  in	  T3SS	  
assembly,	  and	  have	  roles	  such	  as	  preventing	  premature	  oligomerisation	  or	  degradation	  of	  
the	  structural	  proteins.	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Figure	  1-­‐7:	  Structure	  of	  the	  T3SS	  apparatus.	  The	  basal	  body	  of	  the	  T3SS	  spans	  the	  bacterial	  inner	  and	  outer	  
membrane	  and	  forms	  a	  base	  for	  the	  needle	  filament	  that	  comes	  into	  contact	  with	  and	  inserts	  into	  the	  host	  
cell	  membrane.	  
	  
1.4.2	  Protein	  translocation	  by	  the	  T3SS	  
	  
Activation	   of	   Type	   3	   secretion	   is	   strictly	   regulated	   by	   several	   influences	   including	  
environmental	  factors,	  global	  regulators,	  and	  LEE-­‐encoded	  regulators.	  The	  inner	  diameter	  
of	   the	   EspA	   filament	   has	   been	  measured	   at	   2.5	   nm	   (Daniell	   et	   al.,	   2003),	   too	   small	   to	  
allow	  passage	  of	  structurally	  folded	  proteins.	  The	  effector	  proteins	  often	  have	  dedicated	  
associated	   chaperone	   proteins,	   which	   are	   not	   exported	   with	   the	   effector.	   It	   has	   been	  
implied	   that	   these	   proteins	   help	   target	   the	   export	   of	   effectors,	   provide	   storage	   of	  
proteins	   in	   an	   appropriate	   state	   prior	   to	   export,	   and	   help	   mask	   cellular	   localisation	  
domains	   (reviewed	   by	   Cornelis,	   2006).	   In	   Salmonella	   Typhimurium,	   the	   ATPase	   EscN	  
homologue	   InvC	   is	   involved	   in	   the	   unfolding	   of	   effector	   proteins	   prior	   to	   export	   by	  
removal	  of	  the	  effector’s	  chaperone	  (Akeda	  &	  Galán,	  2005).	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1.4.3	  T3SS-­‐mediated	  formation	  of	  the	  attaching/effacing	  lesion	  
	  
All	   genes	   required	   for	   formation	   of	   attaching/effacing	   lesions,	   including	   seven	   effector	  
proteins,	  are	  encoded	  by	  the	  LEE.	  The	  first	  protein	  involved	  in	  T3SS-­‐mediated	  attachment	  
is	  Tir	  which,	  when	  injected	  into	  the	  host	  cytoplasm,	  is	  directed	  toward	  and	  inserted	  into	  
the	  membrane	  so	  that	  its	  central	  domain	  is	  surface-­‐exposed.	  This	  domain	  then	  interacts	  
with	   the	  bacterial	   surface	  protein	   intimin,	   forming	  a	   tight	  attachment	  between	  the	   two	  
cells	  (Kenny	  et	  al.,	  1997).	  The	  intracellular	  domain	  of	  Tir	  contains	  several	  phosphorylation	  
domains	  that,	  cooperatively	  with	  the	  secreted	  non-­‐LEE-­‐encoded	  effector	  EspFU,	   interact	  
with	  host	  proteins	  in	  the	  cytosol	  such	  as	  neuronal	  Wiskott-­‐Aldrich	  Syndrome	  protein	  (N-­‐
WASP).	   N-­‐WASP	   recruits	   the	   actin-­‐related	   protein	   2/3	   (Arp2/3)	   complex,	   a	   major	  
regulator	   of	   the	   actin	   cytoskeleton,	   which	   nucleates	   actin	   filaments	   and	   results	   in	   the	  
accumulation	  of	  filamentous	  actin	  beneath	  the	  attached	  bacteria.	  This	  is	  accompanied	  by	  
localised	   destruction	   of	   the	   intestinal	   microvilli	   and	   the	   formation	   of	   an	   actin-­‐rich	  
pedestal-­‐like	  structure,	  the	  A/E	  lesion,	  which	  promotes	  bacterial	  colonisation	  (Figure	  1-­‐8).	  
Other	  LEE-­‐encoded	  effectors	  such	  as	  EspB	  and	  EspF	  are	  involved	  in	  the	  subversion	  of	  the	  
host	  cytoskeleton,	  or	  have	  roles	  such	  as	  disruption	  of	  mitochondrial	  function	  (Kodama	  et	  
al.,	  2002;	  Dean	  et	  al.,	  2010).	  
	  
	  
Figure	   1-­‐8:	   Basic	   representation	   of	   T3SS-­‐mediated	   formation	   of	   the	   attaching/effacing	   lesion.	   The	  
effectors	  Tir	  and	  EspFU	  are	  translocated	  across	  the	  bacterial	  and	  host	  cell	  membrane	  by	  the	  T3SS	  into	  the	  
cytosol	  of	  the	  host	  cell.	  Tir	  is	  inserted	  into	  the	  host	  cell	  membrane	  where	  it	  can	  bind	  to	  intimin	  on	  the	  outer	  
surface	   of	   the	   bacteria.	   EspFU	   targets	  N-­‐WASP,	   resulting	   in	   recruitment	   of	   Arp2/3	   and	   polymerisation	   of	  
actin	  beneath	  the	  bacterium.	  This	  creates	  a	  tight	  attachment	  of	  bacteria	  to	  host	  cells	  on	  a	  pedestal	  of	  actin	  
filaments.	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Many	  studies,	  both	  in	  vitro	  and	  in	  vivo,	  have	  implied	  that	  the	  capacity	  to	  form	  A/E	  lesions	  
is	  associated	  with	  virulence,	  with	  bacteria	   lacking	   the	  essential	  proteins	   such	  as	  Tir	  and	  
intimin	   showing	   a	   reduced	   capacity	   for	   epithelial	   cell	   attachment.	   In	   addition,	   EHEC	  
strains	  unable	  to	  produce	  crucial	  components	  of	  T3SS-­‐mediated	  attachment	  demonstrate	  
reduced	  faecal	  shedding	  and	  a	  significant	  decrease	  in	  colonisation	  in	  cattle	  (Dziva,	  2004;	  
Naylor,	  2005)	  providing	  further	  evidence	  that	  the	  T3SS	  is	  vital	  for	  successful	  persistence	  
within	  its	  natural	  host.	  
	  
1.5	  Animal	  models	  of	  O157:H7	  
	  
Evaluation	   of	   the	   effectiveness	   of	   anti-­‐virulence	   strategies	   requires	   the	   availability	   of	  
animal	  models	  that	  can	  recapitulate	  pathogenesis.	  Large	  animal	  models	  of	  EHEC	  infection	  
include	   gnotobiotic	   pigs,	   cows,	   sheep,	   goats,	   chickens,	   macaques	   and	   baboons,	   and	  
replicate	  many	  features	  of	  colonisation	  and	  disease	  (reviewed	  by	  Ritchie,	  2014).	  However,	  
smaller	  models	  such	  as	  mice,	  rats	  and	  rabbits	  are	  preferable	  due	  to	  their	  low	  costs,	  ease	  
of	   breeding,	   handling,	   maintenance,	   and	   availability	   of	   inbred	   and	   transgenic	   strains.	  
Although	   mice	   have	   been	   used	   as	   a	   small	   animal	   model	   for	   EHEC,	   E.	   coli	   does	   not	  
naturally	   colonise	   the	   mouse	   intestine.	   Consequently,	   different	   treatments,	   including	  
those	  that	  modify	  the	  local	  environment	  within	  the	  gut,	  have	  been	  tested	  in	  an	  attempt	  
to	   provide	   a	   model	   in	   which	   EHEC-­‐specific	   colonisation	   and	   disease	   symptoms	   can	   be	  
observed.	  
	  
1.5.1	  The	  infant	  rabbit	  O157:H7	  model	  
	  
The	   O157:H7	   infant	   (3-­‐day-­‐old)	   rabbit	   model,	   first	   developed	   in	   1986,	   produces	  
diarrhoea,	   histological	   changes	   in	   the	   colon,	   and	   bacterial	   attachment	   to	   epithelial	  
intestinal	   cells.	   No	   additional	   treatment	   of	   the	   animal	   is	   required	   as	   EHEC	   readily	  
colonises	   very	   young	   rabbits,	   and	   the	   production	   of	   Shiga	   toxin	   is	   important	   for	   the	  
clinical	   symptoms	   of	   disease	   (Pai	   et	   al.,	   1986).	   A	   study	   by	   Ritchie	   et	   al.	   (2003)	   using	  
deletion	   mutants	   of	   O157:H7	   has	   identified	   the	   roles	   of	   Stx2,	   intimin,	   and	   Tir	   in	   this	  
model.	  In	  particular,	  Stx	  increased	  both	  the	  severity	  and	  duration	  of	  diarrhoea,	  while	  Tir	  
and	   intimin	  were	   essential	   for	   colonisation	   and	   disease	   (Ritchie	   et	   al.,	   2003).	   Although	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some	  in	  vitro	  studies	  have	  implied	  a	  role	  for	  Stx	  in	  T3SS-­‐mediated	  attachment,	  Stx	  had	  no	  
effect	   on	   intestinal	   colonisation	   or	   inflammation	   and,	   contrary	   to	   other	   studies	   which	  
used	   this	   model,	   O157:H7	   did	   not	   cause	   death	   in	   any	   of	   the	   animals.	   Lack	   of	   HUS	  
symptoms	   in	   this	  model	  most	   likely	   reflects	   a	   lack	   of	   Gb3	   receptors	   on	   kidney	   cells	   of	  
rabbits	   (Zoja	   et	   al.,	   1992).	   However,	   the	   combination	   of	   bacterial	   adhesion	   and	   Stx-­‐
induced	  illness	  make	  this	  model	  particularly	  valuable	  for	  studying	  O157:H7	  pathogen-­‐host	  
interactions.	  
	  
1.5.2	  O157:H7	  mouse	  models	  
	  
The	  first	  mouse	  model	  for	  pathogenesis	  of	  O157:H7	  was	  developed	  by	  Wadolkowski	  et	  al.	  
in	  1990	  and	  was	  based	  on	  previous	  models	  for	  other	  E.	  coli	  strains	  (Myhal	  et	  al.,	  1982).	  
Within	  this	  model,	  mice	  were	  treated	  with	  streptomycin	   in	  their	  drinking	  water	  prior	  to	  
infection	  to	  reduce	  the	  normal	  gut	  flora	  and	  thus	  competition	  for	  O157:H7	  (Wadolkowski	  
et	   al.,	   1990).	   Streptomycin	   was	   determined	   to	   be	   a	   suitable	   antibiotic	   as	   it	   greatly	  
reduced	   the	   number	   of	   facultative	   anaerobic	   bacteria	   shed	   faecally	   by	   the	   mice,	   and	  
because	  its	  activity	  was	  directed	  toward	  protein	  synthesis	  and	  not	  cell	  wall	  biogenesis.	  In	  
this	   respect,	   any	   resistance	  would	   be	   less	   likely	   to	   interfere	  with	   cell	  wall	   components	  
involved	  in	  colonisation	  (Myhal	  et	  al.,	  1982).	  In	  the	  O157:H7	  model,	  5-­‐	  to	  8-­‐week-­‐old	  male	  
outbred	  ICR	  mice	  were	  provided	  with	  5	  g/L	  streptomycin	  in	  their	  drinking	  water	  for	  one	  
day,	  followed	  by	  removal	  of	  food	  and	  water	  for	  24	  hours	  before	  oral	  infection	  of	  1010	  CFU	  
O157:H7.	   Bacterial	   colonisation	   was	   monitored	   by	   faecal	   shedding,	   revealing	   that	   the	  
organism	  was	  shed	  at	   levels	  of	  approximately	  107	  CFU/g	  faeces	  for	  a	  period	  of	  25	  days.	  
Lack	   of	   symptoms	   highlighted	   that	   this	   was	   a	   strong	   model	   of	   colonisation	   but	   not	  
disease.	  After	  culling	  of	  the	  animals,	  O157:H7	  was	  recovered	  from	  epithelial	  cells	  of	  the	  
small	   intestine,	   caecum,	   and	   large	   intestine,	   indicating	   that	   these	   are	   the	   sites	   of	  
colonisation	  in	  this	  model	  (Wadolkowski	  et	  al.,	  1990).	  
	  
Other	   O157:H7	   mouse	   models,	   each	   with	   advantages	   and	   limitations,	   have	   been	  
developed	   in	   order	   to	   replicate	   aspects	   of	   infection	   (reviewed	   by	  Mohawk	   &	   O’Brien,	  
2011).	   Diet	   restriction,	   as	   used	   in	   the	   protein-­‐calorie	   malnutrition	   model,	   lowers	   the	  
infectious	   dose	   required	   for	   colonisation	   and	   disease.	   This	   is	   pertinent	   as	   humans	   are	  
sensitive	  to	  low	  doses	  of	  the	  organism	  (<100	  CFU),	  unlike	  the	  streptomycin-­‐treated	  model	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in	   which	   relatively	   high	   doses	   are	   required	   for	   effective	  mouse	   colonisation	   (~109-­‐1010	  
CFU).	  In	  this	  model,	  protein	  in	  the	  diet	  is	  restricted	  to	  5%	  (as	  opposed	  to	  the	  25%	  protein	  
control	   diet)	   for	   two	   weeks	   prior	   to	   infection.	   Subsequent	   intragastric	   inoculation	   of	  
2x106	   CFU	   O157:H7	   resulted	   in	   colonisation	   and,	   five	   days	   post	   infection,	   induction	   of	  
neurological	   symptoms,	   which	   are	   considered	   an	   important	   predictive	   factor	   for	   HUS	  
mortality	  in	  children.	  Ten	  days	  after	  infection,	  75%	  of	  the	  protein-­‐calorie	  restricted	  mice	  
had	  died	  from	  cerebral	  haemorrhage	  while	  the	  control	  mice	  remained	  healthy,	  although	  
no	  significant	  kidney	  pathology	  in	  infected	  mice	  was	  observed	  (Kurioka	  et	  al.,	  1998).	  	  
Gnotobiotic	  mice,	  which	  lack	  competitive	  intestinal	  flora,	  have	  also	  been	  used	  as	  models.	  
In	  these	  mice,	   infectious	  doses	  similar	   to	  those	  used	   in	  the	  streptomycin-­‐treated	  model	  
have	   been	   shown	   to	   cause	   disease	   and	   death	   within	   7	   days	   without	   the	   need	   for	  
streptomycin	   treatment.	   Studies	   by	   Isogai	  et	   al.	   (1998)	   showed	   that	   a	   lower	   infectious	  
dose	  (2x103	  CFU)	  in	  the	  gnotobiotic	  model	  could	  result	  in	  colonisation	  in	  the	  absence	  of	  
disease	  symptoms.	  However,	  when	  mice	  were	  pretreated	  with	  TNF-­‐α,	  a	  cytokine	  induced	  
by	  Stx	  with	  renal-­‐damaging	  properties	  (Harel	  et	  al.,	  1993),	  the	  animals	  developed	  severe	  
neurotoxic	   symptoms	   and	   kidney	   pathology.	   The	   mice	   showed	   evidence	   of	   a	   strong	  
contribution	  by	   cytokines	   to	   initiation	  of	   damage	   in	   the	  brain	   and	   kidney	   (Isogai	  et	   al.,	  
1998).	  	  
	  
Models	  of	  HUS	  using	  C57BL/6	  mice	  have	  also	  been	  developed.	  The	  coadministration	  of	  
LPS	  and	  Stx2	  has	  shown	  reproduction	  of	  major	  HUS	  symptoms	  such	  as	  thrombocytopenia,	  
haemolytic	   anemia,	   and	   renal	   failure	   (Keepers	   et	   al.,	   2006),	   while	   outer	   membrane	  
vesicles	   of	   O157:H7	   containing	   LPS	   and	   Stx2	   produced	   HUS-­‐like	   symptoms	   (Kim	   et	   al.,	  
2011).	   A	   mouse	   model	   that	   does	   not	   require	   the	   presence	   of	   LPS	   has	   also	   been	  
established,	   whereby	   multiple	   sublethal	   doses	   of	   endotoxin-­‐free	   Stx2	   injected	  
intraperitoneally	   over	   7-­‐8	   days	   produce	   symptoms	   similar	   to	   that	   of	   HUS	   in	   humans:	  
increased	   blood	   urea	   nitrogen	   and	   serum	   creatinine	   levels,	   proteinuria,	   glomular	  
endothelial	  damage,	  haemolysis,	  leukocytopenia,	  and	  neutrophilia	  (Sauter	  et	  al.,	  2008).	  
	  
1.5.3	  Citrobacter	  rodentium	  as	  an	  O157:H7	  surrogate	  model	  of	  infection	  
	  
As	   O157:H7	   and	   other	   EHEC	   are	   poorly	   pathogenic	   in	   mice,	   models	   often	   require	  
alteration	  of	  the	  ‘natural’	  niche,	  including	  disruption	  of	  the	  host	  microbiota.	  To	  avoid	  such	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complications,	   an	   alternative	   approach	   makes	   use	   of	   the	   natural	   murine	   pathogen	  
Citrobacter	   rodentium,	   which	   readily	   colonises	   the	   large	   intestine	   of	   the	   mouse.	   C.	  
rodentium	  is	  related	  to	  EHEC	  and	  EPEC	  (Figure	  1-­‐9)	  and,	  like	  these	  pathogens,	  produces	  a	  
T3SS	  that	  is	  required	  for	  the	  formation	  of	  A/E	  lesions.	  Oral	  challenge	  of	  mice	  with	  108-­‐109	  
CFU	  allows	  initial	  colonisation	  of	  the	  lymphoid	  tissue	  surface	  in	  the	  caecum	  (caecal	  patch)	  
followed	  by	   colonisation	   of	   the	   distal	   colon	   a	   few	  days	   later,	  with	   the	   bacteria	   cleared	  
from	  the	  host	  after	  3-­‐4	  weeks	  (Wiles	  et	  al.,	  2004).	  Infection	  of	  mice	  with	  C.	  rodentium	  can	  
result	   in	  colonic	  hyperplasia,	  a	  thickening	  of	  the	  colonic	  tissue,	  although	   in	  most	  mouse	  
strains	  this	  does	  not	  result	  in	  mortality.	  
	  
	  
Figure	   1-­‐9:	   Phylogenetic	   tree	   showing	   the	   relationship	   of	   C.	   rodentium	   to	   E.	   coli	   and	   other	   enteric	  
bacteria.	   Phylogenetic	   relationships	   were	   determined	   from	   the	   nucleotide	   sequences	   of	   seven	  
housekeeping	  genes	  (Petty	  et	  al.,	  2010).	  
	  
The	  C.	  rodentium	  LEE	  is	  closely	  related	  to	  the	  LEE	  of	  EHEC	  and	  EPEC	  (Deng	  et	  al.,	  2001).	  
Genome	  sequencing	  has	  revealed	  that	  C.	  rodentium	  contains	  a	  LEE	  pathogenicity	   island,	  
along	  with	  genes	  encoding	  29	  T3SS	  effectors,	  22	  of	  which	  encode	  all	  the	  core	  effectors	  of	  
the	  EPEC	  E2348/69	  strain.	  EHEC	  and	  C.	  rodentium	  also	  share	  many	  other	  virulence	  factor	  
genes,	   such	   as	   those	   for	   fimbriae	   and	   adhesins,	  many	   of	   which	   are	   located	   on	  mobile	  
genetic	  elements	  (Petty	  et	  al.,	  2010).	  The	  C.	  rodentium	  T3SS	  and	  the	  effectors	  involved	  in	  
A/E	  lesion	  formation	  are	  required	  for	  colonisation,	  with	  strains	  in	  which	  genes	  encoding	  
intimin	  or	   EspB	  have	  been	  mutated	   showing	  no	   virulence	   in	  mice	   as	   a	   consequence	  of	  
colonisation	   failure	   (Schauer	   &	   Falkow,	   1993;	   Newman	   et	   al.,	   1999).	  While	   this	  makes	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Citrobacter	   rodentium	   an	   excellent	   model	   for	   studying	   colonisation	   and	   A/E	   lesions	   in	  
vivo,	  it	  lacks	  many	  other	  O157:H7	  genes,	  including	  those	  encoding	  Stx,	  and	  therefore	  does	  
not	  produce	  symptoms	  associated	  with	  EHEC	  disease.	  
	  
A	   novel	   C.	   rodentium	   strain	   has	   recently	   been	   developed	   to	   address	   the	   issue	   of	   Stx	  
production.	  Mallick	  et	  al.	   (2012)	  constructed	  a	  C.	  rodentium	  strain	  capable	  of	  producing	  
Stx	   by	   inserting	   the	   Stx2dact	   phage	   genome	   into	   the	   C.	   rodentium	   chromosome.	   The	  
resultant	  strain	  λstx2dact	  expresses	  the	  Stx2dact	  toxin	  and	  lyses	  bacteria	  at	  levels	  similar	  to	  
that	  of	  O157:H7.	  When	  this	  strain	  was	  tested	  in	   inbred	  C57BL/6	  mice	  it	  produced	  lethal	  
infection,	  with	  all	  mice	  succumbing	  to	  death	  after	  4-­‐9	  days.	  Citrobacter	  (λstx2dact)-­‐infected	  
animals	  displayed	  significant	  weight	  loss	  (10-­‐20%	  of	  starting	  weight)	  and	  increasing	  faecal	  
water	  content.	  While	  the	  overall	  level	  of	  colonisation	  was	  similar	  to	  that	  of	  the	  wild	  type,	  
the	   Stx	   strain	   produced	   some	   pathological	   changes	   associated	   with	   human	   EHEC	  
infection.	  These	  included	  increased	  levels	  of	  renal	  cytokines	  and	  Stx-­‐mediated	  damage	  as	  
determined	   by	   histopathogical	   evaluation	   of	   tissue.	  While	   the	   kidneys	   did	   not	   show	   a	  
strong	   inflammatory	   response,	   there	   was	   evidence	   of	   proximal	   tubule	   injury	   such	   as	  
flattened	  epithelium,	  loss	  of	  luminal	  brush	  border,	  and	  sloughing	  of	  dead	  cells	  (Mallick	  et	  
al.,	  2012).	  Although	  this	  model	  may	  not	  display	  all	  features	  associated	  with	  EHEC	  disease	  
and	  HUS,	   the	  production	  of	  both	  A/E	   lesion	   formation	  and	  Stx-­‐mediated	   tissue	  damage	  
greatly	  increases	  the	  functionality	  of	  C.	  rodentium	  as	  an	  EHEC	  alternative.	  
	  
1.6	  Development	  of	  a	  human	  vaccine	  to	  prevent	  O157:H7	  infections	  
	  
The	  mortality	  rate	  of	  EHEC	  infections,	  the	  risk	  of	  severe	  and	  long-­‐term	  HUS	  sequelae,	  the	  
limited	   treatment	  options	   available,	   and	   the	  high	   cost	   of	   EHEC	  outbreaks	   –	   not	  merely	  
that	  of	   health	   care	  but	   also	   the	   substantial	   financial	   impact	  on	   the	   agriculture	   industry	  
during	  and	  after	  human	  outbreaks	  –	   implies	  a	  need	  for	  effective	  vaccines	  against	  EHEC.	  
However,	   given	   the	   relatively	   low	   incidence	   of	   EHEC	   infection	   compared	   to	   other	  
infectious	  bacterial	  species,	  the	  high	  cost	  of	  general	  immunisation	  may	  be	  discouraging	  to	  
health	   care	   providers.	   Selective	   immunisation	   of	   individuals	   or	   groups	   at	   high	   risk	   of	  
infection	  is	  also	  hindered	  by	  the	  sporadic,	  unpredictable	  nature	  of	  human	  EHEC	  outbreaks	  
and	   the	   fact	   that	   the	   vast	   majority	   of	   infections	   arise	   from	   unknowingly	   ingesting	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contamined	   food	   rather	   than	   	   by	   human-­‐human	   or	   animal-­‐human	   contact.	   A	   broad-­‐
spectrum	  vaccine	  against	  multiple	  pathotypes	  of	  E.	  coli	  may	  therefore	  be	  a	  more	  viable	  
and	  cost-­‐effective	  approach	  to	  preventing	  EHEC	  outbreaks.	  
	  
1.6.1	  The	  case	  for	  a	  broad-­‐spectrum	  E.	  coli	  vaccine	  
	  
Antibiotic	  resistance	  is	  a	  growing	  problem	  for	  treatment	  of	  bacterial	  pathogens,	  including	  
that	  of	  E.	  coli.	  Diarrhoeal	  infections	  caused	  by	  E.	  coli	  are	  often	  self-­‐limiting	  and	  managed	  
by	  rehydration	  therapies,	  but	  persistent	  infections	  by	  some	  pathotypes	  are	  often	  treated	  
by	  antimicrobials.	  Resistance	  of	  E.	  coli	  has	  been	  observed	  for	  penicillins,	  cephalosporins,	  
aminoglycosides	  and	  fluoroquinalones,	  while	  emerging	  multi-­‐drug	  resistance	  phenotypes,	  
involving	   coresistance	   to	   four	   or	   more	   unrelated	   families	   of	   antibiotics	   has	   also	   been	  
reported	  (reviewed	  by	  Croxen	  et	  al.,	  2013).	  Recently,	  a	  UPEC	  isolate	  from	  a	  patient	  in	  the	  
USA	   was	   found	   to	   carry	   a	   plasmid	   conferring	   resistance	   against	   colistin,	   a	   last-­‐resort	  
antibiotic.	   This	   particular	   phenotype	   had	   previously	   only	   been	   reported	   in	   China	   and	  
Europe,	  and	  while	  the	  strain	  was	  still	  susceptible	  to	  other	  antibiotics	  there	  is	  the	  concern	  
that	   this	  plasmid	  and	   the	   resistance	   it	  provides	  could	  be	   transferred	   to	  other	   strains	  of	  
multi-­‐drug	  resistant	  bacteria	  (McGann	  et	  al.,	  2016).	  
	  
Prophylactics	   for	  management	  of	  pathogenic	  E.	  coli	  are	  therefore	  of	  significant	   interest,	  
and	  vaccines	  against	  all	  pathotypes	  are	  currently	  being	  developed	  and	  evaluated.	  While	  
an	   EHEC-­‐specific	   vaccine	   may	   not	   provide	   enough	   economic	   incentive	   in	   order	   to	   be	  
widely	  adopted,	  a	  vaccine	  that	  protects	  against	  major	  EHEC	  strains	  as	  well	  as	  other	  E.	  coli	  
pathotypes	  with	   high	   clinical	   importance	  would	   be	   greatly	   desirable	   and	   have	   a	  major	  
impact	  on	  global	  human	  health.	  This	  approach	  has	  recently	  been	  explored	  in	  a	  study	  that	  
tested	  in	  vivo	  a	  vaccine	  consisting	  of	  a	  killed	  whole-­‐cell	  mixture	  of	  EAEC,	  EPEC,	  EIEC,	  EHEC	  
and	   ETEC	  pathotypes.	  When	  mice	  were	   subcutaneously	   immunised	  with	   this	   combined	  
vaccine	  candidate,	  a	  significant	  increase	  in	  survival	  compared	  to	  non-­‐immunised	  controls	  
after	  challenge	  with	  a	   living	  combination	  of	  the	  five	  E.	  coli	  pathotypes	  was	  observed,	  as	  
was	  a	  significant	  increase	  in	  immunological	  responses	  (Gohar	  et	  al.,	  2016).	  The	  authors	  of	  
this	   study	  suggest	   that	   this	  combined	  vaccine	   is	  a	  cost-­‐effective	  approach	  with	  promise	  
for	   further	   testing	   in	   humans.	   Another	   possible	   tactic	  may	   be	   development	   of	   a	  multi-­‐
subunit	  vaccine,	  which	  presents	  several	  bacterial	  antigens	  to	  the	  immune	  system.	  If	  these	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selected	   antigens	   are	   highly	   conserved	   across	   E.	   coli	   strains	   and	   pathotypes,	   this	   may	  
provide	  the	  vaccine	  with	  broader	  coverage	  across	  different	  pathotypes.	  
	  
1.6.2	  EHEC	  vaccine	  development:	  Stx	  vaccines	  
	  
Several	  approaches	  towards	  the	  development	  of	  a	  protective	  vaccine	  against	  EHEC	  have	  
been	  undertaken.	  As	  Stx1	  and	  Stx2	  play	  a	  crucial	  role	  human	  disease	  and	  risk	  of	  HUS,	  the	  
ability	   to	   induce	   neutralizing	   antibodies	   to	   Stx	   is	   attractive.	   Additionally,	   targeting	   this	  
antigen	   offers	   the	   potential	   to	   provide	   an	   effective	   vaccine	   against	   other	   non-­‐O157:H7	  
EHEC	  strains,	  an	  important	  consideration	  given	  that	  other	  EHEC	  strains	  are	  responsible	  for	  
a	  large	  number	  of	  outbreaks	  and	  cases	  of	  HUS.	  
	  
Vaccination	  with	  inactive	  Stx	  derivatives	  effectively	  induces	  the	  production	  of	  neutralising	  
antibodies	   and	   protects	   against	   toxaemia	   in	   mouse	   models	   (Ishikawa	   et	   al.,	   2003;	  
Marcato	  et	  al.,	  2005).	  A	  live	  attenuated	  O157:H7	  vaccine	  constructed	  by	  Liu	  et	  al.	  (2009)	  
has	   also	   shown	   promise	   in	   mouse	   models.	   This	   attenuated	   vaccine	   consisted	   of	   an	  
O157:H7	   ler	   stx	   deletion	  mutant	   transformed	   with	   a	   plasmid	   containing	   stx1	   and	   stx2	  
(under	   the	   control	   of	   their	   own	   promoters)	   with	   mutations	   in	   the	   active	   center	   and	  
membrane-­‐spanning	   region	   of	   the	   toxin	   A	   subunit.	   This	   strain	   significantly	   reduced	  
toxicity	  in	  comparison	  with	  wild	  type	  O157:H7	  with	  no	  clinical	  signs	  of	  disease	  displayed	  
by	   infected	  mice.	   Importantly,	  mice	   immunised	  with	   this	   vaccine	   strain	  were	  protected	  
against	  subsequent	  challenge	  with	  wild	  type	  O157:H7	  and,	  when	  pregnant	  females	  were	  
immunised,	   this	   protection	   was	   shown	   to	   be	   horizontally	   transmitted	   to	   suckling	  
newborns	  (Liu	  et	  al.,	  2009).	  	  
	  
A	  DNA	  vaccine	  based	  on	  a	  non-­‐toxic	  Stx2	  gene	  consisting	  of	  the	  last	  32	  amino	  acids	  of	  the	  
A2	  subunit	   sequence	  and	   the	  complete	  B	   subunit	  also	  generates	  a	   systemic	  Stx-­‐specific	  
antibody	   response	   that	   targets	   both	   subunits	   of	   native	   Stx2.	   Antibodies	   against	   Stx2	  
raised	   by	  mice	   immunised	  with	   this	   vaccine	   had	   toxin-­‐neutralising	   activity	   in	   vitro	   and	  
conferred	  partial	  protection	  against	  Stx2	  challenge	  in	  vivo	  (Bentancor	  et	  al.,	  2009).	  Other	  
Stx-­‐based	  vaccine	  approaches	  such	  as	  protein-­‐conjugated	  polysaccharides	  (Konadu	  et	  al.,	  
1999),	   purified	   B	   subunit	   (Zhu	  et	   al.,	   2008),	   and	   synthetic	   peptides	   derived	   from	   the	  B	  
subunit	   (Harari	  &	  Arnon,	   1990)	   have	   exhibited	   varying	   degrees	   of	   protection	   and	   toxin	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neutralisation.	  However,	  these	  candidate	  vaccines	  have	  not	  yet	  proceeded	  beyond	  animal	  
tests,	  partly	  due	  to	  the	  inherent	  difficulty	  of	  organising	  human	  trials,	  as	  EHEC	  outbreaks	  
are	  sporadic	  and	  unpredictable.	  
	  
1.6.3	  EHEC	  vaccine	  development:	  reverse	  vaccinology	  
	  
Other	   conventional	   approaches	   to	   E.	   coli	   vaccines	   have	   relied	   on	   surface-­‐expressed	  
proteins,	  such	  as	  the	  adhesin	  P	  fimbriae	  (Roberts	  et	  al.,	  2004)	  and	  type	  1	  pilus	  subunits	  
(Langermann	  et	  al.,	  1997).	  These	  conferred	  protection	  in	  cynomolgus	  monkey	  and	  mouse	  
models	   respectively,	   but	   failed	   to	   show	   sufficient	   efficacy	   in	   phase	   II	   clinical	   trials	  
(Brumbaugh	   &	   Mobley,	   2012).	   However,	   the	   availability	   of	   genomic	   sequences	   from	  
multiple	  isolates	  of	  particular	  pathogens	  is	  providing	  a	  rich	  resource	  for	  vaccine	  candidate	  
identification.	   Subtractive	   reverse	   vaccinology,	  which	   employs	   bioinformatic	   analysis	   of	  
genomes	  to	  identify	  potential	  antigens,	  was	  first	  used	  in	  the	  development	  of	  the	  recently	  
licensed	   vaccine	   against	   Neisseria	   meningitidis	   Serogroup	   B	   (Pizza	   et	   al.,	   2000).	   This	  
approach	  has	  subsequently	  been	  applied	  to	  other	  bacterial	  pathogens	  including	  S.	  aureus	  
and	   Streptococcus	   pneumoniae.	   Reverse	   vaccinology	   offers	   more	   rapid	   progress	   than	  
conventional	   vaccinology,	   and	   has	   the	   advantage	   of	   identifying	   virtually	   every	   single	  
antigen	   in	   a	   pathogen	   (with	   the	   exception	   of	   non-­‐protein	   antigens	   such	   as	  
polysaccharides	   and	   glycolipids),	   including	   those	   that	   are	   not	   intrinsically	   immunogenic	  
and	  those	  whose	  expression	  is	  transient	  or	  limited	  under	  conditions	  of	  in	  vitro	  cultivation	  
(Rappuoli,	  2000).	  	  
	  
Reverse	  vaccinology	  was	  recently	  employed	  to	  identify	  antigen	  candidates	  for	  inclusion	  in	  
a	   vaccine	   against	   extraintestinal	   pathogenic	   E.	   coli	   (ExPEC)	   (Moriel	   et	   al.,	   2012).	   This	  
approach	  aimed	  to	  determine	  potential	  targets	  by	  comparison	  of	  the	  sequenced	  genome	  
of	   the	   K1	   ExPEC	   strain	   IHE3034	   with	   other	   ExPEC	   and	   non-­‐pathogenic	   strains.	   The	   K1	  
strain	   contained	   19	   genomic	   islands	   that	   were	   not	   present	   in	   non-­‐pathogenic	   strains,	  
accounting	  for	  approximately	  20%	  of	  the	  total	  K1	  genome.	  These	  islands	  contained	  genes	  
for	   230	  unique	   surface-­‐associated	  or	   secreted	  proteins,	   220	  of	  which	  were	   successfully	  
purified	  using	  His-­‐tag	   technology.	   The	  protective	  efficacy	  of	   these	  proteins	   in	  mice	  was	  
determined	   by	   subcutaneous	   injection	   followed	   by	   infection	   with	   pathogenic	   E.	   coli	  
strains.	  Nine	  of	  these	  proteins	   induced	  a	  significant	   level	  of	  protection	  compared	  to	  the	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control	  group,	  with	  a	  protective	  efficacy	  ranging	  from	  13-­‐82%.	  These	  antigens	  were	  not	  
only	  present	   in	  ExPEC	  strains,	  but	  conserved	   in	  many	  other	  pathogenic	  E.	  coli,	   including	  
EHEC	  strains,	  raising	  the	  possibility	  of	  their	  use	  in	  a	  broadly	  cross-­‐reactive	  E.	  coli	  vaccine	  
(Moriel	  et	  al.,	  2010).	  
	  
1.6.4	  Animal	  vaccines	  against	  O157:H7	  
	  
Prophylactic	  treatments	  against	  O157:H7	  are	  not	  limited	  just	  to	  humans;	  animal	  vaccines	  
that	   target	  O157:H7	   in	   its	   reservoir	  host	  are	  also	  of	   interest,	  as	   reduction	  of	  carriage	   in	  
cattle	  may	  lower	  the	  risk	  of	  foodborne	  outbreaks.	  Two	  cattle	  subunit	  vaccines	  have	  been	  
approved	  for	  use	  in	  Canada	  and	  the	  US:	  Econiche,	  which	  raises	  antibodies	  against	  Type	  3-­‐
secreted	   proteins	   (Potter	   et	   al.,	   2004),	   and	   Epitopix	   SRP,	   which	   targets	   O157:H7	  
siderophore	  receptor	  and	  porins	  (Fox	  et	  al.,	  2009).	  Although	  their	  use	  has	  been	  predicted	  
to	  result	  in	  an	  85%	  reduction	  in	  human	  cases	  (Matthews	  et	  al.,	  2013),	  uptake	  by	  farmers	  
has	  been	   low.	  This	   is	   largely	  because	  the	  conditional	   license	  restrictions	  of	  Epitopix	  SRP	  
limits	   purchase	   to	   licenced	   veterinarians,	   and	   the	   production	   of	   Econiche	   has	   been	  
recently	  discontinued.	  
	  
1.7	  Development	  of	  a	  therapeutic	  treatments	  for	  O157:H7	  infections	  
	  
The	   use	   of	   antibiotics	   to	   treat	   infections	   caused	   by	   Stx-­‐expressing	   bacteria	   is	   largely	  
avoided	  to	  prevent	  the	  increase	  in	  Stx	  expression	  and	  release	  caused	  by	  the	  bacterial	  lysis	  
they	   stimulate,	   and	   the	   subsequent	   increased	   risk	   of	   HUS	   development.	   Wong	   et	   al.	  
(2000)	  assessed	  the	  risk	  of	  HUS	  in	  71	  antibiotic-­‐treated	  children	  with	  O157:H7	  infections,	  
finding	   the	   relative	   risk	   of	   HUS	   development	   to	   be	   17.7	   for	   those	   administered	   the	  
antibiotic	  trimethoprim-­‐sulfamethoxazole,	  and	  13.4	  for	  those	  administered	  beta-­‐lactams.	  
In	   vitro	   studies	   by	   McGannon	   et	   al.	   (2010)	   have	   suggested	   that	   the	   increase	   of	   Stx	  
production	   depends	   on	   the	   class	   of	   antibiotic	   used.	   Addition	   of	   sub-­‐inhibitory	  
concentrations	   of	   the	   DNA	   synthesis-­‐targeting	   antibiotics	   ampicillin,	   trimethoprim-­‐
sulfamethoxazole	   and	   ciprofloxacin	   increased	   Stx	   production,	   while	   the	   cell	   wall,	  
ribosome,	   or	   RNA	   polymerase-­‐targeting	   antibiotics	   azithromycin,	   doxycycline,	  
phosphomycin	  and	  gentamycin	  showed	  little	  ability	  to	  induce	  Stx	  production,	  with	  some	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resulting	   in	   decreased	   Stx	   production	   when	   compared	   to	   untreated	   O157:H7.	  
Additionally,	   when	   bacteria	   were	   exposed	   to	   much	   higher	   growth-­‐inhibiting	   levels	   of	  
ciprofloxacin,	  levels	  of	  Stx	  were	  still	  very	  high	  even	  when	  bacterial	  growth	  was	  completely	  
suppressed	  (McGannon	  et	  al.,	  2010).	  Other	  forms	  of	  treatment	  are	  also	  discouraged,	  with	  
anti-­‐motility	   agents	   and	   narcotics	   associated	  with	   increased	  HUS	   risk	   and	  HUS-­‐induced	  
neurological	  effects.	  Non-­‐steroidal	  anti-­‐inflammatory	  agents	  should	  also	  be	  avoided	  due	  
to	  their	  impact	  on	  renal	  blood	  flow	  (Tarr	  et	  al.,	  2005).	  There	  is	  therefore	  a	  urgent	  need	  for	  
alternative	   therapeutic	   options	   that	   restrict	   EHEC	   colonisation	   or	   toxin	   expression,	  
release	  or	  binding,	  without	  initiating	  additional	  Stx	  production.	  
	  
Bacterial	  virulence	  factors	  are	  a	  promising	  target	  for	  novel	  inhibitors,	  as	  interference	  with	  
mechanisms	   essential	   for	   bacterial	   colonisation	   and	   disease	   symptoms,	   such	   as	  
adherence	   to	   and	   invasion	   of	   host	   cells,	   production	   of	   toxins,	   and	   avoidance	   of	   host	  
immune	   responses,	   provide	   an	   opportunity	   to	   prevent	   disease	   without	   modifying	   the	  
prevalence	  of	  these	  strains.	  Without	  the	  capacity	  to	  colonise	  and	  cause	  harm	  to	  the	  host,	  
the	   bacteria	   can	   be	   rapidly	   cleared	   by	   both	   the	   host	   immune	   response	   and	   by	  
competition	  from	  commensal	  bacteria.	  Unlike	  traditional	  antibiotics	  which	  work	  to	  either	  
kill	   or	   inhibit	   growth,	   this	   strategy	   is	   attractive	   as	   by	   inhibiting	  bacterial	   functions	  non-­‐
essential	   for	  survival,	  there	   is	  potentially	   less	  selection	  pressure	  to	  drive	  the	  emergence	  
of	  drug-­‐resistant	  mutants,	  which	  may	  decrease	  the	  rate	  at	  which	  resistance	  occurs	  (Allen	  
et	   al.,	   2014).	   Specific	   targeting	   of	   virulence	   determinants	   also	   has	   the	   advantage	   of	  
avoiding	   alteration	   of	   the	   host	   microbiota,	   which	   could	   prevent	   the	   development	   of	  
diseases	  associated	  with	  disruption	  of	  the	  gut	  flora,	  such	  Clostridium	  difficile	  infections.	  	  
	  
1.7.1	  Inhibition	  of	  Stx	  expression	  and	  binding	  to	  host	  receptors	  
	  
Bacterial	   toxins	   such	   as	   Stx	   are	   an	   obvious	   target	   for	   anti-­‐virulence-­‐based	   approaches,	  
given	  their	  crucial	  role	  in	  disease	  symptoms.	  One	  strategy	  that	  targets	  Stx	  currently	  under	  
investigation	   is	   inhibition	   of	   quorum	   sensing,	   a	   mechanism	   used	   by	   bacteria	   in	   the	  
regulation	  of	  gene	  expression	  in	  response	  to	  changes	  in	  the	  bacterial	  population	  density.	  
This	   involves	  the	  secretion	  and	  detection	  of	  signalling	  molecules	  known	  as	  autoinducers	  
by	  growing	  bacteria,	  which	  regulate	  many	  bacterial	  physiological	  activities	  including	  that	  
of	  toxin	  release	  (Zhu	  et	  al.,	  2002)	  and	  other	  virulence	  factors	  such	  as	  the	  T3SS	  and	  flagella	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(Kanamaru	  et	  al.,	  2000;	  Sperandio	  et	  al.,	  2002).	  An	  O157:H7	  strain	  with	  a	  mutation	  in	  the	  
luxS	   gene,	   whose	   product	   is	   involved	   in	   synthesis	   of	   the	   autoinducers	   AI-­‐2	   and	   AI-­‐3,	  
produced	   less	   Stx2	   when	   compared	   to	   the	   wild	   type	   strain	   (Sperandio	   et	   al.,	   2001),	  
suggesting	   that	   inhibition	  of	  essential	   stages	  of	  quorum	  sensing	  may	   reduce	  or	  prevent	  
production	  of	  Shiga	  toxin.	  
	  
Virulence	  gene	  expression	  can	  also	  be	  modulated	  by	  chemical	  signals	  within	  the	  host.	  The	  
adrenergic	   receptor	   QseC	   acts	   as	   a	   receptor	   for	   the	   mammalian	   stress	   response	  
hormones	   epinephrine	   and	   norepinephrine,	   and	   in	   EHEC	   has	   been	   shown	   to	   activate	  
expression	  of	  metabolic,	   virulence	  and	   stress	   response	  genes,	   including	   that	  of	   stx2	   via	  
recA	   (Hughes	   et	   al.,	   2009).	   When	   a	   rabbit	   model	   was	   infected	   with	   EHEC	   strains	  
containing	   a	   qseC	   deletion,	   these	   strains	   were	   attenuated	   for	   virulence	   (Clarke	   et	   al.,	  
2006).	   These	   findings	   led	   to	   high-­‐throughput	   screening	   by	   Rasko	   et	   al.	   (2008)	   to	   find	  
inhibitors	  for	  QseC,	  which	  identified	  the	  small	  molecule	  LED209.	  LED209	  is	  highly	  selective	  
for	   QseC	   and	   prevents	   its	   autophosphorylation	   by	   allosteric	   modification	   of	   lysines,	  
consequently	  limiting	  activation	  of	  virulence	  gene	  expression	  (Rasko	  et	  al.,	  2008;	  Curtis	  et	  
al.,	  2014).	  Importantly,	  LED209	  showed	  no	  overt	  toxicity	  to	  mammalian	  or	  bacterial	  cells,	  
and	  did	  not	   inhibit	  bacterial	   growth.	   In	  addition,	   secretion	  of	   the	   LEE-­‐encoded	  proteins	  
EspA	  and	  EspB	  was	   inhibited	  by	   LED209	   in	   vitro,	   reducing	   formation	  of	  A/E	   lesions	  and	  
activation	   of	   the	   bacterial	   SOS	   response,	   thus	   preventing	   Stx	   production.	   However,	  
treatment	  of	  EHEC-­‐infected	  rabbits	  with	  LED209	  did	  not	  produce	  a	  statistically	  significant	  
decrease	   in	  colonisation,	  which	  may	  be	  a	   reflection	  of	   the	   rapid	  absorption	  of	   the	  drug	  
from	   the	   gastrointestinal	   tract	   that	   may	   be	   overcome	   by	   the	   development	   of	   a	   non-­‐
absorbable	   formulation	   of	   the	   drug	   (Rasko	   et	   al.,	   2008).	   Furthermore,	   in	   several	   other	  
plant	   and	   animal	   pathogens	   such	   as	   S.	   Typhimurium	   and	   Francisella	   tularensis,	   QseC	  
expression	   is	   inhibited	   by	   LED209	   (Curtis	   et	   al.,	   2014),	   raising	   the	   possibility	   of	   its	  
development	  as	  a	  broad-­‐spectrum	  antimicrobial	  treatment.	  
	  
Other	   attempts	   to	   develop	   therapies	   based	   largely	   on	   preventing	   Stx	   binding	   to	   Gb3	  
receptors	   have	  met	  with	   limited	   success.	   In	   clinical	   trials	   in	  which	   children	  with	   EHEC-­‐
associated	  HUS	  were	   treated	  with	   the	   drug	   SYNSORB	   Pk,	   designed	   to	   bind	   to	  Gb3	   and	  
thus	   limit	  Stx	  binding,	  no	   reduction	  of	  disease	  severity	  was	  observed	   (Trachtman	  et	  al.,	  
2003).	  Compounds	  that	  mimic	  Gb3	  in	  order	  to	  bind	  Stx	  and	  prevent	   it	   from	  reaching	   its	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target	   have	   also	   been	   developed,	   showing	   efficacy	   both	   in	   vitro	   and	   in	   vivo,	   although	  
successful	  clinical	  trials	  have	  remained	  elusive	  (Nishikawa	  et	  al.,	  2005;	  Kitov	  et	  al.,	  2000).	  
	  
Given	   the	   importance	  of	   the	  T3SS	   in	  establishment	  of	   infection	  by	  a	  broad	  spectrum	  of	  
Gram-­‐negative	   pathogenic	   bacteria,	   many	   studies	   have	   investigated	   its	   inhibition	   as	   a	  
therapeutic	  anti-­‐virulence	  strategy,	  and	  a	  number	  of	  inhibitors	  effective	  against	  the	  T3SS	  
of	   Yersinia,	   Chlamydia,	   Salmonella	   and	   E.	   coli	   species	   have	   been	   identified.	   One	  
particularly	  well-­‐characterised	  group	  of	  T3SS	  inhibitors	  are	  the	  salicylidene	  acylhydrazides	  
(SAs),	   identified	  by	  high-­‐throughput	   screening	   in	  Yersinia	   pseudotuberculosis	   (Kauppi	  et	  
al.,	   2003).	   These	   compounds	   are	   effective	   against	   a	   number	   of	   pathogenic	   species	  
including	  Shigella	   flexneri,	  S.	  Typhimurium	  and	  EHEC,	  without	  showing	  any	  antibacterial	  
activity	   (Veenendaal	  et	   al.,	   2009;	   Hudson	  et	   al.,	   2007;	   Tree	  et	   al.,	   2009).	   Although	   the	  
mode	   of	   action	   of	   the	   SAs	   is	   yet	   to	   be	   elucidated,	   their	   targets	   in	  O157:H7	   have	   been	  
identified	  as	  WrbA,	  Tpx	  and	  FolX,	  proteins	  conserved	  across	  many	  Gram-­‐negative	  species	  
and	   involved	   in	   regulation	   of	   T3SS	   gene	   expression.	   This	   has	   lead	   to	   the	   working	  
hypothesis	   that	   the	  SAs	  affect	  expression	  of	   the	  T3SS	  via	  a	   synergistic	  effect	   caused	  by	  
perturbation	  of	  several	  regulatory	  proteins	  (Wang	  et	  al.,	  2011).	  
	  
1.7.2	  Modified	  bacteriocins	  	  
	  
Another	  potential	  bacterial	  treatment	  is	  the	  use	  of	  bacteriocins,	  toxic	  proteins	  produced	  
by	  bacteria	  that	  target	  other	  bacterial	  strains,	  including	  those	  of	  the	  same	  species	  as	  the	  
bacteriocin-­‐producing	  strain.	  Colicins	  are	  bacteriocins	  synthesised	  exclusively	  by	  E.	  coli	  for	  
use	   against	   other	   closely	   related	   E.	   coli	   strains,	   and	   display	   varying	   modes	   of	   action	  
depending	  on	  the	  colicin	  type.	  These	  include	  inhibition	  of	  macromolecular	  synthesis,	  DNA	  
breakdown,	   and	   inhibition	   of	   protein	   synthesis	   (Nomura,	   1963).	   Unfortunately,	   the	  
reported	   enhancement	   of	   Stx	   production	   by	   O157:H7	   upon	   treatment	   with	   DNase	  
colicins,	   caused	  by	   induction	  of	   the	   SOS	   response	   in	   response	   to	   colicin-­‐produced	  DNA	  
damage,	  limits	  their	  potential	  as	  treatments	  against	  Stx-­‐producing	  pathogens	  (Toshima	  et	  
al.,	  2007).	  	  
	  
However,	  pyocins	  produced	  by	  Pseudomonas	  aeruginosa	  strains	  that	  have	  been	  adapted	  
to	  target	  E.	  coli	   instead	  of	  P.	  aeruginosa	  have	  shown	  promise.	  Of	  particular	   interest	  are	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the	   R-­‐type	   pyocins,	   which	   form	   structures	   that	   resemble	   tails	   of	   bacteriophages	   and	  
insert	   themselves	   into	   the	   bacterial	   cell	   membrane	   upon	   contact	   with	   specific	   cell	  
receptors.	   Once	   in	   the	   membrane	   these	   pyocins	   form	   a	   pore,	   resulting	   in	   membrane	  
depolarisation	  and	  death	  of	  the	  bacterium	  (reviewed	  by	  Michel-­‐Briand	  &	  Baysse,	  2002).	  
Recent	   studies	   using	   modified	   pyocins	   have	   shown	   potential	   as	   a	   treatment	   of	   EHEC	  
infections.	  A	  novel	  pyocin	   that	   targets	  O157:H7	  by	   recognising	  and	  degrading	   the	  O157	  
lipopolysaccharide,	   AVR2-­‐V10,	  was	   constructed	   by	   fusion	   of	   the	   tail	   spike	   protein	   from	  
O157-­‐specific	  phage	  φV0	  to	  an	  R-­‐type	  pyocin	   tail	   fiber.	  Killing	  of	  O157:H7	  by	  AVR2-­‐V10	  
was	  highly	  efficient	  and	  specific,	  and	  did	  not	  induce	  Stx	  production	  (Scholl	  et	  al.,	  2009).	  In	  
vivo	  testing	  of	  the	  variant	  AVR2-­‐V10.3	  in	  an	  infant	  O157:H7	  rabbit	  model	  showed	  that	  the	  
pyocin	  reduced	  diarrhoea,	  intestinal	  inflammation,	  bacterial	  carriage	  and	  faecal	  shedding,	  
and	   was	   equally	   effective	   if	   the	   pyocin	   was	   administered	   prophylactically	   or	  
therapeutically	   (Ritchie	   et	   al.,	   2011).	   This	   work	   clearly	   demonstrates	   the	   potential	   of	  
pyocins	   in	   treatment	   of	  O157:H7,	   although	   further	   optimisation	   of	   delivery	   and	   clinical	  
trials	   are	   required.	   The	  potent	   bactericidal	   activity	   of	   pyocins,	   combined	  with	   the	   their	  
ability	   to	   specifically	   target	   certain	   bacterial	   species,	   make	   them	   an	   attractive	   new	  
development.	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  1.7	  Project	  aims	  
	  
The	   intent	   of	   this	   project	   is	   to	   further	   the	   understanding	   and	   development	   of	   new	  
prophylactic	  and	  therapeutic	  treatments	  for	  O157:H7	  and	  other	  E.	  coli.	  We	  aimed	  to	  test	  
the	  hypotheses	  that	  a)	  the	  T3SS	  contributes	  towards	  colonisation	  of	  mice	  by	  EHEC,	  b)	  the	  
potential	  vaccine	  candidate	  proteins	  EaeH	  and	  YghJ	  are	  expressed	  by	  EHEC	  O157:H7	  and	  
EAEC	  LF82,	  and	  c)	  Shiga	  toxin	  expression	  by	  O157:H7	  is	  inhibited	  by	  a	  recently-­‐identified	  
small	  molecule.	  
	  
The	  main	  objectives	  of	  this	  project	  are:	  
	  
1. Establishment	   of	   a	   mouse	   model	   suitable	   for	   in	   vivo	   assessment	   of	   novel	  
EHEC	  anti-­‐virulence	  compounds.	  
	  
Animal	   models	   are	   an	   essential	   step	   in	   the	   development	   of	   new	   anti-­‐virulence	   drugs,	  
revealing	  whether	  compounds	  that	  have	  proven	  activity	  in	  vitro	  are	  able	  to	  work	  in	  vivo,	  
identifying	   possible	   side-­‐effects,	   and	   determining	  whether	   they	   can	   proceed	   to	   human	  
clinical	   trials.	   They	   also	   allow	   the	   issue	   of	   drug	   delivery	   to	   the	   site	   of	   infection	   to	   be	  
addressed;	   for	   example,	   a	   drug	   taken	   orally	   that	   targets	   an	   intestinal	   infection	   has	   to	  
avoid	  being	  degraded	  by	  the	  stomach	  and	  intestine	  in	  order	  to	  reach	  the	  site	  of	  bacterial	  
colonisation.	  We	  are	  interested	  in	  testing	  a	  number	  of	  different	  compounds	  that	  aim	  to	  
prevent	  colonisation	  or	  toxin	  production	  in	  mice,	  and	  therefore	  require	  a	  model	  that	  can	  
consistently	  replicate	  these	  features.	  
	  
2. Investigation	  of	   two	  novel	  E.	  coli	  proteins	   identified	  by	  reverse	  vaccinology	  
as	  protective	  antigens	  for	  ExPEC	   infection.	  This	   focuses	  on	  the	  suitability	  of	  
these	  antigens	  as	  candidates	  for	  a	  general,	  broad-­‐spectrum	  E.	  coli	  vaccine.	  
	  
Reverse	   vaccinology	   has	   identified	   a	   number	   of	   novel	   antigens	   that	   provide	   protection	  
against	  ExPEC	  infection	  using	  a	  mouse	  transurethral	  challenge	  model	  (Moriel	  et	  al.,	  2010).	  
Many	  of	  these	  antigens	  are	  conserved	  across	  a	  large	  number	  of	  pathogenic	  E.	  coli,	  raising	  
the	  possibility	  of	  their	  use	   in	  a	  broad-­‐spectrum	  E.	  coli	  vaccine.	  We	  intend	  to	   investigate	  
the	   expression	   and	   role	   in	   pathogenesis	   of	   two	   of	   these	   antigens,	   EaeH	   and	   YghJ,	   in	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O157:H7	  (EHEC)	  and	  LF82	  (EAEC)	  backgrounds,	  to	  evaluate	  their	  potential	  as	  candidates	  
for	  a	  vaccine	  against	  these	  strains.	  
	  
3. Characterisation	   of	   a	   novel	   compound	   identified	   by	   high-­‐throughput	  
screening	   as	   a	   potential	   inhibitor	   of	   Stx	   expression,	   with	   the	   aim	   of	  
uncovering	  its	  mode	  of	  action.	  
	  
A	   small	   compound	   has	   recently	   been	   identified	   by	   high-­‐throughput	   screening	   by	   the	  
group	  of	  Prof.	  David	  Gally	  at	  the	  University	  of	  Edinburgh	  as	  a	  potential	  inhibitor	  of	  Shiga	  
toxin	   production.	   We	   intend	   to	   assess	   the	   Stx-­‐inhibiting	   effect	   of	   this	   compound	   and	  
several	  other	  modified	  versions,	  and	  to	   identify	   the	  mechanism	  by	  which	  this	   inhibition	  
occurs.	  This	  may	  eventually	  determine	  whether	  these	  compounds	  have	  potential	  for	  use	  
as	  therapeutic	  agents	  in	  humans.	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Chemicals	   used	   were	   purchased	   from	   Sigma-­‐Aldrich,	   Invitrogen	   and	   Fisher	   Scientific,	  
unless	  otherwise	  stated.	  
	  
2.1.2	  Bacterial	  growth	  media	  
	  
Growth	  media	  was	  prepared	   in	  deionised	  water	   (dH2O)	  and	   sterilised	  by	  autoclaving	  or	  
filtration	   with	   0.2	   µM	   filters.	   Luria-­‐Bertani	   broth	   (LB),	   tryptic	   soy	   broth	   (TSB)	   and	   M9	  
minimal	   media	   was	   prepared	   as	   described	   in	   Table	   2-­‐1.	   Dulbecco’s	   Modified	   Eagle’s	  
Medium	   (DMEM)	   and	   Minimal	   Essential	   Media	   (MEM)	   with	   4-­‐(2-­‐hydroxyethyl)-­‐1-­‐
piperazineethanesulfonic	   acid	   (HEPES)	   modification	   (MEM-­‐HEPES)	   was	   purchased	   from	  
Sigma-­‐Aldrich	  (#M7278).	  All	  media	  was	  prepared	  by	  addition	  of	  dH2O	  to	  dry	   ingredients	  
followed	   by	   autoclaving.	   For	   M9	   minimal	   media,	   glucose	   was	   omitted	   from	   the	   dry	  
ingredients	   prior	   to	   autoclaving,	   and	   added	   to	   media	   (in	   sterile	   H2O,	   after	   filter	  
sterilisation)	   after	   autoclaving.	   Solid	  media	  was	   prepared	   by	   addition	   of	   15	   g/L	   agar	   to	  
liquid	  growth	  medium	  prior	  to	  autoclaving.	  
	  
Table	  2-­‐1:	  Bacterial	  growth	  media	  recipes.	  
Media	   Components	  per	  litre	  
Luria-­‐Bertani	  (LB)	   10	  g	  tryptone	  
	  
5	  g	  yeast	  extract	  
	  
10	  g	  NaCl	  
Tryptic	  Soy	  Broth	  (TSB)	   30	  g	  TSB	  (Sigma	  Aldrich,	  #22092)	  
M9	  Minimal	  Media	   6.8	  g	  Na2HPO4	  
	  
3	  g	  KH2PO4	  
	  
0.5	  g	  NaCl	  
	  
1	  ml	  1	  M	  MgSO4	  
	  
100	  µl	  1	  M	  CaCl2	  
	  
4	  g	  glucose	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2.1.3	  Growth	  media	  supplements	  
	  
Antibiotics	   were	   prepared	   as	   concentrated	   stock	   solutions	   in	   either	   dH2O	   or	   100%	  
ethanol,	   and	   were	   filter	   sterilised.	   Stocks	   were	   stored	   at	   -­‐20°C	   and	   used	   at	   final	  
concentrations	  in	  Table	  2-­‐2.	  
	  
Table	  2-­‐2:	  Antibiotic	  concentrations	  for	  bacterial	  growth	  media	  used	  in	  this	  study.	  Asterisks	  denote	  those	  
antibiotics	  prepared	  in	  ethanol.	  
Antibiotic	   Final	  concentration	  (µg/ml)	  
Ampicillin	   100	  
Kanamycin	   50	  
Chloramphenicol	  *	   25	  
Erythromycin	  *	   500	  
Ciprofloxacin	   0.05	  
Tetracycline	   6	  
	  
	  
Isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  was	  prepared	  as	  a	  1	  M	  stock	  in	  dH2O,	  filter	  




All	   buffers	   were	   made	   using	   dH2O	   and	   sterilised	   by	   autoclaving	   or	   filtering	   where	  
necessary.	  Phosphate	  buffered	  saline	  was	  made	  according	  to	  Table	  2-­‐3.	  Tris-­‐acetate-­‐EDTA	  
(TAE),	  3-­‐(N-­‐morpholino)propanesulfonic	  acid	  (MOPS),	  Tris-­‐borate-­‐EDTA	  (TBE)	  and	  NOVEX	  
Transfer	  buffer	  were	  purchased	  as	  concentrated	  stocks	  from	  Invitrogen.	  
	  
Table	  2-­‐3:	  Components	  of	  phosphate	  buffered	  saline	  (PBS).	  
Component	   Concentrations	  
NaCl	   137	  mM	  
KCl	   2.7	  mM	  
NaHPO4	   10	  mM	  
KH2PO4	   1.8	  mM	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2.2	  Bacterial	  strains	  and	  plasmids	  
	  
2.2.1	  Bacterial	  strains	  
	  
All	  bacterial	  strains	  used	  in	  this	  thesis	  are	  listed	  and	  described	  in	  Table	  2-­‐4.	  
	  
Table	  2-­‐4:	  Bacterial	  strains	  used	  in	  this	  study.	  
Strain	   Description	  and	  genotype	   Source	  
Escherichia	  coli	  
	   	  
TUV93-­‐0	   Stx-­‐negative	  derivative	  of	  O157:H7	  EDL933	   (Campellone	  et	  al.,	  2002)	  
TUV93-­‐0	  lux	   lux-­‐positive	  derivative	  of	  TUV93-­‐0	   This	  study	  
TUV93-­‐0	  lux	  StrR	   lux-­‐positive	  Str-­‐resistant	  K42T	  rpsL	  mutant	   This	  study	  
TUV93-­‐0	  RFP	   rfp-­‐positive	  derivative	  of	  TUV93-­‐0	   Prof.	  D.	  Walker	  *	  
OI-­‐148A	  lux	   T3SS-­‐negative,	  deletion	  of	  first	  half	  of	  LEE	   (Campellone	  et	  al.,	  2004)	  
ZAP0273	   Stx-­‐negative	  derivative	  of	  O157:H7	  Sakai	   Prof.	  D.	  Gally	  **	  
LF82	   Crohn’s	  Disease-­‐associated	  ExPEC	   (Miquel	  et	  al.,	  2010)	  
LF82	  lux	   lux-­‐positive	  derivative	  of	  LF82	   This	  study	  
LF82	  lux	  StrR	   lux-­‐positive	  Str-­‐resistant	  K42T	  rpsL	  mutant	   This	  study	  
LF82	  ΔeaeH	   Deletion	  of	  eaeH	  gene	   This	  study	  
LF82	  ΔyghJ	   Deletion	  of	  yghJ	  gene	   This	  study	  
H10407	   Prototypical	  ETEC	  strain	   (Crossman	  et	  al.,	  2010)	  
E2348/69	   Enteropathogenic	  O127:H6	  serogroup	   (Iguchi	  et	  al.,	  2009)	  
JP10819	   MG1655	  strain	  lysogenic	  for	  φP27,	  stx2:tet	   (Quiles-­‐Puchalt	  et	  al.,	  2014)	  
MG1655	   Non-­‐lysogenic	  laboratory	  strain	   (Blattner	  et	  al.,	  1997)	  	  
BL21	  Star	  (DE3)	   Protein	  expression	  strain	   New	  England	  Biolabs	  
XL1-­‐Blue	   Cloning	  strain	   Agilent	  Technologies	  
	   	   	  
Staphylococcus	  
aureus	  
	   	  
JP5011	   RN4220	  strain	  lysogenic	  for	  φSLT,	  pvl::tet	   (Ferrer	  et	  al.,	  2011)	  
RN10359	   RN450	  strain	  lysogenic	  for	  80α	   (Ubeda	  et	  al.,	  2007)	  
RN4220	   Non-­‐lysogenic	  laboratory	  strain	   (Nair	  et	  al.,	  2011)	  
	   	   	  
Citrobacter	  
rodentium	  
	   	  
C.	  rodentium	  lux	   lux-­‐positive	  C.	  rodentium	   (Mallick	  et	  al.,	  2012)	  
λstx2dact	  lux	   lux-­‐positive	  integrated	  Stx2	  prophage	   (Mallick	  et	  al.,	  2012)	  
λstx2dact	  Δtir	  lux	  
lux-­‐positive	  integrated	  Stx2	  prophage,	  tir	  
mutant	  
(Mallick	  et	  al.,	  2012)	  
	  
*	  University	  of	  Glasgow	  
**	  University	  of	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2.2.2	  Storage	  of	  bacterial	  strains	  
	  
Bacterial	   stocks	   for	   storage	  were	  prepared	  by	  addition	  0.5	  ml	  of	   an	  overnight	  bacterial	  
culture	   to	   a	   cryovial	   containing	   1	  ml	   sterile	   glycerol	   (40%)	   and	   peptone	   (2%).	   Bacteria	  
were	  stored	  at	  -­‐80°C.	  
	  
2.2.3	  Bacterial	  growth	  conditions	  
	  
Unless	   specified	   otherwise,	   bacterial	   cultures	   were	   propagated	   from	   a	   single	   colony	  
obtained	  from	  agar	  plates	  streaked	  from	  frozen	  samples,	  and	  grown	  at	  37°C	  and	  200	  rpm	  
in	   an	  orbital	   incubator	   for	   aeration.	  Antibiotics	  were	   included	  when	   required	  using	   the	  
concentrations	  described	  in	  Table	  2-­‐2.	  
	  
2.2.4	  Bacterial	  growth	  curves	  and	  calculation	  of	  colony-­‐forming	  units	  
	  
Growth	   curves	   were	   obtained	   by	   inoculating	  media	   with	   overnight	   cultures	   to	   give	   an	  
initial	  starting	  OD600	  of	  0.08	  and	  grown	  at	  37°C	  and	  200	  rpm.	  The	  OD600	  of	  cultures	  was	  
measured	  hourly	  and	  plotted	  against	  time.	  
	  
The	  number	  of	   colony-­‐forming	  units	   (CFU)	   in	  bacterial	   cultures	  was	  measured	  by	   serial	  
dilution	  of	  cultures	  in	  PBS.	  In	  brief,	  10	  µl	  of	  each	  dilution	  was	  inoculated	  in	  triplicate	  onto	  
LB	  agar	  containing	  appropriate	  antibiotics.	  The	  average	  number	  of	  colony-­‐forming	  units	  
per	   ml	   of	   original	   culture	   (CFU/ml)	   was	   calculated	   by	   multiplication	   of	   the	   number	   of	  




All	  plasmids	  used	  in	  this	  thesis	  are	  listed	  and	  described	  in	  Table	  2-­‐5.	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Table	  2-­‐5:	  Plasmids	  used	  in	  this	  study.	  
Plasmid	   Vector	  type	   Antibiotic	  resistance	   Source	  
p16Slux	   Integration	   Erythromycin	   (Riedel	  et	  al.,	  2007)	  
pET-­‐21b-­‐EaeH	   Expression	   Ampicillin	   Novartis	  Vaccines	  
pET-­‐21b-­‐YghJ	   Expression	   Ampicillin	   Novartis	  Vaccines	  
pAJR70	   Reporter	   Chloramphenicol	   (Roe	  et	  al.,	  2003)	  
prpsM:GFP	   Reporter	   Chloramphenicol	   (Roe	  et	  al.,	  2003)	  
pzm_TE1	   Reporter	   Chloramphenicol	   This	  study	  
pzm_LE1	   Reporter	   Chloramphenicol	   This	  study	  
pzm_LY1	   Reporter	   Chloramphenicol	   This	  study	  
pstx2:GFP	   Reporter	   Chloramphenicol	   Prof	  D.	  Gally	  
pGB2	   Resistance	   Streptomycin	   (Churchward	  et	  al.,	  1984)	  
pKD4	   Template	   Kanamycin	   (Datsenko	  &	  Wanner,	  2000)	  
pKD46	   Helper	   Ampicillin	   (Datsenko	  &	  Wanner,	  2000)	  
StrataClone	   pSC-­‐A-­‐
amp/kan	  vector	  
Storage	   Ampicillin	   Agilent	  Technologies	  
	  
	  
2.3	  Eukaryotic	  cell	  lines	  and	  growth	  conditions	  
	  
2.3.1	  Eukaryotic	  growth	  media	  
	  
Growth	  media	   for	   eukaryotic	   cells	  was	   prepared	   by	   addition	   of	   foetal	   calf	   serum	   (FCS;	  
Invitrogen)	   to	   MEM-­‐HEPES	   at	   a	   final	   concentration	   of	   10%,	   along	   with	   penicillin	   and	  
streptomycin	   at	   final	   concentrations	   of	   100	   units/ml	   and	   100	   µg/ml	   respectively.	  
Prepared	  media	  was	  stored	  at	  4°C	  and	  pre-­‐warmed	  to	  37°C	  before	  use.	  
	  
2.3.2	  Eukaryotic	  cell	  lines	  
	  
All	  cell	  lines	  used	  in	  this	  thesis	  are	  listed	  and	  described	  in	  Table	  2-­‐6.	  
	  
Table	  2-­‐6:	  Eukaryotic	  cell	  lines	  used	  in	  this	  study.	  
Strain	   Biological	  source	   Phenotype	  
Caco-­‐2	   Human	  colon	   Epithelial	  
HeLa	   Human	  cervix	   Epithelial	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2.3.3	  Eukaryotic	  growth	  conditions	  and	  passage	  
	  
Cells	  were	  grown	  at	  37°C	   in	  a	  5%	  CO2	   incubator.	  When	  confluency	  was	   reached,	  media	  
was	   removed	  and	   cells	  washed	   twice	  with	   sterile	  HEPES	   solution.	   Trypsin-­‐EDTA	   (Sigma-­‐
Aldrich)	  was	  added	  to	  flasks,	  which	  were	  left	  at	  room	  temperature	  until	  cells	  detached	  (5-­‐
10	  minutes).	  An	  equal	  volume	  of	  MEM-­‐HEPES	  to	  the	  trypsin	  was	  added	  to	  flasks,	  and	  cells	  
transferred	   to	  new	   flasks	   containing	   growth	  media	   to	   achieve	   a	  dilution	  of	   1/50	  of	   the	  
original	  concentration.	  Monolayers	  were	  considered	  near-­‐confluent	  when	  approximately	  
90%	  confluent.	  	  
	  
2.4	  Molecular	  techniques	  
	  
2.4.1	  Preparation	  of	  genomic	  DNA	  
	  
Genomic	   DNA	   (gDNA)	   was	   extracted	   using	   the	   ChargeSwitch	   gDNA	   Mini	   Bacteria	   kit	  
(#CS11301,	   Invitrogen)	   from	   1	   ml	   of	   overnight	   LB	   cultures.	   The	   extracted	   DNA	   was	  
resuspended	  in	  200	  µl	  nuclease-­‐free	  water	  (Ambion)	  and	  stored	  at	  4°C.	  
	  
2.4.2	  Oligonucleotide	  primers	  
	  
Oligonucleotide	   primers	   used	   to	   amplify	   DNA	   were	   designed	   using	   MacVector	   and	  
synthesised	   by	   Life	   Technologies.	   For	   molecular	   cloning	   and	   confirmation	   primers	  
annealing	   regions	   complementary	   to	   template	   DNA	   were	   typically	   20	   bp	   in	   length,	  
approximately	  50%	  in	  GC	  content,	  and	  had	  a	  melting	  temperature	  of	  55-­‐60°C.	  All	  primers	  
used	  in	  this	  thesis	  are	  listed	  in	  Table	  2-­‐7.	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Table	  2-­‐7:	  Primers	  used	  in	  this	  study.	  
Name	   Sequence	  5’	  to	  3’	   Amplicon	  size	  (bp)	  
p16Slux	  +ve	  5’	   ACACTGGAACTGAGACACGGTCCAGACTCC	  
1,150	  
p16Slux	  +ve	  3’	   TTGTAAAACGACGGCCAGTGAGCGCGCG	  
rpsL	  sequencing	  5’	   AATTCGGCGTCCTCATATTG	  
555	  
rpsL	  sequencing	  3’	   GTGGCATGGAAATACTCCGT	  
eaeH	  promoter	  5’	   GGGGATCCTGTTATCCTTCCGTTATCGTTCATGAG	  
619	  
eaeH	  promoter	  3’	   GGCCATGGGTTTATGACCTGTTTTATAACG	  
yghJ	  promoter	  5’	   GCGGATCCGAGCGTGAGAACATCTAT	  
424	  
yghJ	  promoter	  3’	   GCGGTACCGGCTAACAGGGTTGCGCTTAA	  




Lambda	  red	  eaeH	  3’	  
CGCCTCTGTCACCCCTTCCGGAGCCTCAATGTCGAC
CCACATGGTTCCTCCATATGAATATCCTCCTTAG	  




Lambda	  red	  yghJ	  3’	  
CACTGTTTGATATCAAAGTTTTTCTCTGCCCACTCTT
TCAGCTGCGCGTACATATGAATATCCTCCTTAG	  
ΔeaeH	  +ve	  5’	   CCACCTGATGAGTGGCTACA	  
448	  
ΔeaeH	  +ve	  3’	   TCTACGTGTTCCGCTTCCTT	  
ΔeaeH	  -­‐ve	  5’	   GAAAAGGAAACCGGGAAATC	  
416	  
ΔeaeH	  -­‐ve	  3’	   CTGGTTAGCTTTAGCGGTGG	  
ΔyghJ	  +ve	  5’	   CGATGGCTTTACCTTTACGC	  
347	  
ΔyghJ	  +ve	  3’	   TGTAAGCCCACTGCAAGCTA	  
ΔyghJ	  -­‐ve	  5’	   CGACCATTGCAACATTCAAC	  
301	  
ΔyghJ	  -­‐ve	  3’	   TCAGTCGCAGCATTGTTTTC	  
	  
	  
2.4.3	  Polymerase	  chain	  reaction	  (PCR)	  
	  
PCR	   reactions	   were	   performed	   using	   a	   final	   volume	   of	   25	   µl,	   and	   volumes	   of	   the	   PCR	  
mixture	   components	   are	   shown	   in	   Table	   2-­‐8.	   Initial	   PCR	   temperature	   conditions	   are	  
shown	   in	  Table	  2-­‐9	  and,	   in	  general,	  amplification	   required	  25	  cycles.	   If	  no	  amplification	  
occurred,	  a	  15°C	  gradient	  of	  the	  annealing	  temperature	  was	  used	  to	  identify	  the	  optimal	  
conditions.	  PCR	  of	   individual	  bacterial	  colonies	  was	  performed	  by	  inoculation	  of	  a	  single	  
bacterial	   colony	   into	   100	  µl	   PBS,	   and	   the	   sample	   boiled	   at	   95°C	   for	   10	  minutes	   before	  
brief	   centrifugation	   to	   remove	   cell	   debris.	   One	  microlitre	   of	   the	   supernatant	  was	   then	  
used	  in	  a	  single	  PCR	  reaction.	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Table	  2-­‐8:	  Components	  of	  a	  25	  µl	  PCR	  mixture.	  
Component	   Volume	  used	  (µl)	  
2x	  PfuUltra	  Master	  Mix	  /2x	  GoTaq	  Green	  Master	  Mix	   12.5	  
10	  µM	  5’	  primer	   0.5	  
10	  µM	  3’	  primer	   0.5	  
Template	  DNA	   1	  
Nuclease-­‐free	  H2O	   10.5	  
	  
	  
Table	  2-­‐9:	  Standard	  PCR	  protocol.	  
Step	   Temperature	  (°C)	   Duration	  (seconds)	  
Initial	  denaturing	   95	   300	  
Denaturing	   95	   45	  
Annealing	   55	   45	  
Extension	   72	   60	  (per	  kb)	  
Final	  extension	   72	   600	  
Hold	   4	   ∞	  
	  
	  
2.4.4	  Agarose	  gel	  electrophoresis	  
	  
To	  produce	  1%	  agarose	  gels,	   agarose	  was	  added	   to	  1x	  TAE	  buffer	  and	  heated	  until	   the	  
agarose	  was	  dissolved.	  SYBR	  Safe	  gel	  stain	  (Life	  Technologies)	  was	  added	  at	  a	  dilution	  of	  
1:10,000	  and	  the	  gel	  allowed	  to	  set	  in	  a	  gel	  tray.	  For	  all	  gels,	  1x	  TAE	  was	  used	  as	  running	  
buffer,	  1	  Kb	  Plus	  DNA	  ladder	  (Invitrogen)	  loaded	  to	  provide	  a	  standard	  marker	  of	  size,	  and	  
1x	   BlueJuice	   loading	   buffer	   (Invitrogen)	   added	   to	   samples	   to	   aid	   visualisation	   during	  
loading.	   Gels	   were	   run	   at	   100	   V	   for	   40	   minutes,	   and	   visualised	   using	   an	   AlphaImager	  
transilluminator	  (Alpha	  Innotech).	  
	  
2.5	  Molecular	  cloning	  
	  
2.5.1	  Restriction	  enzyme	  digests	  
	  
All	   restriction	   enzyme	   digests	   were	   performed	   according	   to	   the	   manufacturer’s	  
instructions	  (New	  England	  Biolabs).	  Reaction	  digests	  were	  performed	  in	  volumes	  of	  10-­‐20	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µl,	   and	   volumes	   of	   the	   digest	   components	   are	   shown	   in	   Table	   2-­‐10.	   Reactions	   were	  
incubated	   at	   37°C	   for	   2	   hours,	   and	   digested	   products	   resolved	   by	   agarose	   gel	  
electrophoresis	  to	  visualise	  and	  isolate	  fragments.	  
	  
Table	  2-­‐10:	  Components	  of	  restriction	  enzyme	  digests	  for	  a	  10	  µl	  reaction.	  
Component	   Volume	  (µl)	  
1	  µg/µl	  DNA	   1	  
10	  units	  /	  µl	  restriction	  enzyme	   1	  
10x	  digestion	  buffer	   1	  
Nuclease-­‐free	  H2O	   7	  
	  
	  
2.5.2	  DNA	  gel	  purification	  
	  
Linear	  DNA	  products	  from	  PCR	  or	  restriction	  digests	  resolved	  by	  gel	  electrophoresis	  were	  
excised	   from	   the	   gel	   and	   purified	   using	   the	   Gel	   Extraction	   Kit	   (Qiagen)	   as	   per	  
manufacturer’s	   instructions.	   Purified	   DNA	   was	   eluted	   into	   30	   µl	   dH2O	   and	   the	  
concentration	  determined	  by	  280	  nm	  absorbance	  using	  a	  NanoDrop	  2000	  (Thermo	  Fisher	  
Scientific).	  
	  
2.5.3	  DNA	  ligation	  
	  
All	   ligation	  reactions	  were	  performed	  according	  to	  the	  manufacturer’s	  instructions	  (New	  
England	  Biolabs).	  Ligation	  reactions	  used	  T4	  DNA	  ligase	  (New	  England	  Biolabs)	  and	  were	  
carried	  out	  in	  10	  µl	  volumes.	  Components	  of	  the	  ligation	  mixture	  are	  shown	  in	  Table	  2-­‐11.	  
The	  ligation	  reaction	  was	  incubated	  overnight	  at	  4°C.	  
	  
Table	  2-­‐11:	  Components	  of	  DNA	  ligation	  mixture	  for	  a	  10	  µl	  reaction.	  
Component	   Volume	  (µl)	  
100	  ng/µl	  vector	  DNA	   1	  
100	  ng/µl	  insert	  DNA	   3	  
400	  units/µl	  T4	  DNA	  ligase	   0.5	  
10x	  T4	  DNA	  ligase	  buffer	   1	  
Nuclease-­‐free	  H2O	   4.5	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2.5.4	  Production	  of	  electrocompetent	  E.	  coli	  
	  
An	  overnight	  culture	  of	  bacteria	  grown	  from	  a	  single	  colony	  was	  used	  to	  inoculate	  a	  10	  ml	  
flask	  of	  pre-­‐warmed	  LB	  at	  an	  OD600	  of	  0.08.	  Bacteria	  were	  grown	  at	  37°C	  until	  an	  OD600	  of	  
0.6	  was	  reached.	  Cultures	  were	  chilled	  on	  ice	  for	  10	  minutes,	  centrifuged	  at	  3,000	  x	  g	  for	  
10	  minutes	  at	  4°C,	  and	  pellets	  resuspended	  in	  20	  ml	  ice-­‐cold	  10%	  (v/v)	  glycerol	  before	  a	  
further	  centrifugation	  for	  10	  minutes.	  Pellets	  were	  then	  resuspended	  in	  1	  ml	  10%	  glycerol	  
and	   centrifuged	   for	   2	  minutes,	   and	   this	   step	  was	   repeated	   a	   further	   4	   times.	  After	   the	  
final	  centrifugation,	  the	  pellet	  was	  resuspended	  in	  100	  µl	  of	  ice-­‐cold	  10%	  glycerol	  and	  40	  
µl	  of	  cells	  were	  used	  per	  reaction.	  
	  
2.5.5	  Electroporation	  transformation	  
	  
Electrocompetent	  cells	  were	  transformed	  by	  mixing	  40	  µl	  of	  cells	  with	  either	  2	  µl	  purified	  
plasmid	   or	   5	   µl	   ligation	   reaction	   and	   immediately	   transformed	   using	   an	   Eporator	  
electroporator	  (Eppendorf)	  at	  2.5	  kV	  and	  a	  capacitance	  of	  25	  µF.	  One	  ml	  of	  pre-­‐warmed	  
LB	  was	  added	  to	  the	  transformation	  mixture,	  which	  was	  incubated	  at	  37°C	  or	  30°C	  for	  2	  
hours	   with	   shaking	   at	   200	   rpm.	   The	   mixture	   was	   plated	   onto	   LB	   agar	   containing	  
appropriate	  antibiotics,	  and	  incubated	  at	  37°C	  or	  30°C	  overnight.	  
	  
2.5.6	  Heat-­‐shock	  transformation	  
	  
Chemically	  competent	  BL21	  Star	  (DE3)	  and	  XL-­‐1	  Blue	  cells	   (Table	  2-­‐4)	  were	  transformed	  
by	   adding	   either	   2	   µl	   purified	   plasmid	   or	   5	   µl	   ligation	   reaction	   to	   50	   µl	   chemically	  
competent	   cells,	   which	   was	   incubated	   on	   ice	   for	   30	   minutes.	   Cells	   were	   then	   heat	  
shocked	   by	   submersion	   in	   a	   42°C	   water	   bath	   for	   45	   seconds.	   Cells	   were	   immediately	  
returned	  to	  ice	  for	  2	  minutes	  before	  1	  ml	  of	  pre-­‐warmed	  LB	  was	  added.	  The	  transformed	  
bacteria	  were	  incubated	  at	  37°C	  or	  30°C	  for	  2	  hours	  with	  shaking,	  and	  the	  mixture	  plated	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2.5.7	  p16Slux	  integration	  
	  
All	  bacterial	  strains	  used	  in	  animal	  models	  were	  bioluminescently	  labelled	  by	  integration	  
of	  the	  bacterially	  encoded	  luminescence	  genes	  (lux)	  into	  each	  genome.	  This	  allowed	  live	  
imaging	   of	   infection	   within	   the	   whole	   animal	   using	   an	   in	   vivo	   imaging	   system	   (IVIS)	  
Spectrum	  (PerkinElmer).	  The	  p16Slux	  plasmid	  encodes	  the	  lux	  operon	  from	  Photorhabdus	  
luminescens,	   a	  16S	  RNA	  gene	   insertion	   site,	  and	  an	  erythromycin	   resistance	  cassette	   to	  
allow	   for	   selection	   of	   successful	   integration.	   Bacterial	   strains	   were	   transformed	   with	  
p16Slux	   by	   electroporation,	   plated	   onto	   agar	   containing	   500	   µg/ml	   erythromycin,	   and	  
incubated	  at	  30	  °C	  for	  48	  hours.	  Colonies	  were	  examined	  for	  luminescence	  emission	  using	  
the	   IVIS,	   and	   positive	   colonies	   inoculated	   into	   LB	   containing	   erythromycin	   and	   grown	  
overnight	   at	   30°C.	   The	   overnight	   culture	   was	   diluted	   1:1000	   into	   fresh	   erythromycin-­‐
containing	  LB,	  and	  grown	  for	  18	  hours	  at	  42°C.	  Serial	  dilutions	  of	  the	  culture	  were	  plated	  
onto	  agar	  containing	  erythromycin	  and	  incubated	  at	  42°C	  overnight.	  Plasmid	  integration	  
was	   confirmed	   by	   amplification	   of	   a	   1,150	   bp	   product	   from	   chromosomal	   DNA,	   using	  
primers	  for	  chromosomal	  sequences	  flanking	  the	  integration	  site	  (Table	  2-­‐7).	  
	  
2.5.8	  Creation	  of	  eaeH	  and	  yghJ	  deletion	  mutants	  by	  lambda	  red	  phage	  mutagenesis	  
	  
Lambda	   red	   mutagenesis	   is	   a	   technique	   used	   to	   create	   single	   step	   gene	   knockouts	   in	  
bacteria.	  This	  involves	  PCR	  amplification	  of	  an	  antibiotic	  resistance	  cassette	  that	  contains	  
5’	   and	  3’	   overhangs	   that	   directly	   flank	   the	   target	   gene,	  which	   is	   then	   transformed	   into	  
bacterial	  cells.	  When	   integration	  occurs,	   the	   target	  gene	   is	   replaced	  with	   the	  resistance	  
marker,	  which	  is	  used	  as	  a	  selection	  marker	  for	  identification	  of	  such	  mutants.	  This	  event	  
is	   reliant	   on	   the	   bacteriophage	   Lambda	   Red	   genes	   exo	   (encoding	   a	   5’3’	   dsDNA	  
exonuclease),	   bet	   (encoding	   an	   ssDNA	   annealing	   protein)	   and	   gam	   (encoding	   an	   anti-­‐
exonuclease	   protein).	   These	   genes	   are	   encoded	   on	   the	   arabinose-­‐inducible	   Red	  
recombinase	   expression	   plasmid	   pKD46.	  When	   the	   resistance	   cassette	   is	   introduced	   to	  
bacteria	  transformed	  with	  pKD46,	  the	  Gam	  protein	  prevents	  host	  degradation	  of	  foreign	  
DNA	  by	  RecBCD	  and	  SbcCD	  nucleases,	  Exo	  converts	  the	  5’	  ends	  of	  the	  PCR	  product	  into	  3’	  
ssDNA	  overhangs,	  and	  Bet	  uses	  these	  overhangs	  to	  pair	  them	  with	  their	  complementary	  
target	  (Datsenko	  &	  Wanner,	  2000).	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To	   construct	   the	  kanamycin	   cassette	  with	  either	   the	  eaeH	   or	  yghJ	   flanking	   regions,	   the	  
kanamycin	   resistance	   gene	   was	   amplified	   from	   the	   pKD4	   plasmid	   using	   primers	  
containing	  50	  bp	  of	  eaeH	  (5’:	  +85	  to	  +134,	  3’:+4009	  to	  +4058)	  or	  50	  bp	  of	  yghJ	  (5’:	  +669	  to	  
+718,	   3’:	   +4593	   to	   +4642).	   The	   PCR	   products	   from	   10	   reactions	   were	   run	   on	   a	   0.5%	  
agarose	  gel,	  and	  DNA	  excised	  from	  the	  gel,	  purified	  and	  pooled.	  
	  
Electrocompetent	   LF82	   were	   transformed	   with	   the	   AmpR	   pKD46	   plasmid	   prior	   to	  
transformation	   with	   the	   kanamycin	   cassette.	   Transformants	   were	   recovered	   in	   LB	  
containing	  0.1	  M	  arabinose,	  which	  acts	  as	   the	   inducer	   for	   lambda	  red	   induction,	  plated	  
onto	  LB	  agar	  containing	  arabinose	  and	  ampicillin,	  and	  grown	  overnight	  at	  30°C.	  	  
	  
Transformed	  LF82	  were	  made	  electrocompetent	  again,	  transformed	  with	  approximately	  3	  
µg	  of	   the	  kanamycin	   cassette	  DNA,	  and	  plated	  onto	  kanamycin	  agar	  plates	  which	  were	  
then	   incubated	   overnight	   at	   42°C.	   Colonies	   were	   re-­‐streaked	   on	   LB	   agar	   containing	  
kanamycin,	   and	   incubated	   at	   42°C	   for	   2-­‐3	   days	   to	   allow	   curing	   of	   the	  mutant	   strain	   of	  
temperature-­‐sensitive	   pKD46.	   Colonies	  with	   integration	   of	   the	   cassette	   and	   removal	   of	  
the	   plasmid	   were	   able	   to	   grow	   on	   LB	   agar	   containing	   kanamycin,	   but	   not	   on	   agar	  
containing	  ampicillin.	  Successful	  gene	  knockouts	  were	  identified	  by	  colony	  PCR	  with	  two	  
sets	  of	  primers	  (Table	  2-­‐7).	  One	  set	  of	  primers	  amplified	  300-­‐400	  bp	  DNA	  present	  only	  in	  
the	  genome	  of	  LF82	  in	  which	  either	  eaeH	  or	  yghJ	  had	  been	  replaced	  with	  the	  kanamycin	  
cassette.	  The	  other	  set	  of	  primers	  amplified	  300-­‐400	  bp	  DNA	  in	  the	  genome	  present	  only	  
when	  eaeH	  or	  yghJ	  remained	  intact.	  
	  
2.5.9	  Creation	  of	  spontaneous	  streptomycin-­‐resistant	  mutants	  
	  
Spontaneous	   streptomycin-­‐resistant	   E.	   coli	   mutants	   were	   created	   by	   growing	   the	   lux-­‐
marked	  strains	   in	  25	  ml	  LB	  until	  an	  OD600	  of	  0.6	  was	  reached.	  Bacteria	  were	  pelleted	  by	  
centrifugation,	  resuspended	  in	  500	  µl	  fresh	  LB,	  and	  the	  entire	  inoculum	  plated	  onto	  agar	  
containing	   100	   µg/ml	   streptomycin.	   Plates	   were	   incubated	   overnight	   at	   37°C,	   and	   8	  
colonies	  on	  each	  plate	  selected	  for	  further	  characterisation.	  
	  
To	  determine	  the	  specific	  mutation	  in	  the	  rpsL	  gene	  of	  each	  StrR	  mutant,	  the	  entire	  gene	  
was	   amplified	   by	   PCR	   using	   primers	   described	   in	   Table	   2-­‐7.	   The	   resultant	   product	  was	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cloned	   into	   StrataClone	   Cloning	   Vector	   pSC-­‐A-­‐amp/kan	   (Agilent	   Technologies).	   Clones	  
containing	   the	   insert	   were	   verified	   by	   X-­‐gal	   blue/white	   screening	   and	   sequenced	   by	  
Eurofins	  MWG	  Operon	  using	  a	  T7	  primer.	  
	  
2.6	  Protein	  overexpression	  and	  purification	  
	  
2.6.1	  Protein	  overexpression	  
	  
For	  expression	  of	  recombinant	  proteins,	  plasmids	  encoding	  the	  genes	  were	  transformed	  
into	  BL21(DE3)	  cells	  and	  cultured	  in	  LB	  until	  an	  OD600	  of	  0.6	  was	  reached,	  at	  which	  point	  
expression	   of	   the	   proteins	   was	   induced	   by	   addition	   of	   1	   mM	   IPTG.	   Bacteria	   were	  
incubated	   for	   a	   further	   4	   hours,	   harvested	   by	   centrifugation,	   and	   cell	   pellets	   stored	   at	  	  
-­‐20°C.	  
	  
2.6.2	  Protein	  purification	  
	  
Cell	  pellets	  were	  resuspended	   in	  buffer	  A	  (Table	  2-­‐12)	  with	  DNAase	  (Sigma-­‐Aldrich)	  and	  
protease	   inhibitors	   (Enzo	   Life	   Sciences)	   added.	   Cells	   were	   lysed	   by	   sonication	   using	   a	  
Soniprep	   150	   (MSE)	   sonicator	   at	   an	   amplitude	   of	   40%	   for	   5	   minutes	   with	   pulses	   of	   5	  
seconds	  on	  and	  10	  seconds	  off.	  The	  resultant	  cell	   lysate	  was	  centrifuged	  at	  4000	  x	  g	  for	  
15	  minutes,	   and	   the	   supernatant	   containing	   the	   soluble	   recombinant	  protein	   removed.	  
The	  His-­‐tagged	  proteins	  were	  purified	  using	  immobilised	  metal	  affinity	  chromatography.	  
Lysates	  were	   loaded	  onto	   a	   5	  ml	  Ni2+	  HisTrap	  Column	   (GE	  Healthcare)	   pre-­‐equilibrated	  
with	   buffer	   A.	   Bound	   protein	   was	   eluted	   using	   buffer	   B	   in	   1	   ml	   fractions	   and	   protein	  
identified	   by	   sodium	   dodecyl	   sulphate	   polyacrylamide	   gel	   electrophoresis	   (SDS-­‐PAGE)	  
analysis	   of	   fractions.	   To	   remove	   imidazole	   from	   the	   protein	   fractions,	   samples	   were	  
dialysed	  against	  2	  litres	  of	  20	  mM	  Tris	  pH	  7.5	  and	  500	  mM	  NaCl	  for	  4	  hours.	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Table	  2-­‐12:	  Components	  of	  protein	  purification	  buffers.	  
Buffer	   Components	  
Buffer	  A	   20	  mM	  Tris	  pH	  7.5	  
	  
500	  mM	  NaCl	  
	  
20	  mM	  imidazole	  
Buffer	  B	   20	  mM	  Tris	  pH	  7.5	  
	   500	  mM	  NaCl	  
	   300	  mM	  imidazole	  
	  
2.7	  Phenotypic	  characterisation	  of	  strains	  
	  
2.7.1	  Secretion	  assays	  
	  
To	   induce	  Type	  3	  expression	  and	  protein	   secretion,	  E.	   coli	   strains	  were	  grown	   in	  MEM-­‐
HEPES	   at	   37°C	   with	   shaking	   until	   an	   OD600	   of	   0.8	   was	   reached.	   Cells	   were	   pelleted	   by	  
centrifugation	  at	  4000	  x	  g	  for	  15	  minutes,	  and	  the	  supernatant	  removed	  and	  centrifuged	  
again	  to	  remove	  any	  remaining	  bacteria.	  The	  supernatant	  was	  carefully	  removed	  to	  avoid	  
disturbing	   the	   cell	   pellet,	   and	   trichloroacetic	   acid	   (TCA)	   added	   to	   the	   supernatant	   at	   a	  
final	   concentration	   of	   10%.	   Secreted	   proteins	   were	   precipitated	   overnight	   at	   4°C,	   and	  
pelleted	  by	  centrifugation	  at	  4,000	  x	  g	  for	  45	  minutes.	  The	  supernatant	  was	  removed,	  and	  
the	   pellet	   dried	   and	   resuspended	   in	   1.5	   M	   Tris	   pH	   8.8.	   Secreted	   proteins	   were	   then	  




Samples	  for	  analysis	  by	  SDS-­‐PAGE	  were	  prepared	  in	  NuPAGE	  sample	  buffer	  (Invitrogen)	  at	  
a	  final	  concentration	  of	  1x.	  These	  were	  boiled	  for	  10	  minutes	  at	  95°C	  before	  10-­‐20	  µl	  of	  
the	  sample	  was	  loaded	  onto	  NuPAGE	  4-­‐12%	  Bis-­‐Tris	  pre-­‐cast	  gels	  (Invitrogen).	  SeeBlue+2	  
molecular	   weight	   marker	   (Invitrogen)	   was	   included	   to	   allow	   differentiation	   of	   protein	  
sizes	  and	  MES	  buffer	  (Invitrogen)	  was	  used	  as	  a	  running	  buffer.	  Gels	  were	  run	  at	  150	  V	  for	  
50	  minutes	  and	  then	  stained	  using	  Coomassie	  Blue	  stain	  (Table	  2-­‐13)	  for	  one	  hour.	  Non-­‐
specific	   staining	   was	   removed	   using	   destain	   solution	   or	   water	   until	   the	   background	  
staining	  of	  the	  gels	  was	  clear.	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Table	  2-­‐13:	  Components	  of	  SDS-­‐PAGE	  stains.	  
Stain	   Volume	  used	  (µl)	  
Coomassie	  Blue	   0.5	  g	  Coomassie	  blue	  R250	  
	   400	  ml	  methanol	  
	   100	  ml	  acetic	  acid	  
	   500	  ml	  dH2O	  
Destain	  solution	   400	  ml	  methanol	  
	   100	  ml	  acetic	  acid	  
	   dH2O	  
	  
2.7.3	  Western	  blotting	  
	  
Proteins	   from	   SDS-­‐PAGE	   gels	   were	   transferred	   onto	   Amersham	   Hybond	   enhanced	  
chemiluminescence	   (ECL)	   nitrocellulose	  membrane	   (GE	  Healthcare)	   using	   the	   Sure-­‐Lock	  
Cell	   Blotting	  Module	   (Invitrogen)	   at	   30	   volts	   for	   90	  minutes.	  Membranes	  were	   blocked	  
overnight	   in	   3%	   skimmed	   milk	   (Marvel)	   in	   PBS	   containing	   0.1%	   Tween	   (PBST)	   at	   4°C.	  
Primary	   antibody	   in	   1%	   skimmed	   milk	   made	   with	   PBST	   was	   added	   to	   membranes	   at	  
concentrations	   shown	   in	   Table	   2-­‐14.	   These	   were	   incubated	   for	   1	   hour	   at	   room	  
temperature	  with	   gentle	   rocking,	   and	  unbound	   antibody	   removed	  with	   3	   x	   15	  minutes	  
washes	   with	   PBST.	   The	   membrane	   was	   then	   incubated	   with	   secondary	   antibody	  
conjugated	  to	  horseradish	  peroxidase	  (Invitrogen)	   for	  1	  hour	  at	  room	  temperature	  with	  
rocking.	  Three	  15	  minute	  washes	  with	  PBST	  ensured	  removal	  of	  unbound	  antibody.	  Blots	  
were	   developed	   by	   ECL,	   using	   SuperSignal	   West	   Pico	   Chemiluminescent	   Substrate	  
(Thermo	  Fisher	  Scientific).	  
	  
Table	  2-­‐14:	  Antibodies	  used	  in	  this	  study.	  
Primary	  antibody	   Dilution	   Secondary	  antibody	   Origin	  of	  primary	  antibody	  
Rabbit	  anti-­‐EaeH	   1:5,000	   Goat	  anti-­‐Rabbit	   Novartis	  Vaccines	  
Rabbit	  anti-­‐YghJ	   1:10,000	   Goat	  anti-­‐Rabbit	   Novartis	  Vaccines	  
Rabbit	  anti-­‐GroEL	   1:10,000	   Goat	  anti-­‐Rabbit	   Enzo	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2.7.4	  Motility	  assay	  
	  
Bacterial	  motility	  was	  determined	  using	  LB	  agar	  plates	  containing	  0.25%	  (w/v)	  agar.	  The	  
center	  of	  the	  agar	  was	  inoculated	  with	  5	  µl	  of	  a	  bacterial	  culture	  at	  an	  OD600	  of	  0.8	  and	  
the	   plates	  were	   incubated	   at	   30°C	   overnight.	   The	   diameter	   of	   the	   swimming	   zone	  was	  
measured	  18	  hours	  after	  inoculation.	  
	  
2.7.5	  Bacterial	  adhesion	  assay	  
	  
To	   determine	   bacterial	   adhesion	   to	   epithelial	   cells,	   Caco-­‐2	   cells	   resuspended	   in	  MEM-­‐
HEPES	   containing	   FCS	  and	  penicillin/streptomycin	  were	  used	   to	   seed	  6-­‐well	   plates	  with	  
9.5	  cm2	  wells	  at	  4x104	  cells/well.	  The	  plates	  were	  incubated	  at	  37°C	  in	  a	  5%	  CO2	  incubator	  
until	   cells	   reached	   confluency.	   Overnight	   cultures	   of	   the	   bacterial	   strains	   were	   diluted	  
1/1,000	   in	  MEM-­‐HEPES	   containing	   the	   appropriate	   antibiotics	   and	   grown	   at	   37°C	   with	  
shaking	  until	  cultures	  reached	  an	  OD600	  of	  0.6.	  Caco-­‐2	  cells	  were	  then	  washed	  2x	  with	  1	  
ml	  MEM-­‐HEPES,	  and	  5	  ml	   fresh	  MEM-­‐HEPES	   (without	  penicillin/streptomycin)	  added	   to	  
the	   wells.	   One	   hundred	   microlitres	   of	   bacterial	   culture	   were	   added	   to	   each	   well,	   and	  
plates	   centrifuged	  at	   37	  x	  g	   for	   3	  minutes	  before	   incubation	   at	   37°C	   and	  5%	  CO2	   for	   4	  
hours.	  Non-­‐adherent	   bacteria	  were	   harvested	   by	   removal	   and	   centrifugation	   of	  media,	  
and	  resuspended	  in	  PBS.	  To	  remove	  adherent	  bacteria,	  wells	  were	  gently	  washed	  3x	  with	  
ice-­‐cold	   sterile	   PBS,	   followed	   by	   addition	   of	   1	  ml	   ice-­‐cold	   1%	   saponin	   in	   PBS,	   or	   0.1%	  
Triton	  X-­‐100	  in	  adhesion	  assay	  buffer	  (Table	  2-­‐15).	  Plates	  were	  left	  on	  ice	  for	  5	  minutes,	  
followed	   by	   removal	   of	   the	  wells	   contents	   from	  which	   the	   bacteria	  were	   harvested	   by	  
centrifugation.	  Bacterial	  pellets	  were	   resuspended	   in	  PBS	  and	   serially	  diluted	  onto	  agar	  
plates	  containing	  appropriate	  antibiotics	  to	  determine	  the	  total	  number	  of	  non-­‐	  adherent	  
and	  adherent	  bacteria	  per	  well.	  
	  
Table	  2-­‐15:	  Components	  of	  adhesion	  assay	  buffer.	  
Component	   Concentration	  (mM)	  
Na2HPO4	   60	  
NaH2PO4	   40	  
KCl	   10	  
MgSO4	   1	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2.7.6	  Immunofluorescence	  microscopy	  
	  
To	  allow	  visualisation	  of	  bacterial/epithelial	  cell	  interactions,	  cover	  slips	  (pre-­‐washed	  with	  
70%	   ethanol	   and	   HEPES	   buffer)	   were	   added	   to	   24-­‐well	   plates,	   and	   were	   seeded	   with	  
4x104	   HeLa	   cells	   suspended	   in	  MEM-­‐HEPES	   containing	   FCS	   and	   penicillin/streptomycin.	  
Plates	  were	  incubated	  overnight	  at	  37°C	  in	  a	  5%	  CO2	  incubator.	  Overnight	  cultures	  of	  the	  
bacterial	   strains	   were	   diluted	   1/1,000	   in	   MEM-­‐HEPES	   containing	   the	   appropriate	  
antibiotics	  and	  allowed	  to	  grow	  at	  37°C	  with	  shaking	  until	  the	  cultures	  reached	  an	  OD600	  
of	  0.6.	  At	  that	  point,	  unattached	  HeLa	  cells	  were	  removed	  by	  washing	  the	  wells	  2x	  with	  1	  
ml	  MEM-­‐HEPES,	  and	  400	  µl	  MEM-­‐HEPES	  (without	  FCS	  and	  penicillin/streptomycin)	  added	  
to	  each	  well.	  Bacterial	  cultures	  were	  diluted	  with	  warm	  MEM-­‐HEPES	  to	  an	  OD600	  of	  0.1,	  to	  
achieve	   a	   multiplicity	   of	   infection	   (MOI)	   of	   approximately	   100,	   and	   100	   µl	   of	   diluted	  
bacteria	  added	  to	  each	  well.	  The	  appropriate	  antibiotics	  were	  also	  added	  to	  wells.	  Plates	  
were	  centrifuged	  at	  37	  x	  g	   for	  3	  minutes	  and	  incubated	  for	  1	  hour	  at	  37°C	  and	  5%	  CO2.	  
Wells	  were	   then	  washed	   once	   to	   remove	   unattached	   bacteria,	   and	   500	  µl	   fresh	  MEM-­‐
HEPES	  (containing	  appropriate	  antibiotics)	  added	  to	  each	  well.	  Plates	  were	  incubated	  at	  
37°C	  and	  5%	  CO2	  for	  a	  further	  3	  hours,	  after	  which	  media	  was	  removed.	  
	  
To	   fix	   cells,	   the	  wells	  were	   initially	  washed	  4x	  with	  PBS,	  and	   finally	   fixed	  by	  addition	  of	  
250	   µl	   2%	   paraformaldehyde	   (PFA)	   in	   PBS.	   Plates	   were	   incubated	   statically	   at	   room	  
temperature	  for	  15	  minutes,	  followed	  by	  a	  further	  15	  minutes	  at	  room	  temperature	  with	  
rocking.	  Wells	  were	  washed	  a	  further	  3x	  with	  PBS,	  and	  cells	  permeabilised	  by	  addition	  of	  
250	  µl	  0.1%	  Triton	  X-­‐100	  (Sigma-­‐Aldrich)	  in	  PBS	  for	  5	  minutes	  at	  room	  temperature	  with	  
rocking.	  They	  were	  then	  washed	  4x	  with	  PBS	  to	  remove	  the	  detergent.	  
	  
To	   stain	   for	   actin,	   250	   µl	   (1	   unit)	   Phalloidin	   647	   (Thermo	   Fisher	   Scientific)	   in	   PBS	   was	  
added	  to	  wells,	  and	  plates	   incubated	  for	  60	  minutes	  at	  room	  temperature	  with	  rocking.	  
From	   this	   point	   onwards,	   plates	   were	   kept	   in	   the	   dark	   using	   foil	   to	   prevent	  
photobleaching.	   After	   incubation,	   wells	   were	   washed	   3x	   with	   PBS.	   Cover	   slips	   were	  
mounted	   using	   fluorescent	   mounting	   medium	   (Dako).	   Slides	   were	   left	   in	   the	   dark	  
overnight	   to	   set	   and	   imaged	  on	  a	  Zeiss	  M1	  Axioskop	  microscope.	  Cells	  were	   imaged	  at	  
x100	  and	  were	  captured	  using	  Velocity	  (PerkinElmer)	  software.	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2.7.7	  GFP	  reporter	  fusion	  assays	   	  
	  
Measurement	   of	   gene	   expression	   as	   determined	   by	   GFP	   fluorescence	   was	   carried	   out	  
using	   the	   promoter:GFP	   reporter	   fusion	   constructs	   listed	   in	   Table	   2-­‐5.	   Plasmids	   were	  
transformed	   by	   electroporation	   into	   bacterial	   strains	   and	   transformants	   cultured	  
overnight	  into	  LB	  containing	  chloramphenicol.	  Overnight	  cultures	  were	  diluted	  into	  fresh	  
LB	   to	   an	   OD600	   of	   0.08	   and	   grown	   at	   37°C	   for	   6	   hours,	   with	   OD600	   and	   fluorescence	  
measured	   hourly.	   Fluorescence	   of	   GFP	   was	   recorded	   by	   analysis	   of	   200	   µl	   aliquots	   of	  
culture	  supernatant	  placed	  in	  a	  96-­‐well	  black	  microtiter	  plate	  and	  fluorescence	  measured	  
using	  a	  FLUOstar	  Optima	  plate	  reader	  (BMG	  Labtech).	  Three	  gain	  values	  were	  taken,	  and	  
the	  measurement	   taken	  as	   the	  highest	   gain	   that	  did	  not	   reach	  maximum	   fluorescence.	  
Fluorescence	  was	  plotted	  against	  either	  optical	  density	  or	  time.	  
	  
2.7.8	  Mitomycin	  C	  (MMC)-­‐induced	  Stx-­‐GFP	  reporter	  fusion	  assay	  
	  
The	  Stx-­‐GFP	  reporter	  fusion	  assay	  was	  performed	  as	  described	  in	  2.7.7,	  however	  the	  AHU	  
compounds	  and	  MMC	  were	  added	  to	  the	  culture	  only	  when	   it	  reached	  an	  OD600	  of	  0.7-­‐
0.8.	  The	  AHU	  compounds	  were	  used	  at	  final	  concentrations	  of	  10-­‐200	  µM,	  and	  MMC	  at	  a	  
final	   concentration	   of	   1	   µg/ml.	   Cultures	   contained	   a	   dimethyl	   sulfoxide	   (DMSO)	  
concentration	  of	  1%,	  including	  the	  control	  containing	  0	  µM	  compound.	  
	  
2.7.9	  Phage	  transduction	  assays	  
	  
The	  production	  and	  transduction	  of	  phages	  was	  performed	  using	  two	  strains:	   the	  strain	  
carrying	  the	  specific	  prophage	  genes	  and	   lacking	  other	   lysogenic	  prophages,	  and	  a	  non-­‐
lysogenic	  acceptor	  strain.	  In	  E.	  coli	  the	  acceptor	  strain	  was	  MG1655,	  and	  in	  S.	  aureus	  was	  
RN4220.	  The	  prophage	  strains	  were	  grown	  at	  37	  °C	  until	  an	  OD600	  of	  0.25	  was	  reached,	  
using	  either	   LB	   (E.	   coli	   strains)	  or	  TSB	   (S.	  aureus	  strains).	  At	   this	  point,	   test	   compounds	  
were	  added	  at	  a	  final	  concentration	  of	  50	  µM,	  MMC	  added	  at	  a	  final	  concentration	  of	  2	  
µg/ml,	   or	   ciprofloxacin	   at	   a	   final	   concentration	   of	   50	   ng/ml.	   The	   final	   concentration	   of	  
DMSO	   in	   cultures	  was	   0.25%.	   Cultures	  were	   grown	   at	   32°C	  with	   80	   rpm	   shaking	   for	   4	  
hours	   then	   grown	   overnight	   at	   room	   temperature	   without	   shaking,	   and	   culture	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containing	  the	  phage	  lysate	  filtered	  through	  a	  0.2	  µm	  filter.	  Phage	  lysate	  was	  diluted	  to	  
1:105	  in	  phage	  buffer	  (Table	  2-­‐16),	  and	  100	  µl	  of	  the	  diluted	  phage	  added	  to	  1	  ml	  of	  the	  
acceptor	   strain,	  which	  was	  at	   an	  OD600	  of	  1.4	  and	   contained	  10	  mM	  CaCl2.	   These	  were	  
incubated	  without	  shaking	  at	  37°C	  for	  30	  minutes.	  Three	  milliliters	  of	  LB	  containing	  0.75%	  
agar	  was	   added	   to	   bacteria,	   and	   this	  mixture	   poured	   onto	   LB	   agar	   plates	   containing	   6	  
μg/ml	  tetracycline	  and	  1.7	  mM	  sodium	  citrate.	  Plates	  were	  incubated	  at	  37°C	  overnight,	  
with	  each	  colony	  generated	  reflecting	  a	  successful	  single	  phage	  transduction	  event.	  
	  
Table	  2-­‐16:	  Components	  of	  phage	  buffer.	  
Component	   Concentration	  (mM)	  
NaCl	   100	  
Tris	  pH	  7.8	   500	  
MgSO4	   1	  
CaCl2	   4	  
	  
	  
2.8	  Biophysical	  techniques	  
	  
2.8.1	  Microscale	  thermophoresis	  
	  
RecA	   was	   covalently	   labelled	   with	   NT.Red	   dye	   (NanoTemper	   Technologies),	   and	  
unattached	  dye	  removed	  using	  a	  gravity	  flow	  column.	  AHU3	  was	  prepared	   in	  4%	  DMSO	  
and	  PBS	  at	  concentrations	  between	  12	  pM	  and	  200	  µM,	  while	  RecA	  in	  PBS	  was	  kept	  at	  a	  
constant	  concentration	  of	  100	  µM.	  After	   incubation	  at	  room	  temperature	  of	  5	  minutes,	  
samples	  were	  loaded	  into	  MST	  NT.115	  standard	  glass	  capillaries	  and	  the	  MST	  analysis	  was	  
performed	  using	  a	  Monolith	  NT	  (NanoTemper	  Technologies).	  
	  
2.8.2	  Analytical	  ultracentrifugation	  
	  
The	   effect	   of	   AHU3	   on	   oligomerisation	   of	   RecA	   was	   assessed	   via	   sedimentation	  
equilibrium	   (SE)	   analytical	   ultracentrifugation	   (AUC),	   following	   the	   methodology	   of	  
Brenner	  et	   al.	   (1990).	   AUC	  was	   carried	   out	   in	   an	  Optima	   XL-­‐I	   analytical	   ultracentrifuge	  
(Beckman	   Coulter).	   Samples	   were	   dialysed	   for	   2	   hours	   against	   2	   litres	   of	   50	   mM	   Na-­‐
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citrate,	  5%	  (w/v)	  glycerol	  pH	  6.0,	  buffer	  conditions	  optimal	  for	  maximising	  the	  oligomeric	  
state	  of	  RecA	  (Brenner	  et	  al.,	  1990),	  and	  80	  µl	  of	  each	  sample	  loaded	  into	  double	  sector	  
centerpieces.	  Three	  samples	  were	  studied:	  10	  µM	  RecA,	  10	  µM	  RecA	  +	  0.5%	  (v/v)	  DMSO,	  
and	  10	  µM	  RecA	  +	  0.5%	  (v/v)	  DMSO	  +	  100	  µM	  AHU3.	  Rotor	  speeds	  of	  6,	  10	  and	  14	  k	  rpm	  
at	  a	  temperature	  of	  4°C	  and	  20°C	  were	  used	  (Table	  2-­‐17).	  Scans	  were	  taken	  every	  3	  hours	  
until	   analysis	   with	   WinMATCH	   indicated	   that	   equilibrium	   had	   been	   reached.	  
Sedimentation	  equilibrium	  data	  was	  analysed	  with	  SEDPHAT	  (Vistica	  et	  al.,	  2004)	  by	  Dr.	  
Olwyn	  Byron,	  University	  of	  Glasgow,	  using	   the	  single	  species	  analysis	  model	   in	  order	   to	  
gain	  a	  model-­‐independent	  measure	  of	  the	  whole-­‐cell	  average	  molecular	  weight.	  
	  
Table	  2-­‐17:	  Partial	  specific	  volumes	  of	  proteins,	  and	  densities	  and	  intrinsic	  viscosities	  of	  buffers	  used	  in	  
analytical	  ultracentrifugation.	  Values	  were	  calculated	  using	  SEDNTERP.	  
Temperature	  (°C)	   Partial	  specific	  volume	  (g/ml)	   Buffer	  density	   Buffer	  viscosity	  
4	   0.733	   1.020	   0.018	  
20	   0.740	   1.018	   0.012	  
	  
	  
2.8.3	  ATPase	  assays	  
	  
Colourmetric	  ATPase	  assays	  were	  performed	  using	  a	  commercial	  ATPase	  assay	  kit	  (#601-­‐
0120,	   Innova	   Biosciences),	   which	   is	   based	   on	   the	   formation	   of	   coloured	   complexes	  
between	   an	   inorganic	   phosphate	   and	   a	   dye	   molecule	   under	   acidic	   conditions.	   ATPase	  
reactions	  were	   carried	   out	   in	   Costar	   clear	   flat-­‐bottomed	   96-­‐well	   assay	   plates	   (Corning)	  
following	   the	   manufacturer’s	   protocol.	   RecA,	   poly	   dT	   single-­‐stranded	   DNA	   (ssDNA;	  
Midland	  Certified	  Reagent	  Company)	   and	  AHU	  were	  added	   to	   the	   substrate/buffer	  mix	  
(assay	   buffer,	   MgCl2,	   ATP)	   at	   volumes	   shown	   in	   Table	   2-­‐18.	   RecA	   was	   used	   at	   a	   final	  
concentration	  of	  250	  nM,	  ssDNA	  at	  5	  µM,	  and	  DMSO	  (required	  for	  AHU	  solubility)	  at	  2%	  
(v/v).	  AHU3	  and	  AHU4	  were	  used	  at	   concentrations	  between	  0.1	  µM	  and	  200	  µM.	  The	  
reaction	  was	  incubated	  at	  37°C	  for	  30	  minutes,	  then	  stopped	  by	  addition	  of	  12.5	  µl	  Gold	  
mix	  (PiColorLockTM	  Gold	  with	  1/100	  vol.	  of	  Accelerator	  added),	  followed	  by	  addition	  of	  5	  
µl	  Stabiliser	  2	  minutes	  later.	  After	  30	  minutes	  at	  room	  temperature	  the	  plate	  was	  read	  at	  
a	  wavelength	  of	  650	  nm.	  A	  negative	  control	  lacking	  RecA	  was	  included,	  as	  was	  a	  further	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sample	  which	  lacked	  ssDNA,	  to	  confirm	  that	  the	  reaction	  was	  dependent	  on	  activation	  of	  
RecA	  by	  ssDNA.	  
	  
Table	  2-­‐18:	  Volumes	  of	  components	  in	  a	  single	  ATPase	  assay	  well.	  
Component	   Volume	  used	  (µl)	  
50	  µM	  RecA	   0.25	  
500	  µM	  poly	  dT	  ssDNA	   0.5	  
1-­‐2000	  µM	  AHU3/AHU4	  (in	  20%	  DMSO)	   5	  
Assay	  buffer	   5	  
0.1	  M	  MgCl2	   1.25	  
10	  mM	  ATP	   2.5	  
Nuclease-­‐free	  water	   35.5	  
	  
	  
2.8.4	  AHU	  cytotoxicity	  testing	  
	  
Cytotoxicity	   screening	   of	   the	   compounds	   AHU1-­‐3	   was	   undertaken	   by	   the	   European	  
Screening	   Port	   (Hamburg,	   Germany).	   Briefly,	   Human	   Embryonic	   Kidney	   293	   (HEK	   293)	  
cells	  were	   grown	   until	   80-­‐90%	   confluency,	   before	   being	   harvested	   and	   resuspended	   in	  
DMEM	  in	  384-­‐well	  plates	  containing	  the	  AHU	  compounds	  and	  0.1	  %	  (v/v)	  DMSO.	  After	  24	  
hours	   of	   incubation	   at	   37°C	   in	   the	   presence	   of	   5%	   CO2,	   20	   µl	   of	   CellTiter-­‐Glo	   reagent	  
(#G7571;	  Promega)	  was	  added	   to	  each	  well	  and	   incubated	  at	   room	  temperature	   for	  10	  
minutes.	  Luminescence	  was	  recorded	  as	  a	  measure	  of	  cell	  survival;	  the	  CellTiter-­‐Glo	  assay	  
is	   a	   homogeneous	   method	   of	   determining	   the	   number	   of	   viable	   cells	   based	   on	  
quantitation	   of	   ATP	   present,	   an	   indicator	   of	   metabolically	   active	   cells.	   All	   compounds	  
were	   tested	   on	   three	   different	   days	   in	   duplicate.	   Raw	   data	   was	   processed	   using	  
ActivityBase	   XE	   (IBDS),	   and	   the	   percentage	   cytotoxicity	   relative	   to	   the	   positive	   and	  
negative	   controls	   calculated.	   Compounds	   were	   classed	   as	   actives	   when	   the	   calculated	  
cytotoxicity	  was	  >50%	  of	  that	  relative	  to	  the	  positive	  and	  negative	  controls.	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2.9	  Animal	  experiments	  
	  
2.9.1	  Home	  Office	  animal	  licence	  
	  
All	   procedures	   were	   carried	   out	   in	   strict	   accordance	   with	   the	   Animals	   Act	   (Scientific	  
Procedures,	   1986)	   and	   were	   approved	   by	   the	   Home	   Office,	   United	   Kingdom	   (project	  
license	  number	  PPL60/4218,	  held	  by	  Dr.	  Gillian	  Douce).	  
	  
2.9.2	  Mouse	  maintenance	  
	  
All	   mice,	   aged	   6-­‐8	   weeks	   and	   female,	   were	   purchased	   from	   Harlan	   Laboratories,	   UK.	  
Mouse	   strains	   used	  were	   inbred	   BALB/c,	   C57BL/6	   and	   C3H/HeJ,	   and	   outbred	   ICR	   (also	  
known	  as	  CD-­‐1)	  mice.	  Mice	  were	  housed	  in	  groups	  of	  5	  at	  a	  controlled	  temperature	  (22°C)	  
with	  a	  12	  hour	  light/dark	  cycle,	  and	  were	  fed	  BK001E	  Beekay	  rat	  and	  mouse	  diet	  (Special	  
Diet	   Services)	   at	   libitum	   with	   free	   access	   to	   water	   at	   all	   times.	   Mice	   were	   culled	   by	  
cervical	  dislocation	  or	  by	  terminal	  anaesthesia.	  
	  
2.9.3	  Bacterial	  infection	  of	  mice	  
	  
Bacterial	   strains	   for	  mouse	   infections	   were	   grown	   in	   DMEM	   until	   an	   OD600	   of	   0.8	   was	  
reached.	  Bacteria	  were	  pelleted	  by	  centrifugation	  and	  resuspended	  in	  PBS	  to	  concentrate	  
the	   culture	   100x.	   Bacterial	   viability	   to	   assess	   infection	   dose	   was	   determined	   by	   serial	  
dilution	   of	   the	   inoculum	   and	   plating	   onto	   LB	   agar.	   This	   revealed	   the	   concentration	   of	  
bacteria	  to	  be	  approximately	  1011	  CFU/ml.	  Mice	  were	  infected	  by	  oral	  gavage	  with	  100	  µl	  
each	  strain,	  or	  1010	  CFU/dose.	  Mice	  infected	  with	  E.	  coli	  were	  orally	  gavaged	  30	  minutes	  
prior	  to	  infection	  with	  100	  µl	  of	  0.1	  M	  sodium	  bicarbonate	  to	  reduce	  the	  acid	  pH	  of	  the	  
stomach.	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2.9.4	  Live	  imaging	  of	  infected	  mice	  
	  
Progression	  of	   infection	   in	   individual	  mice	  was	  determined	  using	  the	   IVIS	  Spectrum.	  For	  
imaging,	  mice	  were	  anaesthetised	  by	   inhalation	  of	  2%	   isoflurane	  which	  was	  maintained	  
during	   the	   imaging	   process.	   Luminescence	   as	   photons	   per	   second	   (p/s)	   was	   recorded	  
using	  an	  exposure	  time	  of	  one	  minute,	  with	  large	  or	  medium	  binning.	  
	  
2.9.5	  Faecal	  shedding	  counts	  of	  infected	  mice	  
	  
To	  determine	  bacterial	  colonisation	  by	  faecal	  shedding,	  faecal	  pellets	  were	  collected	  from	  
individual	  mice	  and	  PBS	  added	  to	  give	  a	  faecal	  concentration	  of	  100	  mg/ml.	  Stools	  were	  
softened	   by	   storage	   at	   4°C	   for	   30	  minutes,	   then	   vortexed	   to	   ensure	   breakdown	  of	   the	  
pellet	   and	   release	  of	  bacteria.	  After	   a	  brief	   centrifugation,	   the	   supernatant	  was	   serially	  
diluted	  in	  PBS,	  and	  10	  µl	  of	  each	  dilution	  spotted	  in	  triplicate	  onto	  LB	  agar	  containing	  500	  
µg/ml	   erythromycin,	   and	   other	   antibiotics	   if	   required.	   The	   average	   number	   of	   colony-­‐
forming	  units	  was	  calculated	  from	  the	  dilution	  at	  which	  colonies	  could	  most	  accurately	  be	  
counted	  (~5-­‐50	  colonies).	  
	  
2.9.6	  Tissue	  collection	  and	  histology	  
	  
In	  order	   to	  determine	   the	  extent	  of	  epithelial	   colonisation	  of	   the	   tissue,	  after	  necropsy	  
the	  caecum,	  small	  intestine	  and	  large	  intestine	  were	  removed,	  opened	  longitudinally	  and	  
washed	  in	  5	  ml	  sterile	  PBS.	  The	  washed	  material	  was	  removed	  and	  these	  samples	  diluted	  
and	  plated	  to	  provide	  estimates	  of	  luminal-­‐associated	  bacteria.	  The	  remaining	  tissue	  was	  
washed	  in	  a	  further	  10	  ml	  PBS	  before	  being	  placed	  in	  5	  ml	  fresh	  PBS	  and	  homogenised	  for	  
5	   minutes	   using	   a	   Stomacher	   Lab-­‐Blender	   80	   (Seward).	   Mucosally-­‐associated	   bacteria	  
were	  measured	  by	  serial	  dilution	  of	  the	  PBS	  and	  agar	  plating	  as	  described	  previously.	  	  
	  
For	  kidney	  histology,	  mouse	  kidneys	  were	  longitudinally	  divided	  and	  fixed	  in	  10%	  buffered	  
formalin,	  dehydrated,	  and	  embedded	  in	  paraffin	  blocks.	  Five-­‐micrometer	  tissue	  sections	  
were	   cut	   and	   stained	  with	   hematoxylin	   and	   eosin	   (H&E)	   and	   periodic	   acid-­‐Schiff	   (PAS)	  
stain	   by	   Lynn	   Stevenson,	   Veterinary	   Diagnostics,	   University	   of	   Glasgow.	   Slides	   were	  
2.	  MATERIALS	  &	  METHODS	  
	   67	  
visualised	   using	   an	   Axiovert	   25	   inverted	  microscope	   (Zeiss)	   at	   400x	  magnifications	   and	  
images	  collated	  using	  AxioVision	  (Zeiss)	  imaging	  software.	  Expert	  advice	  on	  the	  extent	  of	  
kidney	  pathology	  was	  provided	  by	  Dr.	  Shana	  Coley,	  University	  of	  Glasgow.	  
	  
2.10	  Analysis	  of	  data	  
	  
Data	   were	   analysed	   using	   Excel	   (Microsoft)	   and	   Prism	   5	   (GraphPad),	   and	   statistical	  
analysis	   performed	   using	   Prism	   5/Instat	   (Student’s	   unpaired	   t-­‐test,	   ANOVA,	   D’Agostino	  
and	  Pearson	  omnibus	  test)	  or	  R	  software	  (General	  Linear	  Model).	  Statistical	  significance	  
was	  indicated	  as	  a	  p-­‐value	  of	  0.05	  or	  below.	  Significant	  differences	  between	  the	  means	  of	  
two	   groups	   was	   determined	   by	   Student’s	   unpaired	   t-­‐test,	   and	   between	   the	   means	   of	  
more	  than	  two	  groups	  by	  ANOVA.	  Unless	  stated	  otherwise,	  all	  data	  was	  determined	  to	  be	  
parametric,	   after	   visualisation	   of	   data	   as	   a	   histogram,	   and	   for	   data	   sets	   with	   a	   large	  
enough	  sample	  size,	  normality	  analysis	  using	  D’Agostino	  and	  Pearson	  omnibus	  test.	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3.1	  Introduction	  
	  
To	   effectively	   test	   novel	   anti-­‐virulence	   compounds	   in	   vivo,	   appropriate	   animal	   models	  
that	  allow	  bacteria	   to	   replicate	   those	  aspects	  of	  pathogenesis	   targeted	  by	   the	  drug	  are	  
required.	  These	  features,	  such	  as	  colonisation	  by	  adhesion	  or	  invasion,	  or	  development	  of	  
illness	  or	   tissue	  damage,	  should	   ideally	  be	  easily	  observable	  and	  sensitive	  to	  changes	   in	  
the	  virulence	  factor	  of	  interest.	  	  
	  
One	  of	  the	  main	  aims	  of	  this	  chapter	  is	  to	  assess	  colonisation	  of	  mice	  by	  E.	  coli,	  which	  is	  
typically	   followed	   by	   shedding	   of	   bacteria	   in	   faeces.	   Quantification	   of	   the	   number	   of	  
bacteria	  secreted	  in	  faecal	  matter	  is	  achieved	  by	  serial	  dilution	  of	  faecal	  supernatant	  and	  
plating	  onto	  agar	  containing	  an	  antibiotic	   that	   the	   infecting	  E.	   coli	   strain	   is	   resistant	   to,	  
with	  this	  resistance	  preferably	  carried	  on	  the	  chromosome	  rather	  than	  on	  a	  plasmid,	  as	  
selective	  pressure	  to	  retain	  the	  plasmid	  may	  be	  lost	  in	  vivo.	  Another	  method	  for	  studying	  
colonisation	   in	   vivo	   is	   by	   live-­‐imaging	  of	   animals	   infected	  with	  bioluminescent	  bacteria,	  
which	  enables	  assessment	  of	   infection	   in	   real	   time	  and	  without	   	   requiring	   sacrifice	  and	  
analysis	  of	  infected	  animals.	  
	  
The	  prerequisite	  for	  live	  imaging	  is	  the	  production	  of	  luminescence	  or	  fluorescence	  by	  the	  
infecting	  bacteria,	  and	  this	   light	  release	  can	  then	  be	  quantified	  and	  localised	  using	  an	   in	  
vivo	   imaging	   system	   (IVIS).	   Luminescence	   is	   commonly	   achieved	   using	   the	   lux	   operon	  
from	   Photorhabdus	   luminescens,	   a	   Gammaproteobacteria	   that	   lives	   in	   the	   gut	   of	  
entomopathogenic	  nematodes.	  The	  lux	  operon	  can	  be	  introduced	  into	  bacteria	  either	  by	  
plasmid	   or	   by	   integration	   into	   the	   chromosome	   via	   transposon	   mutagenesis.	   These	  
methods,	   however,	   carry	   the	   risk	   of	   plasmid	   loss	   or	   integration	   that	   modifies	   gene	  
expression,	   altering	   bacterial	   phenotype.	   One	   approach	   that	   avoids	   these	   risks	   is	  
chromosomal	  integration	  of	  the	  lux	  operon	  into	  a	  specific	  site	  using	  the	  p16Slux	  vector,	  a	  
plasmid	  containing	  the	  P.	  luminescens	  lux	  operon	  and	  a	  16S	  rRNA	  gene	  insertion	  site.	  This	  
has	   been	   designed	   to	   allow	   site-­‐directed	   chromosomal	   integration	   by	   homologous	  
recombination,	  and	  constitutive	  expression	  of	  high	  levels	  of	  luminescence	  in	  a	  wide	  range	  
of	   Gram-­‐negative	   bacteria	   (Riedel	   et	   al.,	   2007).	   This	   location	   is	   a	   desirable	   site	   for	  
chromosomal	   integration	   due	   to	   high	   conservation	   and	   16S	   redundancy	   (Acinas	   et	   al.,	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2004),	  and	  integration	  of	  p16Slux	  has	  shown	  no	  significant	  influence	  on	  bacterial	  growth	  
(Riedel	  et	  al.,	  2007).	  
	  
3.1.1	  Aims	  of	  this	  chapter	  
	  
• To	   identify	   a	   mouse	   model	   in	   which	   high,	   stable	   levels	   of	   E.	   coli	   O157:H7	  
colonisation	  can	  be	  observed	  over	  a	  significant	  period	  of	  10-­‐14	  days,	  rather	  than	  
clearance	  of	  bacteria	  within	  2-­‐3	  days.	  While	  there	  are	  several	  animal	  species	  that	  
are	  used	  as	  models	  for	  E.	  coli,	  we	  are	  limited	  to	  using	  mice	  by	  the	  available	  animal	  
facilities.	   Additionally,	   as	   the	  O157:H7	   strain	   requires	   a	   Category	   3	   containment	  
laboratory,	   we	   chose	   to	   instead	   use	   TUV93-­‐0,	   an	   Stx-­‐negative	   derivative	   of	   the	  
O157:H7	  EDL933	  strain,	  which	  does	  not	  produce	  any	  signs	  of	  illness	  in	  mice.	  	  
	  
• To	  determine	  whether	   colonisation	   in	   this	  model	   is	   dependent,	   or	   is	   observably	  
influenced	  by	  expression	  of	   the	  T3SS.	  As	  we	  aim	  to	  use	  this	  model	   to	  assess	  the	  
influence	   of	   compounds	   that	   target	   the	   T3SS,	   we	   require	   the	   T3SS	   to	   play	   an	  
essential	  role	  in	  colonisation	  of	  this	  model,	  so	  that	  the	  effects	  of	  treatments	  that	  
successfully	  inhibit	  the	  T3SS	  in	  vivo	  are	  easily	  observed	  by	  significant	  decreases	  in	  
faecal	  shedding	  and	  luminescence.	  
	  
• To	   identify	   a	  mouse	  model	   that	   shows	   high	   and	   sustained	   levels	   of	  E.	   coli	   LF82	  
colonisation.	   LF82,	   considered	   a	   prototype	   AIEC	   strain	   associated	   with	   Crohn’s	  
disease,	   was	   chosen	   as	   unlike	   TUV93-­‐0	   and	   other	   EHEC,	   it	   carries	   the	   gene	  
encoding	  YghJ,	  a	  potential	  vaccine	  candidate	  whose	  role	  in	  colonisation	  is	  unclear	  
and	  warranted	  further	  evaluation	  (explored	  further	  in	  Chapter	  4).	  
	  
• To	  evaluate	  a	  recently	  developed	  C.	  rodentium	  mouse	  model	  that	  expresses	  Stx	  as	  
a	  model	   for	  possible	   in	  vivo	   testing	  of	  compounds	  that	   inhibit	  Stx	  production.	  C.	  
rodentium	   is	  often	  used	  as	  a	  surrogate	  model	   for	  E.	  coli	  as	   it	   is	  a	  closely	   related	  
bacterial	  species	  that	  naturally	  colonises	  mice.	  As	  C.	  rodentium	  does	  not	  colonise	  
humans,	   the	   Stx-­‐expressing	   strain	   is	   classed	   as	   a	   Category	   2	   pathogen,	   and	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therefore	  does	  not	  require	  the	  safety	  precautions	  and	  facilities	  that	  a	  Category	  3	  
pathogen	  like	  O157:H7	  does.	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3.2	  Bioluminescent	  labelling	  of	  bacterial	  strains	  
	  
To	   track	   bacterial	   infection	   in	   real	   time,	   all	   strains	   to	   be	   analysed	   in	   vivo	   were	  
luminescently	   marked	   using	   the	   integrating	   p16Slux	   plasmid	   (Riedel	   et	   al.,	   2007).	   All	  
strains	   were	   checked	   for	   positive	   integration	   using	   PCR,	   and	   luminescence	   production	  
using	  the	  IVIS	  (Figure	  3-­‐1).	   Integration	  of	  the	   lux	  operon	  produced	  a	  strong	  luminescent	  
signal,	  detectable	  after	  an	  exposure	  of	  one	   second	   for	  bacteria	  on	  agar	  plates	  and	  one	  
minute	   in	   mice	   infected	   with	   the	   strains.	   Luminescence	   was	   detected	   by	   the	   IVIS	   and	  
displayed	   in	   colour	   as	   photons	   per	   second	   per	   cm2	   per	   steradian	   (p/s/cm2/sr),	   and	  
luminescence	   in	   individual	  mice	  was	  quantified	  by	  selecting	  a	  region	  of	   interest,	   i.e.	   the	  
whole	  mouse,	  and	  determining	  the	  total	  light	  emission	  in	  photons/second	  for	  that	  region.	  
	  
A	   	   	   B	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Figure	  3-­‐1:	  Integration	  of	  the	  lux	  operon	  into	  E.	  coli	  O157:H7	  strain	  TUV93-­‐0	  and	  its	  luminescence	  on	  agar	  
and	   in	  mice.	   	  To	  create	  strains	  capable	  of	  producing	   luminescence	  for	   live-­‐image	  detection	   in	  vivo,	  E.	  coli	  
strains	   were	   transformed	   with	   the	   p16Slux	   plasmid	   and	   the	   lux	   operon	   integrated	   using	   the	   method	  
described	  by	  Riedel	  et	  al.	  (2007).	  Successful	  lux-­‐positive	  integration	  was	  confirmed	  by	  colony	  PCR	  to	  amplify	  
1,250	   bp	   of	   a	   chromosomal	   DNA	   sequence	   (indicated	   by	   arrow)	   present	   only	   when	   the	   lux	   operon	  was	  
correctly	   inserted	   into	   the	   16S	   locus	   (A).	   Luminescence	   production	   was	   confirmed	   by	   a	   1	   second	   IVIS	  
exposure	  of	  WT	  and	   lux-­‐marked	  strains	  grown	  on	  LB	  agar	   (B).	   In	  vivo	  production	  of	   luminescence	  by	   lux-­‐
marked	   bacteria	   were	   shown	   by	   an	   IVIS	   exposure	   of	   1	   minute	   of	   mice	   infected	   by	   oral	   gavage;	   a	  
representative	   image	   of	   in	   vivo	   bacterial	   luminescence	   production	   in	   a	   BALB/c	   mouse	   three	   days	   after	  
infection	  by	  oral	  gavage	  of	  109	  CFU	  lux-­‐integrated	  TUV93-­‐0	  is	  shown	  (C).	  The	  site	  of	  infection	  in	  the	  mouse	  
is	   indicated	  by	   arrow	  and	   is	   likely	   to	  be	   the	   caecum,	  based	  on	   the	   location	   and	   shape	  of	   the	   signal.	   The	  
colour	  scale	  bar	  below	  indicates	  luminescence	  intensity	  in	  p/s/cm2/sr	  for	  both	  the	  bacteria	  on	  agar	  and	   in	  
vivo.	  
WT	   	   	   	  	  	  	  lux	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3.3	  Colonisation	  of	  BALB/c,	  C57	  and	  C3H/HeJ	  mouse	  strains	  by	  TUV93-­‐0	  
	  
As	   the	   genetic	   diversity	   of	   inbred	  mice	   is	  much	   lower	   than	   outbred	   strains,	   potentially	  
decreasing	  the	  variety	  of	  host	  response	  to	  bacterial	  infection,	  we	  selected	  inbred	  mouse	  
strains	   to	   investigate	   E.	   coli	   colonisation.	   Different	   inbred	   mouse	   populations	   show	  
differing	   response	   to	   the	   severity	   of	   disease	   caused	   by	   the	   pathogen	   Citrobacter	  
rodentium	  (Vallance	  et	  al.,	  2003),	  a	  T3SS-­‐producing	  natural	  mouse	  pathogen	  that	  is	  often	  
used	  as	  a	   surrogate	   for	  E.	   coli	   in	  mice.	  To	  assess	  whether	   the	  susceptibility	  of	  different	  
inbred	   mouse	   strains	   could	   also	   influence	   outcome	   of	   infection	   with	   O157:H7,	   three	  
groups	   of	   the	   inbred	   mouse	   strains	   BALB/c,	   C57BL/6,	   and	   C3H/HeJ,	   consisting	   of	   five	  
animals	   in	   each	   group,	   were	   infected	   with	   TUV93-­‐0	   and	   colonisation	   followed	   by	   live	  
imaging	   and	   faecal	   shedding.	   BALB/c	   and	   C57BL/6	   are	   both	  widely-­‐used	  mouse	   strains	  
which	   have	   been	   utilised	   in	   previous	   E.	   coli	   colonisation	   studies,	   while	   C3H/HeJ	   was	  
chosen	  as	  it	  is	  a	  mouse	  strain	  highly	  vulnerable	  to	  C.	  rodentium	  (Vallance	  et	  al.,	  2003).	  A	  
spontaneous	  mutation	  in	  the	  Toll-­‐like	  receptor	  4	  (TLR4)	  gene	  in	  C3H/HeJ	  mice	  confers	  a	  
hyposensitivity	   to	   LPS	   (Hoshino	  et	  al.,	   1999),	   but	   also	  makes	   them	  more	   susceptible	   to	  
infection	   by	   Gram-­‐negative	   organisms	   due	   to	   delayed	   TLR4-­‐induced	   host	   immune	  
responses	  (Khan	  et	  al.,	  2006).	  
	  
After	   infection	  by	  oral	  gavage	  of	  animals,	   similar	   levels	  of	  TUV93-­‐0	   faecal	  shedding	  was	  
observed	  in	  C57BL/6	  and	  C3H/HeJ	  mice	  with	  levels	  of	  shedding	  highest	  (105-­‐106	  CFU/mg	  
faeces)	   1	   day	   after	   infection.	   This	   was	   followed	   by	   a	   decline	   until	   faecal	   shedding	   of	  
TUV93-­‐0	  was	   no	   longer	   detectable	   (<102	   CFU/mg	   faeces)	   11	   days	   post	   infection.	  While	  
BALB/c	  mice	   shed	   TUV93-­‐0	   at	   significantly	   lower	   levels	   (102	   CFU/mg	   faeces)	   than	   both	  
C57BL/6	   and	   C3H/HeJ	   1	   day	   after	   infection,	   faecal	   shedding	   rose	   to	   similar	   levels	   (104	  
CFU/mg	   faeces)	   4	   days	   post	   infection,	   followed	  by	   a	   decrease	   over	   the	   remaining	   post	  
infection	  period,	  reaching	  undetectable	  levels	  after	  8	  days	  (Figure	  3-­‐2	  A).	  	  
	  
Analysis	   of	   bacterial	   luminescence	   revealed	   a	   high	   signal	   two	   days	   post	   infection	   in	  
BALB/c	   mice	   (106	   p/s),	   which	   then	   gradually	   declined.	   In	   contrast,	   luminescence	   in	  
C57BL/6	   mice	   remained	   at	   background	   levels	   (105	   p/s)	   throughout	   the	   infection,	   and	  
C3H/HeJ	  mice	  showed	  similar	   luminescence	   levels	   to	  BALB/c	  mice	  1	  day	  after	   infection,	  
but	  these	  rapidly	  dropped	  to	  background	  levels	  (Figure	  3-­‐2	  B).	  As	  similar	  levels	  of	  faecal	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shedding	  were	  observed	   in	  all	   three	  mouse	  strains,	  we	  concluded	  that	  the	  difference	   in	  
observed	   luminescence	   probably	   reflected	   mouse	   coat	   colour,	   as	   darker	   coat	   colours	  
(such	  as	  those	  associated	  with	  C57BL/6	  mice)	  absorb	  bioluminescence	  more	  readily.	  We	  
therefore	  chose	  to	  use	  BALB/c	  mice	  for	  future	  experiments	  as	  they	  produced	  the	  highest	  
luminescence	  signal	  and	  were	  colonised	  as	  effectively	  (determined	  by	  faecal	  shedding)	  as	  
the	  C57BL/6	  and	  C3H/HeJ	  strains.	  
	   	  
A	   Faecal	  shedding	   	   	   B	   Luminescence	  	  
	   	  
Figure	  3-­‐2:	  Colonisation	  of	  inbred	  mice	  by	  E.	  coli	  TUV93-­‐0.	  Faecal	  shedding	  (A)	  and	  luminescence	  (B)	  of	  lux-­‐
marked	   TUV93-­‐0	   in	   BALB/c,	   C57BL/6,	   and	   C3H/HeJ	  mouse	   strains.	   Each	   group	   of	  mice	   consisted	   of	   five	  
animals,	  and	  faecal	  shedding	  and	  luminescence	  were	  followed	  for	  10	  days	  after	  infection	  with	  109	  CFU	  lux-­‐
marked	  TUV93-­‐0.	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group,	  and	  standard	  deviation	  from	  the	  mean	  
displayed	   as	   error	   bars.	   Time	   points	   at	   which	   a	   significant	   difference	   between	   the	   means	   of	   groups,	  
determined	  by	  one-­‐way	  ANOVA,	  are	  denoted	  by	  an	  asterisk	  (*	  =	  p<0.05;	  **	  =	  p<0.01;	  ***	  =	  p<0.001).	  
	  
3.4	   Colonisation	   of	   dextran	   sodium	   sulfate-­‐treated	   BALB/c	   mice	   by	  	  
TUV93-­‐0	  and	  LF82	  
	  
While	   this	   first	   experiment	   revealed	   that	   high	   numbers	   of	   TUV93-­‐0	   were	   detected	   by	  
faecal	   shedding	   and	   confirmed	   by	   live	   imaging	   24	   hours	   post	   infection,	   colonisation	  
decreased	   steadily	   from	   this	   point	   reaching	   undetectable	   levels	   8-­‐11	   days	   later,	  
suggesting	   that	   bacteria	  were	  unable	   to	   successfully	   colonise	   the	  mouse	   intestine.	   This	  
observation	  is	  consistent	  with	  previous	  studies	  (Mohawk	  &	  O’Brien,	  2011)	  and	  has	  been	  
associated	  with	  the	  competitive	  influence	  of	  the	  microbiome.	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Interestingly,	  recent	  studies	  in	  both	  human	  intestinal	  bowel	  disease	  patients	  and	  animal	  
models	  of	  gut	   inflammation	  have	  shown	   that	   intestinal	  E.	   coli	   increase	  significantly	  and	  
become	  a	  dominant	  species	  when	  the	  microbiota	   is	  disturbed	  by	   inflammation	  (Lupp	  et	  
al.,	  2007).	  Classically,	  mouse	  models	  of	  colitis	  have	  used	  dextran	  sodium	  sulphate	  (DSS),	  a	  
water	   soluble	   polysaccharide,	   to	   induce	   intestinal	   inflammation	   by	   damaging	   the	  
epithelial	   monolayer	   lining	   the	   large	   intestine.	   This	   leads	   to	   dissemination	   of	  
proinflammatory	  intestinal	  bacteria	  and	  their	  products	  into	  underlying	  tissue.	  Histological	  
changes	   caused	   by	   DSS	   at	   concentrations	   of	   2-­‐5%	   in	   drinking	   water	   include	   intestinal	  
mucin	   depletion	   in	   the	   large	   intestine	   (Chassaing	  et	   al.,	   2014a).	   To	   determine	  whether	  
decreasing	  the	  intestinal	  mucosal	  layer	  and	  allowing	  TUV93-­‐0	  and	  LF82	  greater	  access	  to	  
the	  epithelial	  barrier	  may	  promote	  adhesion,	  we	  treated	  mice	  with	  a	  low	  concentration	  of	  
DSS	   (0.25%	   in	   drinking	  water).	  We	  hypothesized	   that	   this	   concentration	  would	   be	   high	  
enough	   to	   reduce	   mucus	   thickness,	   but	   not	   sufficient	   to	   induce	   colitis	   or	   significant	  
intestinal	  inflammation.	  	  
	  
To	  determine	  the	  effect	  of	  DSS	  on	  E.	  coli	  colonisation,	  mice	  were	  provided	  with	  drinking	  
water	  three	  days	  prior	  to	  infection,	  with	  or	  without	  0.25%	  DSS	  (~40	  kDa).	  After	  infection	  
with	  either	  TUV93-­‐0	  or	  LF82	  all	  animals	  were	  provided	  with	  normal	  drinking	  water.	  Using	  
both	  faecal	  shedding	  and	  bioluminescence	  as	  readouts,	  no	  difference	  in	  colonisation	  was	  
observed	   for	   either	   strain	   in	   animals	   treated	   with	   DSS	   compared	   to	   untreated	   mice.	  
TUV93-­‐0	   and	   LF82	   faecal	   shedding	   levels	  of	   both	  pre-­‐treated	  and	  untreated	  mice	  were	  
highest	  1	  day	  after	  infection	  (105-­‐106	  CFU/mg	  faeces),	  and	  declined	  over	  the	  next	  7	  days,	  
with	   no	   significant	   difference	   (p>0.05)	   between	  pre-­‐treated	   and	  untreated	  mice	   at	   any	  
post	   infection	   time-­‐point	   for	   either	   bacterial	   strain	   (Figure	   3-­‐3	   A).	   Luminescence	   of	  
bacteria	   also	   followed	   a	   similar	   trend	   over	   the	   post	   infection	   period	   (Figure	   3-­‐3	   B).	  
Therefore,	  we	  concluded	   that	  pretreatment	  of	  mice	  with	  0.25%	  DSS	  had	  no	  discernible	  
influence	  on	  persistence	  of	  either	  TUV93-­‐0	  or	  LF82	  in	  the	  BALB/c	  host.	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	   	  
C	   Faecal	  shedding	   	   	   D	   Luminescence	  
	  
Figure	   3-­‐3:	   Effect	   of	   DSS	   pretreatment	   on	   E.	   coli	   colonisation.	   TUV93-­‐0	   (A,	   B)	   and	   LF82	   (C,	   D)	   faecal	  
shedding	  (A,	  C)	  and	  luminescence	  (B,	  D)	  in	  BALB/c	  mice.	  Each	  group	  of	  mice	  consisted	  of	  five	  animals,	  and	  
faecal	  shedding	  and	  luminescence	  were	  followed	  for	  7	  days	  after	  infection	  with	  109	  CFU	  lux-­‐marked	  TUV93-­‐
0	   or	   LF82.	   Dark	   blue	   symbols	   represent	   colonisation	   in	   untreated	   animals,	   and	   light	   blue	   symbols	   DSS-­‐
treated	  animals.	  Data	  points	   shown	  are	   the	  mean	  of	  each	  group,	   and	   standard	  deviation	   from	   the	  mean	  
displayed	  as	  error	  bars.	  No	  significant	  differences	  (p<0.05)	  between	  the	  means	  of	  the	  treated	  and	  untreated	  
groups,	   as	  determined	  by	   Student’s	  unpaired	   t-­‐test,	  were	   found	   for	  either	   strain	  at	   any	   time	  point.	  Both	  
TUV93-­‐0	  and	  LF82	  infections	  were	  performed	  concurrently.	  
	  
Weight	   loss	   was	   monitored	   through	   the	   experiment	   as	   this	   has	   previously	   provided	   a	  
reliable	  marker	  of	  acute	  colitis	  (Chassaing	  et	  al.,	  2014a).	  However,	  no	  weight	  loss	  or	  other	  
changes	   in	   behaviour	   were	   observed.	   While	   it	   is	   possible	   that	   increasing	   the	  
concentration	  of	  DSS	  may	  have	  a	  greater	   influence	  on	  E.	  coli	   colonisation,	   it	  carries	   the	  
risk	   of	   causing	   epithelial	   degeneration	   and	   induction	   of	   intestinal	   inflammation	   and	  
colitis.	  We	  therefore	  chose	  not	  to	  raise	  the	  concentration	  of	  DSS	  above	  0.25%.	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3.5	  Colonisation	  of	  streptomycin-­‐treated	  ICR	  mice	  by	  E.	  coli	  
	  
3.5.1	  Colonisation	  of	  streptomycin-­‐treated	  ICR	  mice	  by	  TUV93-­‐0	  carrying	  plasmid-­‐borne	  
StrR	  
	  	  
Further	  evaluation	  of	   the	   literature	  highlighted	   the	  potential	   influence	  of	   antibiotics	  on	  
colonisation	   of	   mice	   with	   E.	   coli	   (Mohawk	   &	   O’Brien,	   2011).	   In	   particular,	   the	   use	   of	  
streptomycin,	  an	  aminoglycoside	  which	  inhibits	  protein	  synthesis,	   is	  capable	  of	  reducing	  
the	  diversity	  of	   the	  microbiome,	  allowing	  more	  effective	  colonisation	  by	  Gram-­‐negative	  
enteric	   pathogens	   such	   as	   E.	   coli	   and	   Salmonella	   species	   (Wadolkowski	   et	   al.,	   1990;	  
Barthel	  et	  al.,	  2003).	  We	  chose	  to	  explore	  the	  use	  of	  this	  antibiotic	  in	  HaM/ICR	  mice,	  an	  
outbred	  strain	  that	  is	  commonly	  used	  in	  streptomycin-­‐treated	  O157:H7	  models	  (Nagano	  
et	  al.,	  2003).	  These	  studies	  implied	  that	  O157:H7	  colonises	  the	  untreated	  ICR	  mouse	  gut	  
for	  longer	  periods	  than	  BALB/c	  mice,	  and	  also	  claimed	  to	  show	  in	  vivo	  evidence	  of	  T3SS-­‐
mediated	  bacterial	  adherence	  in	  the	  outbred	  strain.	  
	  
	  In	  this	  model,	  mice	  were	  supplied	  with	  5	  g/L	  streptomycin	  in	  their	  drinking	  water	  three	  
days	  prior	   to	   infection.	   To	  determine	   the	   long	   term	   impact	  of	   treatment,	   one	  group	  of	  
animals	   was	   provided	   with	   regular	   drinking	   water,	   while	   the	   second	   continued	   with	  
streptomycin	   water	   for	   a	   further	   10	   days,	   after	   which	   they	   were	   returned	   to	   regular	  
water.	  This	  return	  to	  normal	  drinking	  water	  at	  10	  days	  was	  a	  restraint	  imposed	  by	  animal	  
licence	  restrictions.	  
	  
To	  ensure	  that	  E.	  coli	  was	  resistant	  to	  streptomycin,	  TUV93-­‐0	  was	  transformed	  with	  the	  
pGB2	   plasmid,	  which	   encodes	   the	   streptomycin	   resistance	   gene	  aadA.	   Faecal	   shedding	  
and	  bioluminescence	   showed	   that	  24	  hours	  after	   infection,	  both	  groups	  were	   shedding	  
TUV93-­‐0	  at	  105-­‐106	  CFU/mg	  faeces	  (Figure	  3-­‐4).	  In	  mice	  that	  were	  subsequently	  returned	  
to	   normal	   drinking	   water,	   colonisation	   decreased	   steadily,	   and	   9	   days	   post	   infection	  
faecal	   shedding	  was	   undetectable.	   In	   animals	   with	   continuing	   streptomycin	   treatment,	  
high	   and	   consistent	   levels	   of	   shedding	   were	   observed	   throughout	   the	   post	   infection	  
period,	  with	  an	  average	  of	  104	  CFU/mg	  faeces	  observed	  at	  14	  days	  after	  infection.	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B	   	   TUV93-­‐0	   	   	   C	   TUV93-­‐0	  +	  streptomycin	  
	   	  
Figure	   3-­‐4:	   Effect	   of	   streptomycin-­‐treated	   drinking	   water	   on	   faecal	   shedding	   of	   TUV93-­‐0	   in	   ICR	   mice.	  
Average	  faecal	  shedding	  of	  two	  groups	  of	  ICR	  mice,	  five	  mice	  in	  each	  group,	  treated	  with	  5	  g/L	  streptomycin	  
in	  drinking	  water	  for	  3	  days	  before	  infection	  with	  109	  CFU	  lux-­‐marked	  TUV93-­‐0	  transformed	  with	  pGB2,	  and	  
supplied	  with	  either	  normal	  drinking	  water	  (dark	  blue)	  or	  5	  g/L	  streptomycin-­‐containing	  water	  (light	  blue)	  
after	  infection	  (A).	  Individual	  faecal	  shedding	  of	  post	  infection	  untreated	  mice	  (B)	  and	  streptomycin-­‐treated	  
mice	  (C).	  Faecal	  shedding	  was	  followed	  for	  14	  days	  after	  infection.	  In	  (A),	  data	  points	  shown	  are	  the	  mean	  
of	  each	  group,	  and	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  
	  
Colonisation	   was	   confirmed	   using	   live	   imaging	   of	   mice,	   with	   luminescence	   reaching	  
background	   levels	   (<105	   p/s)	   in	   the	   untreated	   group	   9	   days	   post	   infection,	   while	  
luminescence	   was	   not	   reduced	   to	   background	   levels	   until	   day	   14	   in	   the	   streptomycin	  
treated	  group	  (Figure	  3-­‐5).	  While	  the	  average	  luminescence	  of	  the	  streptomycin-­‐treated	  
group	   9-­‐14	   days	   after	   infection	   was	   relatively	   low	   compared	   to	   the	   level	   of	   faecal	  
shedding	  at	  these	  time	  points,	  the	  main	  site	  of	  infection	  at	  that	  point	  of	  infection	  may	  be	  
in	   a	   location	   that	   causes	   greater	   absorption	   of	   the	   luminescent	   signal,	   reducing	   the	  
amount	  that	  is	  detectable.	  Alternatively,	  bacteria	  may	  be	  more	  dispersed	  throughout	  the	  
intestine	   later	   in	   infection,	  which	   could	   result	   in	   a	   lower	   signal	   than	  when	  bacteria	   are	  
more	  highly	  concentrated	  in	  a	  specific	  location.	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Figure	   3-­‐5:	   Effect	   of	   streptomycin-­‐treated	   drinking	   water	   on	   TUV93-­‐0	   colonisation	   of	   ICR	   mice.	   Two	  
groups	  of	  mice,	   five	  animals	   in	  each	  group,	  were	   treated	  with	  5	  g/L	   streptomycin	   in	  drinking	  water	   for	  3	  
days	  before	   infection	  with	  109	  CFU	   lux-­‐marked	  TUV93-­‐0	  transformed	  with	  pGB2,	  and	  supplied	  with	  either	  
normal	   drinking	   water	   (dark	   blue)	   or	   5	   g/L	   streptomycin-­‐containing	   water	   (light	   blue)	   after	   infection.	  
Luminescence	  were	  monitored	  for	  14	  days	  after	  infection.	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group	  
with	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  	  
	  
To	  monitor	   possible	   plasmid	   loss,	   faeces	  were	   plated	   on	   agar	   containing	   erythromycin	  
alone,	   and	   on	   agar	   containing	   erythromycin	   and	   streptomycin.	   If	   plasmid	   loss	   were	   to	  
occur,	  there	  should	  be	  a	  reduction	  in	  the	  number	  of	  colonies	  found	  on	  plates	  containing	  
streptomycin	  compared	  to	  erythromycin	  plates.	  However,	  no	  significant	  difference	  in	  the	  
faecal	   counts	   was	   observed,	   even	   when	   the	   bacteria	   were	   recovered	   from	   mice	   not	  
supplied	  with	  streptomycin	  drinking	  water	  (Figure	  3-­‐6).	  Therefore,	  even	  in	  the	  absence	  of	  
selection	  in	  vivo,	  the	  pGB2	  plasmid	  is	  stably	  maintained	  in	  the	  E.	  coli	  strains	  colonising	  the	  
mouse	  intestine.	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Figure	   3-­‐6:	   pGB2	   plasmid	   stability.	   Faecal	   shedding	  of	   two	   groups	  of	   ICR	  mice,	   five	  mice	   in	   each	   group,	  
treated	   with	   5	   g/L	   streptomycin	   in	   drinking	   water	   for	   3	   days	   before	   infection	   with	   109	   CFU	   lux-­‐marked	  
TUV93-­‐0	   transformed	   with	   pGB2	   (conferring	   streptomycin	   resistance),	   and	   supplied	   with	   either	   normal	  
drinking	  water	   (circular	  symbols)	  or	  5	  g/L	  streptomycin-­‐containing	  water	   (square	  symbols)	  after	   infection.	  
Faecal	  shedding	  was	  monitored	  for	  14	  days	  after	  infection,	  using	  agar	  plates	  containing	  erythromycin	  only,	  
or	  erythromycin	  and	  streptomycin,	  with	   faecal	  counts	   from	  both	  plates	  displayed.	  Data	  points	  shown	  are	  
the	  mean	  of	  each	  group,	  and	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  
	  
3.5.2	  Generation	  of	  StrR	  bacterial	  strains	  
	  
Although	  the	  pGB2	  plasmid	  appeared	  to	  be	  stably	  maintained,	  for	  long	  term	  development	  
of	   the	   model	   a	   strain	   in	   which	   antibiotic	   resistance	   is	   chromosomally	   encoded	   was	  
considered	  desirable.	   Initially	  we	  attempted	  to	  confer	  streptomycin	   resistance	   to	  E.	  coli	  
by	   replacing	   the	   erythromycin	   resistance	   gene	   in	   the	   p16Slux	   plasmid	   with	   the	  
streptomycin	  resistance-­‐encoding	  gene	  aadA.	  This	  strategy	  however	  proved	  unsuccessful	  
and,	   as	   an	   alternative,	   spontaneous	   streptomycin-­‐resistant	   mutants	   of	   E.	   coli	   were	  
created	  and	  characterised.	  
	  
Streptomycin	   is	   an	   antibiotic	   which	   functions	   by	   binding	   the	   small	   16S	   rRNA	   of	   the	  
bacterial	   30S	   ribosome	   subunit,	   interfering	   with	   tRNA	   binding	   to	   the	   ribosome	   and	  
resulting	   in	   codon	   misreading	   and	   inhibition	   of	   protein	   synthesis.	   Spontaneous	  
streptomycin	  resistance	   in	  E.	  coli	   frequently	  arises	  as	  a	  consequence	  of	  mutation	   in	   the	  
rpsL	  gene	  encoding	  the	  ribosomal	  protein	  S12.	  Mutations	  in	  S12	  leads	  to	  slower	  but	  less	  
translational	   error-­‐prone	   ribosomes	   that	   are	   able	   to	   overcome	   the	   effects	   of	  
streptomycin	  (Ruusala	  et	  al.,	  1984).	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To	  generate	  spontaneous	  streptomycin-­‐resistant	  mutants,	  lux-­‐marked	  TUV93-­‐0,	  LF82	  and	  
OI-­‐148A	  (a	  TUV93-­‐0	  strain	  with	  a	  partial	  LEE	  deletion,	  rendering	  it	  unable	  to	  produce	  the	  
T3SS)	  were	  grown	  on	  agar	  containing	  100	  μg/ml	  streptomycin.	  Eight	  colonies	  from	  each	  
strain	  were	  selected	  and	  characterised	  to	  determine	  if	  acquisition	  of	  StrR	  had	  altered	  the	  
phenotypic	  characteristics	  of	  the	  organism.	  Mutants	  were	  tested	  for	  their	  ability	  to	  grow	  
in	   LB,	  MEM	   and	  M9	  media,	   to	   show	  motility	   on	   0.25%	   agar,	   and	   to	   adhere	   to	   human	  
epithelial	  cells	  (Appendices	  9.1).	  
	  
Additionally,	   the	   rpsL	   gene	   of	   each	  mutant	  was	   sequenced	   and	   each	   found	   to	   contain	  
either	   one	   or	   two	   point	   mutations.	   In	   all	   three	   strains	   of	   E.	   coli,	   at	   least	   one	   mutant	  
contained	  a	  single	  point	  mutation	  of	  an	  adenine	   to	  a	  cytosine	  at	  nucleotide	  128,	  which	  
resulted	  in	  a	  lysine	  to	  threonine	  change	  at	  amino	  acid	  42	  (K42T).	  This	  mutation	  has	  been	  
reported	   to	   provide	   streptomycin	   resistance	   with	   a	   minimum	   inhibitory	   concentration	  
(MIC)	   of	   2	   mg/ml,	   without	   making	   the	   bacteria	   dependent	   on	   the	   presence	   of	  
streptomycin	  for	  growth	  (Carr	  et	  al.,	  2005).	  Strains	  with	  this	  mutation	  also	  showed	  good	  
growth,	   motility,	   secretion	   and	   adhesion	   profiles,	   and	   therefore	   those	   containing	   this	  
mutation	  were	  selected	  for	  assessment	  in	  animal	  models.	  
	  
3.5.3	  Colonisation	  of	  streptomycin-­‐treated	  ICR	  mice	  by	  StrR	  TUV93-­‐0	  and	  OI-­‐148A	  
	  
The	   ability	   to	   produce	   T3SS-­‐mediated	   attaching/effacing	   lesions	   on	   the	   surface	   of	   host	  
cells	   is	   a	   defining	   characteristic	   of	   EHEC	   infection,	   and	   allows	   bacteria	   to	   colonise	   and	  
persist	   within	   its	   host.	   To	   evaluate	   the	   importance	   of	   the	   T3SS	   in	   O157:H7	   mouse	  
colonisation,	   ICR	  mice	   given	   5	   g/L	   streptomycin	   in	   their	   drinking	   water	   for	   three	   days	  
were	   infected	  with	  either	  StrR	   lux-­‐marked	  TUV-­‐93	  or	  T3SS-­‐negative	  OI-­‐148A.	  All	  animals	  
were	  supplied	  with	  streptomycin	   in	  their	  drinking	  water	  after	   infection.	  Faecal	  shedding	  
was	   followed	   for	   9	   days	   after	   infection,	   and	   there	   was	   no	   significant	   difference	   found	  
between	  the	  two	  strains	  at	  any	  time	  point.	  Live	   imaging	  of	  the	  two	  groups	  also	  showed	  
no	  difference	  in	  persistence	  (Figure	  3-­‐7).	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  	   	  
	   	   	  
Figure	  3-­‐7:	  Colonisation	  of	  TUV93-­‐0	  and	  OI-­‐148A.	  Two	  groups	  of	  streptomycin-­‐treated	  ICR	  mice,	  15	  mice	  in	  
each	   group,	  were	   infected	  with	   lux-­‐marked	   StrR	   TUV93-­‐0	   (dark	   blue)	   or	   the	   T3SS-­‐negative	  OI-­‐148A	   (light	  
blue),	  and	  colonisation	  monitored	  by	   faecal	  shedding	   (A)	  and	   luminescence	   (B)	   for	  9	  days	  after	   infection.	  
Drinking	  water	  containing	  5	  g/L	  streptomycin	  was	  provided	  to	  both	  groups	   throughout	   the	  post	   infection	  
period.	  Five	  mice	  from	  each	  group	  were	  culled	  at	  days	  3,	  6	  and	  9.	  Data	  points	  shown	  are	  the	  mean	  of	  each	  
group,	  and	  standard	  deviation	   from	  the	  mean	  displayed	  as	  error	  bars.	  No	  significant	  differences	   (p<0.05)	  
between	  the	  means	  of	  the	  two	  groups,	  as	  determined	  by	  Student’s	  unpaired	  t-­‐test,	  were	  found	  for	  at	  any	  
time	  point	  
	  
At	  3,	  5	  and	  9	  days	   following	  challenge,	  5	  mice	   from	  each	  group	  were	  culled	  by	  cervical	  
dislocation	   and	   subjected	   to	   post-­‐mortem	   examination	   to	   determine	   the	   number	   of	  
bacteria	   located	   in	   the	   lumen	   of	   the	   intestine	   and	   those	   more	   intimately	   attached	   to	  
intestinal	  epithelial	  cells.	  The	  entire	  caecum,	  small	   intestine	  (from	  the	  duodenum	  to	  the	  
ileum)	  and	   large	   intestine	  (from	  the	  ascending	  colon	  to	  the	  rectum)	  of	  each	  mouse	  was	  
removed	  and	  separated	  from	  each	  other,	  contents	  removed	  to	  measure	  lumen	  bacteria,	  
and	   tissue	   homogenised	   to	   release	   those	   bacteria	   adhered	   to	   epithelial	   cells.	   Bacteria	  
were	  found	  to	  be	  associated	  with	  all	  areas	  of	  the	  gut,	  with	  the	  caecum	  and	  large	  intestine	  
more	   heavily	   colonised	   than	   the	   small	   bowel.	   However,	   no	   significant	   difference	   in	  
numbers	  of	  bacteria	  in	  either	  the	  lumen	  or	  tissue	  between	  the	  two	  strains	  was	  observed	  
at	   any	   time	   point	   (Figure	   3-­‐8).	   This	   would	   suggest	   that	   while	   TUV93-­‐0	   is	   capable	   of	  
adhesion	  mediated	   through	   expression	   of	   the	   T3SS,	   it	   does	   not	   appear	   relevant	   in	   this	  
model	   as	   O1-­‐148A,	   a	   strain	   unable	   to	   make	   this	   structure,	   was	   recovered	   at	   levels	  
equivalent	  to	  that	  of	  TUV93-­‐0.	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A	   Lumen	  (day	  3)	  	   	   	   B	   Tissue	  (day	  3)	  
	   	  
C	   Lumen	  (day	  6)	  	   	   	   D	   Tissue	  (day	  6)	  
	   	  
E	   Lumen	  (day	  9)	  	   	   	   F	   Tissue	  (day	  9)	  
	   	  
Figure	   3-­‐8:	   Intestinal	   bacterial	   recovery	   of	   TUV93-­‐0	   and	   OI-­‐148A.	   Lumen	   (A,	   C,	   E)	   and	   tissue	   (B,	   D,	   F)	  
colonisation	  of	  the	  small	  intestine,	  caecum	  and	  large	  intestine	  of	  streptomycin-­‐treated	  ICR	  infected	  with	  109	  
CFU	  lux-­‐marked	  StrR	  TUV93-­‐0	  (dark	  blue)	  or	  OI-­‐148A	  (light	  blue).	  Five	  mice	  from	  each	  group	  (which	  initially	  
contained	  15	  mice	   in	  each	  group)	  were	   culled	  at	   time	  points	  of	   3	   (A,	   B),	   6	   (C,	   D)	   and	  9	   (E,	   F)	   days	  after	  
infection	  and	   the	   concentration	  of	   TUV93-­‐0	  or	  OI-­‐148A	  per	  mg	  organ	   tissue	   in	   the	   lumen	  or	   attached	   to	  
tissue	  determined	  for	  the	  three	  organs.	  Symbols	  represent	  bacterial	  counts	  from	  a	  single	  animal.	  The	  mean	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indicated.	   No	   significant	   differences	   (p<0.05)	   between	   the	   means	   of	   the	   two	   groups,	   as	   determined	   by	  
Student’s	  unpaired	  t-­‐test,	  were	  found	  between	  strains	  in	  or	  attached	  to	  any	  organ	  at	  any	  time	  point.	  
	  
As	   no	   significant	   difference	   between	   the	   two	   strains	   was	   observed	   either	   for	   faecal	  
shedding,	   luminescence,	  or	  bacterial	  attachment	   to	   intestinal	   tissue,	  we	  concluded	   that	  
persistence	  of	  the	  organism	  within	  the	  model	  is	  not	  dependent	  on	  the	  T3SS.	  This	  implies	  
that	  colonisation	   is	  due	  to	  the	  bacteria’s	  ability	  to	  survive	  and	  replicate	   in	  the	   intestinal	  
lumen	  in	  the	  absence	  of	  competing	  natural	  gut	  microflora.	  Therefore	  this	  model	  is	  a	  poor	  
replicator	   of	   T3SS-­‐mediated	   colonisation,	   and	   would	   not	   be	   suitable	   for	   use	   in	   in	   vivo	  
testing	  of	  anti-­‐virulence	  drugs	  that	  target	  this	  structure.	  
	  
3.5.4	  Colonisation	  of	  streptomycin-­‐treated	  ICR	  mice	  by	  StrR	  LF82	  
	  
LF82	  is	  an	  adherent	  and	  invasive	  E.	  coli	  strain	  that	  does	  not	  encode	  the	  T3SS.	  However,	  
this	   organism	   encodes	   the	   putative	   lipoprotein	   YghJ,	   whose	   involvement	   in	   LF82	  
colonisation	  of	  mice	  we	  were	   interested	   in	  exploring.	  To	  determine	  how	  effectively	  this	  
strain	   colonised	   the	   streptomycin-­‐treated	  model,	   ICR	  mice	  were	   infected	  with	   StrR	   lux-­‐
marked	  LF82	  and	  streptomycin	  treatment	  continued,	  as	  per	  the	  TUV93-­‐0	  infection	  model.	  
In	  these	  experiments,	  LF82	  was	  shed	  at	  high	  levels	  (105-­‐107	  CFU/mg	  faeces)	  for	  the	  first	  6	  
days	  post	   infection,	  with	   the	  highest	   faecal	   shedding	  observed	  on	  day	  4,	   followed	  by	  a	  
gradual	  decrease	  in	  shedding	  (Figure	  3-­‐9	  A).	  Luminescence	  of	  LF82	  was	  also	  strong,	  with	  
all	  animals	  showing	  strong	  colonisation	  throughout	  the	  post	   infection	  period	  (Figure	  3-­‐9	  
B).	  Both	  these	  levels	  were	  comparable	  to	  those	  of	  TUV93-­‐0.	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	  
Figure	   3-­‐9:	   Colonisation	   of	   LF82.	   Fifteen	   streptomycin-­‐treated	   ICR	  mice	  were	   infected	  with	   109	   CFU	   lux-­‐
marked	  StrR	  LF82	  and	  drinking	  water	  containing	  5	  g/L	  streptomycin	  provided	  throughout	  the	  post	  infection	  
period.	  Colonisation	  was	  monitored	  by	  faecal	  shedding	  (A)	  and	  luminescence	  (B)	  for	  9	  days	  after	  infection.	  
Five	  mice	  were	  culled	  at	  3,	  6	  and	  9	  days	  after	  infection.	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group,	  and	  
standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  
	  
Recovery	  of	  intestinal	  LF82	  from	  mice	  culled	  at	  3,	  6	  and	  9	  days	  after	  infection	  found	  that	  
colonisation	  was	  similar	   to	  that	  of	  TUV93-­‐0;	  counts	  were	  highest	   in	  both	  the	  tissue	  and	  
lumen	   of	   the	   caecum	   and	   large	   intestine,	   although	   the	   small	   intestine	   also	   showed	  
colonisation	  throughout	  the	  post	   infection	  period	  (Figure	  3-­‐10).	  Although	  LF82	  does	  not	  
attach	  to	  host	  epithelial	  tissue	  via	  the	  T3SS,	  the	  high	  levels	  of	  bacteria	  in	  the	  lumen	  of	  the	  
intestine	   coupled	   with	   how	   relative	   colonisation	   levels	   in	   the	   three	   organs	   remains	  
consistent	   over	   time	   suggests	   that,	   like	   TUV93-­‐0,	   LF82	   displays	   persistence	   rather	   than	  
true	  adherence	  and	  colonisation.	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A	   Lumen	  (day	  3)	  	   	   	   B	   Tissue	  (day	  3)	  
	  
C	   Lumen	  (day	  6)	  	   	   	   D	  	   Tissue	  (day	  6)	  
	  
E	   Lumen	  (day	  9)	  	   	   	   F	  	   Tissue	  (day	  9)	  
	  
Figure	  3-­‐10:	   Intestinal	  bacterial	   recovery	  of	  LF82.	  Lumen	  (A,	  C,	  E)	  and	  tissue	   (B,	  D,	  F)	  colonisation	  of	  the	  
small	   intestine,	   caecum	   and	   large	   intestine	   of	   streptomycin-­‐treated	   ICR	  mice	   infected	  with	   109	   CFU	   lux-­‐
marked	  StrR	  LF82.	  Five	  mice	  from	  each	  group	  (which	  initially	  contained	  15	  mice)	  were	  culled	  at	  time	  points	  
of	  3	  (A,	  B),	  6	  (C,	  D)	  and	  9	  (E,	  F)	  days	  after	  infection	  and	  the	  number	  of	  LF82	  per	  mg	  of	  organ	  tissue	  in	  the	  
lumen	  or	  attached	   to	   tissue	  determined	   for	   the	   three	  organs.	   Symbols	   represent	  bacterial	   counts	   from	  a	  
single	  animal.	  The	  mean	  bacterial	   count	  of	  each	  group	   (long	   line)	  and	  standard	  deviation	   from	  the	  mean	  
(short	  line)	  are	  also	  indicated.	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3.6	  Stx-­‐producing	  Citrobacter	  rodentium	  
	  
3.6.1	  Colonisation	  and	  pathogenesis	  of	  Stx-­‐producing	  C.	  rodentium	  
	  
As	   the	   streptomycin-­‐treated	   ICR	  model	   showed	  no	   significant	  difference	   in	   colonisation	  
levels	  between	  the	  wild	  type	  and	  T3SS-­‐negative	  TUV93-­‐0	  strain,	  it	  would	  appear	  that	  this	  
model	  cannot	  be	  used	  to	  screen	  drugs	  that	  target	  this	  structure.	  However,	  the	  capacity	  to	  
generate	  the	  T3SS	  is	  not	  the	  only	  important	  virulence	  trait	  expressed	  by	  E.	  coli	  O157:H7	  
strains.	   The	   expression	   of	   Stx2	   toxin	   results	   in	   significant	   kidney	   damage	   in	   infected	  
individuals,	   and	   so	   drugs	   that	   modify	   Stx2	   also	   warrant	   evaluation.	   Recently,	   a	   novel	  
Citrobacter	   rodentium	   strain	   that	   produces	   Stx2	   at	   comparable	   levels	   to	   O157:H7	   was	  
described	  in	  which	  the	  Stx2dact	  phage	  was	  inserted	  into	  the	  chromosome	  of	  C.	  rodentium	  
(Mallick	  et	  al.,	  2012).	  This	  strain,	  C.	   rodentium	   (λstx2dact),	  has	  been	  reported	  to	  result	   in	  
lethal	  infection	  in	  C57BL/6	  mice,	  as	  a	  consequence	  of	  Stx-­‐mediated	  damage	  to	  kidney	  and	  
intestinal	  tissues.	  The	  use	  of	  C.	  rodentium	  in	  this	  system	  is	  also	  attractive	  as	  adhesion	  of	  
the	  bacteria	  to	  the	  host	  intestinal	  epithelial	  surface	  has	  been	  attributed	  to	  the	  expression	  
of	  the	  T3SS	  (Mallick	  et	  al.,	  2012).	  As	  we	  had	  additional	  interest	  in	  testing	  of	  compounds	  
that	  target	  the	  Shiga	  toxin,	  characterisation	  of	  this	  model	  was	  undertaken.	  
	  
The	  wild	  type	  C.	  rodentium	  and	  the	  λstx2dact	  strain,	  a	  kind	  gift	  from	  Prof.	  John	  Leong	  (Tufts	  
University),	   were	   made	   luminescent	   by	   p16Slux	   integration.	   In	   order	   to	   replicate	   the	  
original	  study	  findings	  (Mallick	  et	  al.,	  2012),	  C57BL/6	  and	  BALB/c	  mice	  were	  infected	  with	  
either	  wild	   type	  or	   Stx2-­‐expressing	  C.	   rodentium.	   As	  weight	   loss	  was	  used	   as	   a	   reliable	  
indicator	  of	  illness	  in	  this	  model,	  animals	  were	  weighed	  daily	  and	  were	  culled	  once	  they	  
lost	  more	  than	  of	  15%	  of	  their	  weight	  at	  the	  start	  of	  the	  experiment.	  
	  
While	  C57BL/6	  and	  BALB/c	  mice	   infected	  with	  wild	   type	  C.	   rodentium	  maintained	  body	  
weight	   throughout	   infection,	   BALB/c	  mice	   infected	  with	  C.	   rodentium	   (λstx2dact)	   rapidly	  
lost	  weight.	  Shortly	  after	  infection,	  three	  animals	  reached	  experimental	  endpoint	  (loss	  of	  
>15%	  of	  their	  starting	  body	  weight)	  5	  days	  after	  infection	  and	  the	  remaining	  two	  animals	  
were	  culled	  by	  day	  6	   (Figure	  3-­‐11	  A,	  B).	  Although	  these	  remaining	  two	  animals	  had	  not	  
yet	  lost	  >15%	  of	  weight,	  strong	  visual	  and	  behavioural	  signs	  suggested	  significant	  illness.	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In	  contrast,	  C57BL/6	  mice	   infected	  with	   the	  same	  C.	   rodentium	   (λstx2dact)	   strain	  showed	  
no	  significant	  weight	   loss	   in	   the	   first	  week	  after	   infection,	   contrary	   to	   the	  Mallick	  et	  al.	  
(2012)	  study.	  Two	  C57BL/6	  mice	  from	  both	  the	  wild	  type	  and	  λstx2dact	  group	  were	  culled	  
at	  day	  6	  for	  histological	  comparison	  to	  the	  BALB/c	  mice.	  Interestingly,	  during	  the	  second	  
week	   after	   infection,	   body	  weight	   of	   all	   three	   C57BL/6	  members	   of	   the	   λstx2dact	   group	  
declined,	  with	  one	  mouse	  reaching	  a	  weight	  loss	  of	  >15%	  by	  day	  10,	  although	  no	  visual	  or	  
behavioural	  signs	  of	  illness	  were	  observed	  for	  any	  of	  the	  animals.	  The	  remaining	  two	  mice	  
showed	  an	  increase	  in	  weight	  between	  days	  12	  and	  14,	  presumably	  due	  to	  clearance	  of	  
bacteria	  (Figure	  3-­‐11	  C,	  D).	  
	  
A	   BALB/c	  ,	  WT	   	   	   	   B	   BALB/c,	  Stx2	  
	   	   	  
C	   C57BL/6,	  WT	   	   	   	   D	   C57BL/6,	  Stx2	  
	   	   	  
Figure	  3-­‐11:	  Weight	  changes	  of	  C.	  rodentium	  and	  C.	  rodentium	  (λstx2dact)-­‐infected	  mice.	  Five	  BALB/c	  (A,	  B)	  
and	   five	   C57BL/6	   (C,	   D)	   mice	   were	   infected	   with	   109	   CFU	   lux-­‐marked	   C.	   rodentium	   (dark	   blue)	   or	   C.	  
rodentium	   (λstx2dact)	   (light	  blue)	  by	  oral	   gavage.	  Animals	  were	  monitored	   for	  weight	   loss	  once	  daily	   after	  
infection,	   and	   animals	   were	   culled	   once	   a	   >15%	   decrease	   in	   starting	   weight	   was	   reached.	   Data	   points	  
represent	  the	  weights	  of	  individual	  mice.	  
	  
Colonisation	  levels,	  as	  measured	  by	  faecal	  shedding	  and	  live	  imaging,	  indicated	  that	  both	  
bacterial	   strains	   were	   present	   in	   the	  mice	   and	   were	   shed	   at	   equivalent	   levels	   in	   both	  
BALB/c	  and	  C57BL/6	  mice	   (Figure	  3-­‐12	  A,	  C).	  High	   faecal	   shedding	  and	   luminescence	   in	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C57BL/6	  mice	  during	  the	  first	  week	  of	  infection	  suggests	  that	  the	  lack	  of	  symptoms	  does	  
not	   reflect	   poor	   bacterial	   colonisation.	   Colonisation	   levels	   in	   C57BL/6	   mice	   decreased	  
during	  the	  second	  week	  of	  infection,	  which	  is	  probably	  due	  to	  the	  natural	  clearance	  of	  the	  
bacteria.	  Interestingly,	  the	  decrease	  in	  weight	  of	  C57BL/6	  mice	  infected	  with	  λstx2dact	  seen	  
during	   the	   second	  week	  of	   infection	  occurs	  at	   the	  point	  at	  which	  bacterial	   colonisation	  
starts	  to	  decrease	  due	  to	  natural	  clearance.	  
	  
While	  both	  faecal	  shedding	  and	  luminescence	  levels	  of	  the	  λstx2dact	  strain	  in	  C57BL/6	  mice	  
appeared	  lower	  than	  that	  of	  the	  wild	  type	  between	  days	  10	  and	  14	  of	  the	  post	  infection	  
period,	   the	   small	   number	   (2-­‐3)	   of	   mice	   in	   each	   group	   at	   these	   time	   points	   likely	  
contributes	  to	  this	  variation	  in	  average	  colonisation	  levels.	  
	  
A	   BALB/c,	  faecal	  shedding	   	   B	   BALB/c,	  luminescence	  
	   	  
C	   C57BL/6,	  faecal	  shedding	   	   D	   C57BL/6,	  luminescence	  
	   	  
Figure	  3-­‐12:	  Colonisation	  of	  wild	  type	  C.	   rodentium	  and	  C.	   rodentium	   (λstx2dact)	   in	  BALB/c	  and	  C57BL/6.	  
Five	  BALB/c	  (A,	  B)	  and	  five	  C57BL/6	  (C,	  D)	  mice	  were	  infected	  with	  lux-­‐marked	  C.	  rodentium	  (dark	  blue)	  or	  
C.	  rodentium	  (λstx2dact)	  (light	  blue).	  Colonisation	  was	  monitored	  by	  faecal	  shedding	  (A,	  C)	  and	  luminescence	  
(B,	  D).	  Data	  points	  represent	  the	  mean	  of	  each	  group	  with	  standard	  deviation	  from	  the	  mean	  displayed	  by	  
error	  bars.	  As	  mice	  were	  culled	  once	  a	  >15%	  decrease	  in	  starting	  body	  weight	  was	  reached,	  the	  number	  of	  
mice	  in	  each	  group	  does	  not	  stay	  consistent	  throughout	  the	  post	  infection	  period.	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After	   all	   animals	   were	   euthanised,	   kidneys	   were	   removed	   and	   prepared	   for	   histology	  
using	  PAS	  and	  H&E	  staining,	  and	  examined	  by	   light	  microscopy.	  Stx-­‐mediated	  pathology	  
was	  observed	   in	  both	  BALB/c	  and	  C57BL/6	  mice	   infected	  with	   the	  λstx2dact	   strain,	  while	  
mice	   infected	   with	   the	   wild	   type	   strain	   showed	   no	   signs	   of	   tissue	   damage.	   Two	  main	  
histological	   changes	   were	   seen	   in	   kidneys	   from	   λstx2dact	   mice:	   tubular	   injury	   and	  
interstitial	   haemorrhage.	   Proximal	   tubules	   showed	   patchy	   degenerative	   changes	   that	  
included	   a	   loss	   of	   apical	   brush	   borders,	   cytoplasmic	   simplification	   and	   vacuolisation,	  
enlarged	   nuclei	   with	   prominent	   nucleoli,	   and	   luminal	   ectasia	   with	   focal	   sloughing	   of	  
epithelial	  cells	  into	  tubular	  lumina	  (Figure	  3-­‐13).	  Microscopy	  images	  were	  blind	  scored	  for	  
tissue	   damage,	  where	   0	   =	   no	   injury,	   1	   =	  mild	   damage,	   2	   =	  moderate	   damage,	   and	   3	   =	  
severe	  damage,	  with	  scoring	  determined	  by	  comparison	  to	  representitive	  renal	  biopsies	  
published	  by	  D’Agati	  et	   al.	   (2005).	   Two	   images	   from	  each	  mouse	  were	   scored,	  with	   all	  
BALB/c	   and	   C57BL/6	  mice	   infected	  with	  C.	   rodentium	   scoring	   0	   for	   both	   PAS	   and	   H&E	  
images.	  BALB/c	  mice	  infected	  with	  λstx2dact	  scored	  an	  average	  of	  1.1	  for	  PAS	  and	  1.5	  for	  
H&E	   images,	  and	  C57BL/C	  mice	   infected	  with	  λstx2dact	   scored	  an	  average	  of	  0.7	   for	  PAS	  
and	   1.0	   for	   H&E.	   Thiese	   findings	   demonstrate	   that	   while	   λstx2dact	   only	   produces	   weak	  
signs	  of	  illness	  in	  C57BL/6	  mice,	  Stx-­‐mediated	  kidney	  damage	  still	  occurs	  during	  infection.	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A	   	   PAS	   	   	   	   	   H&E	  
	  	   	   	  
	  
B	   	   PAS	   	   	   	   	   H&E	  
	  	  	  	   	   	  
	  
C	   	   PAS	   	   	   	   	   H&E	  
	  	  	  	   	   	  
	  
Figure	   3-­‐13:	   C.	   rodentium	   (λstx2dact)	   causes	   tubular	   injury	   and	   interstitial	   haemorrhage	   in	   kidneys	   of	  
BALB/c	   and	   C57BL/6	   mice.	   Representative	   images	   (400x	   magnification)	   of	   PAS	   and	   H&E-­‐stained	   kidney	  
sections	   from	  BALB/c	  mice	   infected	  with	   lux-­‐marked	  C.	   rodentium	   (A)	   or	  C.	   rodentium	   (λstx2dact)	   (B),	   and	  
C57BL/6	   mice	   infected	   with	   C.	   rodentium	   (λstx2dact)	   (C).	   Black	   arrows	   indicate	   proximal	   tubules	   with	  
degenerative	   changes	   including	   focal	   sloughed	   epithelial	   cells.	   White	   arrows	   indicate	   focal	   interstitial	  
haemorrhages.	  BALB/c	  kidneys	  sections	  were	  from	  animals	  culled	  at	  4	  and	  5	  days	  after	  infection,	  and	  kidney	  
sections	  from	  the	  C57BL/6	  example	  were	  obtained	  from	  the	  single	  animal	  culled	  due	  to	  weight	   loss	  at	  10	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3.6.2	  Colonisation	  and	  production	  of	  disease	  by	  C.	  rodentium	  (λstx2dact)	  is	  dependent	  on	  
the	  T3SS	  
	  
To	   confirm	   that	  C.	   rodentium	   (λstx2dact)	   relies	  on	   the	  T3SS	   for	   colonisation	  and	  disease,	  
BALB/c	  mice	  were	  infected	  with	  either	  C.	  rodentium	  or	  the	  Stx-­‐2	  expressing	  tir	  mutant	  C.	  
rodentium	  (λstx2dact)Δtir.	  Mice	  in	  the	  group	  with	  C.	  rodentium	  showed	  colonisation	  levels	  
that	  gradually	   increased	  over	   time,	  while	   those	   infected	  with	   the	  Δtir	   strain	  exhibited	  a	  
rapid	   decline	   in	   the	   number	   of	   bacteria	   recovered	   by	   faecal	   shedding	   or	   detected	   by	  
luminescence	  (Figure	  3-­‐14	  A,	  B).	  Animals	  from	  both	  groups	  did	  not	  lose	  any	  body	  weight	  
(Figure	  3-­‐14	  C),	  or	  display	  any	  signs	  or	  behaviour	   indicating	   illness.	  These	  findings	   imply	  
that	  when	  prevented	  from	  forming	  A/E	  lesions	  by	  the	  lack	  of	  Tir	  expression,	  C.	  rodentium	  
is	  unable	  to	  colonise	  the	  mouse	   intestine	  effectively,	  resulting	   in	  faster	  clearance	  of	  the	  
bacteria	   and	   no	  mortality	   or	   observable	   illness.	   This	   data	   confirms	   that	   the	   T3SS	   is	   an	  
essential	  virulence	  factor	  during	  lethal	  infection	  of	  C.	  rodentium.	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	  
	   C	   Mouse	  weight	  
	   	  
Figure	   3-­‐14:	   Production	   of	   Tir	   is	   required	   for	   colonisation	   and	   production	   of	   disease	   by	   C.	   rodentium	  
(λstx2dact).	  Two	  groups	  of	  BALB/c	  mice,	  five	  mice	  in	  each	  group,	  were	  infected	  with	  10
0	  CFU	   lux-­‐marked	  C.	  
rodentium	   (dark	   blue)	   or	   C.	   rodentium	   (λstx2dact)Δtir	   (light	   blue).	   Colonisation	   was	   monitored	   by	   faecal	  
shedding	  (A)	  and	   luminescence	  (B),	  and	  animals	  were	  weighed	  daily	  to	  monitor	  body	  weight	  changes	  (C).	  
Data	  points	  represent	  the	  mean	  of	  each	  group	  with	  standard	  deviation	  from	  the	  mean	  shown	  by	  error	  bars.	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3.7	  Discussion	  
	  
3.7.1	  Streptomycin	  treatment	  of	  mice	  lowers	  colonisation	  resistance	  to	  E.	  coli	  
	  
The	  original	  aim	  of	  this	  work	  was	  to	  establish	  a	  mouse	  model	  of	  E.	  coli	  colonisation	  using	  
inbred	  mice,	   in	  which	  colonisation	  would	  be	  robust	  and	  dependent	  on	  T3SS	  production.	  
Of	  the	  three	   inbred	  mouse	  strains	  tested,	  no	  differences	   in	  colonisation	  were	  observed,	  
although	   BALB/c	   mice	   proved	   most	   suited	   to	   live-­‐image	   monitoring.	   Pretreatment	   of	  
BALB/c	  mice	  with	  DSS,	  in	  order	  to	  decrease	  the	  intestinal	  mucosal	  layer	  and	  allow	  E.	  coli	  
to	   interact	  more	  directly	  with	  epithelial	   cells,	  produced	  no	   significant	   increase	   in	  either	  
levels	  or	  length	  of	  colonisation	  by	  TUV93-­‐0	  or	  LF82.	  
	  
In	   contrast,	   streptomycin	   pretreatment	   of	   the	   outbred	   ICR	   mouse	   strain	   followed	   by	  
continuation	   of	   streptomycin	   after	   infection	   produced	   high,	   stable	   levels	   of	   bacterial	  
colonisation	  by	  both	  TUV93-­‐0	  and	  LF82.	  The	  chromosomal	  integration	  of	  the	   lux	  operon	  
provided	   an	   additional	   useful	   tool	   for	   monitoring	   colonisation.	   Despite	   the	   greater	  
genetic	   variation	   that	   accompanies	   outbred	   mouse	   strains,	   all	   animals	   infected	   were	  
successfully	  colonised	  and	  showed	  robust	  levels	  of	  colonisation.	  
	  
Streptomycin	   treatment	   has	   a	   history	   of	   use	   in	   animal	   models	   of	   bacterial	   infections,	  
including	  E.	   coli	   in	   cattle	   (Snider	  et	  al.,	   2006),	   and	  mouse	  models	  of	  Salmonella,	  Vibrio,	  
and	  Klebseiella	   (Barthel	  et	   al.,	   2003;	  Olivier	  et	   al.,	   2009;	   Favre-­‐Bonté	  et	   al.,	   1999).	   The	  
exact	  mechanism	   by	   which	   streptomycin	   treatment	   lowers	  mouse	   resistance	   to	   E.	   coli	  
colonisation	   is	   not	   yet	   fully	   understood.	   It	   is	   assumed	   that	   streptomycin	   treatment	  
modifies	  the	  diversity	  of	  bacteria	  within	  the	  gut	  that	  under	  normal	  conditions	  prevent	  E.	  
coli	  colonisation,	  either	  by	  competition	  for	  nutrients	  or	  by	  metabolic	  exclusion	  (Lawley	  &	  
Walker,	   2013).	   Mouse	   models	   using	   gnotobiotic	   animals,	   which	   require	   no	   antibiotic	  
treatment	   for	   E.	   coli	   colonisation	   to	   occur,	   support	   this	   view.	   However,	   an	   alternate	  
hypothesis	   has	   been	   presented	   by	   Spees	   et	   al.	   (2013)	   that	   suggests	   streptomycin	  
produces	   conditions	   favourable	   to	   E.	   coli	   colonisation	   by	   initiating	   low-­‐level	   intestinal	  
inflammation.	   For	   example,	   streptomycin	   makes	   mice	   more	   susceptible	   to	   the	  
development	   of	   DSS-­‐induced	   colitis,	   implying	   that	   streptomycin	   lowers	   colonisation	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resistance	   by	   changing	  mucosal	   immune	   responses.	   In	   this	   published	   work,	   the	   caecal	  
mucosa	  of	  streptomycin-­‐treated	  mice	  showed	  a	  mild	  inflammatory	  infiltrate	  accompanied	  
by	   raised	   expression	   of	   nos2,	   which	   encodes	   inducible	   nitric	   oxide	   synthase.	   Luminal	  
growth	  of	  E.	  coli	  was	  increased	  by	  nitrate	  respiration	  in	  a	  NOS2-­‐dependent	  manner,	  due	  
to	  anaerobic	  respiration	  allowing	  E.	  coli	  to	  utilise	  non-­‐fermentable	  carbon	  sources.	  These	  
findings	  raise	  the	  possibility	  that	  streptomycin	  treatment	  allows	  E.	  coli	  to	  colonise	  by	  not	  
only	   clearing	   competitive	   intestinal	   bacteria,	   but	   by	   creating	   a	   new	   niche	   in	  which	   the	  
organism	  can	  flourish	  (Spees	  et	  al.,	  2013).	  
	  
It	  has	  also	  been	  suggested	  that	  streptomycin	  treatment	  promotes	  E.	  coli	  colonisation	  by	  
altering	  the	  pH	  and	  volatile	  fatty	  acid	  (VFA)	  concentration	  in	  the	  caecum	  (Hentges	  et	  al.,	  
1990).	  When	  caecal	  contents	  of	  Str-­‐treated	  mice	  were	  adjusted	  to	  match	  the	  pH	  and	  VFA	  
conditions	   of	   untreated	   mice,	   the	   growth	   of	   E.	   coli	   was	   reduced	   and	   resembled	   that	  
shown	   by	   E.	   coli	   in	   caecal	   contents	   of	   untreated	   mice.	   Additionally,	   when	   untreated	  
caecal	   contents	  were	   adjusted	   to	   resemble	   the	   streptomycin-­‐treated	   caecum,	   bacterial	  
growth	  was	  increased	  (Hentges	  et	  al.,	  1990).	  
	  
3.7.2	  The	  Str-­‐treated	  TUV93-­‐0	  mouse	  model	  is	  not	  T3SS-­‐dependent	  
	  
As	  we	  required	  a	  T3SS-­‐dependent	  TUV93-­‐0	  model	  for	  in	  vivo	  testing	  of	  novel	  compounds	  
that	  target	  this	  virulence	  factor,	  the	  streptomycin-­‐treated	  model	  needed	  to	  demonstrate	  
an	   observable	   and	   significant	   change	   in	   colonisation	   when	   the	   T3SS	   was	   inhibited.	   To	  
ensure	  persistence	  in	  the	  streptomycin-­‐treated	  gut,	  spontaneous	  StrR	  mutants	  of	  TUV93-­‐
0	  and	  the	  T3SS-­‐negative	  OI-­‐148A	  were	  generated.	  Sequencing	  of	  the	  rpsL	  gene	  of	  these	  
mutants	   allowed	   selection	   of	   strains	   with	   a	   common	  mutation.	   StrR	   mutations	   can	   be	  
classed	  as	  restrictive,	  decreasing	  the	  rate	  of	  translation	  and	  increasing	  cell	  doubling	  time,	  
or	  non-­‐restrictive,	  which	  behave	   in	  a	  similar	  manner	  to	  wild	  type	  strains.	  The	  K42T	  rpsL	  
mutation	  that	  was	  present	  in	  all	  spontaneous	  StrR	  E.	  coli	  strains	  is	  a	  restrictive	  mutation;	  
however,	  growth,	  motility	  and	  adhesion	  profiles	  showed	  that	  none	  of	  these	  traits	  differed	  
greatly	  from	  the	  behavior	  of	  the	  wild	  type	  strain,	  and	  these	  mutants	  were	  subsequently	  
tested	  in	  vivo.	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Infection	   of	   streptomycin-­‐treated	   ICR	  mice	  with	   StrR	   TUV93-­‐0	   or	   the	   T3SS-­‐negative	   OI-­‐
148A	  strain	  resulted	  in	  no	  significant	  difference	  in	  levels	  of	  colonisation.	  Bacterial	  counts	  
recovered	   from	   all	   three	   regions	   of	   the	   gut	   were	   equivalent	   throughout	   the	   infection,	  
with	   no	   difference	   between	   attached	   and	   lumen-­‐associated	   bacteria	   observed.	   This	  
implies	  that	  O157:H7	   is	  able	  to	  persist	   in	  the	   intestinal	   lumen	   in	  the	  absence	  of	  natural	  
gut	  microbiota,	  and	  that	   this	   is	  not	  dependent	  on	  T3SS	  expression.	  While	  our	  study	  did	  
not	   find	   any	  measurable	   difference	   between	  wild	   type	   and	   T3SS-­‐lacking	   O157:H7,	   this	  
does	  not	  mean	  that	  bacteria	  do	  not	  form	  any	  A/E	   lesions	  using	  the	  T3SS,	  as	  A/E	   lesions	  
have	  been	  previously	  reported	  in	  mice	  infected	  by	  O157:H7.	  Using	  the	  mouse	  loop	  model,	  
Girard	  et	  al.	  (2008)	  directly	  infected	  mouse	  ileal	  loops	  with	  109	  CFU	  of	  either	  O157:H7	  or	  
a	   tir	  mutant.	  After	   an	   incubation	  of	   three	  hours,	   tissue	  was	   removed	  and	  examined	  by	  
electron	  microscopy,	   revealing	  A/E	   lesions	   present	   only	   in	   loops	   infected	  with	   the	  wild	  
type.	   However,	   A/E	   lesions	   were	   observed	   infrequently,	   and	   the	   authors	   of	   the	   study	  
conceded	  that	  these	  lesions	  may	  occur	  because	  of	  the	  high	  number	  of	  bacteria	  trapped	  in	  
the	   mouse	   loops	   during	   the	   incubation	   (Girard	   et	   al.,	   2008).	   Considering	   these	  
experiments,	   it	   is	   unsurprising	   that	   we	   were	   unable	   to	   determine	   any	   T3SS	   effect	   on	  
colonisation	  in	  the	  StrR	  mouse	  model.	  
	  
The	  influence	  of	  the	  T3SS	  on	  EHEC	  colonisation	  of	  mice	  has	  also	  been	  previously	  explored	  
by	   Nagano	   et	   al.	   (2003).	   This	   study	   suggested	   that	   the	   T3SS	  may	   confer	   a	   persistence	  
advantage	   at	   a	   time	   point	   later	   than	   considered	   in	   our	   study.	   When	   non-­‐antibiotic-­‐
treated	   ICR	  mice	  were	  orally	   infected	  with	  O157:H7	  GPU96MM,	   this	   strain	  was	   shed	   in	  
faeces	   up	   to	   4	   weeks	   after	   infection.	   In	   contrast,	   a	   strain	   containing	   an	   espA	   deletion	  
mutation	  was	  undetectable	  in	  faeces	  1-­‐2	  weeks	  post	  infection	  (Nagano	  et	  al.,	  2003).	  This	  
implies	  that	  the	  T3SS	  may	  be	  important	  for	  prolonged	  colonisation.	  There	  are,	  however,	  
notable	   differences	   between	   this	   experiment	   and	   the	   ones	   presented	   in	   this	   chapter.	  
Aside	  from	  the	  different	  O157:H7	  strains	  used,	  Nagano	  et	  al.	  (2003)	  used	  untreated	  mice	  
in	  which	  colonisation	  of	  the	  O157:H7	  strain	  was	  high	  and	  sustained	  for	  several	  weeks	  in	  
the	  absence	  of	  antibiotic	   treatment.	  This	   contrasts	  our	   findings	  with	  TUV93-­‐0	  and	  non-­‐
streptomycin-­‐treated	  mice.	  This	   is	  unsurprising,	  as	  colonisation	  of	  O157:H7	  in	  mice	  with	  
an	  intact	  commensal	  flora	  has	  been	  reported	  to	  be	  variable,	  possibly	  due	  to	  differences	  in	  
both	  the	  O157:H7	  strain	  and	  the	  microbiota	  composition	  of	  mice	  from	  different	  suppliers	  
(Mohawk	   et	   al.,	   2010).	   Additionally,	   confocal	   microscopy	   by	   Nagano	   et	   al.	   (2003)	   of	  
3. RESULTS: Mouse models of E. coli infection 
	   97	  
intestinal	   tissue	   taken	   from	   1	   hour	   to	   3	   days	   after	   infection	   by	   GPU96MM	   found	   no	  
evidence	   of	   A/E	   lesions	   on	   either	   the	   large	   or	   small	   intestine,	   despite	   bacteria	   being	  
detected	   in	   the	   intestinal	   mucosa	   very	   soon	   after	   infection.	   However,	   in	   caecal	   tissue	  
samples	  taken	  18	  hours	  to	  3	  days	  after	  infection,	  microcolonies	  and	  diffuse	  adherence	  of	  
GPU96MM	  with	  accumulation	  of	   filamentous	  actin	  beneath	   the	  attached	  bacteria	  were	  
observed	   (Nagano	   et	   al.,	   2003).	   This	   has	   led	   to	   the	   hypothesis	   that	   the	   site	   of	   EHEC	  
colonisation	  in	  mice	  is	  the	  caecum,	  and	  bacteria	  are	  shed	  into	  the	  caecal	  contents	  before	  
passing	  into	  the	  large	  intestine,	  where	  they	  are	  then	  expelled	  in	  faecal	  matter	  (Nagano	  et	  
al.,	  2003;	  Mohawk	  et	  al.,	  2010).	   It	  would	   therefore	  be	   interesting	   to	  explore	  whether	  a	  
significant	   difference	   in	   colonisation	   levels	  would	  occur	   between	   TUV93-­‐0	   and	  OI-­‐148A	  
during	  an	  extended	  post	  infection	  period.	  
	  
Shortly	   after	   completing	   our	   TUV93-­‐0/OI-­‐148A	   experimentation,	   a	   study	   by	   Chen	  et	   al.	  
(2013)	  was	  published	  which	  indicated	  that	  StrR	  mutants	  show	  significantly	  reduced	  Type	  3	  
secretion.	   Spontaneous	   restrictive	   StrR	   mutants,	   including	   the	   K42T	   mutant,	   displayed	  
severely	  reduced	  secretion	  of	  EspA,	   the	  component	  of	   the	  T3SS	  syringe	  tip	  required	  for	  
interaction	  with	  host	  cells,	  and	  EspB,	  a	  protein	  translocated	  into	  the	  host	  and	  necessary	  
for	   formation	   of	   pores	   in	   the	   host	   membrane	   and	   translocation	   of	   Tir.	   The	   decreased	  
secretion	  was	   due	   to	   a	   reduced	   rate	   of	   EspA	   and	   EspB	   protein	   synthesis,	   and	  mutants	  
showed	   compromised	   adherence	   and	   A/E	   formation	   in	   vitro.	   Secretion	   assays	   and	  
immunoblotting	   for	   EspD	   using	   the	   TUV93-­‐0	   K42T	   StrR	   strain	   have	   also	   indicated	   a	  
decrease	   in	   secretion	   of	   this	   T3SS	   protein	   (Tom	   Parker,	   personal	   communication).	   This	  
study	  by	  Chen	  et	  al.	  (2013)	  suggests	  a	  currently	  unknown	  link	  between	  StrR	  mutations	  and	  
the	  T3SS-­‐related	  virulence	  potential	  of	  this	  strain,	  although	  no	   in	  vivo	  experiments	  were	  
performed	  (Chen	  et	  al.,	  2013).	  
	  
These	   findings	   suggested	   that	   the	   lack	   of	   a	   difference	   in	   colonisation	   levels	   between	  
TUV93-­‐0	   and	  OI-­‐148A	  may	   reflect	   the	   inability	   of	   the	   TUV93-­‐0	   StrR	   strains	   to	   form	  A/E	  
lesions.	  To	  address	  this	  issue,	  the	  experiments	  were	  repeated	  using	  TUV93-­‐0	  and	  OI-­‐148A	  
strains	  that	  were	  transformed	  with	  the	  streptomycin	  resistance-­‐encoding	  pGB2	  plasmid.	  
Colonisation	  levels	  of	  these	  strains	  as	  measured	  by	  faecal	  shedding	  and	  live	  imaging	  were	  
very	  similar	  to	  those	  of	  the	  rpsL	  mutants,	  and	  showed	  no	  significant	  difference	  between	  
the	  wild	   type	  and	   the	  T3SS-­‐negative	   strain.	   Luminal	   and	   tissue-­‐attached	  bacteria	   in	   the	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caecum,	   small	   intestine	   and	   large	   intestine	   also	   appeared	   similar	   to	   the	   K42T	  mutants,	  
and	  no	  significant	  difference	  between	  TUV93-­‐0	  and	  OI-­‐148A	  was	  observed	   (Appendices	  
9.2).	   This	   suggests	   that	   our	   initial	   observation	   that	   persistence	   not	   associated	   with	  
generation	  of	  a	  T3SS	  structure	  is	  reliable.	  Therefore,	  the	  ability	  of	  EHEC	  to	  persist	  in	  high	  
numbers	  throughout	  infected	  mice	  without	  the	  model	  displaying	  dependence	  on	  the	  T3SS	  
raises	  the	  issue	  of	  how	  useful	  EHEC	  mouse	  models	  are	  for	  in	  vivo	  testing	  of	  potential	  anti-­‐
virulence	  compounds.	  
	  
3.7.3	   The	   Stx-­‐expressing	  Citrobacter	   rodentium	  mouse	  model	   is	   a	   strong	   replicator	   of	  
T3SS-­‐mediated	  adhesion	  and	  Stx-­‐mediated	  kidney	  damage	  
	  
As	  the	  StrR-­‐treated	  TUV93-­‐0	  model	  was	  deemed	  unsuitable	  for	  studying	  the	  T3SS’	  effect	  
on	  colonisation,	  the	  Stx2dact-­‐expressing	  C.	  rodentium	  model,	  developed	  by	  Mallick	  et	  al.	  
(2012),	  was	   investigated	  as	  an	  O157:H7	  surrogate.	  BALB/c	  mice	   infected	  with	  this	  strain	  
showed	   visual	   signs	   of	   illness	   a	   few	   days	   after	   infection	   along	   with	   decreasing	   body	  
weight,	   while	   colonisation	   levels	   were	   high	   and	   stable	   throughout	   the	   infection.	   All	  
λstx2dact-­‐infected	  animals	  became	  ill	  5-­‐6	  days	  post	  infection	  and	  kidney	  histology	  revealed	  
proximal	   tubule	   injury	  consistent	  with	   the	  Mallick	  et	  al.	   (2012)	   findings.	  A	  C.	   rodentium	  
(λstx2dact)Δtir	   strain	  unable	   to	  produce	  A/E	   lesions	   resulted	   in	  poor	   colonisation	   and	  no	  
signs	  of	  disease	  or	  mortality,	  making	  this	  an	  excellent	  surrogate	  E.	  coli	  model	  for	  studying	  
both	  T3SS-­‐mediated	  adhesion	  and	  Stx-­‐mediated	  illness.	  
	  
Surprisingly,	  C57BL/6	  mice	   infected	  with	  C.	   rodentium	   (λstx2dact)	   showed	  no	  weight	   loss	  
until	  approximately	  8	  days	  after	  infection,	  despite	  strong	  colonisation	  levels.	  This	  weight	  
loss	   in	   the	   second	  week	   of	   infection	  was	   not	   accompanied	   by	   any	   observable	   signs	   of	  
illness,	   and	   only	   one	   out	   of	   the	   three	   λstx2dact	  mice	   reached	   the	   >15%	  weight	   loss	   cull	  
point.	   The	   remaining	   two	  mice	   showed	  a	   recovery	   in	  weight	  over	   the	   final	   two	  days	  of	  
infection,	  likely	  due	  to	  the	  clearance	  of	  C.	  rodentium,	  as	  shown	  by	  faecal	  shedding	  levels.	  
Interestingly,	   kidney	   histology	   found	   λstx2dact	   C57BL/6	   mice	   had	   signs	   of	   Stx-­‐mediated	  
damage,	   suggesting	   that	   Stx	   is	   being	   produced	   by	   C.	   rodentium,	   despite	   the	   poor	  
indications	   of	   illness.	   The	   weight	   loss	   observed	   occurred	   at	   the	   point	   at	   which	   C.	  
rodentium	   colonisation	   in	  mice	   typically	  beings	   to	  decrease,	   suggesting	   the	  explanation	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that	  bacterial	  clearance	  is	  associated	  with	  destruction	  of	  bacteria	  and	  subsequent	  release	  
of	  Stx.	  	  
	  
Immune	  differences	  between	  the	  two	  mouse	  strains	  may	  account	  for	  increased	  sensitivity	  
of	   BALB/c	   mice	   to	   the	   λstx2dact	   strain.	   The	   genetic	   background	   of	   mice	   is	   known	   to	  
influence	  the	  Th1/Th2	  balance,	  with	  C57BL/6	  mice	  favouring	  Th1	  and	  BALB/c	  mice	  biased	  
towards	  Th2	  (Mills	  et	  al.,	  2000).	  This	  difference	  has	  been	  linked	  to	  impaired	  bactericidal	  
activity	   of	   BALB/c	  macrophages	   and	   poor	   bacterial	   clearance	   relative	   to	   C57BL/6	  mice	  
(Watanabe	  et	  al.,	  2004).	  Another	  possibility	  is	  that	  the	  intestinal	  environment	  of	  C57BL/6	  
mice	  produces	  lower	  Stx	  phage	  induction	  than	  the	  BALB/c	  host	  does.	  
	  
Our	  C57BL/6	  observations	  are	  however	  contradictory	  to	  those	  in	  the	  original	  Mallick	  et	  al.	  
(2012)	  publication,	  which	  reported	  C57BL/6	  weight	  loss	  and	  death	  within	  the	  first	  week	  of	  
infection,	  similar	  to	  our	  results	  for	  BALB/c	  mice.	  As	  C57BL/6	  mice	  are	  an	  inbred	  strain,	  it	  is	  
unlikely	  that	  the	  varying	  results	  between	  our	  mice	  and	  those	  used	  by	  Mallick	  et	  al.	  (2012)	  
are	  due	  to	  genetic	  differences.	  Instead,	  we	  suspect	  that	  differences	  in	  the	  microbiota	  of	  
the	   mouse	   gut	   are	   responsible,	   as	   animals	   acquired	   from	   different	   suppliers	   will	   be	  
subject	  to	  differences	   in	  the	  environment,	  diet,	  and	  exposure	  to	  maternal	   flora.	  Studies	  
comparing	  the	  gut	  microbiota	  of	   lab	  mice	  have	  found	  that	  C57BL/6	  mice	  obtained	  from	  
two	   different	   suppliers	   displayed	   significant	   differences	   in	   their	  microbial	   composition,	  
while	  mice	  raised	  in	  separate	  rooms	  of	  the	  same	  breeding	  facility	  showed	  no	  significant	  
difference	  (Hufeldt	  et	  al.,	  2010).	  We	  could	  therefore	  speculate	  that	  commensal	  bacterial	  
strains	   present	   in	   our	   C57BL/6	   mice	   confer	   a	   protective	   advantage	   to	   their	   host,	   for	  
example	  by	  limiting	  the	  effect	  of	  Stx	  expression	  or	  Stx-­‐mediated	  damage	  (although	  not	  C.	  
rodentium	  colonisation).	  However,	  16S	  ribosomal	  RNA	  sequencing	  of	  the	  gut	  microbiota	  
of	   animals	   from	   both	   C57BL/6	   suppliers	  would	   be	   required	   in	   order	   to	   investigate	   this	  
further.	   Nonetheless,	   the	   results	   presented	   here	   demonstrate	   that	   despite	   these	  
differences,	   with	   respect	   to	   final	   outcomes	   and	   damage	   to	   kidney	   tissue	   there	   is	  
consistency	   between	   the	   two	  models.	   This	   is	   an	   important	   consideration	   in	   the	   use	   of	  
animal	   models	   as	   a	   surrogate	   for	   infection	   in	   humans.	   The	   results	   presented	   in	   this	  
chapter	  support	  the	  use	  of	  the	  Citrobacter	  rodentium	  Stx	  strains	  as	  a	  model	  for	  O157:H7	  
infection.	  
4.	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  EaeH	  and	  YghJ	  as	  vaccine	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4.1	  Introduction	  
	  
Surface-­‐exposed	   bacterial	   proteins	   are	   considered	   good	   candidates	   for	   inclusion	   in	  
vaccine	   formulations.	   These	   proteins	   are	   often	   associated	   with	   initial	   host-­‐pathogen	  
interactions,	  and	  thus	  generation	  of	  antibodies	  against	  them	  can	  both	   limit	  colonisation	  
and	   enhance	   uptake	   and	   destruction	   of	   bacteria.	   Reverse	   vaccinology,	   which	   utilises	  
bioinformatics	  to	  analyse	  sequenced	  genomes	  and	  recognise	  genes	  that	  encode	  proteins	  
with	   extracellular	   regions,	   is	   a	   relatively	   recent	   approach	   to	   vaccine	   design	   which	   has	  
been	  used	  to	  create	  a	  successful	  vaccine	  against	  Meningococcus	  B	  (Pizza	  et	  al.,	  2000).	  In	  
2010,	  a	  reverse	  vaccinology	  screen	  identified	  nine	  proteins	  from	  ExPEC	  strains	  capable	  of	  
inducing	  a	  significant	  level	  of	  protection	  in	  a	  mouse	  model	  of	  sepsis.	  The	  ExPEC	  group	  of	  
strains,	   which	   colonise	   and	   induce	   disease	   outside	   of	   the	   intestinal	   tract,	   are	   a	   major	  
health	   concern	   and	   responsible	   for	   diseases	   such	   as	   urinary	   tract	   infections,	   neonatal	  
meningitis	  and	  pneumonia.	  However,	  comparative	  analysis	  of	   the	  genes	  encoding	  these	  
antigens	   with	   genomic	   sequences	   from	   other	   pathogenic	   E.	   coli	   strains	   revealed	  many	  
were	  conserved	  across	  other	  pathotypes,	  and	  were	  present	  in	  intestinal	  E.	  coli	  pathogens	  
(Moriel	   et	   al.,	   2010).	   The	   aim	   of	   our	  work	  was	   to	   investigate	   the	   role	   of	   two	   of	   these	  
proteins,	  EaeH	  and	  YghJ,	  in	  EHEC	  and	  AIEC	  pathogenesis,	  and	  determine	  their	  potential	  as	  
vaccine	  candidates	  against	  O157:H7	  and	  LF82.	  
	  
4.1.1	  EaeH	  as	  a	  vaccine	  candidate	  
	  
The	  eaeH	  gene	  (Figure	  4-­‐1	  A)	  is	  predicted	  to	  encode	  an	  outer	  membrane	  adhesin	  with	  a	  
putative	   amino-­‐terminal	   signal	   sequence,	   and	   shares	   approximately	   30%	   similarity	  with	  
eae,	   which	   encodes	   intimin.	   Intimin	   functions	   as	   the	   bacterial	   receptor	   for	   the	   T3SS-­‐
translocated	  Tir	  in	  EHEC,	  and	  its	  inclusion	  in	  cattle	  vaccines	  reduces	  shedding	  of	  O157:H7	  
(McNeilly	  et	  al.,	  2010).	  Although	  the	  protective	  efficacy	  of	  EaeH	  was	  relatively	  low	  (15%)	  
in	  the	  initial	  screen	  study,	  it	  is	  highly	  conserved	  across	  many	  pathogens,	  including	  strains	  
belonging	   to	   the	   serotypes	   O157:H7,	   O103:H2,	   and	   O26:H11,	   the	   latter	   of	   which	   is	  
considered	  the	  most	  clinically	  important	  non-­‐O157	  EHEC	  (Bielaszewska	  et	  al.,	  2007).	  Thus,	  
inclusion	  of	  EaeH	  within	  a	   vaccine	   could	  broaden	   its	  potential	   as	  an	  efficacious	  vaccine	  
against	  multiple	  E.	  coli	  strains.	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4.1.2	  YghJ	  as	  a	  vaccine	  candidate	  
	  
The	   most	   effective	   antigen	   in	   the	   mouse	   sepsis	   model,	   YghJ,	   is	   a	   putative	   lipoprotein	  
secreted	   by	   the	   Type	   2	   Secretion	   System	   (T2SS).	   YghJ	   shows	   significant	   similarity	   to	  
accessory	   colonisation	   factor	   D	   (AcfD)	   of	  Vibrio	   cholerae,	   and	   provided	   extremely	   high	  
protection	  from	  bacteraemia	  and	  mortality	  in	  mice	  (82%	  efficacy),	  both	  as	  a	  consequence	  
of	   active	   or	   passive	   immunisation	   (Moriel	   et	   al.,	   2010).	   Phylogenetic	   analysis	   has	  
indicated	   that	   YghJ	   clusters	   into	   two	  main	   variants,	   although	   antibodies	   raised	   against	  
one	  variant	  were	  protective	  against	  strains	  that	  encoded	  even	  the	  most	  distant	  variant	  of	  
YghJ	  (Moriel	  et	  al.,	  2010).	  The	  distribution	  of	  yghJ	  in	  573	  isolates	  representing	  the	  entire	  
variation	  shown	  by	  E.	  coli	  phylogeny	  was	  analysed	  by	  Moriel	  et	  al.	  (2010),	  revealing	  that	  
the	   gene	   is	   present	   across	   a	   wide	   range	   of	   pathogenic	   and	   non-­‐pathogenic	   strains,	  
although	  found	  more	  frequently	  in	  intestinal	  and	  extraintestinal	  pathogens	  (70-­‐83%)	  than	  
in	  commensal	  strains	  (59%).	  Interestingly,	  although	  YghJ	  was	  detected	  in	  total	  cell	  lysates	  
from	  non-­‐pathogenic	  strains,	  it	  was	  not	  secreted	  or	  surface	  associated.	  In	  non-­‐pathogenic	  
strains,	   the	   T2SS-­‐encoding	   region	   adjacent	   to	   yghJ	   is	   truncated,	   and	   a	   fully-­‐functional	  
T2SS	  was	  demonstrated	  to	  be	  necessary	  for	  secretion	  of	  YghJ	  (Moriel	  et	  al.,	  2010).	  	  
	  
The	  yghJ	  gene	  is	  not	  present	  in	  O157:H7	  EDL933.	  However,	  it	  is	  present	  in	  the	  genome	  of	  
LF82	  (Figure	  4-­‐1	  B),	  which	  is	  why	  this	  gene	  was	  studied	  in	  this	  strain.	  LF82	  colonises	  the	  
intestinal	   mucosa	   of	   patients	   with	   Crohn’s	   disease	   (Darfeuille-­‐Michaud	   et	   al.,	   1998),	   a	  
chronic	   inflammatory	   bowel	   disease	   that	   is	   believed	   to	   have	   genetic,	   bacterial	   and	  
environmental	   factors	   involved	   in	   its	   development	   (Cosnes	   et	   al.,	   2011).	   The	   strong	  
evidence	  for	   the	   involvement	  of	  LF82	  and	  other	  AIEC	  strains	   in	  pathogenesis	  of	  Crohn’s	  
disease	   makes	   development	   of	   a	   vaccine	   that	   confers	   protection	   against	   these	   strains	  
important.	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Figure	   4-­‐1:	  Genomic	   organisation	  of	  eaeH	  and	  yghJ.	  The	  eaeH	  organsiation	   in	  O157:H7	  EDL933	   (A),	  and	  
yghJ	   organisation	   in	   LF82	   (B).	   Alignment	   of	   these	   genes	   in	   EDL933	   and	   LF82	   with	   those	   carried	   by	   the	  
IHE3034	  strain	  revealed	  both	  eaeH	  and	  yghJ	  were	  located	  in	  similar	  genomic	  positions.	  
	  
4.1.3	  Aims	  of	  this	  chapter	  
	  
• To	   overexpress	   and	   purify	   His-­‐tagged	   IHE3034	   EaeH	   and	   YghJ	   from	   plasmids	  
provided	   by	   Novartis	   Vaccines,	   and	   assess	   their	   suitability	   for	   use	   as	   positive	  
controls	  in	  studies	  that	  explore	  expression	  of	  EaeH	  and	  YghJ	  by	  TUV93-­‐0	  and	  LF82	  
strains.	  
	  
• To	  construct	  eaeH	  deletion	  mutant	  strains	  in	  both	  TUV93-­‐0	  and	  LF82,	  and	  a	  yghJ	  
deletion	  mutant	  strain	  in	  LF82.	  These	  strains	  will	  be	  used	  as	  negative	  controls	  for	  
expression	  studies,	  and	  potentially	  in	  animal	  experiments	  to	  determine	  the	  role	  of	  
these	  genes	  in	  infection.	  
	  
• To	   explore	   expression	   of	   EaeH	   and	   YghJ	   by	   TUV93-­‐0	   and	   LF82	   under	   different	  
growth	  conditions,	  including	  the	  use	  of	  different	  growth	  media	  and	  the	  presence	  
of	  mammalian	  epithelial	  cells.	  Expression	  of	  these	  genes	  will	  be	  determined	  using	  
fluorescence	  reporters,	  which	  will	  require	  the	  construction	  of	  gene	  promoter-­‐GFP	  
fusion	  plasmids,	  and	  by	  immunoblotting	  using	  anti-­‐EaeH/YghJ	  antibodies	  provided	  
by	  Novartis	  Vaccines.	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4.2	  Bacterial	  carriage	  of	  eaeH	  and	  yghJ	  
	  
Bioinformatic	  analysis	  of	  eaeH	   and	  yghJ	   carriage	   in	  1,591	  E.	   coli	   isolates,	   carried	  out	  by	  
Robert	  Goldstone	  (University	  of	  Glasgow)	  using	  the	  method	  described	   in	  Connolly	  et	  al.	  
(2015),	   showed	  that	  eaeH	   is	  highly	  conserved	  across	   the	  E.	  coli	   lineage	  and	   found	   in	  all	  
sub-­‐groups.	   Carriage	   of	   yghJ	   was	   also	   very	   high,	   but	   noticeably	   absent	   from	   nearly	   all	  
members	   of	   sub-­‐group	   E	   (which	   includes	   the	  O157:H7	   strain),	  which	   suggests	   that	   this	  
gene	  was	  lost	  by	  an	  early	  ancestor	  of	  this	  phylogroup	  (Figure	  4-­‐2).	  	  
	  
	  
Figure	  4-­‐2:	  E.	  coli	  carriage	  of	  the	  eaeH	  and	  yghJ	  genes.	  Circularised	  phylogenetic	  tree	  of	  1,591	  E.	  coli	  and	  
Shigella	  isolates	  overlaid	  with	  gene	  carriage	  (>80%	  identity	  over	  >80%	  of	  the	  coding	  sequence)	  for	  the	  eaeH	  
(red)	  and	  yghJ	   (blue)	  genes.	  1,406	  isolates	  contained	  the	  eaeH	  gene,	  while	  1,062	  isolates	  carried	  the	  yghJ	  
gene.	   Phylogenetic	   sub-­‐grouping	   is	   indicated	   by	   branch	   colour	   coding	   as	   follows:	   Phylogroup	   A	   =	   blue;	  
Phylogroup	  B1	  =	  pink;	  Phylogroup	  B2:	  yellow;	  Phylogroup	  C	  =	  purple;	  Phylogroup	  D	  =	  green;	  Phylogroup	  E	  =	  
orange;	  Phylogroup	  F	  =	  olive;	  Shigella	  =	  grey.	  Key	  strains	  are	  labelled	  according	  to	  their	  location	  on	  the	  tree,	  
and	   the	   O157:H7	   EDL933	   and	   LF82	   strains	   used	   in	   this	   study	   are	   indicated	   by	   underline.	   Bioinformatic	  
analysis	  was	  performed	  by	  Robert	  Goldstone	  (University	  of	  Glasgow).	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4.3	  Overexpression	  of	  His-­‐tagged	  EaeH	  and	  YghJ	  
	  
The	  plasmids	  pET-­‐21b-­‐eaeH	  and	  pET-­‐21b-­‐yghJ,	  which	  encode	  polyhistidine-­‐tagged	  EaeH	  
and	  YghJ	  respectively,	  were	  constructed	  by	  Novartis	  Vaccines.	  The	  clones	  were	  generated	  
using	  genomic	  DNA	  from	  the	  E.	  coli	  IHE3034	  strain	  as	  a	  template.	  Protein	  expression	  was	  
controlled	  using	  IPTG	  to	  induce	  the	  T7	  promoter.	  These	  plasmids	  had	  originally	  been	  used	  
to	  produce	  the	  purified	  EaeH	  and	  YghJ	  that	  were	  tested	  in	  the	  mouse	  sepsis	  model,	  and	  
to	  raise	  antibodies	   in	  rabbits	  against	  both	  proteins	  (Moriel	  et	  al.,	  2010).	  The	  amino	  acid	  
sequence	   of	   the	   two	   proteins	   encoded	   by	   IHE3034	   are	   highly	   homologous	   to	   those	  
encoded	   by	   TUV93-­‐0	   and	   LF82	   (92.2%	   identity	   between	   TUV93-­‐0	   and	   IHE3034	   EaeH;	  
92.3%	   identity	   between	   LF82	   and	   IHE3034	   EaeH;	   97.3%	   identity	   between	   LF82	   and	  
IHE3034	  YghJ).	  
	  
To	  overexpress	  EaeH	  and	  YghJ,	  plasmids	  were	  transformed	  into	  E.	  coli	  BL21(DE3)	  cells	  and	  
expression	  induced	  by	  addition	  of	  1	  mM	  IPTG.	  Proteins	  were	  purified	  using	  nickel	  affinity	  
columns	   and	   confirmed	   by	   Western	   blotting,	   using	   rabbit	   anti-­‐EaeH	   and	   anti-­‐YghJ	  
supplied	  by	  Novartis	  Vaccines	  (Figure	  4-­‐3).	  Western	  blot	  analysis	  indicated	  that	  EaeH	  had	  
a	   molecular	   weight	   of	   ~32	   kDa,	   and	   YghJ	   a	   molecular	   weight	   of	   ~100	   kDa,	   both	  
significantly	   lower	  than	  the	  full	  peptide	  sequence	  of	  wild	  type	  EaeH	  (149	  kDA)	  and	  YghJ	  
(167	   kDa).	   Sequencing	   of	   the	   eaeH	   and	   yghJ	   genes	   present	   in	   the	   pET-­‐21b	   plasmids	  
revealed	  that	  both	  genes	  were	  significantly	  truncated,	  with	  only	  ~1,650	  bp	  of	  eaeH	   (full	  
length	  =	  4,254	  bp)	  and	  2,700	  bp	  of	  yghJ	   (full	   length	  =	  4,563	  bp)	  present	   in	  the	  plasmids	  
(Appendices	   9.3).	   Therefore,	   these	   pET-­‐21b-­‐encoded	   proteins	   are	   poorly	   suited	   for	  
comparison	  with	  EaeH	  and	  YghJ	  expressed	  by	  TUV93-­‐0	  and	  LF82.	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A	   	   	   	   	   B	  
	  
Figure	   4-­‐3:	   Expression	   of	   His-­‐tagged	   EaeH	   and	   YghJ.	   Whole-­‐cell	   lysate	   of	   BL21	   transformed	   with	   the	  
plasmids	  pET-­‐21b-­‐eaeH	   or	  pET-­‐21b-­‐yghJ,	  with	  and	  without	   addition	  of	   1	  mM	   IPTG	  when	  growth	   cultures	  
reached	  an	  OD600	  of	  0.6.	  Cultures	  were	  grown	  for	  a	  further	  4	  hours	  after	  the	  IPTG	  addition	  time	  point	  (A).	  
Western	   blots	   of	   EaeH	   and	   YghJ	   from	   IPTG-­‐induced	   cultures	   of	   BL21	   transformed	  with	   pET-­‐21b-­‐eaeH	   or	  
pET-­‐21b-­‐yghJ.	  Proteins	  were	  purified	  by	  affinity	  chromatography	  before	  Western	  blot	  analysis	  (B).	  
	  
4.4	  Construction	  of	  eaeH	  and	  yghJ	  deletion	  mutants	  
	  
To	  explore	   the	  potential	   contribution	  played	  by	  EaeH	  and	  YghJ	   in	  E.	   coli	   colonisation	   in	  
vivo,	  we	  planned	  to	   infect	  mice	  with	  TUV93-­‐0	  and	  LF82	  strains	  containing	  eaeH	  or	  yghJ	  
deletions	  and	  determine	  whether	  there	  was	  an	  effect	  on	  colonisation	  compared	  to	  wild	  
type	  strains.	  Such	  deletion	  mutants	  could	  also	  be	  used	  as	  negative	  controls	  for	  exploring	  
expression	  of	  these	  proteins	  by	  Western	  blot.	   Initial	  attempts	  to	  use	  allelic	  exchange	  to	  
create	   a	   TUV93-­‐0	   ΔeaeH	   strain	   (Emmerson	   et	   al.,	   2006)	   were	   unsuccessful.	   However,	  
both	   ΔeaeH	   and	   ΔyghJ	   LF82	   strains	   were	   created	   using	   lambda	   red	   mutagenesis,	   and	  
confirmation	  that	  these	  genes	  had	  been	  successfully	  knocked	  out	  was	  demonstrated	  by	  
PCR	  (Figure	  4-­‐4).	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  EaeH	   	   	   	   	  	  	  	  	  	  YghJ	   	   	   	  
	  
	  
Figure	   4-­‐4:	   Confirmation	   of	   LF82	   ΔeaeH	   and	  ΔyghJ.	   The	   LF82	   strains	  ΔeaeH	   and	  ΔyghJ	  were	   created	  by	  
lambda	  red	  recombineering.	  These	  strains	  were	  checked	  for	  successful	  gene	  deletion	  by	  PCR;	   two	  sets	  of	  
primers	   to	   amplify	   an	   ~800	   bp	   region	   of	   DNA	   were	   used	   to	   test	   the	   knockout	   strains.	   The	   primers	   for	  
negative	   integration	   (-­‐ve)	   amplify	   a	   region	   of	   DNA	   only	   present	   when	   eaeH	   or	   yghJ	   is	   present	   in	   the	  
chromosome,	  while	   the	  primers	   for	  positive	   integration	  (+ve)	  amplify	  a	  region	  of	  DNA	  only	  present	  when	  
eaeH	  or	  yghJ	  replaced	  by	  the	  kanamycin	  resistance	  cassette.	  The	  gel	  shows	  DNA	  amplified	  from	  wild	  type	  
LF82,	  ΔeaeH,	  and	  ΔyghJ	  by	  the	  two	  sets	  of	  primers.	  	  
	  
4.5	  Reporter	  fusion	  analysis	  of	  eaeH	  and	  yghJ	  expression	  
	  
4.5.1	  Construction	  of	  GFP	  reporter	  fusions	  
	  
To	  explore	  eaeH	  and	  yghJ	  gene	  expression	  by	  TUV93-­‐0	  and	  LF82,	  we	  used	  a	  fluorescence-­‐
based	  reporter	  system	  that	  allows	  monitoring	  of	  gene	  expression	  throughout	  the	  growth	  
cycle.	   GFP	   reporter	   fusions	   were	   constructed	   using	   pAJR70,	   a	   promoterless	   plasmid	  
containing	   the	  gfp	   gene,	   which	   encodes	   for	   green	   fluorescent	   protein	   (Cormack	   et	   al.,	  
1996).	  Briefly,	   the	  putative	  promoter	   regions	  of	  eaeH	   (-­‐568	   to	  +27,	   from	  both	  TUV93-­‐0	  
and	  LF82)	  and	  yghJ	   (-­‐346	   to	  +66,	   from	  LF82	  only)	  were	  amplified	  using	  PCR	  and	  cloned	  
into	  pAJR70	  directly	  upstream	  of	  gfp,	  ensuring	   that	  gfp	   remained	   in	   frame	   (Figure	  4-­‐5).	  
Correct	   insertion	   of	   the	   promoters	   was	   confirmed	   by	   DNA	   sequencing.	   The	   reporter	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fusions	   created	   were	   named	   pzm_TE1	   (TUV93-­‐0	   eaeH),	   pzm_LE1	   (LF82	   eaeH),	   and	  
pzm_LY1	   (LF82	   yghJ).	   For	   all	   experiments,	   the	   reporter	   fusions	   were	   transformed	   only	  
into	  the	  strains	  from	  which	  the	  promoter	  region	  was	  obtained,	  i.e.	  pzm_TE1	  transformed	  
into	   the	   TUV93-­‐0	   background,	   and	   pzm_LE1	   and	   pzm_LY1	   transformed	   into	   the	   LF82	  
background.	  
	  
A	   	   	   eaeH	  promoter	  
	  
	   	   	   yghJ	  promoter	  
	  
B	   	   Cloning	  of	  promoters	  into	  pAJR70	  
	  	  
Figure	  4-­‐5:	  Construction	  of	  eaeH	  and	  yghJ	   reporter	   fusions.	  The	  potential	  promoter	  regions	  upstream	  of	  
eaeH	  and	  yghJ	  were	  amplified	  by	  PCR.	  These	  amplified	  regions	  also	  contained	  the	  first	  few	  codons	  of	  eaeH	  
and	  yghJ.	  The	  sequence	  immediately	  before	  and	  after	  the	  start	  codon	  of	  eaeH	  (from	  TUV93-­‐0)	  and	  yghJ	  is	  
shown.	   The	   putative	   promoter	   consensus	   sequences	   -­‐10	   (TATAAT)	   and	   -­‐35	   (TTGACA)	   are	   indicated	   by	  
underline,	   and	   the	   ATG	   start	   codon	   encoding	   methionine	   labelled	   (A).	   These	   amplified	   sequences	   were	  
inserted	  directly	  upstream	  of	  gfp	  (green)	  in	  pAJR70,	  producing	  pzm_TE1,	  pzm_LE1,	  and	  pzm_LY1	  (B).	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4.5.2	  GFP	  reporter	  fusion	  assays	  
	  
Expression	   of	   GFP	   by	   the	   eaeH	   and	   yghJ	   promoters	   was	   assessed	   during	   exponential	  
growth	  of	  both	  TUV93-­‐0	  and	  LF82	  transformed	  with	  the	  pzm_TE1,	  pzm_LE1	  and	  pzm_LY1	  
plasmids	   respectively.	   Expression	   was	   monitored	   in	   LB,	   MEM	   and	   M9	   medium	   for	   6	  
hours.	   Positive	   expression	   of	   GFP	  was	   shown	   by	   E.	   coli	   transformed	  with	   the	   reporter	  
plasmid	  prpsM:GFP,	  containing	  the	  promoter	  for	  rpsM,	  which	  encodes	  the	  30S	  ribosomal	  
subunit	   protein	   S13	   and	   is	   strongly	   expressed	   in	   the	   growth	   medium	   used.	   Baseline	  
fluorescence	   was	   determined	   by	   E.	   coli	   transformed	   with	   the	   promoterless	   pAJR70	  
plasmid.	  Neither	  eaeH	  (in	  TUV93-­‐0	  and	  LF82)	  or	  yghJ	  (in	  LF82)	  reporter	  fusions	  produced	  
fluorescence	   levels	   above	   that	   of	   the	   baseline	   during	   this	   time	   period	   (Figure	   4-­‐6),	  
indicating	   that	   neither	   of	   these	   promoters	   are	   active	   at	   detectable	   levels	   under	   these	  
conditions.	  
	  
A	   LB	   	   	   B	   MEM	   	   	   C	   M9	  
	  
	  
D	   LB	   	   	   E	   MEM	   	   	   F	   M9
	   	  
Figure	  4-­‐6:	  Expression	  of	  gene:GFP	   reporter	   fusions.	  TUV93-­‐0	  (A-­‐C)	  and	  LF82	  (D-­‐F)	   transformed	  with	  the	  
reporter	   fusions	   pzm_TE1,	   pzm_LE1,	   pzm_LY1,	   pAJR70	   (to	   obtain	   background	   fluorescence	   levels)	   or	  
prpsM:GFP	   (for	   positive	   expression	   of	   GFP)	   were	   grown	   in	   LB	   (A,	   D),	   MEM	   (B,	   E),	   or	  M9	   (C,	   F)	   growth	  
medium	  for	  6	  hours.	  Fluorescence	  and	  OD600	  readings	  were	  taken	  hourly	  and	  fluorescence	  plotted	  against	  













































































































4.	  RESULTS:	  EaeH	  and	  YghJ	  as	  vaccine	  candidates	  
	   110	  
4.5.3	  Expression	  of	  ETEC	  eaeH	  is	  upregulated	  by	  interaction	  with	  host	  cells	  
	  
Many	  bacterial	   virulence	   genes	   have	   been	  demonstrably	   upregulated	   following	   contact	  
with	   host	   epithelial	   cells	   (Zhang	  &	   Normark,	   1996;	   Pettersson	   et	   al.,	   1996).	   In	   2013,	   a	  
transcriptome	  analysis	  study	  that	  investigated	  how	  ETEC	  virulence	  genes	  were	  modulated	  
upon	   contact	  with	  host	   epithelial	   cells	   indicated	   that	  eaeH	   expression	  was	  modified	  by	  
this	   interaction	  (Kansal	  et	  al.,	  2013).	  Using	  a	  β-­‐galactosidase	  eaeH	   reporter	  fusion,	  gene	  
expression	  was	  shown	  to	  be	  significantly	  increased	  in	  ETEC	  H10407	  bacteria	  attached	  to	  
human	   intestinal	   epithelial	   Caco-­‐2	   cells	   relative	   to	   planktonic	   bacteria.	   Additionally,	  
immunofluorescence	   microscopy	   identified	   EaeH	   on	   the	   surface	   of	   ETEC	   attached	   to	  
Caco-­‐2	   cells	   both	   at	   the	   point	   of	   cell	   contact	   and	   diffusely	   distributed	   on	   the	   H10407	  
surface.	   These	   findings	   suggested	   that	   similar	   upregulation	   of	   eaeH	   could	   potentially	  
occur	  in	  O157:H7	  and	  LF82.	  
	  
4.5.4	  Expression	  of	  GFP	  reporters	  upon	  contact	  with	  Caco-­‐2	  cells	  
	  
To	   determine	   if	   epithelial	   contact	   resulted	   in	   expression	   of	   GFP	   by	   the	   eaeH	   and	   yghJ	  
promoters,	   strains	   containing	   the	   reporter	  plasmids	  were	  used	   to	   infect	  near-­‐confluent	  
Caco-­‐2	   monolayers	   for	   5	   hours.	   To	   determine	   gene	   expression,	   fluorescence	   readings	  
were	   taken	   hourly.	   While	   we	   were	   initially	   interested	   in	   eaeH	   expression,	   yghJ	   was	  
included	   in	   this	   assay	   to	   investigate	  whether	  host	   cell	   contact	  modulates	   expression	  of	  
this	   gene.	   Increased	   fluorescence	   over	   time	   was	   observed	   for	   TUV93-­‐0	   and	   LF82	  
containing	   the	   rpsM	   reporter,	   however,	   no	   fluorescence	   above	   baseline	   levels	   was	  
detected	  for	  either	  the	  eaeH	  or	  yghJ	  reporter	  (Figure	  4-­‐7).	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A	   	   TUV93-­‐0	  
	   	   	   	  
B	   	   LF82	  
	   	   	   	  
Figure	  4-­‐7:	  Expression	  of	  GFP	  by	  eaeH	  and	  yghJ	  reporter	  fusions	  in	  contact	  with	  Caco-­‐2	  cells.	  TUV93-­‐0	  and	  
LF82	   transformed	   with	   the	   plasmids	   pzm_TE1,	   pzm_LE1,	   pzm_LY1,	   pAJR70	   (to	   obtain	   background	  
fluorescence	   levels)	   or	   prpsM:GFP	   (for	   positive	   expression	   of	   GFP)	  were	   added	   to	  monolayers	   of	   Caco-­‐2	  
cells	   at	   a	   final	  OD600	  of	  0.1.	  Bacteria	  and	  Caco-­‐2	   cells	  were	   incubated	   together	  at	  37°C	  and	  5%	  CO2	   for	  5	  
hours,	   and	   fluorescence	   measured	   directly	   from	   plates	   every	   hour.	   Experiments	   were	   performed	   in	  
triplicate	  and	  data	  presented	  as	  the	  mean	  fluorescence,	  with	  error	  bars	  displaying	  standard	  deviation	  from	  
the	  mean.	  
	  
These	  reporter	   fusion	  assays	  demonstrated	   that	  no	  eaeH	  or	  yghJ	  promoter	  activity	  was	  
detectable	   by	   this	   method.	   To	   more	   clearly	   visualise	   direct	   eaeH	   expression,	  
immunofluorescence	  microscopy	  was	  used	  to	  examine	  expression	  of	  GFP	  by	  the	  pzm_TE1	  
plasmid	  upon	  contact	  with	  host	  cells.	  HeLa	  cells	  were	  used	  instead	  of	  Caco-­‐2	  cells	  for	  this	  
experiment,	  as	  an	  established	  bacterial	  adhesion	  protocol	  was	  available	  for	  this	  cell	  line	  in	  
which	   clear	   T3SS-­‐mediated	   A/E	   lesions	   could	   be	   observed.	   Additionally,	   we	   selected	   a	  
human	  cell	  line	  rather	  than	  a	  mouse	  intestinal	  cell	  line	  for	  these	  experiments,	  as	  we	  were	  
interested	   in	   determining	   whether	   eaeH	   expression	   is	   upregulated	   on	   contact	   with	  
human	  cells	  before	  assessing	  whether	  murine	  cells	  produce	  a	  similar	  response.	  For	  these	  
studies,	  only	  TUV93-­‐0	  was	  tested.	  To	  further	  help	  bacterial	  visualisation,	  red	  fluorescence	  
protein	  (RFP)-­‐marked	  TUV93-­‐0	  was	  transformed	  with	  the	  pzm_TE1	  reporter	  plasmid.	  This	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strain	  was	   then	  was	   incubated	  with	  near-­‐confluent	  HeLa	   cells	   for	   4	   hours	   before	   fixing	  
and	   staining	   with	   FITC	   Phalloidin	   647	   (far	   red)	   to	   allow	   visualization	   of	   host	   cell	   actin.	  
Bacteria	   were	   identified	   using	   RFP,	   and	   eaeH	   promoter	   activity	   by	   GFP.	   TUV93-­‐0	  
transformed	   with	   the	   prpsM:GFP	   reporter	   fusion	   or	   pAJR70	   plasmid	   were	   used	   as	   a	  
positive	  and	  negative	  control	  for	  GFP	  expression,	  respectively.	  
	  
No	   GFP	   fluorescence	   from	   cells	   transformed	  with	   the	   pzm_TE1	   plasmid	   was	   detected,	  
implying	  that	  the	  eaeH	  promoter	  region	  in	  the	  plasmid	  is	  inactive	  even	  when	  TUV93-­‐0	  is	  
intimately	   attached	   to	   host	   cells	   (Figure	   4-­‐8).	  We	   also	   attempted	   to	   directly	   label	   cell	  
surface-­‐expressed	   EaeH	   using	   antisera;	   however,	   no	   EaeH	   could	   be	   detected	   in	   these	  
experiments	  (data	  not	  shown).	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A	   	  	  	  	  	  	  	  	  RFP,	  actin	  	   	   	   	  	  	  	  	  	  	  	  GFP,	  actin	  
	  	  	  	  	   	  
	  
B	   	  	  	  	  	  	  	  	  RFP,	  actin	  	   	   	   	  	  	  	  	  	  	  	  GFP,	  actin	  
	  	  	  	  	   	  
	  
C	   	  	  	  	  	  	  	  	  RFP,	  actin	  	   	   	   	  	  	  	  	  	  	  	  GFP,	  actin	  
	  	  	  	  	   	  
	  
Figure	   4-­‐8:	   Expression	   of	   eaeH:GFP	   by	   TUV93-­‐0	   adhered	   to	   HeLa	   cells.	   Representative	   fluorescence	  
microscopy	   images	   of	   HeLa	   cells	   with	   adhered	   TUV93-­‐0	   (indicated	   by	   arrows).	   RFP-­‐expressing	   TUV93-­‐0	  
transformed	  with	  pzm_TE1	  (A),	  prpsM:GFP	  (B)	  or	  pARJ70	  (C).	  Bacteria	  were	  incubated	  with	  HeLa	  cells	  for	  4	  
hours.	   After	   fixing	   and	   staining,	   cells	   were	   visualised	   for	   actin	   (far	   red),	   TUV93-­‐0	   (red)	   and	  
pzm_TE1/prpsM:GFP	  expression	  (green).	  Images	  show	  a	  merge	  of	  the	  far	  red	  and	  red	  channels	  (images	  on	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4.6	  Western	  blot	  analysis	  of	  EaeH	  and	  YghJ	  expression	  
	  
4.6.1	  Expression	  and	  detection	  of	  EaeH	  and	  YghJ	  
	  
Western	  analysis	  of	  whole-­‐cell	  lysates	  of	  TUV93-­‐0	  and	  LF82	  indicated	  that	  EaeH	  and	  YghJ	  
were	  both	  expressed	   in	   these	  strains.	   In	  contrast,	   these	  bands	  were	  absent	   in	   the	  LF82	  
ΔeaeH	   and	   ΔyghJ	   strains	   (Figure	   4-­‐9).	   Although	   EaeH	  was	   expressed	   by	   both	   TUV	   and	  
LF82	   wild	   type	   strains,	   it	   was	   produced	   at	   very	   low	   levels,	   requiring	   large	   volumes	   of	  
concentrated	  lysate	  (200	  μg	  total	  lysate	  protein)	  and	  a	  long	  exposure	  (10	  minutes)	  to	  be	  
detected.	  Both	  EaeH	  and	  YghJ	  ran	  at	  molecular	  weights	  approximately	  twice	  the	  size	  of	  
the	  His-­‐tagged	  proteins	   provided	  by	  Novartis	   as	   controls	   (Figure	   4-­‐3	  B),	   although	   given	  
that	  the	  pET-­‐21b	  plasmids	  provided	  by	  Novartis	  encoded	  truncated	  His-­‐tagged	  proteins,	  
these	  differences	  were	  not	  unexpected.	  
	  
Using	  the	  antibody	  against	  EaeH,	  we	  observed	  two	  distinct	  bands	  in	  the	  lysate	  of	  TUV93-­‐0	  
at	   approximately	   80-­‐100	   kDa,	  while	   LF82	   lysate	   showed	   3	   bands	   at	   slightly	   higher	   and	  
lower	  molecular	   sizes	   than	   TUV93-­‐0.	   Presence	   of	   the	   lowest	   band	   in	   the	   ΔeaeH	   lysate	  
suggests	   that	   the	   upper	   bands	   observed	   for	   LF82	   are	   EaeH,	   while	   the	   lower	   band	   (at	  
approximately	  62	  kDa)	  may	  be	  another	  surface	  protein	  to	  which	  the	  antibody	   is	  able	  to	  
bind.	   EaeH	   contains	   tandem	   bacterial	   immunoglobulin-­‐like	   domains	   that	   are	   similar	   to	  
those	   present	   in	   eukaryotic	   cell	   surface	   adhesion	   proteins,	   and	   therefore	   if	   the	   EaeH	  
antibody	  binds	  to	  these	  domains	   in	  EaeH,	   it	   is	  possible	  that	   it	  also	  targets	  proteins	  with	  
similar	  domains	  (Dr.	  Alaullah	  Sheikh,	  personal	  communication).	  Identification	  of	  the	  EaeH	  
band	   in	   TUV93-­‐0	  was	   not	   possible	   using	   this	   approach	   as	   the	   generation	   of	   a	   TUV93-­‐0	  
ΔeaeH	  strain	  proved	  elusive.	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A	   	   EaeH	   	   	   B	   	  	  	  	  	  	   	  	  	  	  YghJ	  
	   	  
Figure	  4-­‐9:	  EaeH	  and	  YghJ	  expression	  by	  TUV93-­‐0	  and	  LF82.	  TUV93-­‐0	  and	  LF82	  lysate	  after	  growth	  in	  MEM	  
media	  showing	  EaeH	  (A)	  and	  YghJ	  (B).	  Lysate	  from	  LF82	  ΔeaeH	  and	  ΔyghJ	  strains	  was	  run	  alongside	  the	  wild	  
type	  to	  identify	  the	  EaeH	  and	  YghJ	  bands	  (indicated	  by	  arrows).	  Bacterial	  lysate	  was	  loaded	  into	  wells	  and	  
contained	  a	  total	  of	  200	  μg	  (for	  EaeH	  blots)	  or	  50	  μg	  (for	  YghJ	  blots)	  protein.	  EaeH	  blots	  were	  exposed	  for	  
10	  minutes	  and	  YghJ	  blots	  for	  5	  minutes.	  
	  
4.6.2	  Expression	  of	  EaeH	  upon	  contact	  with	  Caco-­‐2	  cells	  
	  
As	  EaeH	  production	  by	  TUV93-­‐0	  and	  LF82	  was	  detectable	  by	  Western	  blot,	  this	  technique	  
was	   used	   to	   further	   explore	   whether	   expression	   of	   EaeH	   increased	   when	   the	   bacteria	  
were	  in	  contact	  with	  host	  cells.	  Briefly,	  TUV93-­‐0	  and	  LF82	  cultures	  grown	  in	  LB	  were	  used	  
to	   infect	  monolayers	  of	  Caco-­‐2	  cells	  at	  an	  MOI	  of	  ~100	  for	   four	  hours.	  Control	  TUV93-­‐0	  
and	   LF82	  were	  added	   to	  plates	   that	  did	  not	   contain	  Caco-­‐2	   cells,	   and	  grown	  under	   the	  
same	  conditions.	  Unattached	  bacteria	  were	  harvested	  by	   removal	  and	  centrifugation	  of	  
the	   media,	   and	   resuspended	   in	   PBS.	   After	   the	   Caco-­‐2	   cells	   were	   washed	   with	   PBS,	  
adherent	   bacteria	   were	   removed	   using	   assay	   buffer	   containing	   0.1%	   Triton	   X-­‐100.	   To	  
quantify	  the	  number	  of	  unattached	  and	  adherent	  bacteria,	  serial	  dilutions	  of	  the	  samples	  
were	   performed	   and	   plated	   onto	   LB	   agar.	   This	   confirmed	   that	   approximately	   100x	   less	  
bacteria	   were	   attached	   to	   the	   cells	   than	   were	   unattached	   and	   in	   the	   medium.	   The	  
number	  of	  bacteria	  were	  standardised	  to	  allow	  equal	  volumes	  of	  cell	  lysate	  from	  control,	  
unattached	   and	   attached	   samples	   to	   be	   run	   on	   SDS-­‐PAGE	   gels	   for	   analysis	   of	   EaeH	  
expression	  by	  Western	  blot.	  
	  
This	  analysis	  suggested	  that	  expression	  of	  EaeH	  in	  unattached	  bacteria	  in	  the	  presence	  of	  
Caco-­‐2	  cells	  was	  slightly	  higher	  for	  the	  control	  bacteria.	  This	  finding	  was	  not	  unexpected,	  
as	  expression	  of	  ETEC	  EaeH	  has	  been	  reported	  to	  be	  activated	  using	  media	  conditioned	  by	  
Caco-­‐2	  cells	   (Sheikh	  et	  al.,	  2014).	  Surprisingly,	  adherent	  TUV93-­‐0	  and	  LF82	  appeared	   to	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express	   EaeH	   at	   levels	   that	   were	   no	   different	   than	   the	   control	   bacteria	   (Figure	   4-­‐10).	  
These	  results	  suggest	  that	  some	  upregulation	  of	  eaeH	  might	  occur	  in	  unattached	  bacteria,	  
which	  we	  speculate	  could	  be	  caused	  by	  release	  of	  an	  unknown	  factor	  into	  the	  media	  that	  
enhances	  expression	  of	  eaeH.	  This	  could	  be	  released	  by	  either	  the	  eukaryotic	  cells	  or	  by	  
adherent	  bacteria	  to	  increase	  attachment	  of	  the	  local	  population.	  
	  
A	   TUV93-­‐0	   	   	   B	   LF82	  
	  
Figure	  4-­‐10:	  Expression	  of	  EaeH	  after	  host	  cell	  contact.	  TUV93-­‐0	  (A)	  and	  LF82	  (B)	  lysate	  after	  cell	  adhesion	  
assays	  were	  blotted	  for	  EaeH.	  Expression	  was	  examined	  in	  bacteria	  free	  in	  MEM	  media	  in	  the	  presence	  of	  
Caco-­‐2	   cells	   and	   from	   bacteria	   intimately	   attached	   to	   Caco-­‐2	   cells.	   Bacteria	  were	   incubated	  with	   Caco-­‐2	  
cells	  for	  4	  hours,	  and	  control	  TUV93-­‐0	  and	  LF82	  grown	  in	  the	  same	  media	  but	  without	  the	  presence	  of	  Caco-­‐
2	  cells.	  Gels	  were	  loaded	  with	  identical	  concentrations	  of	  protein	  (100	  μg	  total	  protein),	  and	  blots	  exposed	  
for	  10	  minutes.	  
	  
4.6.3	  Expression	  of	  EaeH	  in	  Caco-­‐2-­‐conditioned	  MEM	  media	  
	  
In	   ETEC	   strains,	   increased	   expression	   of	   EaeH	   has	   been	   shown	   to	   occur	   not	   only	   upon	  
contact	   with	   epithelial	   mammalian	   cells,	   but	   also	   when	   H10407	   is	   grown	   in	   media	  
conditioned	   by	   growth	   of	   Caco-­‐2	   cells	   (Sheikh	   et	   al.,	   2014),	   suggesting	   that	  molecules	  
released	  by	  epithelial	  cells	  may	  be	  sufficient	  to	  initiate	  upregulation.	  To	  explore	  whether	  
conditioned	  media	  also	  causes	  increased	  EaeH	  production	  in	  our	  strains,	  further	  analysis	  
of	   bacterial	   lysates	   were	   performed.	   In	   brief,	   MEM	   medium	   supplemented	   with	   10%	  
foetal	   calf	   serum	   was	   conditioned	   by	   exposure	   to	   near-­‐confluent	   Caco-­‐2	   cells	   for	   24	  
hours.	  Both	  strains	  of	  bacteria	  were	  then	  grown	   in	  this	  media	  until	  an	  OD600	  of	  0.8	  was	  
reached.	   The	   ETEC	  H10407	   strain	  was	   also	   included	   as	   a	   positive	   control	   for	   increased	  
expression	  in	  conditioned	  media.	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Growth	  in	  conditioned	  media	  showed	  no	  obvious	  influence	  on	  expression	  of	  EaeH	  by	  any	  
of	   the	   three	   strains	   of	   E.	   coli	   (Figure	   4-­‐11	   A).	   The	   lower	   band	   of	   each	   sample	   was	  
presumed	   to	  be	  non-­‐specific	  binding,	  based	  on	  Western	  blot	  analysis	  of	  our	   LF82	  eaeH	  
deletion	  mutant,	  and	  the	  reported	  ~150	  kDa	  migration	  of	  EaeH	  observed	  in	  H10407	  (Dr.	  
Alaullah	   Sheikh,	   personal	   communication).	   Lysate	   was	   also	   stained	   for	   GroEL,	   a	  
cytoplasmic	   chaperonin	   protein,	   to	   confirm	   standardisation	   of	   the	   amount	   of	   sample	  
material	  used	  in	  this	  comparative	  analysis	  (Figure	  4-­‐11	  B).	  
	  
A	   	   	   	   EaeH	  
	   	  
B	   	   	   	   GroEL	  
	  
Figure	   4-­‐11:	   Expression	   of	   EaeH	   after	   growth	   in	   conditioned	   or	   unconditioned	   media.	   EaeH	  
immunoblotting	  of	  TUV93-­‐0,	  LF82	  and	  H10407	  lysate	  after	  growth	  in	  conditioned	  or	  unconditioned	  MEM	  (+	  
10%	   FCS).	   A	   total	   of	   200	  μg	   protein	  was	   loaded	   into	   each	  well,	   and	   blots	  were	   exposed	   for	   10	  minutes.	  
Arrows	  indicates	  the	  presumed	  band	  for	  LF82	  and	  H10407	  EaeH	  (A).	  Samples	  were	  also	  blotted	  for	  GroEL	  to	  
quantify	  the	  relative	  concentration	  of	  protein	  in	  the	  lysates	  (B).	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4.7	  Secretion	  of	  YghJ	  by	  LF82	  
	  
YghJ	  has	  been	   reported	   to	  be	   secreted	  by	   the	  T2SS	   in	  E.	   coli	   strains,	  with	   those	   strains	  
containing	   a	   truncated	   T2SS	   operon	   unable	   to	   secrete	   the	   protein.	   This	   was	   first	  
demonstrated	  by	  Moriel	  et	  al.	  (2010)	  using	  Western	  blot	  analysis	  of	  E.	  coli	  cell	  lysate	  and	  
culture	   supernatant.	   In	   these	   experiments,	   YghJ	   was	   detected	   in	   the	   cell	   lysates	   of	   all	  
strains	   carrying	   the	   yghJ	   gene,	   but	   only	   detected	   in	   the	   culture	   supernatants	   of	   those	  
strains	  with	  an	  intact	  T2SS	  operon	  (Moriel	  et	  al.,	  2010).	  
	  
Analysis	   of	   the	   sequenced	   LF82	   genome	   reveals	   an	   intact	   T2SS	   operon	   (Miquel	   et	   al.,	  
2010),	   suggesting	   that	   this	   strain	   is	   capable	  of	   secreting	  YghJ.	   To	  examine	   this,	   analysis	  
performed	   and	   described	   by	   Moriel	   et	   al.	   (2010)	   was	   replicated.	   Three	   strains	   were	  
assessed:	  LF82,	  MG1655	  (which	  carries	   the	  yghJ	  gene	  but	  has	  a	  truncated	  T2SS	  region),	  
and	   the	   EPEC	   strain	   E2348/69.	   This	   strain	   was	   included	   as	   a	   positive	   control	   as	   T2SS-­‐
mediated	  secretion	  of	  YghJ	  has	  been	  reported	   in	  E2348/69	   (Baldi	  et	  al.,	  2012).	  Bacteria	  
were	  grown	   in	  MEM	  media	  until	   an	  OD600	  of	  0.8	  was	   reached.	  Cells	  were	  harvested	  by	  
centrifugation,	   and	   proteins	   in	   the	   culture	   media	   precipitated	   with	   10%	   TCA.	   The	  
presence	  of	  YghJ	  in	  both	  the	  lysate	  and	  culture	  supernatant	  was	  tested	  by	  Western	  blot.	  
To	   ensure	   that	   culture	   supernatants	   did	   not	   contain	   protein	   released	   by	   lysed	   cells	   or	  
inclusion	   of	   cell	   pellets,	   staining	   for	   the	   cytoplasmic	   protein	   GroEL	   was	   performed	   in	  
parallel.	  	  
	  
YghJ	   was	   detected	   in	   the	   cell	   lysate	   of	   all	   three	   strains,	   at	   similar	   concentrations.	   As	  
expected,	   the	  MG1655	   strain	   showed	   no	   presence	   of	   YghJ	   in	   the	   culture	   supernatant,	  
while	  the	  EPEC	  strain	  demonstrated	  secretion	  of	  YghJ.	  However,	  no	  YghJ	  was	  detected	  in	  
the	   culture	   supernatant	   of	   LF82	   suggesting	   that	   although	   the	   LF82	   genome	   appears	   to	  
contain	  an	  intact	  T2SS	  operon,	  the	  T2SS	  is	  either	  not	  expressed	  or	  functional	  under	  these	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A	   	   	   YghJ	  
	  
B	   	   	   GroEL	  
	   	  	  
Figure	  4-­‐12:	  Expression	  and	  secretion	  of	  YghJ.	  Lysate	  and	  culture	  supernatant	  from	  E.	  coli	  LF82,	  MG1655	  
and	  E2348/69	  (EPEC)	  strains	  grown	  to	  an	  OD600	  of	  0.8	  were	  blotted	  for	  YghJ	  (A).	  Samples	  were	  also	  blotted	  
for	   GroEL	   to	   quantify	   the	   relative	   concentration	   of	   protein	   in	   the	   lysate,	   and	   to	   show	   that	   the	   culture	  
supernatant	  did	  not	  contain	  cytoplasmic	  protein	  (B).	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4.8	  Discussion	  
	  
4.8.1	  Expression	  of	  EaeH	  by	  TUV93-­‐0	  and	  LF82	  
	  
The	  bacterial	  protein	  EaeH,	  which	  had	  previously	  been	  identified	  	  as	  an	  antigen	  capable	  of	  
conferring	  protection	  against	  ExPEC	  infections	  and	  thus	  a	  potential	  vaccine	  candidate,	   is	  
highly	  conserved	  across	  a	  number	  of	  pathogenic	  E.	  coli	  strains	  (Moriel	  et	  al.,	  2010).	  Our	  
initial	  aim	  was	  to	  investigate	  EaeH	  expression	  in	  the	  strains	  TUV93-­‐0	  and	  LF82,	  in	  order	  to	  
assess	  its	  suitability	  as	  a	  component	  of	  such	  a	  vaccine.	  	  
	  
GFP	   reporter	   fusion	   assays	   revealed	   that	   when	   grown	   in	   LB,	   MEM	   or	   M9	   media,	  
expression	   of	   EaeH	   by	   TUV93-­‐0	   and	   LF82	   was	   too	   low	   to	   be	   observed.	   These	   findings	  
were	  consistent	  with	  our	  own	  RNAseq	  analysis	  of	  TUV93-­‐0	  gene	  expression	  in	  MEM	  (Dr.	  
James	  Connolly,	  personal	  communication),	  which	   indicated	  that	   transcription	  of	  eaeH	   is	  
extremely	   low	   in	  artificial	  growth	  media;	  with	  an	  average	  of	  33	  reads	  mapped	  for	  eaeH	  
(4254	  bp),	  compared	  to	  7683	  for	  intimin-­‐encoding	  eae	  (2805	  bp)	  and	  920	  for	  rpsM	  (357	  
bp).	  	  
	  
Western	   blotting	   of	   EaeH	   in	   TUV93-­‐0	   and	   LF82	   lysate	   revealed	   differences	   in	   band	  
migration	   between	   the	   two	   strains,	   which	   was	   surprising	   given	   the	   high	   similarity	  
between	  TUV93-­‐0	  and	  LF82	  EaeH	  sequences	  (92.3%	  identity).	  As	  the	  protein	  sequence	  of	  
TUV93-­‐0	   and	   LF82	   EaeH	   differs	   in	   length	   by	   only	   one	   amino	   acid,	   it	   is	   possible	   that	  
different	  post-­‐translational	  modification	  results	   in	  the	  migration	  observed.	  The	   larger	  of	  
the	  two	  EaeH	  bands	  remained	  unaffected	  by	  the	  length	  of	  time	  that	  samples	  were	  boiled	  
prior	   to	   loading,	   or	   by	   addition	   of	   highly	   denaturing	   Laemmli	   loading	   buffer	   (data	   not	  
shown).	   Alternatively,	   EaeH	   may	   be	   binding	   to	   unknown	   bacterial	   proteins,	   and	   this	  
interaction	  does	  not	  dissociate	  under	  SDS	  denaturing	  conditions.	  
	  
In	   recent	  years,	   studies	   investigating	   the	  expression	  of	  EaeH	  by	  ETEC	  strains	  have	  been	  
published,	   and	   have	   emphasised	   the	   importance	   of	   bacterial-­‐host	   cell	   interaction	   for	  
upregulation	  of	  this	  gene.	  Transcriptome	  analysis	  of	  ETEC	  H10407	  genes	  after	  interaction	  
with	  human	  epithelial	   intestinal	  cells	   first	   identified	  eaeH	  as	  one	  such	  upregulated	  gene	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(Kansal	   et	   al.,	   2013).	   Further	   investigation	   of	   eaeH	   expression	   discovered	   that	  
upregulation	  does	  not	  require	  direct	  contact	  with	  host	  cells,	  but	  can	  be	  initiated	  in	  media	  
conditioned	   by	   intestinal	   Caco-­‐2	   cells	   (Sheikh	   et	   al.,	   2014).	   In	   our	   TUV93-­‐0	   and	   LF82	  
strains,	  increased	  expression	  of	  EaeH	  was	  not	  observed	  in	  bacteria	  grown	  in	  conditioned	  
media.	  However,	  expression	  of	  EaeH	  by	  the	  positive	  control	  strain	  H10407	  strain	  also	  did	  
not	  differ,	   contradicting	   the	   findings	  published	  by	  Sheikh	  et	  al.	   (2014).	  Discussions	  with	  
the	   corresponding	   authors	   of	   this	   paper	   confirmed	   that	   an	   identical	   protocol	   for	  
conditioning	   of	  media	   by	   Caco-­‐2	   cells	   was	   followed.	   However,	   it	   should	   be	   noted	   that	  
increased	   EaeH	   expression	   reported	   by	   Sheikh	   et	   al.	   (2014)	   was	   observed	   by	   flow	  
cytometry,	  whereas	  we	  studied	  expression	  by	  Western	  blotting.	  
	  
While	   it	   is	  possible	  that	  the	  promoter	  region	  in	  the	  pzm_TE1	  and	  pzm_LE1	  plasmids	  did	  
not	   contain	   the	   complete	  eaeH	   promoter	   sequence,	   the	   region	  we	   selected	   for	   cloning	  
contained	   the	   entire	   region	   upstream	  of	  eaeH,	   and	  was	   highly	   similar	   to	   the	   promoter	  
region	  used	   in	   the	  H10407	  β-­‐galactosidase	   reporter	   plasmid	  pQL002	   (Figure	   4-­‐13).	   This	  
region	   has	   been	   used	   successfully	   to	   show	   eaeH	   expression	   under	   similar	   cell	   contact	  
conditions	  (Kansal	  et	  al.,	  2013),	  making	  this	  explanation	  unlikely.	  	  
	  
	  
Figure	   4-­‐13:	   Comparison	   of	   the	   promoter	   regions	   used	   for	   eaeH	   expression	   reporters.	   The	   promoter	  
region	   from	   our	   GFP	   reporters	   pzm_TE1/pzm_LE1	   and	   the	   promoter	   region	   from	   the	   H10407	   β-­‐
galactosidase	  reporter	  pQL002	  (Sheikh	  et	  al.,	  2014)	  are	  aligned	  against	  the	  full	  upstream	  region	  and	  start	  of	  
the	  eaeH	  gene.	  
	  
4.8.2	  The	  function	  of	  EaeH	  in	  E.	  coli	  
	  
The	  role	  of	  EaeH	  has	  also	  been	  explored	   in	  a	  recent	  study	  by	  Sheikh	  et	  al.	   (2014).	  EaeH	  
was	  assumed	  to	  be	  an	  outer	  membrane	  adhesin	  as	   it	  shares	  a	  region	  of	  homology	  with	  
intimin	   that	   is	   predicted	   to	   fold	   into	   a	   transmembrane	   β-­‐barrel.	   EaeH	   also	   contains	   a	  
series	  of	   tandem	  bacterial	   immunoglobulin-­‐like	  domains	  similar	   to	   those	   found	   in	  other	  
bacterial	  virulence	  proteins	  involved	  in	  adherence	  to	  eukaryotic	  host	  cells	  (Sheikh	  et	  al.,	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2014).	  To	  examine	   the	  ability	  of	  EaeH	   to	   facilitate	  adhesion,	  Sheikh	  et	  al.	   (2014)	  added	  
purified	  latex	  beads	  coated	  with	  recombinant	  EaeH	  to	  monolayers	  of	  Caco-­‐2	  cells.	  After	  a	  
3	  hour	  incubation,	  scanning	  electron	  microscopy	  revealed	  that	  EaeH-­‐coated	  beads	  bound	  
to	   the	   cell	   surface,	   with	   some	   appearing	   partially	   engulfed	   by	   the	   Caco-­‐2	   cells.	   This	  
implied	  that	  EaeH	  on	  its	  own	  was	  capable	  of	  promoting	  intimate	  attachment	  of	  bacteria	  
to	  host	  cells.	  An	  ETEC	  H10407	  eaeH	  deletion	  mutant	  showed	  decreased	  adhesion	  to	  Caco-­‐
2	   cells	  when	   compared	   to	   the	  wild	   type	   strain,	   and	  was	  also	   impaired	   in	  delivery	  of	   LT	  
toxin.	  Purified	  anti-­‐EaeH	  antisera	  added	  to	  wild	  type	  H10407	  and	  Caco-­‐2	  cells	  resulted	  in	  
inhibition	  of	  bacterial	  adhesion	  to	  host	  cells,	  along	  with	  inhibition	  of	  bacterial	  activation	  
of	  Caco-­‐2	  cyclic	  adenosine	  monophosphate	  (cAMP)	  (Sheikh	  et	  al.,	  2014).	  
	  
These	  findings	  imply	  that	  EaeH	  plays	  a	  role	  in	  ETEC	  interactions	  with	  its	  host.	  To	  explore	  
this	  protein’s	   contribution	   to	   colonisation	   in	   vivo,	   Sheikh	  et	  al.	   (2004)	  orally	   challenged	  
streptomycin-­‐treated	   mice	   with	   H10407	   and	   an	   eaeH	   deletion	   mutant	   in	   competition	  
experiments.	   No	   significant	   difference	   in	   total	   intestinal	   colonisation	   between	   the	  wild	  
type	  and	   the	  mutant	  was	  observed;	   however,	  when	   the	   intestinal	  mucosa	  of	  mice	  was	  
examined	  by	  immunofluorescence	  microscopy,	  significantly	  higher	  numbers	  of	  wild	  type	  
bacteria	  were	   reported	   attached	   to	   the	   epithelial	   surface	   of	   the	   intestine	   compared	   to	  
the	  mutant	  strain	  (Sheikh	  et	  al.,	  2014).	  
	  
4.8.3	  Expression	  and	  secretion	  of	  YghJ	  by	  LF82	  
	  
The	  location	  of	  yghJ	  immediately	  upstream	  of	  genes	  encoding	  a	  T2SS,	  and	  the	  significant	  
similarity	  YghJ	  shares	  with	  the	  Type	  2-­‐secreted	  Vibrio	  cholerae	  AcfD	  protein	  implies	  that	  
YghJ	   is	   an	   effector	   of	   this	   secretion	   system.	   Transcription	   of	   yghJ	   and	   the	   Type	   2	   gsp	  
genes	   are	   also	   co-­‐regulated	   in	   the	   E.	   coli	   H10407	   strain	   (Yang	   et	   al.,	   2006).	   Secretion	  
assays	   initially	   performed	   by	  Moriel	   et	   al.	   (2010)	   involving	   a	   number	   of	   E.	   coli	   strains	  
carrying	  the	  yghJ	  gene	  revealed	  that	  the	  T2SS	  is	  necessary	  for	  the	  secretion	  of	  YghJ	  into	  
culture	  supernatant.	  	  
	  
Comparison	  of	  the	  promoter	  region	  used	  in	  the	  construction	  of	  pzm_LY1	  to	  the	  promoter	  
region	   of	   PsslE-­‐luxCDABE,	   an	   ExPEC	   IHE3034	   eaeH	   expression	   reporter	   plasmid	   able	   to	  
detect	   in	  vivo	  activity	  of	  the	  eaeH	  promoter	  (Nesta	  et	  al.,	  2014),	   indicated	  that	  a	  similar	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region	  was	  cloned	  (Figure	  4-­‐14).	  Despite	  this,	   fluorescence-­‐based	  reporter	   fusion	  assays	  




Figure	  4-­‐14:	  Comparison	  of	  the	  promoter	  regions	  used	  for	  yghJ	  expression	  reporters.	  The	  promoter	  region	  
from	   our	   GFP	   reporter	   pzm_LY1	   and	   the	   promoter	   region	   from	   the	   IHE3034	   luciferase	   reporter	   PsslE-­‐
luxCDABE	  (Nesta	  et	  al.,	  2014)	  are	  aligned	  against	  the	  full	  upstream	  region	  and	  start	  of	  the	  yghJ	  gene.	  
	  
Expression	   of	   YghJ	   by	   LF82	   was	   however	   detected	   in	   whole-­‐cell	   lysate	   by	   Western	  
blotting.	  As	  LF82	  was	  not	  one	  of	  the	  strains	  previously	  investigated	  for	  YghJ	  secretion,	  we	  
replicated	   the	   secretion	  assay,	   using	   the	  EPEC	  E2348/69	   strain	   as	   a	  positive	   control	   for	  
YghJ	  secretion	  (Baldi	  et	  al.,	  2012).	  Surprisingly,	  as	  genome	  sequencing	  has	  indicated	  that	  
LF82	   contains	   an	   intact	   T2SS	   (Miquel	   et	   al.,	   2010),	   YghJ	   was	   not	   detected	   in	   culture	  
supernatants,	  and	  therefore	  was	  not	  being	  secreted	  under	  the	  conditions	  tested.	  	  
	  
Two	  distinct	  and	  highly	  conserved	  T2SSs	  have	  been	  identified	  in	  E.	  coli,	  termed	  T2SSα	  and	  
T2SSβ	   (Strozen	   et	   al.,	   2012).	   The	   LF82	   strain	   carries	   a	   truncated	   T2SSα	   operon	   and	   a	  
complete	   T2SSβ	   operon,	   the	   latter	   of	  which	   contains	   the	  yghJ	   gene.	   The	  H10407	   T2SSβ	  
assembles	   and	   functions	   under	   standard	   laboratory	   conditions	   (Strozen	   et	   al.,	   2012),	  
although	   assembly	   of	   the	   LF82	   T2SS	   was	   not	   investigated	   in	   this	   study.	   Further	  
exploration	  of	  the	  T2SS	  in	  LF82	  would	  be	  required	  to	  reveal	  whether	  this	  lack	  of	  secretion	  
by	  LF82	  is	  YghJ	  dependent,	  or	  a	  failure	  of	  T2SS	  functionality.	  	  
	  
Our	  observation	   that	   LF82	  does	  not	   secrete	  YghJ	   is	   supported	  by	  a	   recent	   comparative	  
analysis	   of	   secretomes	   produced	   by	   the	   H10407	   and	   LF82	   strains.	   Using	   a	   mass	  
spectrometry-­‐based	   Stable	   Isotope	   Labeling	   with	   Amino	   acids	   in	   Cell	   culture	   (SILAC)	  
quantitative	   proteomics	   method,	   Boysen	   et	   al.	   (2015)	   compared	   the	   protein	   levels	   in	  
outer	   membrane	   vesicles	   (OMVs)	   and	   culture	   supernatant	   from	   LF82	   and	   H10407	   to	  
those	   of	   the	   non-­‐pathogenic	   MG1655	   strain,	   identifying	   shared	   and	   unique	   proteins	  
secreted	  or	  released	  in	  OMVs	  by	  the	  pathogenic	  strains.	  Notably,	  while	  YghJ	  was	  detected	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in	   OMVs	   and	   culture	   supernatant	   of	   the	   H10407	   strain,	   it	   was	   not	   detected	   in	   these	  
fractions	  taken	  from	  the	  LF82	  strain	  (Boysen	  et	  al.,	  2015).	  
	  
4.8.4	  The	  function	  of	  YghJ	  
	  
Several	   studies	   investigating	   the	   role	  of	  YghJ	   in	  E.	   coli	   have	  been	   recently	  published.	   In	  
EPEC	   E2348/69,	   YghJ	   has	   been	   implicated	   in	   formation	   of	   biofilm,	   an	   aggregation	   of	  
bacteria	  that	  protects	  against	  mechanical	  removal	  and	  phagocytosis	  (Baldi	  et	  al.,	  2012).	  In	  
this	  study,	  YghJ	  was	  determined	  to	  be	  located	  on	  the	  outer	  cell	  surface	  of	  this	  strain	  and	  
secreted	   into	   culture	   supernatant.	   Deletion	   mutants	   of	   both	   yghJ	   and	   essential	   T2SS	  
genes	  constructed	  by	  Baldi	  et	  al.	  (2012)	  did	  not	  show	  impaired	  growth	  or	  elicit	  the	  global	  
stress	   response	   σE,	   but	   were	   attenuated	   for	   biofilm	   formation.	   When	   a	   yghJ	   deletion	  
mutant	   in	   the	   rabbit-­‐specific	  EPEC	   strain	  E22	  was	   tested	   in	  a	   rabbit	  model	  of	   infection,	  
lower	  bacterial	  counts	  were	  observed	  in	  rectal	  swabs	  post	  infection	  compared	  to	  the	  wild	  
type	  strain.	  In	  addition,	  these	  animals	  had	  fewer	  days	  of	  diarrhoea	  and	  displayed	  normal	  
weight	  gain	  (Baldi	  et	  al.,	  2012).	  However,	  in	  atypical	  EPEC	  (aEPEC),	  diarrhoeal	  pathogens	  
that	  carry	  the	  LEE	  but	  are	  negative	  for	  bundle-­‐forming	  pilus	  production,	  the	  role	  of	  YghJ	  in	  
pathogenicity	   is	   less	   defined;	   yghJ	   deletion	   mutants	   constructed	   in	   the	   aEPEC	   1551-­‐2	  
strain	  did	  not	  show	  changes	  in	  adherence	  to	  HeLa	  cells	  nor	  biofilm	  formation	  compared	  
to	  the	  wild	  type	  strain	  (Hernandes	  et	  al.,	  2013).	  
	  
Although	  several	  non-­‐pathogenic	  E.	  coli	  strains	  are	  deficient	  for	  secretion	  of	  YghJ,	  there	  is	  
also	  evidence	  that	  secretion	   is	  not	  restricted	  to	  pathogenic	  strains,	  suggesting	  that	  YghJ	  
may	   also	   play	   a	   role	   in	   colonisation	   by	   non-­‐pathogenic	   strains.	   For	   example,	   the	   non-­‐
pathogenic	   W	   strain	   encodes	   a	   functional	   T2SS	   that	   secretes	   YghJ,	   and	   phenotypic	  
microarray	  analysis	   revealed	   that	  deletion	  of	  yghJ	  or	  essential	  T2SS	  genes	  provided	   the	  
mutants	   with	   a	   slight	   increase	   in	   urea	   tolerance.	   This	   implies	   that	   YghJ	   secretion	   or	  
display	  of	  this	  protein	  on	  the	  bacterial	  cell	  surface	  influences	  the	  cell	  physiology,	  resulting	  
in	  an	  increased	  sensitivity	  to	  urea.	  (Decanio	  et	  al.,	  2013).	  
	  
Further	   publications	   using	   ETEC	   strains	   have	  provided	   evidence	   that,	   in	   this	   pathotype,	  
YghJ	   plays	   an	   important	   role	   in	   colonisation	   of	   the	   host	   intestine.	   YghJ	   is	   required	   for	  
efficient	  delivery	  of	  the	  T2SS	  effector	  and	  major	  virulence	  factor	  LT	  enterotoxin,	  although	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not	  for	  secretion	  of	  the	  toxin	  (Luo	  et	  al.,	  2014).	   In	  this	  publication,	  both	  a	  yghJ	  deletion	  
mutant	  and	  treatment	  of	  the	  wild	  type	  H10407	  strain	  with	  antibodies	  raised	  against	  YghJ	  
resulted	   in	   significantly	   impaired	   delivery	   of	   LT,	   determined	   by	   reduced	   activation	   of	  
cAMP	   in	   host	   epithelial	   cells.	   This	   led	   the	   authors	   to	   hypothesise	   that	   YghJ	   acts	   to	  
facilitate	   bacterial	   access	   to	   the	   enterocyte	   surface,	   allowing	   toxin	   access	   to	   host	   cell	  
receptors.	  
	  
A	   layer	   of	   heavily	   glycosylated	  proteins	   called	  mucins	   protects	   the	   surface	  of	   the	   small	  
intestine.	  Bacteria	  must	  pass	  through	  this	  layer	  to	  gain	  access	  and	  attach	  to	  the	  epithelial	  
cells.	  In	  vitro	  experiments	  by	  Luo	  et	  al.	  (2014)	  identified	  MUC2,	  the	  major	  luminal	  mucin	  
in	  the	  small	   intestine,	  as	  a	  possible	  target	  of	  YghJ.	  When	   incubated	   in	  MUC2-­‐containing	  
media,	  the	  yghJ	  deletion	  mutant	  was	  more	  frequently	  coated	  with	  MUC2	  relative	  to	  the	  
wild	  type	  strain.	  Analysis	  of	  the	  YghJ	  protein	  sequence	  has	  identified	  a	  conserved	  putative	  
metalloprotease	  motif	   suggesting	   that	   YghJ	   is	   a	  metalloprotease	   that	   degrades	  mucins,	  
allowing	  bacterial	  access	   to	   the	  enterocyte	   layer.	  This	  hypothesis	  was	  supported	  by	   the	  
finding	   that	   YghJ	  bound	  and	  degraded	  purified	  MUC2	   in	   a	  dose-­‐dependent	  manner,	   an	  
activity	   that	   was	   abolished	   by	   chelation	   of	   metal	   from	   recombinant	   YghJ.	   This	   MUC2-­‐
degradation	  activity	  was	  subsequently	  restored	  by	  supplementation	  of	  divalent	  cations	  to	  
the	  chelated	  protein.	  YghJ	  also	  degraded	  MUC3,	  the	  most	  abundant	  cell-­‐bound	  mucin	  in	  
the	  small	  intestine,	  but	  was	  inactive	  against	  mucin-­‐like	  CD43,	  bovine	  submaxillary	  mucin,	  
gelatin,	  or	  IgG	  (Luo	  et	  al.,	  2014).	  	  
	  
In	  vivo	  ETEC	  studies	  by	  Luo	  et	  al.	  (2014)	  using	  a	  streptomycin-­‐treated	  ICR	  mouse	  model,	  
however,	   provided	   limited	   evidence	   that	   YghJ	   plays	   a	   major	   role	   in	   bacterial	  
pathogenesis.	   In	   the	  small	   intestine,	  MUC2	  forms	  a	  barrier	   to	  the	  epithelial	  surface	  and	  
contributes	  to	  removal	  of	  pathogens	  that	  are	  loosely	  associated	  with	  epithelial	  tissue	  by	  
peristaltic	  flow.	  If	  YghJ	  degrades	  mucins	  and	  enables	  stronger	  persistence	  of	  EPEC	  within	  
the	   host,	   it	   would	   be	   expected	   that	   the	   yghJ	   deletion	   mutant	   would	   show	   decreased	  
faecal	   shedding.	   However,	   no	   significant	   difference	   in	   faecal	   shedding	   between	   the	  
mutant	  and	  wild	  type	  was	  observed,	  which	  the	  authors	  postulated	  could	  be	  due	  to	  other	  
proteins	   produced	   by	   EPEC	   that	   share	   YghJ’s	   mucinase	   activity.	   Only	   when	   intestinal	  
tissue	  was	  examined	  by	  immunofluorescence	  microscopy	  were	  differences	  seen	  between	  
the	  strains;	  bacteria	  were	  identified	  in	  the	  lumen	  and	  on	  the	  enterocyte	  surface	  of	  mice	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infected	  with	  both	  strains,	  but	  fewer	  organisms	  on	  the	  enterocyte	  surface	  were	  detected	  
in	   mice	   infected	   with	   the	   yghJ	   mutant.	   Substantial	   decreases	   in	   cAMP	   activation	   by	  
mouse	   intestinal	   epithelial	   cells	   compared	   to	   the	   wild	   type	   strain	   were	   also	   observed,	  
supporting	  the	  hypothesis	  that	  YghJ	  is	  involved	  in	  efficient	  delivery	  of	  LT	  to	  host	  cells	  (Luo	  
et	  al.,	  2014).	  
	  
The	  influence	  of	  YghJ	  on	  pathogenesis	  of	  the	  ExPEC	  strain	  IHE3034	  also	  implies	  the	  mucin-­‐
degrading	  activity	  of	  this	  protein	  is	  utilised	  by	  different	  pathotypes	  of	  E.	  coli.	  Upregulation	  
of	   YghJ	   production	   occurred	   when	   IHE3034	   intimately	   attached	   to	   human	   mucus-­‐
producing	   intestinal	   cells.	   When	   gut	   cells	   were	   infected	   with	   a	   yghJ	   deletion	   mutant,	  
fewer	  bacteria	  were	  able	  to	  reach	  the	  cell	  surface	  underneath	  the	  mucus	  layer	  compared	  
to	   the	   wild	   type.	   Expression	   of	   YghJ	   may	   also	   provide	   a	   metabolic	   benefit	   as	   when	  
bacteria	   were	   incubated	   with	   mucus-­‐secreting	   cells,	   an	   enhanced	   growth	   rate	   was	  
observed	  (Valeri	  et	  al.,	  2015).	  	  
	  
4.8.5	  YghJ	  function	  in	  LF82	  
	  
The	  hypothesis	   that	  YghJ	  plays	  a	   role	   in	  colonisation	  of	   the	  host	   intestine	  by	   facilitating	  
bacterial	   traversal	   of	   the	   mucus	   barrier	   has	   been	   supported	   by	   recent	   research	  
investigating	   its	   role	   in	   ETEC	  and	  ExPEC	   isolates.	  However,	   the	   function	  of	   YghJ	   in	  AIEC	  
strains	  has	  not	   yet	  been	  explored.	  Comparison	  of	   the	   LF82	  YghJ	  protein	   sequence	  with	  
the	   H10407	   sequence	   revealed	   LF82	   contains	   the	   metalloprotease	   core	   motif	   HEXXHX	  
(Nakjang	   et	   al.,	   2012),	   along	   with	   conservation	   of	   the	   22-­‐amino	   acid	   region	   extending	  
from	  the	  motif	  reported	  to	  contain	  the	  active	  site	  of	  YghJ	  (Luo	  et	  al.,	  2014).	  This	  implies	  
that	   LF82	   YghJ	   is	   also	   capable	   of	   degrading	  mucin,	   and	  with	   techniques	   established	   to	  
assess	  YghJ	  function	  in	  ETEC	  and	  ExPEC	  strains,	  given	  more	  time	  it	  would	  be	  interesting	  to	  
determine	  whether	  LF82	  YghJ	  also	  degrades	  MUC2	  and	  MUC3	  to	  enhance	  penetration	  of	  
the	  mucus	   layer.	  As	  LF82	  cells	  colonise	  the	   intestinal	  mucosa	  and	  are	  able	  to	  adhere	  to	  
and	  invade	  intestinal	  epithelial	  cells,	  it	  is	  possible	  that	  YghJ	  aids	  colonisation	  of	  this	  strain.	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4.8.6	  YghJ	  and	  EaeH	  as	  vaccine	  candidates	  
	  
Since	  YghJ	  was	  identified	  as	  a	  potential	  vaccine	  candidate	  in	  2010,	  over	  400	  sequences	  of	  
this	   gene	   from	   E.	   coli	   strains	   have	   been	   analysed.	   The	   sequences	   have	   revealed	   that	  
variability	   is	   distributed	   along	   the	   entire	   protein,	   with	   identity	   ranging	   from	   86-­‐100%.	  
Importantly,	   the	   metalloprotease	   motif	   was	   fully	   conserved	   in	   all	   sequences	   analysed	  
(Nesta	   et	   al.,	   2014).	   Despite	   this	   variation,	   polyclonal	   antibodies	   raised	   by	  Nesta	   et	   al.	  
(2014)	   against	   a	   variant	   I	   YghJ	   inhibited	   the	   ability	   of	   all	   E.	   coli	   pathotypes	   tested	   to	  
transverse	   the	   mucin-­‐based	   matrix.	   Additionally,	   the	   structural	   similarity	   of	   YghJ	   was	  
further	   demonstrated	   in	   vivo	   when	   mice	   immunised	   intranasally	   with	   recombinant	  
variant	  I	  YghJ	  from	  an	  ExPEC	  strain	  were	  challenged	  with	  a	  ETEC	  strain	  expressing	  a	  YghJ	  
variant	   II.	  A	  significant	  reduction	   in	  caecum-­‐associated	  bacterial	  counts	  was	  observed	   in	  
mice	  immunised	  with	  YghJ	  compared	  to	  those	  mock-­‐immunised	  with	  saline,	  and	  anti-­‐YghJ	  
responses	   in	   immunised	  mice	  consisted	  of	  both	  IgG	  and	  IgA	  antibody	   isotypes	  (Nesta	  et	  
al.,	  2014).	  The	  authors	  of	  this	  study	  suggested	  that	  antibody	  cross-­‐reactivity	  occurs	  due	  to	  
immunogenicity	  of	  the	  conserved	  metalloprotease	  domain.	  
	  
Although	   our	   work	   provides	   limited	   evidence	   for	   secretion	   of	   YghJ	   in	   LF82	   and	  
consequently	   implies	   it	   is	   unattractive	   as	   a	   vaccine	   candidate	   against	   AIEC	   strains,	   this	  
protein	   still	   has	   strong	   potential	   for	   use	   in	   vaccines	   designed	   against	   ETEC,	   EPEC	   and	  
ExPEC.	  The	  carriage	  of	   this	  protein	  by	  a	   large	  variety	  of	  pathogenic	  bacteria,	  along	  with	  
the	  discovery	  of	   its	   role	   in	  colonisation	  and	  evidence	  of	  expression	   in	  vivo	   (Nesta	  et	  al.,	  
2014),	  make	  YghJ	   a	   viable	   candidate	   for	   the	  development	  of	   a	   broad-­‐spectrum	  vaccine	  
against	  pathogenic	  E.	  coli.	  
	  
Expression	  of	  EaeH	  has,	  to	  date,	  been	  shown	  to	  be	  upregulated	  only	   in	  ETEC	  strains.	  As	  
predicted	   by	   its	   protein	   sequence,	   EaeH	   has	   been	   identified	   on	   the	   outer	   surface	   of	  
bacteria,	  making	   it	  an	  attractive	  target	   for	  vaccines.	  However,	   further	  study	  of	  how	  this	  
protein	  is	  expressed	  and	  utilised	  in	  colonisation,	  particularly	  in	  clinically	  relevant	  strains,	  
is	  required	  before	  its	  potential	  as	  an	  E.	  coli	  vaccine	  candidate	  can	  be	  determined.	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4.8.7	  LF82	  yghJ	  and	  eaeH	  deletion	  mutants	  in	  vivo	  
	  
Originally,	  one	  of	  the	  main	  aims	  of	  this	  work	  was	  to	  assess	  the	  contribution	  of	  EaeH	  and	  
YghJ	  to	  bacterial	  colonisation	  in	  a	  mouse	  model	  of	  LF82	  infection	  using	  deletion	  mutant	  
strains.	   However,	   we	   ultimately	   decided	   not	   to	   test	   these	   strains	   in	   the	   streptomycin-­‐
treated	  ICR	  model	  of	  LF82	  infection,	  as	  analysis	  of	  this	  model	  showed	  it	  to	  be	  ineffective	  
for	  studying	  bacterial	  attachment	  to	  epithelial	  host	  cells.	  When	  LF82	  colonisation	  of	  mice	  
was	  explored	   (Chapter	  3.5.4),	  high	   levels	  of	  bacterial	  prevalence	   in	   the	   intestinal	   lumen	  
was	   observed	   throughout	   the	   infection,	   indicating	   that	   in	   the	   streptomycin-­‐treated	  
mouse	  gut,	  LF82	  is	  able	  to	  persist	  without	  attachment	  and	  resist	  mechanical	  removal.	  As	  
we	   could	   not	   directly	   confirm	   that	   bacterial	   attachment	   had	   a	   significant	   influence	   on	  
colonisation	   of	   the	   mouse	   model,	   it	   was	   not	   deemed	   worthwhile	   to	   test	   the	   deletion	  
mutants	   in	   mice.	   Complementation	   of	   the	   mutant	   strains	   was	   initially	   considered	   for	  
controls	   in	  animal	  experiments,	  however,	  as	  we	  ultimately	  decided	  not	  to	  pursue	  these,	  
complementation	   plasmids	   expressing	   EaeH	   and	   YghJ	   under	   control	   of	   their	   own	  
promoters	  were	  not	  created.	  
	  
Furthermore,	   in	  2014	  Fleckenstein	  and	   colleagues	  published	   studies	   in	  which	  eaeH	   and	  
yghJ	  deletion	  mutants	  were	  tested	  in	  an	  ETEC	  murine	  model	  (Sheikh	  et	  al.,	  2014;	  Luo	  et	  
al.,	  2014).	  Colonisation	  of	  mice	  by	  both	  mutants,	  monitored	  by	  faecal	  shedding,	  did	  not	  
show	  a	  difference	   from	  that	  of	   the	  wild	   type	  strain.	  Only	  when	  sections	  of	   the	   infected	  
mouse	   intestine	   were	   examined	   by	   immunofluorescence	   microscopy	   were	   significant	  
differences	   in	   attachment	   to	   the	   intestinal	   epithelial	   surface	   reported.	   Therefore,	   the	  
ability	  of	  E.	  coli	  to	  persist	  in	  the	  lumen	  without	  the	  need	  for	  attachment	  masks	  the	  true	  
contribution	   of	   EaeH	   and	   YghJ	   to	   pathogenesis.	   An	   alternate	   animal	   model	   in	   which	  
intimate	  attachment	  can	  be	  directly	  measured	  would	  thus	  be	  more	  appropriate	  for	  in	  vivo	  
assessment	  of	  these	  two	  proteins.	  
5.	  RESULTS:	  Shiga	  toxin	  inhibitors	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5.1	  Introduction	  
	  
Production	  of	  EHEC	  Shiga	  toxin,	  essential	  for	  manifestation	  of	  HUS,	  also	  limits	  treatment	  
options	   as	   antibiotic	   use	   results	   in	   increased	   Stx	   release	   and	   thus	   greater	   risk	   of	   HUS	  
development.	  Novel	  therapeutic	  treatments	  that	  aim	  to	  reduce	  or	  prevent	  the	  production	  
of	   Stx	  may	   therefore	   lead	   to	   a	   reduction	   in	   clinical	   symptoms.	   EHEC	   can	   produce	   two	  
types	   of	   Shiga	   toxin:	   Stx1	   and	   Stx2,	   which	   are	   both	   encoded	   by	   temperate	   lysogenic	  
bacteriophages	  but	  are	  controlled	  by	  different	   repressors.	  While	   inhibition	  of	  both	  Stx1	  
and	   Stx2	   expression	  would	   be	   ideal,	   Stx2	   is	   a	  more	   desirable	   target	   for	   inhibition	   than	  
Stx1,	   as	  epidemiological	   and	   in	   vitro	   studies	  demonstrate	   that	   Stx2	   is	  more	   likely	   to	  be	  
associated	  with	  more	  serious	  human	  disease	  (Fuller	  et	  al.,	  2011;	  Bergan	  et	  al.,	  2012),	  and	  
studies	  in	  primates	  have	  shown	  that	  Stx2	  alone	  can	  produce	  symptoms	  of	  HUS	  while	  Stx1	  
administration	  at	  the	  same	  concentration	  does	  not	  (Mayer	  et	  al.,	  2012).	  	  
	  
Recently,	   high-­‐throughput	   screening	   at	   the	   University	   of	   Edinburgh	   identified	   several	  
small	   compounds	   as	   potential	   inhibitors	   of	   Stx2	   expression	   (Prof.	   David	  Gally,	   personal	  
communication).	  This	  was	  achieved	  through	  the	  use	  of	  fluorescence	  reporter	  constructs	  
designed	   to	  monitor	   Stx2	   expression,	   SOS	   induction	   and	   growth.	   These	   reporters	  were	  
used	   to	   screen	   17,500	   chemically	   diverse	   compounds	   from	   the	   ChemBridge	   library	  
(ChemBridge).	   This	   screen	   identified	  77	   inhibitors,	   6	  of	  which	  were	   selected	   for	   further	  
studies	  after	  dose-­‐response	  validation.	  The	  inhibitory	  potential	  of	  these	  lead	  compounds	  
was	   further	   investigated	   using	   E.	   coli	   transformed	   with	   a	   plasmid	   containing	   an	   stx2	  
promoter	  fused	  to	  a	  GFP	  gene,	  in	  which	  GFP	  expression	  could	  be	  induced	  by	  mitomycin	  C	  
(MMC).	   The	   compound	   that	   was	   most	   effective	   at	   limiting	   MMC-­‐induced	   stx2:GFP	  
fluorescence	   was	   5324835,	   which	   revealed	   concentration-­‐dependent	   inhibition	   of	   GFP	  
expression	   between	   25	   and	   200	   µM.	   The	   dose-­‐response	   effect	   of	   5324836	   on	   MMC-­‐
induced	   Stx	   production	  was	   subsequently	   confirmed	   by	   enzyme-­‐linked	   immunosorbent	  
assay.	  This	  implies	  5324836	  inhibits	  Stx	  production,	  although	  does	  not	  reveal	  whether	  the	  
compound	   directly	   interferes	   with	   stx2	   transcription	   or	   with	   events	   that	   modify	  
transcription	  activation.	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5.1.1	  Aims	  of	  this	  chapter	  
	  
• To	  validate	  the	  inhibition	  of	  Stx	  expression	  by	  compound	  5324836,	  using	  the	  Stx-­‐
GFP	  reporter	  system	  in	  the	  Stx-­‐negative	  O157:H7	  ZAP0273	  strain.	  
	  
• To	  expand	  our	  knowledge	  regarding	  the	  active	  site	  of	  the	  5324836	  compound	  by	  
evaluating	   modifications	   of	   the	   compound	   in	   the	   GFP	   reporter	   system,	   and	   to	  
evaluate	  the	  efficacy	  of	  these	  modified	  compounds	  relative	  to	  that	  of	  5324836.	  
	  
• To	   uncover	   the	  mode	   of	   action	   of	   this	   compound	   and	   to	   identify	   the	   bacterial	  
target	   or	   targets,	   and	   employ	   biophysical	   techniques	   to	   characterise	   these	  
interaction.	  
	  
• If	  the	  compounds	  show	  with	  potential	  as	  Stx-­‐inhibiting	  drugs,	  to	  test	  them	  in	  vivo	  
using	  the	  Stx-­‐producing	  C.	  rodentium	  mouse	  model.	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5.2	  Modification	  of	  the	  hit	  compound	  5324836	  (AHU1)	  
	  
The	  258.1	  Da	  compound	  5324836,	   renamed	  AHU1,	   is	  a	  planar	  molecule	  composed	  of	  a	  
maleimide	   and	   a	   morpholine	   moiety	   connected	   by	   a	   benzene	   ring	   (Figure	   5-­‐1).	   This	  
compound	  is	  insoluble	  in	  water,	  and	  therefore	  was	  routinely	  solubilised	  in	  100%	  DMSO	  at	  
20	   mM	   stock	   concentration.	   However,	   the	   compound	   showed	   stability	   in	   much	   lower	  
concentrations	  of	  DMSO	  (Alejandro	  Huerta	  Uribe,	  personal	  communication).	  	  
	  
	  
Figure	   5-­‐1:	   Structure	   of	   AHU1.	   The	   compound	   contains	   a	   maleimide	   (blue),	   benzene	   (green),	   and	  
morpholine	  (orange)	  moiety,	  and	  has	  a	  molecular	  weight	  of	  258.10	  g/mol.	  
	  
In	   order	   to	   understand	   the	   structure-­‐activity	   of	   this	   compound,	   modifications	   were	  
performed	   on	   AHU1	   by	   Alejandro	   Huerta	   Uribe,	   a	   PhD	   student	   at	   the	   University	   of	  
Glasgow.	  The	  morpholine	  moiety	  was	  initially	  selected	  for	  modification,	  as	  the	  presence	  
of	   a	   heteroatom	   (a	   non-­‐carbon	   atom	   in	   a	   ring	   structure)	   on	   the	   six-­‐membered	   ring	  
facilitates	   chemical	   manipulation.	   Briefly,	   the	   morpholine	   ring	   was	   replaced	   with	   an	  
isostere	   piperazine	   in	   order	   to	   perform	   modifications	   on	   the	   nitrogen	   atom,	   and	   the	  
addition	  of	  a	  methyl	  group	  and	  a	  butyl	  chain	  on	  this	  position	  gave	  the	  compounds	  AHU2	  
and	  AHU3,	  respectively	  (Figure	  5-­‐2	  A,	  B).	  As	  we	  believed	  the	  maleimide	  of	  the	  compound	  
was	   likely	  to	  be	  the	  active	  part	  of	  the	  molecule	  due	  to	  the	  reactivity	  of	  this	  moiety,	  the	  
compound	   AHU4	   was	   produced	   by	   the	   addition	   of	   a	   phenyl	   group	   to	   the	   maleimide	  
moiety	  (Figure	  5-­‐2	  C).	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A	   AHU2	   	   	  	  	  	  	  	  	  B	   	  	  	  	  	  	  	  AHU3	   	   C	   AHU4	  
	  
Figure	  5-­‐2:	  Structures	  of	   the	  modified	  AHU	  compounds.	  Compounds	  shown	  are	  AHU2	  (A),	  AHU3	  (B)	  and	  
AHU4	  (C).	  Butyl,	  methyl	  and	  phthalimide	  modifications	  are	  indicated	  in	  green.	  The	  molecular	  weights	  of	  the	  
compounds	  are	  271.13,	  313.18,	  and	  308.33	  g/mol,	  respectively.	  
	  
5.3	  Stx2	  reporter-­‐fusion	  assays	  
	  
5.3.1	  Inhibition	  of	  bacterial	  lysis	  and	  pstx2:GFP	  expression	  by	  AHU1	  
	  
Under	  normal	  growth	  conditions,	  Stx2	  is	  expressed	  at	  very	  low	  levels.	  Expression	  can	  be	  
upregulated	   by	   DNA-­‐damaging	   agents	   that	   activate	   the	   SOS	   response,	   and	   is	   often	  
induced	  experimentally	  by	  addition	  of	  MMC,	  a	  potent	  DNA	  crosslinker.	  To	  evaluate	   the	  
effect	  of	  AHU1-­‐4	  on	  stx2	  expression,	   the	  pstx2:GFP	  promoter-­‐fusion	  plasmid	  containing	  
the	   stx2c	   promoter	   fused	   to	   a	   GFP	   gene	   was	   transformed	   into	   Stx-­‐negative	   Sakai	  
ZAP0273,	  a	  lysogenic	  strain.	  Bacteria	  in	  mid-­‐logarithmic	  growth	  were	  exposed	  to	  AHU1	  at	  
concentrations	   between	   10-­‐200	   µM,	   and	   the	   SOS	   response	   activated	   by	   addition	   of	   1	  
µg/ml	  MMC,	  a	  concentration	  that	  initially	  allows	  growth	  to	  continue	  after	  MMC	  addition,	  
but	   eventually	   results	   in	   bacterial	   lysis	   after	   3-­‐4	   hours.	   Growth	   (OD600)	   and	   GFP	  
expression	  (fluorescence)	  was	  measured	  at	  intervals	  of	  1	  hour,	  for	  a	  maximum	  of	  6	  hours,	  
following	  addition	  of	  compounds	  and	  MMC.	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Figure	   5-­‐3:	   Stx2:GFP	   reporter	   assay.	  When	   E.	   coli	   transformed	   with	   the	   pstx2:GFP	   reporter	   fusion	   are	  
treated	  with	  MMC	  to	  produce	  DNA	  damage	  and	  induction	  of	  the	  SOS	  response,	  the	  activated	  stx2	  promoter	  
results	  in	  expression	  of	  GFP	  and	  production	  of	  fluorescence.	  
	  
To	   determine	   any	   inhibitory	   effects	   of	   AHU1	   on	   bacterial	   survival	   or	   replication,	  
uninduced	   cultures	   containing	   10-­‐200	   µM	   AHU1	   were	   grown	   alongside	   MMC-­‐induced	  
cultures.	  Overall,	  AHU1	  alone	  inhibited	  bacterial	  growth	  at	  high	  concentrations	  (200	  µM)	  
(Figure	   5-­‐4	   A).	   In	   MMC-­‐induced	   cultures,	   bacterial	   growth	   decreased	   3	   hours	   after	  
addition	   of	  MMC	  when	   no	   AHU1	   was	   present,	   an	   effect	   that	   reflects	   phage-­‐mediated	  
bacterial	   cell	   lysis	   initiated	   by	   activation	   of	   the	   SOS	   response	   by	  MMC.	   In	   contrast,	   at	  
concentrations	  of	  50-­‐100	  µM	  AHU1,	  some	  inhibition	  of	  this	  lysis	  was	  observed	  (Figure	  5-­‐4	  
B).	  
	  
A	   Non-­‐induced	   	   	   	  	  	  	  B	   	  	  	  	  MMC-­‐induced	  
	  	   	  	  
Figure	  5-­‐4:	  Inhibition	  of	  MMC-­‐induced	  bacterial	  lysis	  by	  AHU1.	  ZAP0273	  transformed	  with	  pstx2:GFP	  were	  
grown	   in	   the	  presence	  or	   absence	  of	   10-­‐200	  µM	  AHU1	   (A)	   and	   induced	  with	  1	  µg/ml	  MMC	   (B),	   and	   the	  
OD600	   of	   cultures	  measured	   hourly.	   Asterisks	   denote	   those	   time	   points	   at	   which	   a	   significant	   difference	  
Experiments	  were	  performed	   in	   triplicate	  with	  each	  replicate	  subcultured	  separately,	  and	  data	  plotted	  as	  
the	  mean	  with	  standard	  deviation	  from	  the	  mean	  displayed	  by	  error	  bars.	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GFP	  expression	  was	  not	  observed	  in	  the	  absence	  of	  MMC,	  and	  was	  not	  influenced	  by	  the	  
addition	   of	   AHU1	   (Figure	   5-­‐5	   A).	   As	   expected,	   stx2:GFP	   was	   detected	   3-­‐6	   hours	   after	  
induction	   with	   MMC,	   coinciding	   with	   the	   lysis	   stage,	   and	   was	   inhibited	   in	   a	   dose-­‐
dependent	   manner	   by	   AHU1	   (Figure	   5-­‐5	   B).	   Our	   results	   have	   therefore	   confirmed	   the	  
original	   observation	   that	   this	   compound	   influences	   expression	   through	   the	   stx2	  
promoter.	  
	  
A	   Non-­‐induced	   	   	   	   B	   MMC-­‐induced	  
	  	   	   	  
Figure	   5-­‐5:	   Dose-­‐dependent	   inhibition	   of	   MMC-­‐induced	   stx2:GFP	   expression	   by	   AHU1.	   ZAP0273	  
transformed	  with	  pstx2:GFP	  were	  grown	  in	  the	  presence	  or	  absence	  of	  10-­‐200	  µM	  AHU1	  (A)	  and	  induced	  
with	  1	  µg/ml	  MMC	  (B),	  and	  fluorescence	  measured	  hourly.	  Experiments	  were	  performed	  in	  triplicate	  with	  
each	   replicate	   subcultured	   separately,	   and	   data	   plotted	   as	   the	   mean	   with	   standard	   deviation	   from	   the	  
mean	  displayed	  by	  error	  bars.	  
	  
5.3.2	  Inhibition	  of	  bacterial	  lysis	  and	  stx2:GFP	  expression	  by	  AHU2	  and	  AHU3.	  
	  
The	  stx2:GFP	  reporter	  system	  was	  used	  to	  evaluate	  the	  inhibitory	  effects	  of	  the	  modified	  
compounds	  AHU2	  and	  AHU3	  on	  growth,	  lysis,	  and	  GFP	  expression.	  Both	  AHU2	  and	  AHU3	  
showed	   increased	   efficacy,	   with	   concentrations	   of	   50	   µM	   inhibiting	   bacterial	   lysis	   and	  
stx2:GFP	   expression	   (Figure	   5-­‐6),	   approximately	   halving	   the	   dose	   required	   for	   optimal	  
inhibition	  by	  AHU1.	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A	   AHU2	  -­‐	  Non-­‐induced	   	   B	   AHU2	  -­‐	  MMC-­‐induced	  
	   	  
C	  	   AHU2	  -­‐	  Non-­‐induced	   	   D	  	   AHU2	  -­‐	  MMC-­‐induced	  
	  
	   E	   AHU3	  -­‐	  Non-­‐induced	   	   F	  	   AHU3	  -­‐	  MMC-­‐induced	  
	   	  
G	   AHU3	  -­‐	  Non-­‐induced	   	   H	  	   AHU3	  -­‐	  MMC-­‐induced	  
	   	  	  
Figure	  5-­‐6:	  Effect	  of	  AHU2	  and	  AHU3	  on	  bacterial	  growth,	  MMC-­‐induced	  lysis,	  and	  MMC-­‐induced	  stx2:GFP	  
expression.	  ZAP0273	  transformed	  with	  pstx2:GFP	  were	  grown	  in	  the	  presence	  of	  10-­‐200	  µM	  AHU2	  (A-­‐D)	  or	  
AHU3	  (E-­‐H)	  and	  uninduced	  (left)	  or	  induced	  with	  1	  µg/ml	  MMC	  (right).	  Growth	  (OD600)	  and	  stx2	  expression	  
(GFP)	  were	  measured	  hourly.	  Both	  AHU2	  and	  AHU3	  cause	  inhibition	  of	  growth	  at	  higher	  concentrations	  (A,	  
E),	  inhibition	  of	  bacterial	  lysis	  at	  25-­‐100	  µM	  (B,	  F)	  and	  inhibition	  of	  MMC-­‐induced	  lysis	  (D,	  H).	  Experiments	  
were	  performed	  in	  triplicate	  with	  each	  replicate	  subcultured	  separately,	  and	  data	  plotted	  as	  the	  mean	  with	  
standard	  deviation	  from	  the	  mean	  displayed	  by	  error	  bars.	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To	  compare	  the	  stx2:GFP	  inhibitory	  properties	  of	  AHU1,	  AHU2	  and	  AHU3,	  the	  percentage	  
inhibition	  of	  stx2:GFP	  expression	  at	  6	  hours	  post-­‐MMC	  induction	  was	  calculated	  using	  the	  
following	  formula:	   100(1− 𝐹!"# − 𝐹!"#𝐹!"# −   𝐹!"# )	  
	  
where	   FAHU	   =	   fluorescence	   at	   6	   hours	   with	   MMC	   induction	   and	   AHU	   present,	   Fmin	   =	  
fluorescence	  at	  6	  hours	  with	  no	  MMC	  induction,	  and	  Fmax	  =	  fluorescence	  at	  6	  hours	  with	  
MMC	   induction.	   Two	   concentrations	   of	   AHU1-­‐3	   were	   selected:	   25	   µM	   and	   50	   µM,	   as	  
inhibition	  of	   lysis	  and	  GFP	  expression	  was	  effective	  at	  these	  concentrations	  for	  all	  three	  
compounds.	   All	   showed	   inhibition	   at	   25	   µM,	   although	   AHU3	   had	   significantly	   more	  
inhibitory	  activity	  than	  AHU1.	  At	  50	  µM,	  both	  AHU2	  and	  AHU3	  produced	  near-­‐complete	  
inhibition	  of	  stx2:GFP	  expression,	  which	  was	  significantly	  higher	  than	  that	  of	  AHU1	  (Figure	  
5-­‐7).	  As	  AHU3	  was	  the	  most	  effective	  of	  the	  three	  compounds,	  this	  was	  selected	  for	  use	  in	  
all	  further	  experiments.	  
	  
	  
	   	   	   	   	  
Figure	  5-­‐7:	   Inhibition	  of	  stx2:GFP	  expression	  by	  25	  and	  50	  µM	  AHU1,	  AHU2	  and	  AHU3	  at	  6	  hours	  after	  
addition	  of	  AHU1-­‐3	  and	  MMC.	  Data	  was	  calculated	  from	  triplicate	  experiments	  	  and	  displayed	  as	  the	  mean	  
inhibition	  with	   error	   bars	   showing	   the	   standard	  deviation	   from	   the	  mean.	  Asterisks	   indicate	   a	   significant	  
difference	  (**	  =	  p<0.001)	  from	  inhibition	  by	  AHU1	  at	  the	  same	  concentration	  inhibition.	  Inhibition	  by	  AHU2	  
at	   50	   µM	   was	   significantly	   higher	   than	   that	   of	   AHU1	   (p<0.001,	   4	   degrees	   of	   freedom,	   t=14.942),	   and	  
inhibition	   by	   AHU3	   was	   significantly	   higher	   than	   that	   of	   AHU1	   at	   both	   25	   µM	   (p<0.001,	   4	   degrees	   of	  
freedom,	   t=9.056)	   and	   50	   µM	   (p<0.001,	   4	   degrees	   of	   freedom,	   t=14.597).	   Statistical	   significance	   was	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5.3.3	  Inhibition	  of	  bacterial	  lysis	  and	  stx2:GFP	  expression	  by	  AHU4.	  
	  
The	  final	  compound	  to	  be	  tested	  was	  AHU4,	  in	  which	  a	  phthalimide	  group	  was	  added	  to	  
the	  maleimide	  ring	  of	  the	  compound.	  This	  change	  resulted	  in	  a	  loss	  of	  activity	  of	  the	  drug,	  
with	  bacterial	  lysis	  and	  GFP	  expression	  equivalent	  to	  untreated	  cells.	  Bacterial	  growth	  was	  
also	  unaffected	   (Figure	  5-­‐8).	   From	   this,	   it	  would	  appear	   that	   that	   the	  maleimide	   ring	   is	  
essential	   for	   the	   inhibitory	   property	   of	   the	   compounds,	   and	   is	   the	   active	   site	   of	   this	  
molecule.	  
	  
	   A	   Non-­‐induced	   	   	   	   B	   MMC-­‐induced	  
	  	   	   	  
C	   Non-­‐induced	   	   	   	   D	   MMC-­‐induced	  
	   	   	  
Figure	   5-­‐8:	   Effect	   of	   AHU4	   on	   bacterial	   growth,	   MMC-­‐induced	   lysis,	   and	   MMC-­‐induced	   stx2:GFP	  
expression.	   ZAP0273	   transformed	  with	  pstx2:GFP	  were	   grown	   in	   the	  presence	  or	   absence	  of	   10-­‐200	  µM	  
AHU4,	   (A,	   C)	   and	   induced	   with	   1	   µg/ml	   MMC	   (B,	   D).	   Growth	   (OD600)	   and	   stx2	   expression	   (GFP)	   were	  
measured	  hourly.	  Growth	  (A),	  MMC-­‐induced	  lysis	  (B),	  and	  both	  stx2:GFP	  expression	  in	  the	  absence	  (C)	  and	  
presence	  (D)	  of	  MMC	  remained	  unaffected	  by	  AHU4.	  Experiments	  were	  performed	  in	  triplicate	  with	  each	  
replicate	   subcultured	   separately,	   and	   data	   plotted	   as	   the	  mean	  with	   standard	   deviation	   from	   the	  mean	  
displayed	  as	  error	  bars.	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5.3.4	  The	  maleimide	  group	  on	  its	  own	  can	  inhibit	  lysis	  and	  Stx	  expression	  
	  
As	   the	  maleimide	  moiety	   appeared	   responsible	   for	   the	   inhibition	  of	  MMC-­‐induced	   lysis	  
and	   stx2:GFP	   expression	   by	   the	   AHU	   compounds,	   the	   impact	   of	   purified	   maleimide	  
(#129585,	  Sigma-­‐Aldrich)	  on	  these	  activities	  was	  tested.	  In	  comparative	  experiments	  with	  
AHU3,	  maleimide	  elicited	  a	  stronger	  inhibitory	  effect	  on	  growth	  than	  AHU3	  (Figure	  5-­‐9	  A),	  
with	  the	  OD600	  of	  culture	  containing	  50	  µM	  maleimide	  decreasing	  over	  the	  last	  two	  hours	  
of	   the	   experiment	   (Figure	   5-­‐9	   B),	   which	   contrasted	   with	   cultures	   treated	   with	   50	   µM	  
AHU3.	   Inhibition	   of	   stx2:GFP	   expression	   by	   maleimide	   occurred	   at	   similar	   efficacy	   to	  
AHU3	   (Figure	   5-­‐9	   C,	   D).	   These	   results	   indicated	   that	   cell	   lysis	   was	   occurring	   in	   the	  
maleimide-­‐containing	   culture	   and	   thus	   inhibition	  of	   phage-­‐mediated	   lysis	   by	  maleimide	  
was	  less	  efficient	  than	  AHU3.	  
	  
	   A	   Non-­‐induced	   	   	   	   B	   MMC-­‐induced	  
	   	   	  
	   C	   Non-­‐induced	   	   	   	   D	   MMC-­‐induced	  
	   	   	  	  
Figure	  5-­‐9:	  Comparison	  of	  inhibitory	  effects	  of	  AHU3	  and	  maleimide.	  ZAP0273	  transformed	  with	  pstx2:GFP	  
were	  grown	  in	  the	  presence	  or	  absence	  of	  25	  or	  50	  µM	  AHU3	  or	  maleimide	  (A,	  C),	  and	  induced	  with	  1	  µg/ml	  
MMC	  (B,	  D).	  Growth	  (OD600)	  and	  stx2	  expression	  (GFP)	  were	  measured	  hourly.	  While	  AHU3	  and	  maleimide	  
demonstrated	   similar	  stx2:GFP	   inhibition	  efficacy,	  maleimide	  had	  a	   stronger	   inhibitory	  effect	  on	  bacterial	  
growth	  at	  25	  µM	  than	  AHU3	  at	  the	  same	  concentration	  (A).	  Experiments	  were	  performed	  in	  triplicate	  with	  
each	   replicate	   subcultured	   separately,	   and	   data	   plotted	   as	   the	   mean	   with	   standard	   deviation	   from	   the	  
mean	  displayed	  as	  error	  bars.	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These	  findings	  suggest	  that	  the	  non-­‐maleimide	  groups	  of	  AHU3	  have	  an	  unknown	  role	  in	  
increasing	  the	  specificity	  of	  the	  molecule.	  Therefore,	  we	  chose	  to	  further	  evaluate	  AHU3,	  
which	   appeared	  be	   an	   effective	   inhibitor	   of	   Stx	   expression	  without	   strong	   limitation	  of	  
bacterial	  growth.	  
	  
5.3.5	  AHU3	  does	  not	  inhibit	  expression	  of	  rpsM	  and	  tir	   	  
	  
The	  specificity	  of	  AHU3	  was	  explored	  using	  expression	  reporters	  for	  rpsM,	  which	  encodes	  
the	   30S	   ribosomal	   protein	   S13	   and	   is	   a	   commonly	   used	   growth	   control	   in	   biological	  
assays,	   and	   tir,	   encoding	   the	   Type	   3-­‐secreted	   receptor	   protein	   Tir.	   To	   determine	   if	   the	  
presence	  of	  AHU3	  has	  any	  influence	  on	  the	  expression	  of	  these	  genes,	  reporter	  constructs	  
were	  transformed	  into	  ZAP0273	  cells.	  These	  were	  grown	  in	  the	  presence	  or	  absence	  of	  50	  
µM	   AHU3,	   and	   fluorescence	   measured	   against	   OD600.	   As	   expression	   of	   T3SS	   genes	   is	  
dependent	   on	   environmental	   signals,	   bacteria	   were	   grown	   in	   MEM-­‐HEPES	   media	   to	  
induce	  expression	  of	   tir.	  AHU3	  did	  not	  affect	  expression	  of	  GFP	  controlled	  by	  either	  the	  
rpsM	  and	  tir	  promoters	  (Figure	  5-­‐10),	  implying	  that	  AHU3	  does	  not	  influence	  expression	  
of	  either	  of	  these	  genes.	  
	  
A	   	   prpsM:GFP	   	   	   B	   	   ptir:GFP	  
	   	  
Figure	  5-­‐10:	  Effect	  of	  AHU3	  on	   rpsM:GFP	  and	   tir:GFP	  expression.	  ZAP0273	  transformed	  with	  prpsM:GFP	  
(A)	   or	   ptir:GFP	   (B)	   were	   grown	   in	   the	   presence	   or	   absence	   of	   50	   µM	   AHU3	   for	   6	   hours.	   OD600	   and	  
fluorescence	  were	  measured	  hourly,	  and	  fluorescence	  plotted	  against	  the	  OD600	  of	  that	  time	  point.	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5.4	  AHU3	  inhibits	  phage	  production	  	  
	  
5.4.1	  Inhibition	  of	  Stx	  phage	  production	  by	  AHU3	  
	  
The	   stx2:GFP	   reporter	   assays	   demonstrate	   that	   the	   AHU	   compounds	   inhibit	   general	  
phage-­‐mediated	  lysis	  of	  ZAP0273.	  Although	  this	  strain	  has	  had	  the	  Stx2	  phage	  deleted,	  it	  
undergoes	   lysis	   in	   the	   presence	   of	   MMC,	   suggesting	   that	   other	   integrated	   lysogenic	  
phages	  are	  responsible	  and	  that	  the	  AHU	  compounds	  interfere	  with	  their	  expression.	  To	  
confirm	   that	   AHU3	   directly	   inhibits	   production	   of	   the	   Stx2	   phage,	   phage	   transduction	  
assays	   were	   performed	   using	   E.	   coli	   JP10819,	   which	   only	   carries	   the	   lysogenic	   Stx	  
prophage	  φP27.	   This	   prophage	   contains	   a	   tetracycline	   resistance	   cassette	   inserted	   into	  
the	   stx2	   toxin	   gene	   providing	   tetracycline	   resistance	   and	   preventing	   production	   of	   Stx.	  
Phage	  production	  was	  induced	  by	  2	  µg/ml	  MMC	  in	  the	  presence	  and	  absence	  of	  50	  µM	  
AHU3,	  the	  concentration	  at	  which	  stx2:GFP	  expression	  and	  bacterial	  lysis	  were	  effectively	  
inhibited	   in	  the	  GFP	  reporter	  assay,	  and	  the	  phages	  produced	   isolated	  by	   filtration.	  The	  
non-­‐lysogenic	  E.	  coli	  strain	  MG1655	  was	  incubated	  with	  serial	  dilutions	  of	  the	  recovered	  
phage	  and	  grown	  on	  agar	  containing	  tetracycline,	  as	  MG1655	  infected	  with	  the	  Stx	  phage	  
acquire	   resistance	   against	   this	   antibiotic.	   Each	   colony	   was	   counted	   as	   a	   single	   phage	  
transductant,	   and	   differences	   in	   phage	   production	   by	   the	   four	   samples	   were	   analysed	  
using	  the	  general	  linear	  model	  (GLM)	  test.	  	  
	  
Bacteria	   that	   were	   not	   induced	   with	   MMC	   produced	   low	   levels	   of	   Stx	   phage	   (~104	  
transductants/ml	  JP10819),	  which	  significantly	   increased	  to	  ~108	  transductants/ml	  when	  
induced	  with	  MMC.	  Inclusion	  of	  50	  μM	  AHU3	  resulted	  in	  a	  highly	  significant	  decrease	  in	  
the	   amount	   of	   phage	   produced	   by	  MMC-­‐induced	   bacteria	   (Figure	   5-­‐11).	   However,	   the	  
difference	   in	   phage	   production	   between	   non-­‐induced	   bacteria	  with	   and	  without	   AHU3	  
treatment	  was	  also	  significant,	  which	  probably	  reflects	  the	  inhibition	  of	  growth	  by	  AHU3.	  
GLM	   analysis	   of	   the	   interaction	   between	   MMC	   induction	   and	   AHU3	   treatment	   was	  
determined	   to	   be	   highly	   significant.	   This	   demonstrated	   that	   the	   statistically	   significant	  
reduction	  in	  phage	  production	  by	  MMC-­‐induced	  cells	  observed	  is	  not	  merely	  the	  result	  of	  
the	   inhibitory	   effect	   AHU3	   has	   on	   bacterial	   growth.	   This	   implies	   that	   MMC-­‐induced	  
expression	  of	  Stx	  phage	  genes	  is	  inhibited	  by	  AHU3.	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Figure	  5-­‐11:	  Reduction	  of	  MMC-­‐induced	  Stx	  phage	  production	  by	  50	  µM	  AHU3.	  Induction	  of	  JP10819	  with	  
2	   µg/ml	   MMC	   resulted	   in	   significantly	   increased	   phage	   production	   (p<0.001,	   4	   degrees	   of	   freedom,	  
t=17.780).	   Addition	   of	   50	   µM	   AHU3	   produced	   a	   significant	   decrease	   in	   phage	   production	   by	   both	   non-­‐
induced	   (p=0.0158,	   4	   degrees	   of	   freedom,	   t=4.022)	   JP10819	   and	   MMC-­‐induced	   JP10819	   (p<0.001,	   4	  
degrees	   of	   freedom,	   t=18.840),	   and	   the	   interaction	   between	   MMC	   and	   AHU3	   determined	   significant	  
(p<0.001,	   8	   degrees	   of	   freedom,	   t=8.884).	   Asterisks	   indicate	   a	   significant	   difference	   (*	   =	   p<0.05,	   **	   =	  	  
p<0.001)	  in	  phage	  production.	  The	  data	  shown	  is	  the	  average	  of	  triplicate	  individual	  experiments	  with	  each	  
replicate	  subcultured	  separately,	  with	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  Statistical	  
significance	  was	  determined	  by	  GLM	  analysis.	  
	  
5.4.2	  Inhibition	  of	  Gram-­‐positive	  phage	  production	  by	  AHU3	  
	  
As	   the	   AHU	   compounds	   appeared	   to	   inhibit	   phage-­‐mediated	   bacterial	   lysis,	   we	   next	  
explored	  whether	  these	  drugs	  could	  inhibit	  other	  non-­‐Stx	  phages,	  including	  those	  carried	  
by	  Gram-­‐positive	  bacteria.	  To	  evaluate	  their	  activity,	  two	  strains	  of	  S.	  aureus	  harbouring	  
different	   phages	   were	   tested	   with	   AHU3:	   JP5011,	   which	   carries	   the	   ϕSLT	   phage	   that	  
produces	   the	   pore-­‐forming	   Panton-­‐Valentine	   leukocidin	   toxin	   (Ferrer	   et	   al.,	   2011),	   and	  
RN10359,	   which	   carries	   the	   prophage	   80α,	   involved	   in	   mobilisation	   of	   S.	   aureus	  
pathogenicity	  islands.	  
	  
Similar	   to	   the	   Stx2	   phage	   in	   JP10819,	   the	   SLT	   phage	   in	   the	   JP5011	   strain	   contains	   a	  
tetracycline	   resistance	  gene	   integrated	   into	   the	  phage	  plv	   gene	   that	  encodes	   the	   toxin.	  
When	   induced	   by	   MMC,	   approximately	   106	   transductants/ml	   of	   JP5011	   culture	   were	  
produced.	  In	  contrast,	  only	  102	  transductants/ml	  were	  generated	  from	  uninduced	  JP5011.	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reduction	   in	   the	   number	   of	   transductants	   generated,	   but	   did	   not	   reduce	   this	   to	   levels	  
observed	   in	   non-­‐induced	   controls,	   while	   treatment	   of	   the	   uninduced	   culture	   did	   not	  
result	  in	  a	  significant	  change	  in	  phage	  transduction	  (Figure	  5-­‐12).	  	  
	  
	   	   	   	  
Figure	  5-­‐12:	  Reduction	  of	  MMC-­‐induced	  SLT	  phage	  production	  by	  AHU3.	  Induction	  of	  JP5011	  with	  2	  µg/ml	  
MMC	   resulted	   in	   significantly	   increased	   phage	   production	   (p<0.001,	   4	   degrees	   of	   freedom,	   t=	   53.94).	  
Addition	   of	   50	   µM	   AHU3	   produced	   a	   significant	   decrease	   in	   phage	   production	   by	  MMC-­‐induced	   JP5011	  
(p<0.001,	  4	  degrees	  of	  freedom,	  t=19.97).	  Asterisks	  indicate	  a	  significant	  difference	  (**	  =	  p<0.001)	  in	  phage	  
production.	   The	   data	   shown	   is	   the	   average	   of	   triplicate	   individual	   experiments	   with	   each	   replicate	  
subcultured	   separately,	   with	   standard	   deviation	   from	   the	   mean	   displayed	   as	   error	   bars.	   Statistical	  
significance	  was	  determined	  by	  GLM	  analysis.	  
	  
Inhibition	  of	  80α	  phage	  production,	  a	  highly	  lysogenic	  phage,	  was	  measured	  by	  following	  
growth	  of	  RN10359	  in	  LB.	  Cultures	  were	  induced	  with	  500	  ng/ml	  MMC	  and	  AHU3	  added	  
at	   concentrations	  between	  10-­‐200	  µM,	  and	  OD600	  measured	   for	  6	  hours.	  While	   growth	  
and	   lysis	   of	   S.	   aureus	   in	   the	   presence	   of	   AHU3	  was	   not	   as	   noticeably	   different	   to	   the	  
control,	  50	  µM	  AHU3	  resulted	  in	  a	  significant	  reduction	  of	  OD600	  compared	  to	  the	  control	  
at	   the	   3-­‐6	   hour	   time	   points	   (Figure	   5-­‐13).	   Concentrations	   of	   100	   and	   200	   µM	   AHU3	  
showed	   lower	  OD600	   values	   than	   the	   control,	   indicating	   that	   AHU3	   also	   slows	   bacterial	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Figure	  5-­‐13:	  Effect	  of	  AHU3	  on	  MMC-­‐induced	  bacterial	  lysis	  by	  80α.	  RN10359	  were	  grown	  in	  the	  presence	  
or	  absence	  of	  10-­‐200	  µM	  AHU3	  and	   induced	  with	  500	  ng/ml	  MMC.	  The	  OD600	  of	   cultures	  was	  measured	  
hourly,	  and	  the	  time	  points	  at	  which	  the	  OD600	  of	  the	  50	  µM	  AHU3	  culture	  were	  significantly	  higher	  than	  the	  
untreated	   culture	   are	   indicated	   by	   asterisks	   (*	   =	   p<0.05).	   Experiments	  were	   performed	   in	   triplicate	  with	  
each	   replicate	   subcultured	   separately,	   with	   data	   plotted	   as	   the	  mean,	   and	   standard	   deviation	   from	   the	  
mean	  displayed	  by	  error	  bars.	  Statistical	  significance	  was	  determined	  by	  Student’s	  unpaired	  t-­‐test.	  
	  
While	  inhibition	  of	  phage	  production	  in	  S.	  aureus	  by	  AHU3	  is	  less	  effective	  than	  that	  seen	  
in	   E.	   coli,	   it	   provides	   some	   evidence	   that	   AHU3	   can	   affect	   Gram-­‐positive	   phage	  
production.	   It	   also	   demonstrates	   that	   AHU3	   does	   not	   specifically	   target	   expression	   or	  
production	  of	  only	  the	  Stx2	  phage,	  but	  has	  a	  broader	  and	  more	  general	  impact	  on	  phage	  
biology.	  	  
	  
5.5	  AHU3	  does	  not	  target	  mitomycin	  C	  
	  
One	  mechanism	  by	  which	  the	  AHU	  compounds	  could	  work	   is	   through	  direct	   interaction	  
with	  MMC,	  preventing	  its	  capacity	  to	  damage	  bacterial	  DNA.	  To	  determine	  whether	  MMC	  
was	  the	  target	  of	  AHU3,	  Stx	  phage	  transduction	  and	  GFP-­‐Stx	  reporter	  fusion	  assays	  were	  
repeated	   using	   ciprofloxacin	   instead	   of	   MMC.	   Ciprofloxacin	   is	   a	   member	   of	   the	  
fluoroquinolone	  group	  of	  antibiotics	  which	  induce	  Stx	  bacteriophage	  in	  vivo	  (Zhang	  et	  al.,	  
2000).	  The	  bactericidal	  action	  of	  ciprofloxacin	  is	  achieved	  by	  inhibition	  of	  topoisomerases	  
II	  and	  IV,	  which	  are	  essential	  for	  DNA	  replication,	  transcription,	  repair	  and	  recombination,	  
thus	  resulting	  in	  DNA	  damage	  and	  activation	  of	  the	  SOS	  response.	  If	  AHU3	  inhibits	  MMC	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directly,	   bacterial	   lysis	   and	   Stx	   expression	   would	   be	   unaffected	   if	   AHU3	   is	   used	   in	  
combination	  with	  ciprofloxacin.	  
	  
The	   SOS	   response	   was	   effectively	   induced	   using	   a	   concentration	   of	   50	   ng/ml	  
ciprofloxacin.	  Importantly,	  the	  presence	  of	  AHU3	  resulted	  in	  dose-­‐dependent	  inhibition	  of	  
both	   lysis	   and	   stx2:GFP	   expression	   similar	   to	   that	   seen	   when	   MMC	   was	   used	   as	   the	  
inducing	  agent	  (Figure	  5-­‐14	  A,	  B).	  Additionally,	  AHU3	  was	  able	  to	  significantly	  reduce	  Stx	  
phage	   production	   by	   ciprofloxacin-­‐induced	   JP10819	   (Figure	   5-­‐14	   C).	   From	   this,	   we	  
concluded	   that	   the	   inhibition	   observed	   in	   previous	   assays	   was	   not	   the	   result	   of	   direct	  
interaction	  of	  AHU3	  with	  MMC.	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Figure	  5-­‐14:	  AHU3	  prevents	   ciprofloxacin-­‐mediated	  SOS	   response.	  ZAP0273	  transformed	  with	  pstx2:GFP	  
were	  grown	  the	  presence	  or	  absence	  of	  10-­‐200	  µM	  AHU3,	  and	  induced	  with	  50	  ng/ml	  ciprofloxacin.	  AHU3	  
inhibited	   ciprofloxacin-­‐induced	   bacterial	   lysis	   (A)	   and	   stx2:GFP	   expression	   (B).	   AHU3	   also	   inhibited	  
ciprofloxacin-­‐induced	  Stx	  phage	  production	  (C).	   Induction	  of	  JP10819	  with	  50	  ng/ml	  ciprofloxacin	  resulted	  
in	   significantly	   increased	  phage	  production	   (p=0.002,	   4	   degrees	  of	   freedom,	   t=7.295).	  Addition	  of	   50	  µM	  
AHU3	  produced	   a	   significant	   decrease	   in	   phage	  production	  by	   ciprofloxacin-­‐induced	  bacteria	   (p=0.002,	   4	  
degrees	  of	   freedom,	  t=6.868).	  Asterisks	   indicate	  a	  significant	  difference	  (*	  =	  p<0.05)	   in	  phage	  production.	  
The	   data	   shown	   is	   the	   average	   of	   triplicate	   individual	   experiments	   with	   each	   replicate	   subcultured	  
separately,	   with	   standard	   deviation	   from	   the	   mean	   displayed	   as	   error	   bars.	   Statistical	   significance	   was	  
determined	  by	  GLM	  analysis.	  
	  
5.6	  Identifying	  the	  possible	  target	  of	  AHU3	  	  
	  
As	   AHU3	   inhibits	   phage	   production	   in	   both	  Gram-­‐negative	   and	  Gram-­‐positive	   bacteria,	  
including	   phages	   unrelated	   to	   Stx,	   it	   appeared	   likely	   that	   AHU3	   acts	   on	   an	   essential	  
component	  of	  the	  SOS	  response	  involved	  in	  the	  induction	  of	  phage	  expression.	  Prophage	  
genes	  are	  under	  the	  control	  of	  phage	  repressors	  that,	  under	  non-­‐stressed	  cell	  conditions,	  
prevent	  the	  phage	  from	  entering	  the	  lytic	  cycle	  and	  causing	  bacterial	  host	  lysis.	  When	  the	  
SOS	  response	  is	  initiated,	  RecA	  filaments	  mediate	  autocleavage	  of	  the	  key	  SOS	  response	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repressor	   LexA	   as	   well	   as	   autocleavage	   of	   phage	   repressors,	   thus	   allowing	   gene	  
expression	  and	  production	  of	  assembled	  phage	  particles	  and	  toxins.	  Therefore,	  inhibition	  
of	   the	   SOS	   response	   by	   AHU3	   through	   prevention	   of	   RecA-­‐mediated	   autocleavage	   of	  
prophage	  repressors	  could	  help	  to	  explain	  the	  results	  observed:	  inhibition	  of	  both	  Gram-­‐
negative	   and	   Gram-­‐positive	   phage	   production,	   inhibition	   of	   prophage-­‐encoded	   toxin	  
expression,	  and	  inhibition	  of	  phage-­‐mediated	  bacterial	  lysis.	  To	  be	  effective	  in	  both	  Gram-­‐
negative	   and	   Gram-­‐positive	   bacteria,	   AHU3	   would	   need	   to	   target	   a	   protein	   highly	  
conserved	  across	  the	  bacterial	  species.	  
	  
We	  therefore	  hypothesised	  that	  the	  most	  likely	  target	  of	  the	  AHU	  compounds	  was	  RecA,	  
which	  fits	  the	  above	  criteria.	  Inactivation	  of	  this	  protein	  by	  AHU3,	  either	  by	  preventing	  it	  
binding	   damaged	   DNA,	   forming	   activated	   filaments,	   or	   interacting	   with	   prophage	  
repressors,	   would	   block	   expression	   of	   phage	   genes	   (Figure	   5-­‐15).	   LexA	   was	   also	  
considered	  but,	  as	  this	  would	  require	  the	  compounds	  to	  bind	  to	  a	  region	  of	  the	  protein	  
that	  shared	  high	  similarity	  with	  many	  different	  phage	  repressors,	  RecA	  was	  thought	  more	  
likely	   to	  be	   the	   target.	   Inhibition	  of	  either	  gene	  expression	  or	  protein	   function	  of	  other	  
SOS	   components	   is	   unlikely,	   as	  while	   this	  would	   inhibit	   the	   SOS	   response,	   phage	   gene	  
expression	  would	  be	  unaffected.	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Figure	   5-­‐15:	   Possible	   stages	   of	   SOS	   response	   activation	   that	   AHU3	   may	   inhibit.	   LexA	   and	   prophage	  
repressor	  autocleavage,	  which	  results	   in	  expression	  of	  SOS	  response	  and	  prophage	  genes,	   is	  mediated	  by	  
activated	  RecA	  filaments.	  These	  are	  assembled	  when	  RecA	  monomers	  recognise	  damaged	  DNA.	  AHU3	  may	  
therefore	   inhibit	   induction	   of	   the	   SOS	   response	   either	   by	   preventing	   RecA	   from	   recognising	   DNA	   (A),	  
inhibiting	  oligomerisation	  of	  RecA	  into	  activated	  filaments	  (B),	  or	  by	  blocking	  the	  RecA	  filament’s	  ability	  to	  
mediate	  autocleavage	  of	  LexA/prophage	  repressors	  (C).	  	  
	  
5.7	  Microscale	  thermophoresis	  of	  AHU3	  and	  RecA	  
	  
Microscale	   thermophoresis	   (MST)	  was	  used	   to	  determine	  whether	  AHU3	   interacts	  with	  
RecA	   directly.	   MST	   analyses	   biomolecule	   interaction	   by	   measuring	   the	   directed	  
movement	   of	   molecules	   in	   a	   microscopic	   temperature	   gradient.	   This	   molecular	  
behaviour,	   termed	   thermophoresis,	   is	   detected	   through	   fluorescence	   of	   one	   of	   the	  
binding	   partners,	   either	   by	   labelling	   the	   molecule	   with	   a	   fluorescent	   tag	   or	   using	   its	  
intrinsic	  fluorescence.	  Thermophoresis	  is	  dependent	  on	  factors	  such	  as	  size,	  charge,	  and	  
solvation	  shell	  of	  the	  molecule,	  and	  therefore	  when	  the	  labelled	  molecule	  binds	  a	  target	  
these	  properties	  are	  altered,	  resulting	  in	  a	  detectable	  change	  in	  thermophoresis.	  MST	  has	  
several	   advantages	   over	   other	   well-­‐established	   techniques	   for	   molecule	   interaction	  
investigation	   such	   as	   isothermal	   titration	   calorimetry	   and	   surface	   plasmon	   resonance.	  
Notably,	  it	  does	  not	  require	  immobilisation	  of	  one	  of	  the	  molecules,	  a	  step	  that	  can	  cause	  
binding	  difficulties	  due	   to	   steric	  hindrance	  at	   the	   interface.	   In	  addition,	   lysate	  or	  whole	  
cell	  extract	  can	  be	  used	  in	  place	  of	  purified	  proteins.	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To	   assess	   RecA	   and	   AHU3	   binding,	   we	   fluorescently	   labelled	   RecA	   through	   covalent	  
attachment	  of	  NT.Red	  dye.	   In	  these	  experiments	  the	   inactive	  derivative	  AHU4	  was	  used	  
as	   a	   negative	   control.	   The	   concentration	   of	   RecA	  was	   kept	   constant	   at	   100	   µM,	  while	  
AHU3	  and	  AHU4	  concentrations	  ranged	  from	  12-­‐200	  µM.	  Incubation	  of	  RecA	  with	  AHU3	  
provided	   supportive	   evidence	   that	   binding	   occurred	   between	   RecA	   and	   AHU3,	   while	  
AHU4	  showed	  no	  affinity	  for	  RecA	  (Figure	  5-­‐16).	  	  
	  
	  
Figure	  5-­‐16:	   Interaction	  of	  RecA	  with	  AHU3	  and	  AHU4.	  AHU3	  (green)	  and	  AHU4	  (blue)	   in	  4%	  DMSO	  and	  
PBS	  were	  added	  at	  concentrations	  between	  12-­‐200	  µM	  to	  100	  µM	  fluorescently-­‐labelled	  RecA	  in	  PBS.	  The	  
signal	  corresponds	  to	  the	  fraction	  of	  fluorescence	  formed	  as	  a	  consequence	  of	  complex	  formation.	  
	  
5.8	  AHU3	  inhibits	  the	  ATPase	  activity	  of	  RecA	  
	  
Previous	  studies	  of	  RecA	   inhibitors	  have	  used	  ATP	  assays	  which	  quantify	   the	  amount	  of	  
free	   phosphate	   as	   a	   measure	   of	   ATP	   hydrolysis,	   as	   an	   indirect	   measure	   of	   RecA	  
nucleoprotein	  filament	  assembly	  (Wigle	  &	  Singleton,	  2007;	  Wigle	  et	  al.,	  2009;	  Sexton	  et	  
al.,	  2010).	  We	  attempted	  to	  replicate	  the	  phosphomolybdate-­‐blue	  ATPase	  assay	  as	  used	  
by	  Sexton	  et	  al.	  (2010),	  wherein	  compounds	  that	  inhibit	  RecA	  produce	  a	  decrease	  in	  A825.	  
However,	   we	   were	   unable	   to	   reproduce	   this	   assay.	   We	   therefore	   used	   the	   Innova	  
Biosciences	  ATPase	  assay	  kit,	  which	  produces	  a	  Pi-­‐dye	  complex	  when	   free	  phosphate	   is	  
produced	   by	   ATPase-­‐mediated	   hydrolysis	   of	   ATP.	   Optimal	   final	   concentrations	   of	   RecA	  
and	   ssDNA	   were	   250	   nM	   and	   5	   µM	   respectively,	   with	   higher	   concentrations	   of	   RecA	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causing	   precipitation	   due	   to	   the	   presence	   of	   detergent	   in	   the	   RecA	   buffer.	   DMSO	  was	  
required	   for	   solubility	   of	   AHU3	   and	   kept	   at	   a	   final	   concentration	   of	   2%,	   as	   >5%	  DMSO	  
inhibited	   the	   reaction.	   A	   reaction	   lacking	   RecA	   was	   used	   as	   a	   background	   absorbance	  
control,	  and	  a	   reaction	   that	   included	  RecA	  but	  no	  ssDNA	  was	  used	   to	  confirm	  that	  ATP	  
hydrolysis	   was	   dependent	   on	   the	   presence	   of	   ssDNA.	   AHU3	   was	   included	   at	  
concentrations	   between	   0.1-­‐100	   µM,	   and	   a	   positive	   control	   with	   no	   AHU3	   present	  
included.	  The	  presence	  of	  AHU3	  resulted	  in	  a	  concentration-­‐dependent	  decrease	  in	  A650,	  
implying	   that	   AHU3	   inhibits	   RecA	   in	   a	   manner	   that	   prevents	   it	   from	   catalysing	   ATP	  
hydrolysis.	   While	   the	   ATPase	   assay	   is	   not	   a	   direct	   measure	   of	   nucleoprotein	   filament	  
formation,	   it	  provides	  further	  evidence	  that	  the	  AHU	  compounds	  are	  inhibitors	  of	  RecA,	  
and	  validates	  our	  MST	  findings.	  	  
	  
The	  data,	  as	  a	  percentage	  of	   the	  average	  absorbance	  of	   the	  0	  µM	  control,	  generated	  a	  
dose-­‐response	   curve	   that	  was	  used	   to	  determine	   IC50	   values	   (Figure	   5-­‐17).	   The	   relative	  
IC50	  calculated	  was	  7.721	  µM,	  similar	   to	   the	  single-­‐digit	  micromolar	  values	  obtained	   for	  
the	  most	  potent	  of	  other	  previously	  studied	  RecA	   inhibitors,	  and	  a	  shallow	  Hill	   slope	  of	  
0.109,	   which	   was	   lower	   than	   the	   >5.0	   values	   of	   the	   other	   reported	   RecA	   inhibitors	  
(Sexton	  et	  al.,	  2010;	  Peterson	  et	  al.,	  2012).	  
	  
	  
Figure	   5-­‐17:	   AHU3	   inhibits	   RecA-­‐mediated	   ATP	   hydrolysis.	   Dose-­‐response	   curve	   of	   AHU3	   showing	   the	  
inhibition	   of	   ATPase	   activity	   by	   different	   concentrations	   of	   0.1-­‐100	   µM	   AHU3.	   Data	   is	   plotted	   as	   a	  
percentage	  of	  the	  average	  absorbance	  of	  the	  assay	  wells	  containing	  0	  µM	  AHU3.	  The	  curve	  exhibits	  an	  IC50	  
value	  of	  7.721	  µM	  and	  a	  Hill	  slope	  of	  0.109.	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The	   inactive	   AHU4	   compound	   was	   also	   tested	   for	   ATPase	   inhibition	   and	   showed	   no	  
evidence	  of	  ATPase	  activity	  (Figure	  5-­‐18),	  confirming	  that	  the	  maleimide	  is	  responsible	  for	  
ATPase	  inhibition.	  	  
	  
	  
Figure	  5-­‐18:	  AHU4	  does	  not	   inhibit	  RecA-­‐mediated	  ATP	  hydrolysis.	  Concentrations	  of	  AHU4	  between	  25-­‐
200	  µM	  showed	  no	  dose-­‐dependent	  effect	  on	  RecA-­‐mediated	  ATP	  hydrolysis	  and	  no	  dose-­‐response	  curve	  
could	  be	  fitted.	  Data	  is	  plotted	  as	  a	  percentage	  of	  the	  average	  absorbance	  of	  the	  assay	  wells	  containing	  0	  
µM	  AHU4.	  
	  
5.9	  AHU3	  inhibits	  RecA	  oligomerisation	  
	  
Analytical	   ultracentrifugation	   (AUC),	   a	   versatile	  method	   for	   the	   quantitative	   analysis	   of	  
macromolecules,	   employs	   a	   centrifugal	   field	   to	   study	   the	   sedimentation	   of	   proteins	   in	  
solution.	  Centrifugation	  at	  high	   speed	   separates	  proteins	  according	   to	   their	   shapes	  and	  
masses,	   and	   concentrations	   of	   these	   different	   protein	   species	   are	   measured	   using	  
absorbance	  or	  interference	  optics,	  allowing	  for	  characterisation	  of	  the	  oligomeric	  state	  of	  
the	  protein	  and	   its	   gross	   shape.	  There	  are	   two	  main	   types	  of	  AUC	  used:	   sedimentation	  
velocity	   (SV),	   which	   interprets	   the	   movement	   of	   macromolecules	   using	   hydrodynamic	  
theory	  to	  determine	  the	  size,	  shape,	  and	  interactions	  of	  the	  protein,	  and	  sedimentation	  
equilibrium	   (SE),	   which	   uses	   equilibrium	   concentration	   gradients	   to	   define	   molecule	  
mass,	   assembly	   stoichiometry,	   association	   constants,	   and	   solution	   non-­‐ideality	   (Cole	   et	  
al.,	  2008).	  	  
	  



















5.	  RESULTS:	  Shiga	  toxin	  inhibitors	  
	   152	  
The	  oligomerisation	  of	  E.	  coli	  RecA	  has	  previously	  been	  thoroughly	  characterised	  by	  SE.	  
Brenner	  et	   al.	   (1990)	   observed	  monomeric	   RecA	   in	   reversible	   equilibrium	  with	   trimers,	  
hexamers	   and	   dodecamers	   under	   specific	   solution	   conditions.	   Equilibrium	  was	   strongly	  
temperature	  dependent;	  as	  the	  temperature	  was	  raised	  from	  1°C	  to	  21°C	  polymerisation	  
was	  favoured	  and	  shown	  to	  be	  reversible	  upon	  lowering	  of	  temperature.	  Distribution	  of	  
RecA	   oligomers	   was	   dependent	   on	   solution	   conditions,	   and	   thermodynamic	   analysis	  
indicated	   that	   these	   different	   species	   were	   in	   reversible	   equilibrium	   with	   each	   other	  
(Brenner	  et	  al.,	  1990).	  To	  assess	  whether	  AHU3	  affects	   the	  oligomerisation	  dynamics	  of	  
RecA,	   we	   studied	   RecA	   sedimentation	   under	   similar	   conditions	   to	   those	   described	   by	  
Brenner	  et	  al.	  (1990)	  in	  the	  presence	  and	  absence	  of	  AHU3.	  
	  
The	  overall	  oligomerisation	  state	  of	  RecA	  was	  studied	  under	  three	  conditions:	  RecA	  alone,	  
RecA	  +	  0.5%	  DMSO,	  and	  RecA	  +	  0.5%	  DMSO	  +	  100	  µM	  AHU3.	  The	  concentration	  of	  RecA	  
was	  10	  µM	  in	  all	  samples,	  while	  AHU3	  was	  included	  in	  a	  10-­‐fold	  excess.	  RecA	  was	  dialysed	  
into	  50	  mM	  Na-­‐citrate,	  5%	  glycerol	  pH	  6.0,	   in	  order	  to	  maximise	  the	  oligomeric	  state	  of	  
RecA	  (Brenner	  et	  al.,	  1990),	  and	  rotor	  speeds	  of	  6,	  10	  and	  14k	  rpm	  at	  a	  temperature	  of	  
4°C	  and	  20°C	  used	  to	  explore	  the	  landscapes	  of	  molecular	  weights	  in	  the	  system.	  
	  
Raw	   sedimentation	  data	   showed	  AHU3	  had	  an	  effect	  on	  RecA	  oligomerisation;	  RecA	   in	  
the	  presence	  of	  AHU3	  produced	  a	  markedly	  shallower	  equilibrium	  distribution	  (Figure	  5-­‐
19	   A).	   The	   SE	   data	   was	   analysed	   with	   SEDPHAT	   by	   Dr.	   Olwyn	   Byron	   (University	   of	  
Glasgow)	  using	   the	   single	   species	  analysis	  model	   in	  order	   to	  gain	  a	  model-­‐independent	  
measure	  of	  the	  whole-­‐cell	  weight	  average	  molecular	  weight.	  The	  average	  molecular	  mass	  
of	   RecA	   oligomers	   in	   the	   absence	   of	   both	   AHU3	   and	  DMSO	  was	   661.8	   kDa	   at	   6k	   rpm,	  
556.0	  kDa	  at	  10k	  rpm,	  and	  404.0	  kDa	  at	  14k	  rpm.	  When	  DMSO	  was	  present	  there	  was	  a	  
decrease	   in	   the	   average	   molecular	   mass	   at	   rotor	   speeds	   of	   10k	   rpm	   and	   14k	   rpm,	  
although	  at	  6k	  rpm	  the	  average	  mass	  increased	  to	  791.7	  kDa.	  However,	  when	  AHU3	  was	  
present	   in	   the	   sample,	   the	   average	   molecular	   mass	   of	   RecA	   oligomers	   was	   greatly	  
reduced	  at	  all	  rotor	  speeds,	  with	  kDas	  below	  both	  those	  for	  RecA	  alone	  and	  RecA	  +	  DMSO	  
(Figure	   5-­‐19	   B).	   This	   implies	   that	   AHU3	   is	   inhibiting	   the	   formation	   of	   larger	   oligomeric	  
RecA	   species,	   resulting	   in	   an	   increase	   in	   lower	   molecular	   weight	   oligomers	   observed.	  
While	   SE	   only	   measures	   the	   average	   molecular	   weight	   of	   RecA	   and	   does	   not	   give	   an	  
indication	   of	   the	   proportion	   of	   different	   oligomeric	   species	   present,	   it	   still	   provides	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evidence	  to	  support	  our	  hypothesis	  that	  AHU3	  inhibits	  the	  SOS	  response	  by	  targeting	  and	  
inhibiting	  RecA.	  It	  also	  further	  indicates	  that	  it	  is	  the	  initial	  oligomerisation	  stage	  of	  RecA	  






Figure	  5-­‐19:	  AHU3	  decreases	  RecA	  oligomerisation.	  Raw	  sedimentation	  equilibrium	  data	  for	  RecA,	  RecA	  in	  
the	  presence	  of	  0.5%	  DMSO,	  and	  RecA	  in	  0.5%	  DMSO	  and	  100	  µM	  AHU3	  (A).	  Oligomeric	  RecA	  species	  at	  6,	  





































+ 0.5% DMSO + 100 µM AHU3
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5.10	  Cytotoxicity	  of	  the	  AHU	  compounds	  
	  
Before	  considering	  in	  vivo	  testing	  of	  the	  AHU	  compounds,	  we	  required	  confirmation	  that	  
they	  were	  not	  toxic	  to	  eukaryotic	  cells.	  AHU1-­‐3	  were	  tested	  for	  cytotoxicity	  against	  HEK	  
293	  cells	  by	  the	  European	  Screening	  Port	  (Hamburg,	  Germany).	  At	  a	  concentration	  of	  100	  
µM,	  all	  three	  compounds	  were	  highly	  toxic	  with	  no	  viable	  cells	  remaining	  after	  treatment.	  
Full	   dose-­‐response	   curves	   were	   generated	   and	   all	   three	   compounds	   revealed	   an	   IC50	  
value	  of	  approximately	  5	  µM	  (Table	  5-­‐1).	  While	  there	  is	  a	  selectivity	  window	  based	  on	  the	  
dose	   required	   to	   inhibit	   bacterial	   virulence,	   at	   this	   stage	   of	   drug	   discovery	   a	   lead	  
compound	   should	   ideally	   show	   no	   cytotoxicity	   at	   a	   dose	   of	   10	   µM.	   Therefore,	   these	  
compounds	   are	   not	   considered	   suitable	   for	   testing	   in	   the	   Stx-­‐expressing	   Citrobacter	  
rodentium	  model,	  and	  will	  require	  further	  modification	  to	  reduce	  cytotoxicity	  before	  they	  
can	  be	  considered	  for	  inclusion	  in	  future	  animal	  trials.	  
	  
Table	   5-­‐1:	   Cytotoxicity	   of	   AHU1-­‐3.	   Toxicity	   of	   the	   compounds	   to	   HEK293	   cells	   was	   calculated	   at	  
concentrations	  of	  AHU1-­‐3	  between	  0.01-­‐1	  mM.	  Dose-­‐response	  curves	  for	  the	  three	  compounds	  were	  used	  
to	  calculate	  the	  IC50	  and	  Hill	  slope	  values.	  
Compound	   Toxicity	  at	  100	  µM	   Hill	  slope	   pIC50	  (µM)	  
AHU1	   100%	   5.19	  ±	  0.47	   5.10	  ±	  0.01	  
AHU2	   100%	   4.30	  ±	  0.25	   5.30	  ±	  0.01	  
AHU3	   100%	   5.30	  ±	  0.30	   5.09	  ±	  0.01	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5.11	  Discussion	  
	  
Our	  studies	  confirmed	  that	  the	  compound	  AHU1	  inhibits	  MMC-­‐induced	  stx2	  expression,	  
and	  the	  efficacy	  of	  this	   inhibition	  was	  increased	  by	  modification	  of	  the	  morpholine	  ring.	  
The	  AHU	  compounds	  also	  caused	  inhibition	  of	  MMC-­‐induced	  bacterial	  lysis,	  implying	  that	  
their	   action	  was	   not	   limited	   to	   stx2	   expression,	   but	   had	   a	   broader	   effect	   on	   lysogenic	  
prophages	  encoded	  by	   the	  E.	   coli	   Sakai	   genome.	  This	  was	   validated	  by	   the	  observation	  
that	   AHU3	   additionally	   inhibited	   transduction	   of	   Gram-­‐positive	   phages.	   The	   ability	   of	  
AHU3	   to	   inhibit	   a	  wide	   range	  of	   very	   different	   phages	   suggests	   that	   instead	  of	   directly	  
inhibiting	   expression	   of	   phage	   genes,	   AHU3	  works	   by	   inhibiting	   an	   earlier	   process	   that	  
controls	  expression	  of	  all	  phage	  genes:	  the	  SOS	  response.	  We	  hypothesised	  that	  the	  AHU	  
compounds	  target	  RecA,	  an	  early	  and	  essential	  component	  of	  the	  SOS	  response,	  and	  have	  
shown	  that	  AHU3	   interacts	  with	  RecA,	   inhibiting	   its	  ability	   to	  oligomerise	  and	  hydrolyse	  
ATP	  and	  thus	  preventing	  it	  from	  mediating	  cleavage	  of	  the	  SOS	  and	  prophage	  repressors.	  	  
	  
5.11.1	  The	  AHU	  compounds	  target	  the	  SOS	  response	  protein	  RecA	  
	  
To	  determine	  whether	  AHU3	  targets	  RecA,	  several	  techniques	  to	  explore	  interaction	  were	  
performed.	  AHU3	  was	   shown	   to	   inhibit	  ATP	  hydrolysis	   by	  RecA,	   an	  event	   that	  plays	   an	  
essential	   role	   in	   repair	   of	   DNA	   by	   homologous	   recombination.	   Microscale	  
thermophoresis,	   which	   analyses	   the	   interaction	   of	   two	   molecules	   by	   measuring	   their	  
movement	   in	   temperature	  gradients,	   implied	   that	  AHU3	  binds	  RecA.	   Finally,	  AHU3	  was	  
shown	  by	  AUC	  to	  reduce	  oligomerisation	  of	  RecA,	  the	  essential	  first	  step	  in	  activation	  of	  
the	   SOS	   response.	   Together,	   this	   data	   provides	   compelling	   evidence	   that	   the	   AHU	  
compounds	  interact	  with	  and	  inhibit	  RecA.	  
	  
Under	  non-­‐stressed	  growth	  conditions,	  RecA	  exists	   in	  an	   inactive	  state	  and	   is	  unable	   to	  
initiate	  high	  expression	  of	  SOS	  or	  prophage	  genes.	  Activity	  first	  requires	  the	  formation	  of	  
a	  helical	  homopolymeric	  filament	  of	  ATP-­‐bound	  RecA	  on	  ssDNA,	  followed	  by	  hydrolysis	  of	  
ATP.	  The	  active	  RecA-­‐DNA	  filament	  is	  then	  able	  to	  mediate	  recombinant	  DNA	  repair	  and	  
homologous	  exchange,	  as	  well	  as	  autocleavage	  of	  the	  LexA	  and	  prophage	  repressors.	  The	  
ability	  of	  AHU3	  to	  inhibit	  this	  essential	  initial	  step	  of	  the	  SOS	  response	  was	  studied	  using	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SE-­‐AUC,	  which	   revealed	   that	   the	   presence	   of	   AHU3	   results	   in	   lower	   numbers	   of	   larger	  
oligomeric	   RecA	   species,	   suggesting	   that	   AHU3	   is	   inhibiting	   RecA	   oligomerisation.	  
Additionally,	  ATPase	  assays	  showed	  that	  AHU3	  inhibits	  RecA-­‐mediated	  ATP	  hydrolysis.	  As	  
ATPase	   activity	   by	   RecA	   requires	   the	   binding	   of	   RecA	   to	   ssDNA	   and	   formation	   of	   RecA	  
filaments,	  we	  propose	  that	  AHU3	  binds	  inactive	  RecA	  monomers,	  preventing	  them	  from	  
forming	   filaments	   that	   can	   hydrolyse	   ATP,	   and	   thereby	   inhibiting	   activation	   of	   the	   SOS	  
response.	  	  
	  
It	   is	   also	   likely	   that	   the	   AHU	   compounds	   target	   other	   bacterial	   proteins,	   as	   at	   higher	  
concentrations	  (100-­‐200	  µM)	  bacterial	  growth	  was	  either	  slowed	  or	  completely	  inhibited.	  
However,	   growth	   was	  minimally	   inhibited	   at	   the	   lower	   concentrations	   which	  modified	  
RecA	  activity.	  Additionally,	  expression	  of	  rpsM	  and	  tir	  was	  unaffected	  when	  bacteria	  were	  
grown	  in	  the	  presence	  of	  50	  µM	  AHU3,	  suggesting	  AHU3	  displays	  specificity	  for	  RecA.	  We	  
attempted	  to	  identify	  other	  non-­‐RecA	  proteins	  with	  which	  AHU3	  interacts	  by	  synthesising	  
affinity-­‐tagged	   AHU3,	   which	   could	   be	   attached	   to	   an	   immobile	   surface	   and	   incubated	  
with	  bacterial	  cell	  lysate.	  After	  washing	  to	  remove	  unbound	  material,	  the	  proteins	  bound	  
to	  AHU3	  could	  then	  be	  eluted	  with	  an	  excess	  of	  free	  drug	  or	  denaturing	  conditions,	  and	  
analysed	   by	   SDS-­‐PAGE	   with	   protein	   bands	   identified	   by	   mass	   spectrometry.	  
Unfortunately,	   attempts	   to	   synthesise	   a	   biotinylated	   derivative	   of	   AHU3	   were	  
unsuccessful,	  and	  thus	  further	  targets	  of	  AHU3	  remain	  to	  be	  identified.	  
	  
5.11.2	  The	  maleimide	  moiety	  of	  the	  AHU	  compounds	  inhibits	  bacterial	  RecA	   	  
	  
The	   role	   of	   the	   maleimide	   moiety	   with	   respect	   to	   the	   inhibitory	   activity	   of	   the	   AHU	  
compounds	  was	  always	  considered	  to	  be	  significant,	  and	  was	  confirmed	  by	  the	  synthesis	  
of	  AHU4.	   In	   this	  drug,	  addition	  of	  a	  phenyl	  group	  resulted	   in	  blocking	  of	   the	  maleimide	  
double	   bond.	   When	   tested	   in	   the	   GFP	   reporter	   assay,	   this	   compound	   did	   not	   exhibit	  
activity	   against	   bacterial	   growth,	   stx2:GFP	   expression,	   or	   MMC-­‐induced	   bacterial	   lysis,	  
confirming	   that	   the	   maleimide	   is	   essential	   for	   all	   inhibitory	   abilities.	   Interestingly,	  
maleimide	  on	  its	  own	  was	  sufficient	  to	  cause	  inhibition	  of	  stx2:GFP	  expression.	  However,	  
at	   50	   µM	   maleimide	   strongly	   affected	   bacterial	   growth,	   and	   therefore	   the	   additional	  
moieties	  of	  AHU3	  may	   increase	   its	  specificity	   for	  RecA	  while	  decreasing	   its	   influence	  on	  
other	  cellular	  processes.	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Maleimide	  is	  a	  5-­‐membered	  ring	  whose	  reactivity	  is	  derived	  from	  its	  electrophilic	  nature,	  
and	   readily	   forms	  covalent	  bonds	  with	   thiols.	   The	  carbons	  on	  either	   side	  of	   the	  double	  
bond	  are	  susceptible	  to	  addition	  either	  by	  Michael	  or	  via	  Diels-­‐Alder	  reactions,	  and	  could	  
react	   with	   the	   nucleophilic	   thiol	   group	   (-­‐SH)	   of	   a	   surface-­‐exposed	   cysteine	   residue,	  
forming	   a	   stable	   carbon-­‐sulfur	   covalent	   bond	   between	   RecA	   and	   AHU3	   (Figure	   5-­‐20).	  
Although	   some	   other	   amino	   acids	   are	   also	   nucleophilic,	   maleimides	   specifically	   target	  
cysteine	  residues	  at	   intracellular	  pH	   levels,	  due	   to	   the	  much	  higher	  susceptibility	  of	   the	  
sulfhydryl	  group	  to	  oxidisation	  (Bednar,	  1990).	  The	  protein	  sequence	  of	  RecA	  reveals	  that	  
it	  contains	  three	  cysteine	  residues	  that	  may	  interact	  with	  the	  electrophilic	  carbons	  in	  the	  
AHU3	  maleimide.	   Covalent	   binding	   between	   the	   inhibitor	   and	  protein	   is	   an	   irreversible	  
event,	   and	   therefore	   while	   our	   MST	   experiment	   suggests	   binding	   is	   occurring,	   this	  
analysis	   cannot	   be	   used	   to	   determine	   the	   kinetics	   of	   binding.	   Although	   further	  
experiments	   are	   required	   to	   confirm	   that	   AHU3	   is	   binding	   covalently,	   the	   known	  
selectivity	   of	   the	   thiol-­‐maleimide	   reaction	   in	   aqueous	   environments,	   rapid	   kinetics	  
associated	   with	   this	   reaction,	   and	   stability	   of	   the	   thiol-­‐maleimide	   product	   (Nair	   et	   al.,	  
2014)	  support	  our	  hypothesis	  that	  this	  reaction	  is	  occurring	  between	  AHU3	  and	  RecA.	  
	  
	  
Figure	  5-­‐20:	  Proposed	  covalent	  attachment	  of	  AHU3	  to	  RecA.	  The	  electrophilic	  maleimide	  moiety	  of	  AHU3	  
undergoes	   nucleophilic	   attack	   by	   the	   thiol	   group	   (-­‐SH)	   of	   a	   surface-­‐exposed	   cysteine	   residue	   of	   RecA,	  
forming	  a	  stable	  covalent	  bond	  between	  compound	  and	  protein.	  
	  
Cysteine	   residues	   in	   proteins	   are	   often	   involved	   in	   disulphide	   bonds,	   covalent	   bonds	  
formed	  from	  two	  thiol	  groups.	  These	  occur	  between	  pairs	  of	  cysteines	  that	  are	   in	  close	  
proximity	   to	   each	   other,	   and	   can	   enhance	   the	   stability	   of	   the	   protein	   structure.	   A	   free	  
thiol	  group	  is	  however	  required	  for	  covalent	  binding	  with	  AHU3.	  Non-­‐disulphide	  cysteine	  
residues	  exposed	  on	  the	  surface	  of	  proteins	  are	  often	  found	  in	  the	  active	  sites	  of	  proteins	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due	  to	  their	  high	  reactivity,	  but	  are	  also	  found	  on	  protein	  surfaces	  in	  locations	  not	  directly	  
involved	  with	  protein	   function.	  The	   three	  cysteines	   in	  RecA	  are	   located	  at	  positions	  91,	  
117,	  and	  130.	  PyMol	  analysis	  of	   the	  RecA	  monomer	  structure	   in	  the	  biological	  hexamer	  
crystal	   of	   RecA	   (Xing	  &	  Bell,	   2004)	   suggests	   that	   only	   one	  of	   these	   residues,	   Cys117,	   is	  
predicted	   to	   be	   on	   the	   surface	   of	   the	   protein	   and	   therefore	   easily	   accessible	   to	   AHU3	  
(Figure	  5-­‐21	  A).	  This	  residue	  is	  not	  located	  in	  the	  ATP	  hydrolysis	  site	  of	  RecA,	  but	  is	  found	  
in	  one	  of	   the	   two	  RecA-­‐RecA	   interfaces.	  When	  the	  RecA	  monomer	   is	  bound	  to	  another	  
monomer,	  the	  cysteine	  residue	  in	  this	  interface	  is	  inaccessible	  to	  the	  surface	  (Figure	  5-­‐21	  
B).	  Labelling	  of	  surface	  accessible	  cysteines	   in	  the	  hexameric	  structure	  of	  RecA	  revealed	  
that	  Cys117	  is	  only	  surface-­‐located	  on	  the	  RecA	  monomer	  at	  one	  end	  of	  the	  filament,	  and	  
all	  other	  cysteines	  in	  the	  filament	  are	  inaccessible	  (Figure	  5-­‐21	  C).	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Figure	  5-­‐21:	  Cysteine	  residues	  are	  not	  solvent	  accessible	  in	  oligomeric	  RecA.	  The	  solvent	  accessible	  surface	  
of	  E.	  coli	  RecA	  as	  a	  monomer	  displaying	  both	  sides	  of	  the	  molecule	  (A),	  and	  two	  monomers	  coloured	  light	  
and	  dark	  grey	  (B)	  from	  the	  biological	  hexamer	  of	  RecA	  (Xing	  &	  Bell,	  2004;	  PDB	  id	  1XMS).	  Cysteine	  residues	  
are	  coloured	  red,	  and	  the	  monomer-­‐monomer	  interfaces	  (residues	  within	  4	  Å	  of	  each	  other)	  are	  coloured	  
green	  and	  cyan.	  Residues	  within	  4	  Å	  of	  the	  non-­‐hydrolysable	  analogue	  of	  ATP	  (MnAMP-­‐PNP,	  blue	  sticks)	  are	  
coloured	  orange.	  The	  solvent	  accessible	  surface	  of	  RecA	  as	  a	  hexamer	  with	  cysteine	  residues	  coloured	  red	  
(C)	   shows	   that	   the	   solvent	   accessible	   cysteine	   residues	   in	   the	   filament	   are	   inaccessible	   when	   RecA	  
undergoes	  oligomerisation,	  due	  to	  their	  position	  in	  the	  monomer-­‐monomer	  interface.	  
	  
The	  position	  of	  Cys117	  in	  oligomeric	  RecA	  supports	  our	  hypothesis	  that	  AHU3	  inhibits	  the	  
SOS	   response	   by	   preventing	   RecA	  monomers	   from	   binding	   to	   each	   other	   and	   forming	  
active	  filaments.	  By	  covalently	  attaching	  to	  cysteines	  present	  in	  the	  RecA-­‐RecA	  interface	  
on	  monomers	  or	  at	  the	  end	  of	  RecA	  oligomers,	  AHU3	  would	  inhibit	  filamentation	  of	  RecA.	  
However,	  further	  experiments	  are	  required	  to	  confirm	  that	  Cys117	  is	  the	  target	  of	  AHU3.	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One	   approach	   to	   determine	   the	   impact	   of	   AHU3	   binding	   to	   Cys117	   would	   be	   to	  
genetically	  modify	  this	  amino	  acid.	  However,	  as	  mutagenesis	  of	  Cys117	  could	  also	  render	  
RecA	   unable	   to	   oligomerise	   and	   therefore	   non-­‐functional	   due	   to	   modification	   of	   the	  
interface	   site,	   this	   is	   not	   a	   favoured	  method.	   In	   silico	   digest	   and	  mass	   spectrometry	   of	  
AHU3-­‐bound	  RecA	  would	   therefore	  be	  better	   suited	   for	   investigation	  of	  which	   cysteine	  
residues	  interact	  with	  RecA.	  
	  
5.11.3	  Antimicrobial	  properties	  of	  maleimide	  compounds	  
	  
Very	   few	   natural	   maleimides	   have	   been	   identified	   to	   date.	   Pencolide,	   a	   maleimide-­‐
containing	  metabolite	  produced	  by	  fungal	  Penicillium	  strains,	  is	  bacteriostatic	  against	  the	  
non-­‐pathogenic	  E.	  coli	  ATCC	  25922	  strain,	  as	  well	  as	  Streptococcus	  pyogenes,	  S.	  aureus,	  
and	   Salmonella	   Typhimurium,	   and	   exhibits	   fungicidal	   activity	   against	   Candida	   albicans	  
(Lucas	  et	   al.,	   2007).	   Another	   fungal	  maleimide	   compound	   is	   farinomalein,	   produced	  by	  
Isaria	  farinosa,	  and	  has	  shown	  potent	  activity	  against	  plant	  pathogen	  oomycetes	  (Putri	  et	  
al.,	  2014).	  	  
	  
A	   maleimide	   compound	   produced	   by	   bacteria	   has	   also	   been	   identified;	   showdomycin,	  
first	   isolated	   from	  Streptomyces	  showdoensis	   (Nishimura	  et	  al.,	  1964),	  which	  has	  a	  high	  
structural	   similarity	   to	   uridine	   and	   pseudouridine.	   This	   compound	   has	   shown	   activity	  
against	  both	  Gram-­‐positive	  and	  Gram-­‐negative	  strains,	  and	  was	  particularly	  active	  against	  
Streptococcus	  hemolyticus	  and	  S.	  pyogenes	  (Böttcher	  &	  Sieber,	  2010).	  To	  investigate	  the	  
target	   of	   showdomycin,	   Böttcher	   and	   Sieber	   (2010)	   synthesised	   a	   showdomycin	   probe	  
which	   identified	   13	   different	   enzymes	   from	   S.	   aureus,	   multidrug	   resistant	   S.	   aureus	  
(MRSA),	   Pseudomonas	   aeruginosa,	   and	   Listeria	   monocytogenes.	   These	   showdomycin-­‐
binding	  enzymes	  were	  subsequently	  placed	  into	  two	  major	  classes,	  oxidoreductases	  and	  
transferases,	   for	  which	  several	  substrates	   that	  contain	  nucleosides	  such	  as	  uridine	  have	  
been	  identified.	  Many	  targets	  contain	  a	  cysteine	  residue	  in	  their	  active	  site,	  which	  could	  
interact	   with	   the	   double	   bond	   of	   the	  maleimide	  moiety.	   All	   targets	   are	   enzymes	   with	  
important	  cellular	   functions	  or	   involved	   in	  virulence,	  growth	  and	  persistence,	  with	  roles	  
such	  as	  primary	  metabolism,	  nucleotide	  biosynthesis,	  cell	  wall	  biosynthesis	  and	  oxidative	  
stress	  resistance	  (Böttcher	  &	  Sieber,	  2010).	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As	   the	   electrophilic	  maleimide	  has	   the	  potential	   to	   interact	  with	   any	   available	   cysteine	  
residue,	  the	  authors	  hypothesised	  that	  the	  maleimide	  moiety	  in	  showdomycin	  is	  sterically	  
restricted	  by	  its	  ribose	  moiety,	  preventing	  it	  from	  non-­‐specific	  interactions.	  To	  test	  this,	  S.	  
aureus	   proteome	   lysates	   were	   incubated	   with	   either	   labelled	   maleimide	   or	   labelled	  
showdomycin	   and	   their	   targets	   identified;	   while	   maleimide	   bound	   to	   nearly	   all	   the	  
proteins	   present	   in	   the	   lysate,	   showdomycin	  was	   far	  more	   selective,	   only	   binding	   to	   a	  
very	   limited	  number	  of	   proteins.	   Showdomycin	  was	  particularly	   effective	   against	   the	  S.	  
aureus	  proteins	  MurA1	  and	  MurA2,	  important	  antibacterial	  targets	  due	  to	  their	  essential	  
roles	   in	   catalysing	   the	   first	   step	   of	   cell	   wall	   biosynthesis.	   A	   substrate	   inhibition	   assay	  
found	  that	  showdomycin	  inhibited	  MurA1	  with	  an	  IC50	  of	  10	  µM,	  while	  full	  saturation	  of	  
the	   majority	   of	   the	   other	   targets	   was	   achieved	   by	   50	   µM	   showdomycin	   (Böttcher	   &	  
Sieber,	  2010).	  
	  
A	   	   	   	  	  B	   	   	   	  	  C	  
	  
Figure	   5-­‐22:	   Structures	   of	   natural	  maleimides.	   The	   structures	   of	   pencolide	   from	  Penicillium	   species	   (A),	  
farinomalein	  from	  Isaria	  farinosa	  (B),	  and	  showdomycin	  from	  Streptomyces	  showdoensis	  (C).	  The	  maleimide	  
ring	  of	  each	  molecule	  is	  coloured	  black,	  with	  the	  rest	  of	  the	  compound	  in	  green.	  
	  
Like	  AHU3,	  these	  three	  natural	  maleimides	  are	  small	  compounds,	  allowing	  them	  to	  be	  cell	  
permeable	   and	   enter	   bacteria	   to	   inhibit	   cytosolic	   proteins.	   Unlike	   AHU3,	   however,	   all	  
three	   natural	   maleimides	   contain	   a	   substituted	   maleimide,	   with	   an	   additional	   group	  
adjacent	  to	  the	  double	  bond.	  This	  makes	  the	  maleimide	  moiety	  less	  reactive	  as	  it	  contains	  
only	  one	  electrophilic	  carbon,	  which	  may	  limit	  the	  number	  of	  cysteine-­‐containing	  proteins	  
to	   which	   it	   covalently	   binds.	   Further	   work	   to	   explore	   this	   speculation	   would	   involve	  
testing	  of	  a	  synthesised	  AHU3	  derivative	  with	  this	  maleimide	  modification	  for	  cytotoxicity	  
and	  RecA	  inhibition.	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5.11.4	  RecA	  as	  a	  target	  of	  anti-­‐virulence	  therapies	  
	  
RecA	  is	  a	  particularly	  appealing	  target	  for	  novel	  anti-­‐virulence	  therapies.	  Not	  only	  does	  it	  
allows	   bacteria	   to	   survive	   potentially	   lethal	   stress	   caused	   by	   DNA-­‐damaging	   agents	   by	  
mediating	   repair	   and	   homologous	   recombination,	   but	   late	   genes	   involved	   in	   the	   SOS	  
response	  promote	  genome-­‐wide	  mutations	  and	  therefore	  the	  potential	  development	  of	  
genetic	   mutations.	   Additionally,	   the	   production	   and	   release	   of	   phages	   by	   the	   SOS	  
response	  can	  lead	  to	  transmission	  of	  virulence	  factors	  across	  pathogenic	  bacterial	  strains.	  
In	   the	   case	   of	   EHEC,	   antibiotic	   treatment	   can	   result	   in	   further	   release	   of	   toxins	   via	  
activation	  of	  the	  SOS	  response,	  increasing	  the	  severity	  of	  disease.	  Therefore,	  therapeutic	  
treatments	  that	  prevent	  initiation	  of	  the	  bacterial	  SOS	  response	  could	  be	  valuable	  when	  
used	  in	  combination	  with	  conventional	  antibiotics.	  Such	  drugs	  could	  be	  used	  to	  limit	  the	  
harmful	  impact	  of	  antibiotic	  treatment	  such	  as	  Shiga	  toxin	  release,	  and	  prevent	  horizontal	  
transfer	  of	  resistance	  or	  virulence	  genes.	  RecA	  is	  also	  a	  highly	  conserved	  protein	  found	  in	  
all	  bacteria,	   raising	   the	  possibility	  of	  drugs	   that	   inhibit	   this	  protein	  being	  used	  against	  a	  
wide	  range	  of	  pathogenic	  bacteria.	  However,	  this	  also	  makes	  the	  effect	  of	  RecA	  inhibitors	  
very	  broad	  spectrum,	  and	   they	  are	  probably	  best	   considered	   for	  use	  alongside	   strongly	  
selective	   treatments,	   to	   minimise	   disruption	   of	   the	   microbiota.	   RecA	   inhibitors	   may	  
therefore	   have	   greatest	   potential	   when	   used	   to	   limit	   the	   harmful	   side-­‐effects	   of	   drug	  
treatment	   (such	  as	  Stx	   release),	  de	  novo	  development	  of	  antibiotic	   resistance	  genes,	  or	  
horizontal	  transfer	  of	  antibiotic	  resistance	  and	  phage-­‐borne	  virulence	  genes.	  
	  
Not	  all	   reported	  RecA	   inhibitors	  are	  suitable	  for	  therapeutic	  use,	  due	  to	  their	  molecular	  
size.	  ATPase	  and	  stx2:GFP	  assays	  performed	  by	  Dr.	  James	  Connolly,	  University	  of	  Glasgow,	  
have	   found	   that	   the	   reported	   RecA	   inhibitors	   Congo	   Red,	   Suramin	   and	   Bis-­‐ANS	   show	  
activity	   in	   the	   ATPase	   assay	   but	   are	   unable	   to	   inhibit	   stx2:GFP	   production	   (Dr.	   James	  
Connolly,	  personal	  communication).	  This	  is	   likely	  to	  reflect	  the	  large	  molecular	  sizes	  and	  
negative	   charges	   of	   these	   compounds	   (Wigle	   &	   Singleton,	   2007)	   which	   renders	   them	  
membrane-­‐impermeable.	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5.11.5	  The	  future	  of	  AHU3	  as	  an	  anti-­‐virulence	  therapy	  
	  
Although	   the	   AHU	   compounds	   have	   shown	   potential	   as	   anti-­‐virulence	   compounds,	   the	  
finding	  that	  they	  are	  cytotoxic	  to	  eukaryotic	  cells,	  even	  at	  very	  low	  concentrations,	  makes	  
them	  unsuitable	  in	  their	  current	  form	  for	  further	  testing	  in	  vivo.	  This	  cytotoxicity	  is	  likely	  
due	  to	  the	  maleimide	  moiety	  of	  the	  compound	  binding	  to	  available	  cysteine	  residues	  on	  
other	  essential	  eukaryotic	  proteins,	  which	  may	   limit	   the	  options	   for	  modification	  as	   the	  
maleimide	   is	  essential	   for	  RecA	  inhibition.	  There	  are,	  however,	  possible	  solutions	  to	  the	  
issue	  of	  cytotoxicity,	  such	  as	  steric	  hindrance	  by	  addition	  of	  compounds	  to	  the	  maleimide	  
to	  increase	  their	  selectivity,	  or	  modification	  of	  the	  maleimide	  group	  to	  reduce	  its	  toxicity	  
while	   retaining	   its	   RecA-­‐binding	   activity.	   While	   eukaryotic	   cells	   produce	   the	   RecA	  
homologue	  Rad51,	  also	  involved	  in	  DNA	  repair,	  the	  low	  protein	  sequence	  similarity	  (27%)	  
between	  Rad51	  and	  RecA	  makes	  it	  unlikely	  that	  Rad51	  is	  targeted	  in	  a	  similar	  fashion	  by	  
AHU3,	  although	  this	  would	  need	  to	  be	  confirmed	  experimentally.	  	  
	  
The	  work	  presented	  in	  this	  chapter	  has	  shown	  that	  the	  AHU	  compounds	  inhibit	  the	  SOS	  
response	   rather	   than	   specifically	   targeting	   Stx	   expression.	   While	   RecA	   and	   the	   SOS	  
response	  are	  appealing	   targets	   for	  novel	   therapeutic	   treatments	   in	   their	  own	   right,	   the	  
assays	  we	  have	  developed	  for	  exploring	  the	  effect	  of	  AHU3	  on	  Stx	  expression	  and	  phage	  
production	  are	  well-­‐suited	   for	  evaluating	  other	   compounds	   that	  have	  been	   reported	   to	  
inhibit	  EHEC	  Shiga	   toxin	  expression	  and	   release.	  Additionally,	   the	  availability	  of	   the	  Stx-­‐
producing	   C.	   rodentium	  mouse	  model	  means	   that	   ultimately	   in	   vivo	   assessment	  of	   Stx-­‐
targeting	  compounds	  can	  be	  carried	  out	  in	  a	  well-­‐characterised	  small	  animal	  model	  of	  the	  
disease.
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6.1	  Introduction	  
	  
Work	   undertaken	   for	   this	   thesis	   revealed	   that	   while	   the	   T3SS-­‐specific	   colonisation	   of	  
EHEC	  can	  be	  modeled	  by	  C.	  rodentium	   in	  mice,	   infection	  using	  the	  EHEC	  strain	  TUV93-­‐0	  
results	   in	   persistence	   that	   is	   not	   dependent	   on	   the	   T3SS	   specifically.	   This	   information	  
provides	   the	   opportunity	   to	   choose	   the	  most	   appropriate	  model	  when	   evaluating	   new	  
potential	  interventional	  strategies.	  In	  this	  chapter,	  work	  is	  described	  in	  which	  two	  models	  
were	  used,	   in	  collaboration	  with	  other	  researchers	  at	   the	  University	  of	  Glasgow,	  to	  test	  
several	   different	   compounds	   that	   have	   shown	   anti-­‐virulence	   activity	   in	   vitro.	   These	  
include	  three	  which	  target	  the	  T3SS	  and	  one	  with	  potential	  bactericidal	  activity.	  	  
	  
6.1.1	  Aims	  of	  this	  chapter	  
	  
• To	   investigate	   the	  effect	  of	  disulfiram,	  an	  acetaldehyde	  dehydrogenase	   inhibitor	  
currently	   licenced	   for	   treatment	   of	   alcoholism,	   on	   C.	   rodentium	   colonisation	   of	  
mice.	  We	  hypothesise	   that	   inhibition	  of	   the	  bacterial	  protein	  AdhE	  by	  disulfiram	  
will	   result	   in	   downregulation	   of	   the	   T3SS,	   leading	   to	   reduced	   A/E	   lesions	   and	   a	  
decrease	  in	  colonisation.	  
	  
• To	   test	   the	   effect	   of	   the	   RCZ20	   compound,	   a	   derivative	   of	   a	   salicylidene	  
acylhydrazide	   (SA),	   on	   C.	   rodentium	   colonisation	   of	   mice.	   This	   compound	   has	  
demonstrated	  downregulation	  of	  T3SS	  proteins	   in	  vitro,	  and	  we	  therefore	  aim	  to	  
explore	   any	   potential	   effect	   on	   colonisation	   in	   vivo	  when	  mice	   are	   treated	  with	  
this	  compound	  after	  infection.	  
	  
• To	   investigate	   the	  effect	  of	   the	  amino	  acid	  D-­‐serine,	  which	   causes	   repression	  of	  
T3SS	   genes	   in	   vitro,	   on	   colonisation	   of	   mice	   by	   C.	   rodentium	   when	   D-­‐serine	   is	  
provided	   in	   drinking	   water.	   We	   will	   also	   explore	   any	   effect	   D-­‐serine	   or	   C.	  
rodentium	  colonisation	  has	  on	  the	  mouse	  gut	  flora	  by	  short-­‐chain	  fatty	  acid	  (SCFA)	  
analysis	  of	  faecal	  matter.	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• To	  assess	   the	  effect	  of	  colicin	  E1,	  which	  has	   in	  vitro	  antibacterial	  activity	  against	  
LF82,	   on	   colonisation	   of	   mice	   by	   this	   strain.	   This	   colicin	   has	   also	   been	  
encapsulated,	  allowing	  it	  to	  avoid	  degradation	  in	  the	  stomach	  and	  be	  released	  in	  
the	  colon,	  to	  increase	  the	  likelihood	  of	  it	  reaching	  the	  site	  of	  LF82	  colonisation.	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6.2	  The	  effect	  of	  disulfiram	  on	  C.	  rodentium	  colonisation	  
	  
6.2.1	  Salicylidene	  acylhydrazides,	  AdhE	  and	  the	  T3SS	  
	  
The	   salicylidene	   acylhydrazides	   are	   a	   group	   of	   T3SS	   inhibitors	   effective	   against	   several	  
species	  of	  Gram-­‐negative	  pathogens,	  including	  EHEC,	  whose	  bacterial	  targets	  in	  O157:H7	  
have	   been	   identified	   by	   affinity	   pull-­‐down	   assay	   and	  mass	   spectrometry	   (Wang	   et	   al.,	  
2011).	  One	  of	   the	   nineteen	  putative	   targets	   of	   the	   SAs	  was	  AdhE,	   a	  metabolic	   enzyme	  
involved	  in	  the	  fermentation	  of	  glucose,	  leading	  to	  production	  of	  ethanol	  (Clark	  &	  Cronan,	  
1980).	   Evidence	   of	   a	   possible	   role	   in	   bacterial	   virulence	   for	   AdhE	   has	   also	   come	   from	  
studies	  suggesting	  a	  link	  between	  this	  protein	  and	  expression	  of	  the	  T3SS	  (Bäumler	  et	  al.,	  
1994;	   Abernathy	   et	   al.,	   2013),	   although	   the	   mechanism	   by	   which	   AdhE	   affects	   T3SS	  
expression	  was	  not	  elucidated.	  
	  
An	   O157:H7	   TUV93-­‐0	   adhE	   deletion	   mutant	   constructed	   by	   Beckham	   et	   al.	   (2014)	  
generated	   a	   strain	   with	   no	   growth	   defects	   in	   a	   range	   of	   minimal	   and	   rich	   media,	   but	  
which	   displayed	   a	   decrease	   in	   Type	   3	   secretion	   and	   an	   increased	   level	   of	   flagellar	  
expression,	   a	   phenotype	   similar	   to	   wild	   type	   E.	   coli	   treated	   with	   SA	   compounds.	   The	  
expression	   of	   T3SS	   and	   flagellar	   genes	   is	   cross-­‐regulated	   (Saini	   et	   al.,	   2010),	   and	   the	  
switch	  from	  expression	  of	  the	  flagella	  to	  expression	  of	  the	  T3SS	  is	  an	  important	  event	  in	  
bacterial	   infection.	  The	  flagella	  are	  required	  for	  motility,	  and	  mediate	   initial	  attachment	  
of	   bacteria	   to	   host	   cells	   (Mahajan	   et	   al.,	   2009).	   However,	   flagella	   are	   also	   potent	  
activators	  of	  the	  host	  immune	  system.	  The	  flagellar	  filament	  is	  composed	  of	  polymerised	  
flagellin	   protein,	   which	   stimulate	   the	   Toll-­‐like	   receptor	   5	   (TLR5)	   response,	   resulting	   in	  
production	  of	  inflammatory	  cytokines	  and	  thus	  leading	  to	  inflammation	  and	  infiltration	  of	  
immune	  cells	  (Hayashi	  et	  al.,	  2001).	  To	  avoid	  host	  immune	  responses,	  the	  downregulation	  
of	   flagellar	   genes	   occurs	   after	   initial	   host	   cell	   contact,	   and	   the	   T3SS	   is	   produced	   to	  
mediate	  intimate	  attachment	  (Iyoda	  et	  al.,	  2006).	  Previous	  analysis	  of	  the	  ΔadhE	  mutant	  
confirmed	   that	   it	   secreted	   more	   flagellin	   than	   the	   wild	   type,	   and	   produced	   a	  
correspondingly	  stronger	  TLR5	  response	  (Beckham	  et	  al.,	  2014).	  Furthermore,	  the	  flagella	  
of	  the	  ΔadhE	  mutant	  appeared	  to	  be	  non-­‐functional,	  reducing	  the	  motility	  of	  the	  mutant	  
and	  rendering	  it	  unable	  to	  interact	  with	  host	  cells	  to	  initiate	  contact.	  As	  AdhE	  is	  involved	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in	   the	   generation	   of	   acetaldehyde	   and	   ethanol,	   deletion	   of	   AdhE	   increases	   the	  
concentration	  of	  metabolites	  in	  this	  pathway.	  Two	  of	  these	  metabolites	  are	  acetate	  and	  
cAMP,	   both	   of	   which	   stimulate	   expression	   of	   flagellar	   genes.	   Accumulation	   of	   these	  
metabolites	  has	  been	  proposed	  by	  Beckham	  et	  al.	  (2014)	  to	  result	  in	  strong	  upregulation	  
of	  flagella	  that	  correspondingly	  reduces	  expression	  and	  secretion	  of	  T3SS	  proteins.	  It	  has	  
been	  suggested	  by	  Beckham	  et	  al.	  (2014)	  that	  the	  assembled	  flagella	  are	  unable	  to	  rotate	  
properly	  due	  to	  either	  misassembly	  of	  a	  key	  component	  or	  inappropriate	  acetylation	  of	  a	  
flagellar	  component	  (Figure	  6-­‐1).	  
	  
	  
Figure	  6-­‐1:	  Proposed	  model	  of	  adhE	  deletion	  in	  E.	  coli	  O157:H7.	  By	  switching	  from	  flagellar	  expression	  to	  
T3SS	   expression,	   E.	   coli	   are	   able	   to	   move	   from	   a	   motile	   state	   to	   a	   phenotype	   that	   allows	   intimate	  
attachment	  to	  host	  cells	  and	  formation	  of	  A/E	  lesions.	  The	  ΔadhE	  mutant	  is	  prevented	  from	  changing	  to	  the	  
T3SS-­‐expressing	  phenotype,	  and	  has	  reduced	  motility	  due	  to	  non-­‐functional	  flagella.	  Figure	  is	  adapted	  from	  
Beckham	  (2014,	  p.228).	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6.2.2	  Disulfiram	  as	  a	  potential	  inhibitor	  of	  AdhE	  
	  
AdhE	  is	  an	  attractive	  drug	  target	  as	   inhibition	  of	   its	  activity	  could	  result	   in	  a	  decrease	  in	  
the	   proteins	   associated	  with	   T3SS	   production,	   thus	   limiting	   adhesion	   and	   subsequently	  
colonisation	  of	  E.	  coli.	  An	  increase	  of	  flagellar	  production	  may	  also	  aid	  removal	  of	  bacteria	  
by	   the	   immune	   system	   due	   to	   the	   immunogenic	   nature	   of	   flagellin,	  while	   inhibition	   of	  
motility	  could	  further	  decrease	  bacterial	  pathogenicity	  (Beckham,	  2014).	  
	  
The	  drug	  disulfiram,	  which	  is	  licensed	  for	  use	  in	  the	  treatment	  of	  chronic	  alcoholism,	  has	  
been	  explored	  as	  a	  possible	   inhibitor	  of	  AdhE	   (Beckham,	  2014).	  Disulfiram	   functions	  by	  
inhibiting	  human	  acetaldehyde	  dehydrogenase,	  which	  is	  one	  of	  the	  functional	  domains	  of	  
AdhE	  (Membrillo-­‐Hernandez	  et	  al.,	  2000).	  Addition	  of	  disulfiram	  to	  TUV93-­‐0	  produced	  a	  
similar	  bacterial	  phenotype	  to	  that	  of	  the	  ΔadhE	  mutant:	  strongly	  repressed	  secretion	  of	  
the	   T3SS	   effectors	   EspA	   and	   Tir,	   an	   increase	   in	   FliC	   expression,	   reduced	   attachment	   to	  
host	   cells,	   and	   reduced	   bacterial	   motility	   (Beckham,	   2014).	   Disulfiram	   is	   a	   prodrug,	  
requiring	   enzymatic	   metabolism	   in	   vivo	   to	   produce	   multiple	   metabolites,	   including	  
intermediary	  metabolites,	  and	  thus	  evidence	  of	  direct	  binding	  to	  AdhE	  was	  not	  possible.	  	  
However,	   as	   disulfiram	   treatment	   significantly	   affected	  major	   virulence	   factors	   in	   vitro,	  
we	  were	  interested	  in	  determining	  its	  impact	  in	  vivo.	  	  
	  
6.2.3	  Effect	  of	  disulfiram	  on	  C.	  rodentium	  colonisation	  in	  vivo	  
	  
The	  lux-­‐marked	  C.	  rodentium	  mouse	  model	  was	  selected	  for	  in	  vivo	  testing	  of	  disulfiram,	  
as	  this	  strain	  is	  dependent	  on	  T3SS-­‐mediated	  attachment	  for	  successful	  colonisation	  and	  
thus	  any	  decrease	  in	  T3SS	  expression	  should	  be	  detected	  by	  reduced	  faecal	  shedding.	  The	  
use	  of	  this	  model	  was	  thought	  relevant	  as	  the	  AdhE	  of	  C.	  rodentium	  is	  highly	  homologous	  
to	  AdhE	  from	  E.	  coli	  O157:H7,	  sharing	  91%	  protein	  sequence	  identity.	  	  
	  
Three	  groups	  of	  mice,	  consisting	  of	  five	  animals	  each,	  were	  orally	   infected	  with	  109	  CFU	  
lux-­‐marked	  C.	   rodentium.	   The	   first	   group	  was	   given	  C.	   rodentium	   (untreated)	  while	   the	  
second	  group	  was	  given	  C.	  rodentium	  cultured	  in	  the	  presence	  of	  10	  μM	  disulfiram	  (pre-­‐
DSF),	  and	  the	  third	  group	  given	  C.	  rodentium	  cultured	  in	  the	  presence	  of	  10	  μM	  disulfiram	  
and	  treated	  daily	  with	  2	  mg	  disulfiram	  in	  100	  μl	  corn	  oil	  by	  oral	  gavage	  from	  one	  day	  after	  
6.	  RESULTS:	  In	  vivo	  testing	  of	  novel	  therapies	  
	   170	  
infection	  until	  the	  end	  of	  the	  experiment	  (pre-­‐/post-­‐DSF).	  Colonisation	  was	  followed	  for	  9	  
days	   after	   infection	   by	   faecal	   shedding	   and	   live	   imaging.	   All	   groups	   of	   mice	   displayed	  
strong	  levels	  of	  colonisation	  post	  infection	  (Figure	  6-­‐2	  A),	  and	  analysis	  of	  the	  three	  groups	  
by	   ANOVA	   identified	   a	   significant	   difference	   between	   the	  mean	   luminescence	   of	   each	  
group	   at	   6	   and	   8	   days	   after	   infection	   (Figure	   6-­‐2	   B).	   Post-­‐test	   Tukey’s	   Multiple	  
Comparison	   showed	   that	   on	   day	   6	   there	   was	   a	   significant	   difference	   between	   the	  
untreated	   and	   pre-­‐DSF	   group,	   and	   on	   day	   8	   the	   untreated	   group	   was	   significantly	  
different	   from	   both	   the	   pre-­‐DSF	   and	   the	   pre/post-­‐DSF	   group.	   However,	   no	   significant	  
difference	  in	  faecal	  shedding	  between	  the	  three	  groups	  was	  identified	  at	  any	  time	  point.	  
	  
A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	   	  	   	  	  
Figure	  6-­‐2:	  Effect	  of	  disulfiram	  on	  colonisation	  of	  BALB/c	  mice	  by	  lux-­‐marked	  C.	  rodentium.	  BALB/c	  mice	  
were	   infected	  with	   109	   CFU	   lux-­‐marked	  C.	   rodentium	   grown	   in	  DMEM	   (dark	   red),	   109	   CFU	   lux-­‐marked	  C.	  
rodentium	   grown	   in	   DMEM	   and	   10	   μM	   disulfiram	   (red),	   or	   109	   CFU	   lux-­‐marked	   C.	   rodentium	   grown	   in	  
DMEM	   and	   10	   μM	   disulfiram	   and	   2	  mg	   disulfiram	   in	   100	   μl	   corn	   oil	   administered	   to	  mice	   daily	   by	   oral	  
gavage	   (yellow).	   Each	  group	  of	  mice	   consisted	  of	   five	   animals,	   and	   colonisation	  was	  monitored	  by	   faecal	  
shedding	   (A)	   and	   luminescence	   (B).	   A	   significant	   difference	   between	   the	   mean	   luminescence	   of	   mouse	  
groups	  was	  present	  on	  day	  6	  (p=0.028)	  and	  day	  8	  (p=0.002).	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group,	  
and	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  Significant	  differences	  between	  the	  means	  
of	  groups	  are	  denoted	  by	  an	  asterisk	  (*=p<0.05;	  **=p<0.01)	  and	  were	  determined	  by	  one-­‐way	  ANOVA	  with	  
post-­‐test	  Tukey’s	  Multiple	  Comparison.	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6.3	  The	  effect	  of	  RCZ20	  on	  C.	  rodentium	  colonisation	  
	  
6.3.1	  RCZ20	  is	  a	  derivative	  of	  the	  salicylidene	  acylhydrazide	  ME0055	  
	  
ME0055,	  one	  of	  the	  most	  effective	  members	  of	  the	  SAs,	   is	  a	  highly	  efficient	   inhibitor	  of	  
O157:H7	  T3SS	   expression	   in	   vitro,	   reducing	   expression	  of	   Tir	   and	   EspD	   to	  undetectable	  
levels	  (Tree	  et	  al.,	  2009).	  Transcriptome	  analysis	  and	  reporter	  fusion	  assays	  by	  Tree	  et	  al.	  
(2009)	   of	   TUV93-­‐0	   grown	   in	   the	   presence	   of	   20	   μM	  ME0055	   revealed	   this	   compound	  
produces	  significant	  downregulation	  of	  genes	   in	  all	  5	  LEE	  operons,	   including	   that	  of	   the	  
gene	  encoding	  Ler,	  the	  master	  regulator	  of	  T3SS.	  ME0055	  treatment	  of	  TUV93-­‐0	  cultured	  
with	  HeLa	  cells	  also	  reduced	  the	  number	  of	  bacteria	  on	  the	  cell	  surface	  associated	  with	  
A/E	  lesions.	  
	  
Although	  ME0055	  has	  shown	  potential	  as	  an	  anti-­‐virulence	  compound	  in	  vitro,	  it	  has	  low	  
solubility	   and	   is	  hydrolysed	  by	  both	  basic	   and	  acidic	   conditions,	  undesirable	   traits	   for	   a	  
therapeutic	   drug.	   The	   compound	   was	   subsequently	   structurally	   modified	   by	   Riccardo	  
Zambelloni	   (University	  of	  Glasgow)	   to	  optimise	   its	   stability	  and	   improve	   its	  activity.	  The	  
most	   effective	   derivative	   of	  ME0055,	   RCZ20	   (Figure	   6-­‐3),	   had	  no	   influence	  on	  bacterial	  
growth	  and	  when	   incubated	  with	  growing	  cultures	  of	  TUV93-­‐0	  at	  a	  concentration	  of	  50	  
μM,	   significantly	   reduced	   expression	   and	   secretion	   of	   EspD	   (Riccardo	   Zambelloni,	  
personal	  communication).	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Figure	   6-­‐3:	   Structures	   of	  ME0055	   and	   RCZ20.	   Alkylation	  of	   the	   imine	  bond	   (red)	   of	  ME0055	   results	   in	   a	  
more	  stable	  compound	  that	  is	  not	  easily	  hydrolysed.	  
	  
6.	  RESULTS:	  In	  vivo	  testing	  of	  novel	  therapies	  
	   172	  
6.3.2	  Effect	  of	  RCZ20	  on	  C.	  rodentium	  colonisation	  in	  vivo	  
	  
To	  investigate	  the	  potential	  of	  RCZ20	  to	  reduce	  colonisation	  of	  EHEC	  in	  vivo,	  mice	  infected	  
with	   lux-­‐marked	  C.	  rodentium	  were	  treated	  with	  RCZ20	  both	  before	  and	  after	   infection,	  
and	  colonisation	  monitored	  by	  faecal	  shedding	  and	  luminescence.	  
	  
For	  delivery	  of	  the	  compound	  by	  oral	  gavage,	  RCZ20	  was	  solubilised	  in	  10%	  DMSO,	  40%	  
PEG400	  at	  a	  concentration	  of	  2.5	  mg/ml	  (5.88	  mM),	  and	  administered	   in	  a	  200	  μl	  dose.	  
This	  dose	  is	  similar	  to	  that	  of	  the	  T3SS	  inhibitor	  aurodox	  which	  protects	  mice	  from	  a	  lethal	  
dose	  of	  C.	  rodentium	  (Kimura	  et	  al.,	  2011).	  RCZ20	  was	  not	  tested	  at	  higher	  concentrations	  
as	  this	  would	  require	  addition	  of	   further	  DMSO	  to	  aid	  solubility,	  which	  was	  not	   feasible	  
given	  its	  toxicity	  in	  mice	  at	  high	  concentrations	  (Jacob	  &	  Rosenbaum,	  1966).	  
	  
Two	  groups	  of	  mice,	  consisting	  of	  5	  animals	  each,	  were	  orally	  dosed	  with	  either	  RCZ20	  in	  
DMSO/PEG400	   or	   mock-­‐treated	   with	   DMSO/PEG400	   buffer	   one	   day	   prior	   to	   infection	  
with	  109	  CFU	  lux-­‐marked	  C.	  rodentium.	  Both	  groups	  were	  also	  given	  daily	  doses	  of	  RCZ20	  
or	   the	   control	   after	   infection,	   for	   9	   days.	   No	   significant	   difference	   in	   either	   faecal	  
shedding	  or	   luminescence	  was	  observed	  between	  groups	  at	  any	  time	  point	  (Figure	  6-­‐4),	  
implying	  that	  oral	  administration	  of	  RCZ20	  has	  no	  significant	  effect	  on	  C.	  rodentium	  T3SS	  
expression	   in	   vivo.	   Mouse	   weight	   was	   also	   monitored	   throughout	   the	   post	   infection	  
period,	  with	  neither	  group	  displaying	  an	  obvious	  change	  in	  body	  weight	  (data	  not	  shown),	  
suggesting	  that	  RCZ20	  treatment	  and	  the	  solution	  it	  was	  administered	  in	  have	  no	  adverse	  
effect	  on	  mice.	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	  
Figure	  6-­‐4:	  Effect	  of	  RCZ20	  on	  colonisation	  of	  BALB/c	  mice	  by	  lux-­‐marked	  C.	  rodentium.	  BALB/c	  mice	  were	  
infected	   with	   109	   CFU	   lux-­‐marked	   C.	   rodentium	   and	   dosed	   once	   daily	   (including	   one	   pre-­‐infection	  
treatment)	  with	  either	  200	  μl	  10%	  DMSO,	  40%	  PEG400	  (red),	  or	  0.5	  mg	  RCZ20	   in	  200	  μl	  10%	  DMSO,	  40%	  
PEG400	  (orange).	  Each	  group	  of	  mice	  consisted	  of	  five	  animals,	  and	  colonisation	  was	  monitored	  by	  faecal	  
shedding	  (A)	  and	  luminescence	  (B).	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group,	  and	  standard	  deviation	  
from	   the	   mean	   displayed	   as	   error	   bars.	   No	   significant	   differences	   (p<0.05)	   between	   the	   means	   of	   the	  
treated	  and	  untreated	  groups,	  as	  determined	  by	  Student’s	  unpaired	  t-­‐test,	  were	  found	  for	  either	  strain	  at	  
any	  time	  point.	  
	  
6.4	   The	   effect	   of	   D-­‐serine	   on	   Citrobacter	   rodentium	   colonisation	   and	  
microflora	  short-­‐chain	  fatty	  acid	  (SCFA)	  production	  
	  
6.4.1	  D-­‐serine	  metabolism	  by	  E.	  coli	  
	  
The	  ability	  to	  compete	  with	  the	  gut	  microbiome	  and	  occupy	  a	  distinct	  niche	  is	  an	  essential	  
trait	   for	   colonisation	   by	   enteric	   bacterial	   pathogens.	   To	   achieve	   this,	   pathogenic	  E.	   coli	  
have	  evolved	  to	  utilise	  various	  host	  metabolites	  as	  their	  energy	  source,	  allowing	  them	  to	  
colonise	  specific	  sites	  within	  the	  gastrointestinal	  tract,	  with	  distinct	  pathotypes	  of	  E.	  coli	  
able	   to	  metabolise	  different	   types	  of	   sugars	   (Meador	  et	  al.,	  2014).	  As	  well	  as	   sugars,	  E.	  
coli	  can	  also	  make	  use	  of	  different	  chiral	  forms	  of	  amino	  acids;	  UPEC	  strains	  are	  capable	  
of	  using	  the	  D	  form	  of	  serine	  as	  a	  carbon	  source,	  a	  useful	  trait	  given	  that	  the	  urinary	  tract,	  
the	  site	  of	  UPEC	  colonisation,	  contains	  the	  highest	  concentration	  of	  D-­‐serine	  in	  the	  body	  
(Huang	  et	  al.,	  1998).	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Although	   both	   D-­‐	   and	   L-­‐amino	   acids	   are	   chemically	   identical	   and	   available	   to	   living	  
organisms	   in	   the	   environment,	   their	   abundance	   and	   role	   in	   biological	   systems	   is	   very	  
different.	   L-­‐amino	  acids	  are	   the	  predominant	   form	   in	   cells,	   as	  D-­‐amino	  acids	   cannot	  be	  
incorporated	  into	  proteins	  by	  ribosomes.	  However,	  D-­‐amino	  acids	  have	  functions	  in	  both	  
eukaryotic	  and	  prokaryotic	  cells,	  for	  example	  in	  proteins	  not	  synthesised	  by	  ribosomes,	  or	  
as	  signalling	  molecules	  in	  the	  brain	  (reviewed	  by	  Cava	  et	  al.,	  2011).	  In	  bacteria,	  D-­‐amino	  
acids	  are	  also	  present	  in	  the	  peptidoglycan	  layer	  of	  the	  bacterial	  cell	  wall	  (Vollmer	  et	  al.,	  
2008).	  
	  
The	   ability	   of	  UPEC	   to	  metabolise	  D-­‐serine	   is	   due	   to	   the	   presence	   of	   the	  dsdCXA	   locus	  
which	  encodes	  three	  proteins	  that	  transport	  and	  metabolise	  D-­‐serine,	  enabling	  UPEC	  to	  
utilise	  D-­‐serine	  as	  a	  sole	  carbon	  source	   (Anfora	  &	  Welch,	  2006).	  EHEC	  strains,	   including	  
O157:H7,	  carry	  a	  truncated	  dsdCXA	   locus	  that	  renders	  them	  unable	  to	  convert	  D-­‐serine,	  
as	  well	  as	  making	   them	  susceptible	   to	   the	  bacteriostatic	  consequences	  of	  high	  D-­‐serine	  
concentrations	  (Cosloy	  &	  McFall,	  1973).	  As	  it	  is	  likely	  that	  EHEC	  strains	  encounter	  D-­‐serine	  
both	   in	   the	   intestine	   and	   outside	   the	   host	   (such	   as	   in	   animal	   waste),	   this	   raises	   the	  
question	  of	  why	  EHEC	  strains	  have	  lost	  the	  ability	  to	  utilise	  this	  amino	  acid.	  
	  
6.4.2	  D-­‐serine	  represses	  the	  T3SS	  and	  induces	  the	  SOS	  response	  
	  
A	   recent	   study	  by	  Connolly	  et	  al.	   (2015)	  explored	   the	   role	  of	  D-­‐serine	   in	  modulation	  of	  
O157:H7	  virulence	  factors	  and	  showed	  that	  D-­‐serine	  causes	  repression	  of	  T3SS	  genes	  and	  
induces	   the	   SOS	   response.	   Transcriptome	   analysis	   of	   the	   TUV93-­‐0	   strain	   revealed	   that	  
treatment	   with	   1	   mM	   D-­‐serine	   led	   to	   downregulation	   of	   26	   out	   of	   the	   42	   LEE	   genes,	  
including	   those	   encoding	   both	   structural	   and	   effector	   T3SS	   proteins.	   Attachment	   of	  
TUV93-­‐0	   to	   epithelial	   cells	   in	   vitro	   was	   also	   significantly	   reduced	   by	   D-­‐serine,	   with	  
treatment	  resulting	  in	  lower	  numbers	  of	  infected	  host	  cells,	  as	  well	  as	  lower	  numbers	  of	  
bacteria	   on	   infected	   cells	   and	   fewer	   actin	   pedestals	   formed	   by	   attached	   bacteria.	   This	  
implied	   that	   two	   LEE-­‐associated	   transcriptional	   activators,	   IhfA	   and	   YhiF,	   which	   are	  
differentially	  expressed	  in	  response	  to	  D-­‐serine,	  regulated	  T3SS	  expression.	  Additionally,	  
intracellular	   accumulation	   of	   D-­‐serine	   led	   to	   upregulation	   of	   21	   genes	   from	   the	   SOS	  
regulon,	  including	  recA	  and	  lexA,	  and	  was	  independent	  of	  T3SS	  repression	  (Connolly	  et	  al.,	  
2015).	   The	   authors	   of	   this	   study	   also	   analysed	   the	   prevalence	   of	   dsdCXA	   and	   the	   LEE	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sequences	   in	   chromosomes	   of	   1,591	   E.	   coli	   strains,	   revealing	   that	   carriage	   of	   both	   is	  
extremely	  rare	  due	  to	  incompatibility	  between	  these	  two	  loci	  caused	  by	  a	  strong	  selective	  
pressure	  to	  lose	  dsdCX	  when	  bacteria	  obtain	  the	  LEE	  operon.	  	  
	  
6.4.3	  Effect	  of	  D-­‐serine	  on	  C.	  rodentium	  colonisation	  of	  mice	  
	  
Downregulation	   of	   the	   T3SS	   by	   D-­‐serine	   could	   potentially	   limit	   colonisation	   of	   those	  
strains	  of	  pathogenic	  E.	  coli	  that	  rely	  on	  this	  virulence	  factor	  for	  pathogenicity.	  To	  explore	  
the	  effect	  of	  D-­‐serine	  on	  bacterial	  colonisation	  in	  vivo,	  two	  groups	  of	  5	  BALB/c	  mice	  were	  
given	   either	   normal	   drinking	  water	   or	   drinking	  water	   supplemented	  with	   125	  μg/ml	  D-­‐
serine	  3	  days	  prior	   to	   infection	  with	  1010	  CFU	  C.	   rodentium.	   The	  mouse	  group	  given	  D-­‐
serine	   water	   was	   continued	   on	   this	   treatment	   throughout	   the	   post	   infection	   period.	  
Colonisation,	   as	   followed	   by	   faecal	   shedding	   and	   live	   imaging,	   was	   not	   significantly	  
different	   at	   any	   time	   point	   in	   the	   D-­‐serine-­‐treated	  mice	   compared	   to	   the	   non-­‐treated	  
mice	  (Figure	  6-­‐5),	  implying	  that	  D-­‐serine	  in	  drinking	  water	  has	  no	  discernible	  influence	  on	  
T3SS	  expression	  in	  vivo.	  
	  
A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	  
Figure	  6-­‐5:	  Effect	  of	  D-­‐serine	  treatment	  on	  colonisation	  of	  C.	  rodentium.	  Two	  groups	  of	  mice,	  consisting	  of	  
five	  mice	  in	  each	  group,	  were	  given	  normal	  drinking	  water	  (red)	  or	  drinking	  water	  containing	  125	  μg/ml	  D-­‐
serine	   (yellow)	  3	  days	  prior	   to	   infection.	  Mice	  were	   infected	  with	  1010	  CFU	   lux-­‐marked	  C.	   rodentium,	   and	  
colonisation	  monitored	  by	   faecal	   shedding	   (A)	  and	   luminescence	   (B).	  Data	  points	  shown	  are	   the	  mean	  of	  
each	   group,	   and	   standard	   deviation	   from	   the	   mean	   displayed	   as	   error	   bars.	   No	   significant	   differences	  
(p<0.05)	  between	  the	  means	  of	  the	  treated	  and	  untreated	  groups,	  as	  determined	  by	  Student’s	  unpaired	  t-­‐
test,	  were	  found	  for	  either	  strain	  at	  any	  time	  point.	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6.4.4	  Effect	  of	  D-­‐serine	  on	  SCFA	  production	  
	  
D-­‐serine’s	  potential	  influence	  on	  SCFA	  production	  by	  host	  microflora	  was	  also	  explored	  in	  
both	   infected	   and	   uninfected	   mice,	   as	   an	   indication	   of	   population	   changes	   within	   the	  
microflora.	   SCFAs	   are	   metabolites	   1-­‐6	   carbons	   in	   length,	   and	   are	   derived	   from	  
fermentation	  of	  non-­‐digestible	  polysaccharides	  by	  bacteria	   in	   the	  colon.	   In	  humans,	   the	  
most	  abundant	  SCFAs	  in	  the	  gut	  are	  acetate,	  propionate	  and	  butyrate.	  SCFAs	  are	  utilised	  
by	   the	   host	   organism	   for	   a	   wide	   range	   of	   purposes,	   including	   energy	   sources	   for	  
colonocytes,	   modulators	   of	   intracellular	   pH	   and	   cell	   volume,	   regulation	   of	   cell	  
proliferation	  and	  differentiation,	  and	  regulation	  of	  gene	  expression	  (Wong	  et	  al.,	  2006).	  
They	  also	  have	  anti-­‐inflammatory	  properties,	  inducing	  differentiation	  of	  regulatory	  T	  cells	  
that	   prevents	   proinflammatory	   responses	   by	   the	   host	   immune	   system	   in	   response	   to	  
intestinal	  commensal	  bacteria	  (Smith	  et	  al.,	  2013).	  
	  
To	   assess	   the	   effect	   of	   D-­‐serine	   on	   SCFA	   production	   in	   uninfected	   or	   C.	   rodentium-­‐
infected	  mice,	  4	  groups	  of	  mice	  consisting	  of	  5	  animals	  in	  each	  were	  given	  either	  normal	  
drinking	  water	  or	  drinking	  water	  supplemented	  with	  125	  μg/ml	  D-­‐serine	  3	  days	  prior	  to	  
infection.	   Two	   groups	   of	  mice,	   one	   on	   regular	  water	   and	   one	   on	  D-­‐serine	  water,	  were	  
infected	  with	  1010	  CFU	  C.	  rodentium	  (the	  same	  two	  groups	  of	  mice	  used	  in	  the	  experiment	  
in	   Chapter	   6.5.3),	   and	   the	   other	   two	   groups	   of	   mice	   given	   a	   mock	   infection	   of	   PBS.	  
Individual	   mouse	   weights	   and	   food	   weight	   consumed	   by	   groups	   was	   measured	   daily,	  
showing	  no	  difference	  between	  groups	  (data	  not	  shown).	  Faecal	  samples	  were	  obtained	  
from	   animals	   at	   0,	   3,	   7	   and	   14	   days	   after	   infection	   (faecal	   samples	   from	   day	   0	   were	  
collected	   prior	   to	   infection),	   and	   faecal	   water	   analysed	   for	   SCFA	   composition	   by	   gas	  
chromatography	   by	   Michael	   Logan	   (University	   of	   Glasgow).	   Total	   levels	   of	   SCFA	  
production	  showed	  an	  eventual	  decline	  over	  the	  post	  infection	  period	  in	  all	  four	  groups,	  
and	  no	  significant	  difference	  between	  groups	  was	  observed	  at	  any	  time	  point	  (Figure	  6-­‐6).	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Figure	  6-­‐6:	   SCFA	  production	   in	  mice	   treated	  with	  D-­‐serine	  and	   infected	  with	  C.	   rodentium.	  Total	   faecal	  
SCFA	   was	   analysed	   from	   faecal	   water	   by	   gas	   chromatography,	   from	   mice	   either	   uninfected	   (dark	   red,	  
orange),	   or	   infected	  with	   1010	   CFU	  C.	   rodentium	   (red,	   yellow),	   and	   provided	  with	   either	   regular	   drinking	  
water	   (dark	   red,	   red)	   or	   125	   μg/ml	   D-­‐serine-­‐supplemented	   water	   (orange,	   yellow).	   Each	   group	   of	   mice	  
consisted	  of	  five	  animals.	  Data	  represent	  the	  average	  SCFA	  concentration	  in	  μM/mg	  faecal	  matter	  of	  each	  
group,	   with	   standard	   deviation	   displayed	   as	   error	   bars.	   No	   significant	   differences	   (p<0.05)	   between	   the	  
means	  of	  the	  groups,	  as	  determined	  by	  ANOVA,	  were	  found	  for	  either	  strain	  at	  any	  time	  point.	  
	  
To	   determine	   any	   possible	   difference	   in	   the	   SCFA	   profile	   between	   groups	   of	  mice,	   the	  
relative	   percentages	   of	   the	   three	   major	   SCFAs	   detected,	   acetate,	   propionate	   and	  
butyrate,	  were	   analysed.	   Acetate	  was	   the	   predominant	   SCFA	   from	   all	   samples,	   ranging	  
from	   75.8-­‐98.9%	   throughout	   the	   post	   infection	   period,	   while	   propionate	   and	   butyrate	  
were	   0-­‐10%	   of	   total	   SCFA	   detected.	   However,	   a	   significant	   difference	   in	   relative	  
percentages	   between	   groups	   was	   only	   found	   for	   acetate	   and	   butyrate	   faecal	   samples	  
taken	   at	   day	   0,	   and	   not	   at	   any	   other	   time	   point	   (Figure	   6-­‐7).	   Although	   some	   groups	  
appeared	  to	  show	  large	  variation	  in	  relative	  percentage	  at	  certain	  time	  points,	  such	  as	  the	  
C.	  rodentium	  +	  D-­‐serine	  group	  on	  day	  0,	  this	  was	  often	  due	  to	  an	  individual	  mouse	  in	  the	  
group.	   Therefore,	   we	   concluded	   that	   neither	   D-­‐serine	   nor	   C.	   rodentium	   are	   able	   to	  
significantly	  alter	   the	  production	  of	   these	  SCFAs	  by	   intestinal	  bacteria	   to	  an	  extent	   that	  
any	  changes	  can	  be	  detected	  from	  faecal	  matter.	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A	   Acetate	   	   	   	   B	   Propionate	  
	  
C	   Butyrate	  
	   	  	  
Figure	   6-­‐7:	   Effect	   of	   D-­‐serine	   treatment	   and	   C.	   rodentium	   infection	   on	   faecal	   SCFA	   composition.	   The	  
amount	  of	  acetate	   (A),	  propionate	   (B)	   and	  butyrate	   (C)	   as	  a	  percentage	  of	   total	  SCFA	  was	  analysed	   from	  
faecal	  water	  by	  gas	  chromatography,	  from	  mice	  either	  uninfected	  (dark	  red,	  orange),	  or	  infected	  with	  1010	  
CFU	  C.	  rodentium	  (red,	  yellow),	  and	  provided	  with	  either	  regular	  drinking	  water	  (dark	  red,	  red)	  or	  125	  μg/ml	  
D-­‐serine-­‐supplemented	   water	   (orange,	   yellow).	   Each	   group	   of	   mice	   consisted	   of	   five	   animals.	   Boxes	  
represent	   the	   standard	  deviation	  of	  each	  group,	  and	  whiskers	   represent	   the	   range	  of	  data	  values	   in	   that	  
group.	   SCFA	   analysis	   was	   performed	   by	   Michael	   Logan	   (University	   of	   Glasgow).	   Significant	   differences	  
between	  the	  means	  of	  groups	  are	  denoted	  by	  an	  asterisk	  (*=p<0.05;	  **=p<0.01)	  and	  were	  determined	  by	  
one-­‐way	  ANOVA	  with	  post-­‐test	  Tukey’s	  Multiple	  Comparison.	  
	  
6.4.5	  D-­‐serine	  concentration	  in	  urine	  is	  higher	  in	  mice	  treated	  with	  D-­‐serine	  in	  drinking	  
water	  	  
	  
Although	  D-­‐serine	  was	  supplied	  to	  mice	   in	  drinking	  water,	   this	   is	  not	  the	  only	  source	  of	  
serine	  for	  them,	  as	  both	  forms	  of	  serine	  can	  be	  obtained	  from	  diet	  or	  synthesised	  by	  mice	  
themselves	   (Foltyn	  et	  al.,	   2010).	   To	  examine	   the	   impact	  providing	  additional	  dietary	  D-­‐
serine	  had	  on	  the	  amount	  of	  D-­‐serine	   in	  the	  urine,	  the	  relative	   levels	  of	  L-­‐	  and	  D-­‐serine	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from	   mice	   treated	   with	   and	   without	   D-­‐serine	   were	   measured	   (Glasgow	   Polyomics,	  
University	   of	   Glasgow).	  Mice	   that	   had	   been	   given	   normal	   drinking	  water	   had	   very	   low	  
levels	  of	  D-­‐serine	  in	  their	  urine	  (3.93%	  average),	  with	  no	  D-­‐serine	  detected	  in	  7	  out	  of	  the	  
11	  samples	  analysed.	  Mice	  treated	  with	  D-­‐serine	  showed	  significantly	  higher	  levels	  of	  D-­‐
serine	  (25.75%	  average)	  (Figure	  6-­‐8).	  
	  
	   	  	   	   	  
Figure	  6-­‐8:	  D-­‐serine	  treatment	  increases	  the	  relative	  abundance	  of	  urinary	  D-­‐serine.	  Urine	  was	  collected	  
from	  mice	  given	  drinking	  water	  with	  or	  without	  125	  μg/ml	  D-­‐serine	  supplementation.	  Data	  represents	  the	  
average	   percentages	   of	   L-­‐	   (dark	   red)	   and	   D-­‐serine	   (orange)	   present	   in	   11	   samples	   from	   each	  
treated/untreated	  group	   taken	  3,	   6,	   10	  and	  17	  days	   after	  D-­‐serine	   treatment	  was	   started,	  with	   standard	  
deviation	  displayed	  as	  error	  bars.	  The	  increase	  in	  D-­‐serine	  resulted	  in	  a	  significant	  increase	  from	  an	  average	  
of	  3.93%	  to	  an	  average	  of	  25.75%	  (p=0.0204,	  20	  degrees	  of	  freedom,	  t=2.518),	  determined	  using	  Student’s	  
unpaired	  t-­‐test.	  
	  
6.5	  The	  effect	  of	  colicin	  E1	  on	  LF82	  colonisation	  
	  
6.5.1	  Colicin	  E1	  is	  an	  antimicrobial	  against	  AIEC	  LF82	  
	  
One	   class	   of	   antimicrobial	   agents	   that	   have	   shown	   promise	   as	   potential	   interventional	  
therapies	   are	   the	   bacteriocins.	   These	   are	   antimicrobial	   peptides	   produced	   by	   bacteria	  
that	  enable	  the	  bacteriocin-­‐producing	  strain	  to	  compete	  effectively	  within	  an	  established	  
microbial	   niche	   through	   killing	   of	   closely	   related,	   competitive	   neighbouring	   strains.	  
Colicins,	  bacteriocins	  produced	  by	  E.	  coli	  and	  encoded	  on	  colicinogenic	  plasmids,	  are	  high	  
molecular	   weight	   proteins	   that	   specifically	   target	   other	   E.	   coli	   strains.	   Their	   activity	   is	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without	  significant	  modification	  to	  the	  healthy	  microbiota	  (Rea	  et	  al.,	  2011;	  Smith	  et	  al.,	  
2012).	  Recent	  work	  by	  Carla	  Brown	  (University	  of	  Glasgow)	  has	  explored	  the	  efficacy	  of	  
colicins	  against	  AIEC	  infection	  associated	  with	  Crohn’s	  disease.	  
	  
Colicin	  E1,	  which	  kills	  bacteria	  by	  forming	  a	  pore	  and	  depolarising	  the	   inner	  membrane,	  
has	  in	  vitro	  antibacterial	  activity	  against	  the	  AIEC	  LF82	  strain.	  This	  colicin	  was	  also	  found	  
to	   be	   effective	   against	   LF82	   both	   when	   bound	   to	   intestinal	   epithelial	   cells	   or	   located	  
within	  macrophages	   (Brown	   et	   al.,	   2015).	   To	   determine	   the	   potential	   of	   this	   colicin	   in	  
vivo,	  we	  considered	  its	  use	  in	  reduction	  of	  LF82	  persistence	  in	  the	  streptomycin-­‐treated	  
mouse	   model.	   Before	   in	   vivo	   testing,	   colicin	   E1	   was	   encapsulated	   to	   protect	   it	   from	  
degradation	  in	  the	  stomach	  and	  duodenum.	  Pectin	  was	  used	  as	  a	  delivery	  system	  for	  the	  
colicin	  as	  it	  is	  a	  natural	  gastroresistant	  polysaccharide	  selectively	  digested	  by	  microflora	  in	  
the	  colon,	  and	   is	   considered	  an	   ideal	   carrier	   for	   colon-­‐specific	   treatments	   (Wong	  et	  al.,	  
2011).	  Purified	  colicin	  E1	  was	  encapsulated	  in	  pectin/zein	  hydrogel,	  forming	  small	  beads	  
containing	  approximately	  700	  ng	  colicin	  per	  bead,	  and	  these	  beads	  retained	  the	  cytotoxic	  
activity	  of	  the	  colicin	  (Brown,	  2015).	  
	  
6.5.2	  Effect	  of	  encapsulated	  colicin	  E1	  on	  LF82	  colonisation	  in	  vivo	  
	  
Two	   groups	   of	   ICR	   mice,	   consisting	   of	   6	   animals	   in	   each,	   were	   treated	   with	   5	   g/L	  
streptomycin	   in	   their	   drinking	  water	   3	   days	   prior	   to	   infection	  with	   109	   CFU	   lux-­‐marked	  
StrR	  LF82.	  One	  group	  was	  treated	  with	  daily	  with	  10	  colicin	  beads	  per	  mouse,	  a	  total	  of	  
approximately	   7	   μg	   colicin	   E1/mouse,	   while	   the	   other	   was	   given	   10	   control	   beads	   per	  
mouse.	   Administration	   of	   colicin	   E1	   or	   control	   beads	   continued	   for	   seven	   days	   after	  
infection,	   and	   colonisation	   was	   monitored	   by	   faecal	   shedding	   and	   live	   imaging	   until	   9	  
days	   after	   infection.	   Although	   both	   faecal	   shedding	   and	   luminescence	   of	   LF82	   by	   the	  
colicin-­‐treated	   mice	   appeared	   slightly	   lower	   than	   that	   of	   the	   non-­‐treated	   group	  
throughout	  the	  post	  infection	  period,	  this	  difference	  was	  not	  significant	  at	  any	  time	  point	  
(Figure	  6-­‐9).	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	   	  
Figure	   6-­‐9:	   Effect	   of	   colicin	   E1	   treatment	   on	   LF82	   colonisation.	   BALB/c	   mice	   pre-­‐treated	   with	   5	   g/L	  
streptomycin	   in	   drinking	  water	   for	   three	  days	  were	   infected	  with	   109	  CFU	   lux-­‐marked	   StrR	   LF82.	  Animals	  
were	  dosed	  daily	  with	  either	  control	  beads	  (dark	  red)	  or	  colicin	  beads	  containing	  a	  total	  of	  ~7	  μg	  colicin	  E1	  
(red)	   for	   the	   first	   7	   days	   after	   infection.	   Each	   group	   of	   mice	   consisted	   of	   six	   animals.	   Streptomycin	  
treatment	   was	   continued	   throughout	   the	   post	   infection	   period.	   Colonisation	   was	   monitored	   by	   faecal	  
shedding	  (A)	  and	  luminescence	  (B).	  Data	  points	  shown	  are	  the	  mean	  of	  each	  group,	  and	  standard	  deviation	  
from	   the	   mean	   displayed	   as	   error	   bars.	   No	   significant	   differences	   (p<0.05)	   between	   the	   means	   of	   the	  
treated	  and	  untreated	  groups,	  as	  determined	  by	  Student’s	  unpaired	  t-­‐test,	  were	  found	  for	  either	  strain	  at	  
any	  time	  point.	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6.6	  Discussion	  
	  
6.6.1	  Disulfiram	  does	  not	  reduce	  Citrobacter	  rodentium	  colonisation	  of	  mice	  
	  
Prior	   treatment	   of	   C.	   rodentium	   with	   the	   acetaldehyde	   dehydrogenase	   inhibitor	  
disulfiram	  before	   infection	   resulted	   in	   slightly	   lower	   levels	   of	   colonisation	   compared	   to	  
those	   animals	   given	   disulfiram	   daily.	   However,	   colonisation	   of	   mice	   treated	   daily	   with	  
disulfiram	  was	  similar	  to	  that	  of	  the	  untreated	  group,	  and	  only	  two	  time	  points	  reported	  a	  
significant	   difference	   in	   bacterial	   luminescence	   between	   the	   untreated	   and	   treated	  
groups.	  While	  it	  is	  possible	  that	  the	  significant	  decrease	  in	  bacterial	  colonisation	  seen	  at	  
days	  6	  and	  8	  is	  a	  result	  of	  lower	  initial	  T3SS-­‐mediated	  attachment	  of	  treated	  bacteria	  to	  
host	   tissues,	   the	   lack	   of	   a	   significant	   difference	   in	   colonisation	   at	   other	   time	   points	  	  
suggests	   that	  neither	  disulfiram	  treatment	  of	  bacteria	  before	  nor	  after	   infection	  have	  a	  
major	  influence	  on	  bacterial	  colonisation.	  
	  
This	  finding	  probably	  reflects	  the	  treatment	  of	  an	  intestinal	  bacterial	  infection	  with	  a	  drug	  
that	  is	  rapidly	  absorbed	  and	  metabolised	  by	  the	  body.	  Post	  ingestion,	  disulfiram	  is	  rapidly	  
absorbed	   from	   the	   gastrointestinal	   tract	   and	   reduced	   to	   diethyldithiocarbamate.	   This	  
compound	   is	   then	   converted	   by	   hepatic	   thiol	   methyltranferases	   to	   multiple	   different	  
metabolites	  that	  are	  distributed	  in	  different	  body	  tissues.	  These	  metabolites	  are	  excreted	  
via	  the	  kidneys,	  lungs,	  and	  faeces,	  with	  5-­‐20%	  of	  an	  oral	  dose	  excreted	  in	  the	  faeces	  alone	  
(reviewed	  by	   Johansson,	   1992).	   It	   is	   therefore	   likely	   that	   disulfiram	  and	   its	  metabolites	  
reach	   the	   site	   of	  C.	   rodentium	   colonisation	   in	   the	   caecum	  and	   lower	   colon	   at	   very	   low	  
concentrations.	  
	  
Although	  disulfiram	  is	  converted	  into	  its	  active	  metabolites	  by	  human	  methyltransferases,	  
bacteria	   are	   also	   believed	   to	   be	   capable	   of	   metabolising	   disulfiram.	   The	   effect	   of	  
disulfiram	   on	   T3SS	   and	   flagellar	   expression,	   and	   experimentally	   linked	   to	   inhibition	   of	  
AdhE,	   strongly	   suggests	   that	   E.	   coli	   can	   convert	   the	   prodrug	   into	   the	  metabolites	   that	  
have	   binding	   activity.	   Disulfiram	   also	   displays	   antitubercular	   activity	   against	   a	   large	  
number	   of	   Mycobacterium	   tuberculosis	   clinical	   isolates,	   and	   is	   capable	   of	   killing	   M.	  
tuberculosis	   both	   within	   macrophages	   and	   in	   a	   mouse	   model	   of	   chronic	   tuberculosis	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(Horita	  et	  al.,	  2012).	  Additionally,	  while	   it	  has	  weak	  antibiotic	  activity	  against	  S.	  aureus,	  
disulfiram	   produces	   a	   strongly	   synergistic	   inhibition	   of	   bacterial	   growth	   when	  
administered	   alongside	   the	   antibiotic	   minocycline	   (Ejim	   et	   al.,	   2011).	   Therefore,	  
disulfiram	   does	   not	   require	   metabolism	   by	   human	   enzymes	   in	   order	   to	   inhibit	   AdhE,	  
although	  delivery	  to	  the	  site	  of	   infection	  still	   remains	  an	   issue.	  Although	  repurposing	  of	  
disulfiram	   is	  appealing	  as	   it	   is	  already	   licenced	   for	  human	  use,	   the	  difficulty	  of	   its	   rapid	  
absorption	  and	  distribution	  throughout	  the	  body	  means	  that	  novel	  AdhE	   inhibitors	  may	  
be	  better	  suited	  for	  an	  anti-­‐virulence	  strategy	  that	  targets	  this	  protein.	  
	  
Although	   C.	   rodentium	   is	   dependent	   on	   the	   T3SS	   for	   colonisation,	   making	   it	   a	   good	  
surrogate	  for	  EHEC	  mouse	  infections,	  this	  model	  is	  limited	  by	  the	  inability	  of	  C.	  rodentium	  
to	   express	   functional	   flagella,	  which	   renders	   the	   bacteria	   non-­‐motile.	   A	   lack	   of	   flagella	  
may	  also	  limit	  the	  TLR5	  response,	  and	  thus	  the	  influence	  of	  the	  host	  immune	  system	  on	  
bacterial	   clearance	   may	   be	   lower	   in	   the	   C.	   rodentium	   model	   than	   it	   would	   be	   for	  
O157:H7.	   However,	   our	   discovery	   that	   the	   T3SS	   has	   no	   perceptible	   effect	   on	   E.	   coli	  
colonisation	  in	  mice	  means	  that	  the	  E.	  coli	  mouse	  model	  cannot	  be	  used	  for	  assessment	  
of	  disulfiram’s	  effect	   in	  vivo.	   The	   infant	   rabbit	  O157:H7	  model	  may	   therefore	  be	  better	  
suited	   for	  exploration	  of	   the	  effect	  of	  potential	  AdhE	   inhibitors	  on	  both	  T3SS	   inhibition	  
and	  flagella-­‐mediated	  stimulation	  of	  the	  host	  immune	  response.	  	  
	  
Another	  point	  of	  consideration	   is	   the	   large	   infectious	  dose	  of	  C.	   rodentium	  used,	  which	  
may	   result	   in	   colonisation	   levels	   that	   are	   too	   high	   to	   be	   significantly	   affected	   by	   the	  
amount	  of	  disulfiram	  that	  reach	  the	  site	  of	  infection.	  Mice	  were	  treated	  with	  109	  CFU	  C.	  
rodentium	  in	  order	  to	  produce	  high	  and	  easily	  detected	  colonisation,	  however	  this	  is	  not	  
representative	  of	  natural	  infection	  of	  mice.	  Transmission	  of	  C.	  rodentium	  occurs	  between	  
infected	  and	  uninfected	  littermates	  via	  coprophagy,	  and	  faecally-­‐shed	  bacteria	  are	  much	  
more	  infectious	  than	  those	  grown	  in	  culture	  (Wiles	  et	  al.,	  2005).	  As	  inhibition	  of	  AdhE	  is	  
hypothesised	   to	   inhibit	   the	   switch	   from	   flagellar	   to	   T3SS	   expression	   and	   thus	   prevent	  
initial	   attachment	   of	   bacteria	   to	   host	   tissues,	   AdhE	   inhibitors	   will	   potentially	   function	  
more	  effectively	  as	  prophylactic	  treatments	  for	  at-­‐risk	  individuals	  rather	  than	  therapeutic	  
treatment	   of	   infected	   patients.	   Therefore,	   a	   mouse	   model	   that	   mixes	   C.	   rodentium-­‐
infected	  mice	  with	  uninfected	  mice	  that	  are	  treated	  with	  AdhE	  inhibitors	  may	  be	  a	  more	  
suitable	  model	  of	  infection	  for	  assessing	  this	  type	  of	  anti-­‐virulence	  compound.	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6.6.2	  The	  RCZ20	  compound	  does	  not	  reduce	  colonisation	  in	  vivo	  
	  
Treatment	   of	   mice	   with	   RCZ20	   before	   and	   after	   infection	   with	   C.	   rodentium	   had	   no	  
significant	  effect	  on	  bacterial	  colonisation.	  While	   it	   is	  possible	  that	  RCZ20	  has	   limited	  or	  
no	   influence	  on	  T3SS	  modulation	   in	  vivo,	   the	  therapeutic	  concentration	  of	  RCZ20	  at	  the	  
site	  of	  C.	   rodentium	   infection	  remains	  unknown.	  Mice	  were	  treated	  with	  200	  μl	  of	  5.88	  
mM	   RCZ20	   daily,	   a	   concentration	   much	   higher	   than	   that	   required	   to	   see	   significant	  
downregulation	  of	  T3SS	  genes	  and	  decrease	  in	  T3	  effector	  secretion	   in	  vitro	  (20-­‐50	  μM).	  
RCZ20	  may,	   however,	   be	  metabolised	   before	   it	   reaches	   the	   intestine.	  Use	   of	   a	   labeled	  
compound	  in	  future	  in	  vivo	  experiments	  would	  allow	  the	  compound	  to	  be	  tracked	  within	  
the	   mouse	   after	   administration,	   and	   the	   relative	   RCZ20	   abundance	   in	   the	   colon	  
estimated.	  
	  
6.6.3	  D-­‐serine	  does	  not	  affect	  C.	  rodentium	  colonisation	  or	  SCFA	  metabolism	  by	  the	  gut	  
microflora	  
	  
Supplementation	   of	   drinking	   water	   with	   125	   μg/ml	   D-­‐serine	   resulted	   in	   significantly	  
higher	  amounts	  of	  D-­‐serine	  in	  the	  urine	  of	  mice	  compared	  to	  untreated	  control	  animals.	  	  
This	  led	  us	  to	  conclude	  that	  using	  this	  approach,	  D-­‐serine	  levels	  in	  mice	  can	  be	  increased	  
through	   diet.	   Although	  D-­‐serine	  modulates	   expression	   of	   the	   T3SS	   in	   vitro,	   resulting	   in	  
decreased	  bacterial	  adhesion	  to	  host	  cells,	  mice	  infected	  with	  C.	  rodentium	  and	  supplied	  
with	   D-­‐serine	   in	   drinking	  water	   showed	   no	   discernible	   difference	   in	   colonisation	  when	  
compared	   to	   infected	   mice	   given	   normal	   drinking	   water.	   This	   suggests	   that	   either	   D-­‐
serine	  is	  unable	  to	  modulate	  the	  T3SS	  in	  vivo,	  or	  that	  the	  concentration	  of	  D-­‐serine	  in	  the	  
intestine	   of	   C.	   rodentium-­‐infected	   mice	   is	   simply	   not	   high	   enough	   to	   influence	   T3SS	  
expression.	  Although	  the	  concentration	  of	  D-­‐serine	  in	  the	  drinking	  water	  (1.19	  mM)	  was	  
similar	  to	  that	  used	  to	  reduce	  T3SS	  expression	   in	  vitro	   (1	  mM)	  (Connolly	  et	  al.,	  2015),	   it	  
might	  not	  reflect	   the	  concentration	  of	  D-­‐serine	  at	   the	  site	  of	  C.	   rodentium	   colonisation.	  
While	   the	   average	   amount	   of	   D-­‐serine	   in	   the	   urine	   of	   treated	  mice	   was	   found	   to	   the	  
higher	  (approximately	  25%	  of	  total	  D-­‐serine),	  the	  proportion	  of	  D-­‐serine	  in	  the	  intestine	  is	  
likely	   to	   be	   lower	   than	   that	   observed	   in	   urine.	   Additionally,	   although	   C.	   rodentium	  
expresses	  a	  highly	   similar	  T3SS	   to	  O157:H7,	   it	  differs	   from	  O157:H7	  by	  carriage	  of	  both	  
the	   LEE	   and	   the	   dsdCXA	   locus	   (Petty	   et	   al.,	   2010),	   and	   thus	   this	   strain’s	   ability	   to	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metabolise	   D-­‐serine	   may	   prevent	   intracellular	   accumulation	   of	   D-­‐serine	   at	   sufficient	  
concentrations	  to	  influence	  T3SS	  expression.	  
	  
The	   second	   aim	  of	   our	  D-­‐serine	   and	  C.	   rodentium	   experiment	  was	   to	   assess	   the	   effect	  
both	   had	   on	   the	   production	   of	   SCFAs	   produced	   by	   intestinal	   bacteria,	   as	   these	   are	  
metabolites	   important	   to	   colonic	   health.	   Interestingly,	   treatment	   of	  mice	  with	  D-­‐serine	  
did	  not	  result	  in	  significant	  changes	  to	  either	  the	  total	  amount	  of	  SCFAs	  produced	  or	  the	  
relative	  abundances	  of	  the	  three	  most	  prevalent	  SCFAs.	  The	  lack	  of	  changes	  in	  the	  SCFA	  
profile	  may	  be	  because	  additional	  D-­‐serine	   in	  the	   intestine	  has	  no	  noticeable	   impact	  on	  
the	   microbiota	   in	   the	   context	   of	   SCFA	   metabolism,	   or	   is	   due	   to	   limited	   D-­‐serine	  
concentration	  in	  the	  gastrointestinal	  tract	  for	  reasons	  discussed	  previously.	  It	  should	  also	  
be	  noted	  that	  the	  SCFA	  compositions	  obtained	  were	  measured	  from	  faecal	  material.	  This	  
may	  not	  provide	  an	  accurate	  reflection	  of	  SCFAs	   in	   the	   intestine	  as	  SCFAs	  are	  absorbed	  
from	  the	  intestine	  and	  transported	  to	  other	  sites	  of	  the	  body.	  
	  
While	   the	   total	   amount	   and	   profile	   of	   SCFAs	   was	   also	   unaffected	   by	   C.	   rodentium	  
infection,	  colonisation	  of	  the	  mouse	  intestine	  by	  this	  strain	  is	  known	  to	  be	  accompanied	  
by	   changes	   in	   both	   intestinal	   mucosally	   adhered	   and	   luminal	   bacteria.	   In	   particular,	  
alterations	  in	  relative	  abundance	  of	  Protobacteria,	  Deferribacteres,	  Lactobacillaceae	  and	  
Clostridia	   have	   been	   observed	   (Hoffmann	   et	   al.,	   2009).	   These	   changes	   have	   been	  
attributed	  to	  either	  direct	  competition	  between	  C.	   rodentium	  and	  the	  microbiota,	  or	   to	  
immune	  responses	  elicited	  by	  C.	  rodentium	  that	  affect	  the	  microbiota.	  However,	  we	  must	  
conclude	   that	   these	   alterations	   do	   not	   result	   in	   any	   major	   changes	   to	   the	   overall	  
production	  of	  SCFAs.	  
	  
While	  the	  ability	  of	  D-­‐serine	  to	  decrease	  T3SS	  expression	   in	  vitro	  suggests	  it	  may	  have	  a	  
use	  in	  treatment	  of	  bacterial	  infections	  that	  rely	  on	  this	  virulence	  factor	  for	  colonisation,	  
the	   independent	   upregulation	   of	   the	   SOS	   response	   may	   also	   produce	   a	   result	   that	   is	  
highly	   undesirable	   for	   EHEC	   infections.	   The	   SOS	   response	  modulates	   the	   expression	   of	  
Shiga	  toxin	  and	  therefore	  an	   increase	   in	  SOS	  gene	  expression	  may	   lead	  to	   increased	  Stx	  
release,	  resulting	  in	  a	  higher	  risk	  of	  HUS	  development.	  As	  the	  C.	  rodentium	  mouse	  model	  
does	  not	  carry	  Stx,	  we	  were	  unable	  to	  determine	  whether	  D-­‐serine	  treatment	  affects	  the	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SOS	  response	  in	  vivo.	  However,	  this	  could	  potentially	  be	  explored	  using	  the	  Stx-­‐producing	  
C.	  rodentium	  (λstx2dact)	  model.	  
	  
6.6.4	  Colicin	  treatment	  does	  not	  affect	  LF82	  colonisation	  in	  vivo	  
	  
Colicin	  E1	  treatment,	  delivered	  by	  oral	  gavage	  of	  purified	  colicin	   in	  pectin/zein	  hydrogel	  
beads,	  failed	  to	  show	  any	  significant	  influence	  on	  LF82	  infection	  in	  streptomycin-­‐treated	  
mice.	   Further	   mouse	   infection	   studies	   performed	   by	   Carla	   Brown	   and	   Dr.	   Gill	   Douce	  
(University	   of	   Glasgow)	   in	   which	   mice	   were	   orally	   administered	   1	   mg	   purified	  
unencapsulated	  colicin	  E1	  daily	  also	   failed	   to	   show	  a	  significant	  decrease	   in	  LF82	   faecal	  
shedding.	  Testing	  for	  colicin	  activity	  in	  the	  intestinal	  organs	  of	  uninfected	  mice	  harvested	  
shortly	   after	   treatment	  with	   purified	   colicin	   E1	   revealed	   that	   while	   colicin	   activity	   was	  
detectable	   in	   stomach	  samples,	  no	  colicin	  activity	  was	   found	   in	   small	   intestine,	   caecum	  
and	   colon	   tissues,	   implying	   that	   colicin	   E1	   is	   degraded	   in	   the	   small	   intestine	   (Brown,	  
2015).	  
	  
These	  findings	  indicate	  that	  colicin	  E1	  is	  not	  effective	  against	  LF82	  in	  this	  mouse	  model.	  
However,	  lack	  of	  an	  effective	  delivery	  system	  for	  the	  colicin	  to	  the	  site	  of	  LF82	  infection	  is	  
relevant.	  The	  poor	  efficiency	  of	  colicin	  encapsulation	  resulted	  in	  mice	  being	  treated	  with	  
~7	  μg	  colicin/mouse/day,	  far	  lower	  than	  the	  100	  μg/ml	  concentration	  at	  which	  colicin	  E1	  
is	  toxic	  to	  LF82	   in	  vitro	   (Brown	  et	  al.,	  2015).	  Furthermore,	  as	  release	  of	  colicin	  from	  the	  
hydrogel	  requires	  digestion	  of	  pectin	  by	  the	  gut	  microbiota,	  clearance	  of	  the	  natural	  gut	  
flora	   by	   streptomycin	   treatment	   may	   potentially	   decrease	   the	   amount	   of	   pectinase	  
activity	  in	  the	  intestine,	  limiting	  or	  slowing	  the	  delivery	  of	  colicin.	  
	  
Colicin	   treatment	  was	   explored	   by	   Brown	   (2015)	   as	   a	   potential	   therapy	   targeting	   AIEC	  
that	  are	  associated	  with	  Crohn’s	  disease.	  The	  streptomycin-­‐treated	   ICR	  mouse	  model	   is	  
therefore	   perhaps	   not	   the	  most	   appropriate	   small	   animal	  model	   in	   this	   context	   as	   the	  
model	  does	  not	  replicate	  any	  aspects	  of	  Crohn’s	  disease.	  Alternative	  murine	  models	  that	  
induce	  colitis	  and	  thus	  more	  accurately	  depict	  the	  role	  of	  LF82	  in	  Crohn’s	  disease,	  such	  as	  
LF82	  infection	  of	  TLR5-­‐deficient	  germ-­‐free	  mice	  (Chassaing	  et	  al.,	  2014b)	  or	  LF82	  infection	  
of	   transgenic	  mice	   expressing	   human	   CEACAMs	   (Carvalho	   et	   al.,	   2009),	   may	   be	   better	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suited	  for	  in	  vivo	  assessment	  of	  colicin	  E1.	  Use	  of	  these	  models	  would	  allow	  the	  effect	  of	  
colicins	  on	  AIEC-­‐induced	  symptoms	  to	  be	  assessed	  alongside	  bacterial	  persistence.	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7.1	  Mouse	  models	  of	  EHEC	  infection	  
	  
Our	  initial	  aim	  was	  to	  establish	  a	  mouse	  model	  of	  a	  Shiga	  toxin-­‐negative	  O157:H7	  strain	  
that	   showed	   high	   and	   consistent	   levels	   of	   colonisation	   over	   approximately	   10-­‐14	   days,	  
and	  then	  determine	  the	  influence	  of	  the	  T3SS	  on	  colonisation.	  Although	  this	  strain	  was	  a	  
poor	   coloniser	   of	   inbred	   mice,	   streptomycin-­‐treated	   outbred	   ICR	   mice	   were	   strongly	  
colonised.	   However,	   this	   colonisation	  was	   revealed	   to	   be	   non-­‐dependent	   on	   the	   T3SS,	  
making	  it	  unsuitable	  for	  testing	  T3SS-­‐inhibiting	  anti-­‐virulence	  compounds.	  
	  
7.1.1	  C.	  rodentium	  and	  C.	  rodentium	  (λstx2dact)	  as	  in	  vivo	  EHEC	  surrogates	  
	  
As	  O157:H7	  was	   deemed	   unsuitable	   for	   T3SS-­‐focused	  mouse	   studies,	   the	  C.	   rodentium	  
model	  was	  explored	  as	  a	  surrogate	  for	  EHEC	  infection,	  as	  this	  strain	  is	  highly	  dependent	  
on	  the	  T3SS	  for	  colonisation.	  Infection	  of	  BALB/c	  mice	  by	  an	  Stx2-­‐expressing	  C.	  rodentium	  
strain	  produced	  strong	  symptoms	  of	  disease,	   including	  weight	   loss,	  kidney	  damage,	  and	  
death	  within	  the	  first	  week	  of	  infection.	  This	  model	  was	  particularly	  appealing	  as	  it	  allows	  
the	   testing	   of	   compounds	   that	   potentially	   inhibit	   Stx	   production.	   Interestingly,	   disease	  
was	  very	  poor	   in	  C57BL/6	  mice	  despite	  high	  bacterial	   colonisation	   levels,	   in	   contrast	   to	  
the	  original	  study	  by	  Mallick	  et	  al.	  (2012),	  probably	  reflecting	  the	  significant	  role	  that	  the	  
host	   intestinal	   flora	   has	   on	   bacterial	   pathogenesis.	   The	   differences	   in	   microbiota	  
composition	  of	  mice	  obtained	  from	  different	  suppliers	  is	  a	  major	  issue	  when	  it	  comes	  to	  
the	   reproducibility	   of	  models,	   as	   commensal	   bacteria	   are	   known	   to	   not	   just	   affect	   the	  
intestinal	  colonisation	  of	   introduced	  strains	  and	  their	  ability	  to	  cause	   illness,	  but	  also	  to	  
influence	   host	   immune	   responses	   (Macpherson	   &	   Harris,	   2004).	   Therefore,	   a	   better	  
understanding	   of	   the	   intestinal	   strains	   that	   are	   involved	   in	   colonisation	   resistance	   to	  
pathogenic	   E.	   coli	   may	   aid	   the	   development	   of	   a	   more	   reproducible	   mouse	   infection	  
model.	  
	  
Although	   the	   Stx-­‐producing	   C.	   rodentium	   (λstx2dact)	   mouse	   model	   demonstrates	   both	  
strong	  colonisation	  and	  manifestation	  of	  disease	  without	  the	  requirement	  for	  alteration	  
of	  the	  normal	  gut	  flora,	  there	  are	  several	  notable	  limitations	  of	  this	  model.	  Unlike	  EHEC,	  
C.	   rodentium	   does	   not	   produce	   flagella,	   which	   provide	   motility	   and	   act	   as	   primary	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adhesins.	  Expression	  of	  the	  flagella	  is	  also	  coordinated	  with	  T3SS	  expression	  in	  EHEC,	  and	  
therefore	  therapies	  that	  target	  regulation	  of	  the	  T3SS	  may	  show	  limited	  effect	   in	  the	  C.	  
rodentium	   model.	   A	   number	   of	   other	   EHEC	   proteins	   are	   not	   found	   within	   the	   C.	  
rodentium	   genome,	   making	   the	   study	   of	   treatments	   that	   influence	   the	   regulation	   or	  
function	   of	   anti-­‐virulence	   factors	   difficult	   to	   assess.	   In	   addition,	   while	   useful	   as	   a	  
surrogate	   for	   O157:H7	   infection,	   the	   λstx2dact	   model	   produces	   the	   Stx2dact	   variant	   of	  
Shiga	  toxin,	  which	  has	  not	  been	  identified	  in	  O157:H7	  strains.	  
	  
Irrespective	  of	  these	  obstacles,	  C.	  rodentium	  is	  still	  a	  strong	  model	  for	  in	  vivo	  studies	  that	  
focus	   on	   the	   T3SS	   compared	   to	   the	   current	   alternatives.	   Intestinal	   xenograft	   murine	  
models	  are	  also	  a	  recent	  development	  with	  the	  potential	  for	  use	  in	  colonisation	  studies,	  
as	  they	  have	  demonstrated	  T3SS-­‐dependent	  lesion	  formation	  on	  human	  intestinal	  tissue	  
(Golan	  et	  al.,	  2011).	  However,	   the	   infant	   rabbit	  model	  of	  EHEC	   infection	   is	  perhaps	   the	  
most	  appropriate	  small	  animal	  model	  currently	  available	  for	  colonisation	  studies,	  as	  it	   is	  
strongly	  dependent	  on	  the	  T3SS	  and	  uses	  the	  original	  EHEC	  strain	  instead	  of	  a	  surrogate,	  
allowing	   the	   influence	   of	   other	   non-­‐T3SS	   EHEC	   virulence	   factors	   to	   be	   assessed.	   This	  
model	  has	  previously	  been	  used	  to	  identify	  non-­‐T3SS	  factors	  that	  contribute	  to	  intestinal	  
colonisation	  and	  disease,	  with	   studies	   implying	   that	   surface-­‐exposed	   structures	   such	  as	  
the	   long	   polar	   fimbriae,	   curli,	   and	   the	   O-­‐antigen	   capsule	   have	   a	   significant	   effect	   on	  
colonisation	  and	  survival	  within	  the	  intestine	  (Ritchie	  &	  Waldor,	  2005;	  Shifrin	  et	  al.,	  2008;	  
Lloyd	  et	  al.,	  2012).	  	  
	  
7.1.2	  The	  importance	  of	  the	  T3SS	  in	  human	  pathogenesis	  
	  
The	  question	  of	  whether	  the	  T3SS	  dependence	  and	  A/E	  lesions	  observed	  in	  these	  animals	  
models	  is	  actually	  a	  true	  reflection	  of	  what	  occurs	  in	  humans	  needs	  to	  be	  considered.	  Due	  
to	   the	   unavailability	   of	   human	   studies,	   our	   understanding	   of	   the	   processes	   involved	   in	  
human	  intestinal	  colonisation	  by	  EHEC	  is	  relatively	  limited,	  and	  both	  the	  site	  of	  bacterial	  
colonisation	  and	  the	  significance	  of	  the	  T3SS	  varies	  between	  the	  different	  animal	  models	  
(reviewed	  by	  Ritchie,	  2014).	  Human	  volunteer	  studies	  of	  EPEC	  infection,	  however,	  which	  
do	  not	  carry	  the	  risk	  of	  kidney	  damage	  and	  death,	  have	  provided	  insights	  into	  the	  role	  of	  
the	   T3SS	   in	   virulence,	   which	   may	   be	   similar	   to	   its	   function	   in	   EHEC.	   In	   two	   separate	  
human	  studies	  exploring	  the	  virulence	  of	  eae	  and	  espB	  deletion	  mutants	  relative	  to	  the	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wild	  type,	  the	  mutants	  produced	  a	  significantly	  lower	  incidence	  and	  severity	  of	  diarrhoea	  
(Donnenberg	   et	   al.,	   1993;	   Tacket	   et	   al.,	   2000),	   although	   the	   similar	   level	   of	   mutant	  
bacteria	  shed	  in	  stool	  samples	  to	  that	  of	  the	  wild	  type-­‐infected	  control	  group	  implies	  that	  
other	  adhesion	  factors	  are	  also	  important.	  	  
	  
In	  conclusion,	  although	  different	  animal	  models	  of	  EHEC	  have	  shown	  varying	  results	  when	  
assessing	  the	  role	  of	  the	  T3SS	  in	  pathogenesis,	  they	  provide	  strong	  evidence	  that	  it	  plays	  
an	   important	   function	   in	   colonisation,	  and	   that	   inhibitors	  of	   the	  T3SS	  have	  potential	   as	  
new	  therapeutic	  strategies.	  Furthermore,	  selection	  of	  the	  most	  appropriate	  animal	  model	  
and	   consideration	  of	   its	  differences	   in	  bacterial	  pathogenesis,	  host	   responses,	   and	  host	  
microbiota	   influence	   needs	   to	   be	   carefully	   contemplated	   during	   in	   vivo	   evaluation	   of	  
novel	  T3SS-­‐targeting	  drugs.	  
	  
7.2	  Candidates	  for	  a	  broadly	  protective	  vaccine	  against	  E.	  coli	  
	  
The	  development	  of	  a	  vaccine	   that	  could	  effectively	  protect	  against	  O157:H7	  and	  other	  
EHEC	   strains	  would	   have	   a	  major	   impact	   on	   human	   health	   and	   economy.	   Broad-­‐range	  
vaccines	  that	  target	  not	  only	  EHEC	  but	  other	  E.	  coli	  pathotypes	  are	  highly	  desirable,	  given	  
the	   wide	   range	   of	   clinically	   important	   diseases	   they	   cause.	   Reverse	   vaccinology	   is	   an	  
approach	   designed	   to	   rapidly	   identify	   protein	   candidates	   that	   offer	   protection	   and	   has	  
been	   used	   successfully	   to	   develop	   vaccines	   against	   other	   pathogenic	   bacteria	   such	   as	  
Meningococcus	   B	   and	   Group	   A	   Streptococcus.	   Recently,	  Moriel	   et	   al.	   (2010)	   used	   this	  
technique	  to	  identify	  conserved	  antigens	  that	  could	  be	  used	  in	  a	  broad-­‐spectrum	  vaccine	  
against	  E.	  coli	  pathogens.	  The	  intention	  of	  work	  outlined	  in	  this	  thesis	  was	  to	  explore	  the	  
expression	   and	   function	   of	   two	   of	   these	   antigens,	   EaeH	   and	   YghJ,	   to	   determine	   their	  
protective	  potential	  against	  EHEC	  and	  AIEC	  strains.	  	  	  
	  
7.2.1	  Expression	  of	  EaeH	  and	  YghJ	  in	  E.	  coli	  strains	  
	  
Expression	   of	   EaeH	   in	   both	   TUV93-­‐0	   and	   LF82	   was	   very	   low,	   and	   no	   upregulation	   of	  
transcription	  was	  identified	  under	  any	  of	  the	  conditions	  we	  tested,	  including	  the	  presence	  
of	  human	  intestinal	  epithelial	  cells.	  Expression	  of	  YghJ	  in	  LF82	  occurred	  at	  a	  similar	  level	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to	  that	  of	  EPEC	  YghJ	  but,	  despite	  encoding	  the	  genes	  required	  for	  a	  functional	  T2SS,	  YghJ	  
was	  not	  secreted	  by	  LF82	  under	  the	  same	  conditions	  as	  EPEC	  YghJ.	  While	  this	  difference	  is	  
not	  surprising	  given	  that	  LF82	  belongs	  to	  a	  very	  different	  pathotype,	  the	  similar	   level	  of	  
LF82	  YghJ	  expression	  to	  that	  of	  EPEC	  despite	  its	  lack	  of	  secretion	  is	  intriguing,	  and	  raises	  
the	  possibility	  of	  another	  intracellular	  function	  for	  LF82	  YghJ.	  Further	  work	  to	  characterise	  
the	   T2SS	   of	   LF82	   and	   determine	   its	   role	   in	   pathogenesis	   could	   therefore	   help	   reveal	   if	  
YghJ	  is	  secreted	  by	  this	  E.	  coli	  strain.	  	  
	  
Although	   our	   studies	   did	   not	   demonstrate	   strong	   expression	   or	   secretion	   of	   EaeH	   and	  
YghJ	   in	   the	   two	   strains	   tested,	   in	   the	   last	   few	   years	   their	   functions	   in	   colonisation	   and	  
disease	  have	  been	  elucidated	   in	  ETEC	  and	  ExPEC	   strains.	   Studies	   focusing	  on	  YghJ	  have	  
implied	   that	   this	  protein	  has	   strong	  potential	   as	   a	   vaccine	   component	   and,	  despite	   the	  
variation	  present	  in	  YghJ	  from	  different	  strains,	  conserved	  motifs	  within	  the	  protein	  have	  
allowed	  the	  production	  of	  antibodies	  that	  show	  broad	  cross-­‐reactivity	  between	  variants	  
(Nesta	  et	  al.,	  2014).	  Further	  exploration	  of	  the	  production	  of	  YghJ	  by	  a	  greater	  number	  of	  
clinically	  important	  E.	  coli	  strains	  and	  the	  ability	  of	  YghJ	  to	  confer	  protection	  against	  them	  
could	  advance	  the	  development	  of	  a	  vaccine	  against	  pathogenic	  E.	  coli.	  
	  
7.2.2	  Recent	  insights	  into	  the	  other	  identified	  ExPEC	  vaccine	  candidates	  
	  
Further	   exploration	   of	   the	   other	   potential	   E.	   coli	   vaccine	   candidates	   identified	   by	   the	  
Moriel	   et	   al.	   (2010)	   study	   has	   also	   been	   undertaken.	   Hemolysin	   A,	   one	   of	   the	   most	  
protective	   candidates	   in	   the	   sepsis	  mouse	  model,	   has	   also	   been	   evaluated	   in	   an	   acute	  
cystitis	   mouse	  model.	  Mice	   immunised	   with	   a	   hemoysin	   A	   toxoid	   showed	   significantly	  
lowered	  severity	  of	  cystitis	  and	  10-­‐fold	  lower	  bacterial	  titers	  in	  their	  urine,	  implying	  that	  
vaccination	   with	   hemolysin	   A	   reduces	   UPEC-­‐produced	   bladder	   pathology	   (Smith	   et	   al.,	  
2015).	  Other	  studies	  have	  also	   investigated	   the	  expression	  and	   function	  of	   some	  of	   the	  
vaccine	   candidates	   that	   were	   poorly	   understood	   at	   the	   time	   of	   identification.	   One	   of	  
these,	  IrmA,	  was	  found	  to	  be	  coexpressed	  with	  factors	  associated	  with	  biofilm	  formation,	  
and	   secreted	   into	   culture	   supernatant.	   The	   structure	   of	   IrmA	   displayed	   similarity	   to	  
human	   cytokine	   receptor	   binding	   domains,	   and	   purified	   IrmA	   shown	   to	   bind	   to	   their	  
cognate	  cytokines,	  suggesting	  this	  protein	  manipulates	  host	  immune	  responses	  (Moriel	  et	  
al.,	   2016).	   Another	   antigen,	   EsiB,	   also	   has	   implied	   immunomodulatory	   functions.	   EsiB	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interacts	   with	   secretory	   immunoglobulin	   A	   (SigA),	   inhibiting	   SigA-­‐mediated	   signalling	  
events	  (Pastorello	  et	  al.,	  2013).	  The	  authors	  of	  this	  study	  proposed	  that	  EsiB	  interference	  
with	  immune	  signalling	  may	  help	  the	  bacteria	  avoid	  clearance	  by	  neutrophils,	  and	  reduce	  
immune	  cell	  recruitment	  to	  the	  site	  of	  infection.	  
	  
7.3	  Inhibitors	  of	  Shiga	  toxin	  production	  and	  the	  bacterial	  SOS	  response	  
	  
Therapeutic	  treatments	  that	  disrupt	  production	  and	  release	  of	  bacterial	  toxins	  are	  widely	  
regarded	  as	  suitable	  strategies	  for	  effectively	  reducing	  the	  impact	  of	  bacterial	   infections	  
without	   applying	   selective	   pressure	   on	   the	   organism.	   The	   Shiga	   toxin	   of	   EHEC	   is	   a	  
particularly	   appealing	   target	   for	   new	   anti-­‐virulence	   drugs,	   as	   use	   of	   conventional	  
antibiotic	  treatment	  is	  associated	  with	  serious	  and	  life-­‐threatening	  secondary	  sequelae.	  
	  
7.3.1	  The	  AHU	  compounds	  prevent	  Stx	  expression	  by	  inhibiting	  RecA	  
	  
The	  aim	  of	  our	  work	  with	  the	  AHU	  compounds	  was	  to	  validate	  and	  explore	  the	  structure-­‐
activity	  relationship	  of	  these	  potential	  Stx	  inhibitors.	  Using	  expression	  reporter	  assays,	  we	  
determined	   the	  maleimide	   ring	  of	   the	  compounds	   to	  be	  essential	   for	  both	   inhibition	  of	  
Stx	  production	  and	  MMC-­‐induced	  bacterial	   lysis,	  while	  phage	  transduction	  studies	  using	  
both	  E.	  coli	  and	  S.	  aureus	  strains	  revealed	  that	  these	  compounds	  inhibit	  the	  production	  of	  
phages	   other	   than	   Stx.	   RecA,	   the	  major	   regulator	   of	   the	   SOS	   response,	  was	   ultimately	  
identified	  as	   the	   target	  of	   the	  AHU	  compounds,	  with	  biophysical	   studies	   indicating	   that	  
AHU3	  acts	  by	  preventing	  oligomerisation	  of	  RecA,	  an	  essential	   first	  step	   in	  activation	  of	  
the	  SOS	  response	  and	  phage	  expression.	  Analysis	  of	  the	  structure	  of	  RecA	  and	  the	  known	  
propensity	   of	   maleimide	   to	   readily	   form	   covalent	   bonds	   with	   thiols	   suggested	   that	  
covalent	  binding	  of	  AHU3	   to	   an	  exposed	   cysteine	   residue	  on	  RecA	  prevents	  monomers	  
from	   binding	   to	   each	   other.	   Further	   work	   to	   confirm	   this	   activity	   is	   currently	   being	  
undertaken.	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7.3.2	  Covalent	  binding	  as	  a	  mode	  of	  action	  for	  therapeutic	  drugs	  
	  
Although	   covalently-­‐binding	   drugs	   comprise	   a	   significant	   percentage	   of	   approved	  
treatments	  on	  the	  market,	  including	  well-­‐known	  drugs	  such	  as	  aspirin	  and	  penicillin,	  they	  
have	   previously	   been	   considered	   toxic	   due	   to	   their	   irreversible	   mode	   of	   binding	   and	  
potential	  for	  non-­‐specific	  reactivity.	  In	  recent	  years,	  however,	  there	  has	  been	  a	  renewed	  
interest	   in	   covalent	   drugs	   and	   the	   benefits	   to	   drug	   development	   they	   offer.	   The	  
advantages	   they	   have	   include	   high	   potency	   and	   selectivity,	   a	   dissociation	   of	  
pharmacokinetics	   from	   pharmacodynamics	   as	   the	   latter	   will	   be	   dependent	   on	   protein	  
resynthesis,	   and	   the	   potential	   for	   proteins	  with	   a	   shallow	  binding	   site	   to	   be	   effectively	  
targeted	  (Mah	  et	  al.,	  2014).	  Thus,	  we	  did	  not	  consider	  AHU3’s	  mode	  of	  action	  with	  RecA	  
to	  be	  a	  considerable	  impediment.	  
	  
7.3.3	  The	  AHU	  compounds	  are	  toxic	  to	  mammalian	  cells	  
	  
Cytotoxicity	  testing	  of	  the	  AHU	  compounds	  revealed	  that	  they	  were	  highly	  toxic,	  with	  this	  
toxicity	   most	   probably	   due	   to	   non-­‐specific	   interaction	   of	   the	   maleimide	   moiety	   with	  
eukaryotic	  proteins.	  As	  the	  maleimide	  is	  essential	  for	  inhibition	  of	  RecA,	  the	  potential	  of	  
this	   compound	   to	   be	   successfully	   modified	   is	   likely	   to	   be	   limited.	   However,	   our	  
characterisation	   of	   the	   AHU3/RecA	   interaction	   has	   required	   the	   development	   and	  
optimisation	   of	   assays	   that	   can	   be	   applied	   to	   rigorously	   test	   other	   compounds	   with	  
potential	  Stx-­‐	  or	  RecA-­‐inhibiting	  activity.	  These	  may	  potentially	  be	  used	  to	  study	  a	   large	  
number	  of	  small	  compounds	  reported	  to	  reduce	  Stx	  production	  that	  have	  been	  identified	  
by	   high-­‐throughput	   screening	   (reviewed	   by	  Upadhyay	   et	   al.,	   2015).	   Characterisation	   of	  
some	  of	  these	  compounds	  is	  currently	  ongoing	  by	  Alejandro	  Huerta	  Uribe,	  and	  the	  most	  
promising	  inhibitors	  will	  eventually	  be	  tested	  in	  the	  C.	  rodentium	  (λstx2dact)	  mouse	  model.	  
	  
7.4	  Future	  directions	  
	  
The	   work	   presented	   in	   this	   thesis	   demonstrates	   that	   future	   in	   vivo	   studies	   testing	  
potential	   anti-­‐virulence	   therapies	   that	   target	   the	   T3SS	   should	   involve	   the	  C.	   rodentium	  
infection	  mouse	  model,	   or,	   if	   possible,	   the	   EHEC	   infant	   rabbit	  model,	  which	   allows	   the	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influence	  of	  other	  E.	  coli	  genes	  on	  pathogenesis	  to	  be	  assessed.	  One	  major	  consideration	  
raised	   by	   in	   vivo	   testing	   of	   the	   anti-­‐virulence	   drugs	   in	   Chapter	   6	   is	   the	   problem	   of	  
delivering	   an	   active	   compound	   to	   the	   site	   of	   bacterial	   infection	   at	   a	   high	   enough	  
concentration	  for	  it	  to	  be	  effective.	  With	  the	  exception	  of	  the	  E1	  colicin	  tested	  in	  the	  LF82	  
mouse	  model,	   the	   compounds	  we	   evaluated	   in	   vivo	   were	   not	   encapsulated	   to	   protect	  
them	  from	  being	  degraded	  or	  absorbed	  before	  reaching	  their	  target,	  and	  before	  further	  
assessment	  of	  these	  compounds	  in	  animals	  is	  undertaken,	  encapsulation	  should	  perhaps	  
be	   explored.	   Additionally,	   as	   the	   terminal	   rectum	   is	   the	   main	   site	   of	   C.	   rodentium	  
colonisation,	   alternative	   delivery	   of	   compounds	   tested	   in	   this	   model,	   such	   as	   rectal	  
administration,	  could	  be	  considered.	  
	  
Although	   the	   function	   of	   EaeH	   as	   an	   adhesin	   has	   in	   recent	   years	   been	   elucidated,	   its	  
mammalian	  protein	  target	   is	  currently	  unknown.	  Experiments	  to	  uncover	  the	  identity	  of	  
this	   receptor,	   for	  example	  pull-­‐down	  assays,	   co-­‐immunoprecipitation,	  or	   the	  yeast	   two-­‐
hybrid	   screen,	  may	  help	   to	   further	   our	   knowledge	  of	   this	   vaccine	   candidate.	  While	   the	  
function	  and	  targets	  of	  YghJ	  has	  also	  been	  revealed	   in	   the	   last	   few	  years,	  our	  work	  has	  
shown	   LF82	   to	   be	   the	   only	   reported	   strain	   which	   contains	   an	   apparently	   intact	   T2SS	  
operon	   but	   does	   not	   secrete	   YghJ	   under	   conditions	   that	   other	   strains	   do.	   The	   T2SS	   of	  
LF82,	   which	   is	   relatively	   unexplored,	   is	   therefore	   worth	   investigating	   to	   determine	  
whether	  it	  is	  assembled	  and	  functional,	  possibly	  by	  methods	  such	  as	  the	  use	  of	  antibodies	  
against	  T2SS	  structural	  proteins	  to	  identify	  the	  T2SS	  in	  LF82	  membrane	  fractions.	  
	  
Our	   studies	   with	   the	   AHU3	   compound	   have	   demonstrated	   that	   suppression	   of	   the	  
bacterial	   SOS	   response	   is	  a	  potential	   route	   to	   inhibition	  of	  prophage-­‐encoded	  virulence	  
factors	   such	   as	   the	   Shiga	   toxin.	   We	   have	   shown	   evidence	   that	   AHU3	   binds	   RecA	  
monomers	  and	  inhibits	  their	  polymerisation,	  and	  this	  binding	  is	  currently	  believed	  to	  be	  
covalent.	  Further	  investigation	  into	  this	  interaction	  to	  examine	  this	  hypothesis	  is	  currently	  
being	  undertaken	  as	  part	  of	  the	  PhD	  project	  of	  Alejandro	  Huerta	  Uribe,	  and	  will	  involve	  in	  
silico	   digest	  and	  crystallisation	  of	   the	  AHU3-­‐RecA	  complex.	  While	   cytotoxicity	   testing	  of	  
the	   AHU	   compounds	   has	   indicated	   that	   they	   are	   ultimately	   unsuitable	   as	   therapeutic	  
drugs	   for	   humans,	   the	   assays	   we	   have	   developed	   to	   assess	   Stx	   inhibition	   and	   RecA	  
binding	  can	  be	  applied	   to	  many	  of	   the	  other	  SOS-­‐inhibiting	  compounds	   that	  have	  been	  
identified	  but	  not	  yet	  fully	  characterised.	  Finally,	   little	  is	  currently	  understood	  about	  the	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three	  natural	  maleimide-­‐containing	  metabolites,	  and	  given	  the	  scarcity	  of	  this	  moiety	   in	  
nature,	  studies	  to	  characterise	  these	  compounds	  and	  determine	  their	  targets	  and	  mode	  
of	  action,	  as	  well	  as	  any	  potential	  for	  leads	  as	  antibacterial	  therapies,	  would	  be	  of	  great	  
interest.	  
	  
7.5	  Concluding	  remarks	  
	  
In	   conclusion,	   the	  work	   presented	   in	   this	   thesis	   has	   provided	   new	   insights	   into	   several	  
different	   and	   important	   areas	   of	   prevention	   and	   treatment	   of	   EHEC	   infections:	  
assessment	   of	   mouse	   models	   for	   the	   study	   of	   T3SS-­‐mediated	   bacterial	   colonisation,	  
evaluation	  of	   the	   role	   and	   vaccine	   candidate	  potential	   of	   two	   antigens	   in	   two	   clinically	  
important	   E.	   coli	   strains,	   and	   characterisation	   of	   the	   AHU	   group	   of	   compounds	   with	  
elucidation	  of	  their	  target	  and	  mode	  of	  action.	  In	  the	  long-­‐term,	  the	  work	  presented	  may	  
contribute	  to	  the	  development	  of	  novel	  strategies	  to	  limit	  EHEC	  infection.	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9.1	  Characterisation	  of	  E.	  coli	  StrR	  mutants	  
	  
The	  eight	   spontaneous	  StrR	  mutants	  of	  each	  E.	   coli	   strain	  were	   characterised	   to	  ensure	  
that	  the	  mutant	  selected	  for	  use	  in	  animals	  was	  as	  phenotypically	  similar	  to	  the	  wild	  type	  
as	   possible.	   The	   characteristics	   studied	   included	   growth,	   motility,	   secretion	   in	   MEM	  
media	  (data	  not	  shown)	  and	  adherence	  to	  Caco-­‐2	  cells.	  	  
	  
9.1.1	  Bacterial	  growth	  in	  LB,	  MEM	  and	  M9	  media	  
	  
Growth	  of	  the	  wild	  type	  and	  mutant	  strains	  in	  LB,	  MEM	  and	  M9	  media	  over	  6	  hours	  found	  
that	  the	  majority	  of	  StrR	  mutants	  displayed	  a	  growth	  curve	  very	  similar	  to	  that	  of	  the	  wild	  
type,	  although	  all	  StrR	  mutants	  showed	  slightly	  slower	  growth	  in	  M9	  media	  (Figure	  9-­‐1).	  
	  
A	   LB	   	   	   B	   MEM	   	   	   C	   M9	  
	   	   	  
D	   LB	   	   	   E	   MEM	   	   	   F	   M9	  
	   	   	  
G	   LB	   	   	   H	   MEM	   	   	   I	   M9	  
	   	  	  
Figure	  9-­‐1:	  Growth	  curves	  of	  E.	  coli	  StrR	  mutants.	  Bacterial	  growth	  of	  wild	  type	  (red)	  and	  StrR	  (blue)	  TUV93-­‐
0	  (A-­‐C),	  OI-­‐148A	  (D-­‐F)	  and	  LF82	  (G-­‐I)	  in	  LB,	  MEM	  and	  M9	  media.	  Data	  shown	  is	  from	  a	  single	  experiment.	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9.1.2	  Bacterial	  motility	  
	  
Motility	  of	  strains	  was	  assessed	  by	  measuring	  the	  diameter	  growth	  of	  bacteria	  on	  0.25%	  
agar	   after	   24	   hours	   at	   30°C	   (Figure	   9-­‐2).	   Strains	   with	   the	   K42T	   mutation	   had	   similar	  
motility	  profiles	  to	  that	  of	  the	  wild	  type,	  and	  out	  of	  the	  available	  K24T	  StrR	  mutants	  we	  
selected	  those	  that	  were	  most	  similar	  to	  the	  wild	  type	  for	  use	  in	  animal	  models	  (TUV93-­‐0:	  
StrR	  1;	  OI-­‐148A:	  StrR	  5;	  LF82:	  StrR	  6).	  
	  
A	   TUV93-­‐0	   	   B	   OI-­‐148A	   	   C	   LF82	  
	   	   	  
Figure	  9-­‐2:	  Motility	  of	  StrR	  mutants.	  WT	  (red)	  and	  StrR	  (blue)	  bacteria	  were	  grown	  on	  0.25%	  agar	  at	  30	  °C	  
for	  16	  hours,	  and	  the	  diameter	  growth	  of	  bacteria	  measured.	  Experiments	  were	  performed	  in	  triplicate	  and	  
data	  shown	  as	  the	  average	  diameter	  with	  standard	  deviation	  from	  the	  mean	  displayed	  as	  error	  bars.	  	  
	  
9.1.3	  Bacterial	  adherence	  to	  Caco-­‐2	  cells	  
	  
Adherence	  of	  the	  K42T	  StrR	  E.	  coli	  strains	  to	  Caco-­‐2	  cells	  was	  determined	  by	  incubation	  of	  
the	  mutant	  or	  the	  wild	  type	  with	  90%	  confluent	  Caco-­‐2	  monolayers	  for	  four	  hours,	  after	  
which	  growth	  media	  was	  removed,	  Caco-­‐2	  cells	  washed,	  and	  adhered	  E.	  coli	  harvested	  by	  
a	  five	  minute	  saponin	  wash.	  Non-­‐adherent	  bacteria	  were	  collected	  by	  pooling	  the	  growth	  
media	  and	  washes,	  and	  pelleting	  cells	  by	  centrifugation.	  Bacteria	  were	  quantified	  by	  serial	  
dilution	   onto	   LB	   agar.	   Comparison	   of	   StrR	   bacteria	   in	   the	   adhered	   and	   non-­‐adhered	  
fractions	  to	  those	  of	  the	  corresponding	  wild	  type	  found	  no	  significant	  difference	  (p>0.05)	  
in	   either	   the	   number	   of	   bacteria	   in	   the	  media	   or	   attached	   to	   cells	   for	   all	   three	   E.	   coli	  
strains	  (Figure	  9-­‐3).	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A	   TUV93-­‐0	   	   B	   OI-­‐148A	   	   C	   LF82	  
	   	   	  
Figure	  9-­‐3:	  Bacterial	   adherence	   to	  Caco-­‐2	   cells.	  Total	  numbers	  of	  WT	  (red)	  and	  K42T	  StrR	   (blue)	  mutants	  
free	  in	  media	  (non-­‐adherent)	  or	  attached	  to	  Caco-­‐2	  cells	  (adherent)	  after	  incubation	  in	  9.5	  cm2	  wells	  for	  4	  
hours.	  Experiments	  were	  performed	  in	  triplicate	  and	  shown	  as	  the	  average	  count	  with	  standard	  deviation	  
from	  the	  mean	  displayed	  as	  error	  bars.	  
	  
9.2	  The	  T3SS	  in	  O157:H7	  colonisation	  of	  streptomycin-­‐treated	  ICR	  mice	  
	  
While	  mouse	  colonisation	  studies	  with	  StrR	  TUV93-­‐0	  and	  OI-­‐148A	  revealed	  that	  the	  T3SS	  
has	  no	  noticeable	  affect	  on	  colonisation	  of	  mice,	  the	  finding	  that	  the	  K42T	  rpsL	  mutation	  
conferring	   streptomycin	   resistance	   also	   decreases	   production	   of	   proteins	   essential	   for	  
formation	  of	  A/E	  lesions	  (Chen	  et	  al.	  2013)	  raises	  the	  consideration	  that	  this	  mutation	  is	  
responsible	   for	   the	   lack	  of	  difference	  between	  the	  two	  strains	  we	  observed.	  To	  explore	  
this	   possibility,	   colonisation	  by	  non-­‐mutant	   TUV93-­‐0	   and	  OI-­‐148A	   strains	  was	   assessed,	  
using	  the	  pGB2	  plasmid	  for	  streptomycin	  resistance.	  
	  
Colonisation	  of	  mice	  by	  pGB2-­‐transformed	   lux-­‐marked	  TUV03-­‐0	  and	  OI-­‐148A	  found	  that	  
both	  faecal	  shedding	  and	  luminescence	  levels	  of	  the	  two	  were	  highly	  similar	  to	  that	  of	  the	  
K42T	   rpsL	   mutants.	   Importantly,	   no	   significant	   difference	   in	   shedding	   or	   luminescence	  
was	   shown	   at	   any	   time	   point	   (Figure	   9-­‐4),	   implying	   that	   the	   rpsL	   mutation	   had	   no	  
discernible	   influence	   on	   colonisation	   and	   that	   the	   ability	   of	   the	   T3SS-­‐negative	   OI-­‐148A	  
strain	   to	   colonise	   as	   effectively	   as	   TUV93-­‐0	   is	   due	   to	   the	   T3SS	   having	   no	   detectable	  
influence	  on	  colonisation	  dynamics	  in	  the	  streptomycin-­‐treated	  mouse	  model.	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A	   Faecal	  shedding	   	   	   B	   Luminescence	  
	   	  
Figure	  9-­‐4:	  Colonisation	  of	  pGB2-­‐transformed	  TUV93-­‐0	  and	  OI-­‐148A.	  Streptomycin-­‐treated	  ICR	  mice	  were	  
infected	  with	   lux-­‐marked	  TUV93-­‐0	  or	  the	  T3SS-­‐negative	  OI-­‐148A,	  both	  transformed	  with	  the	  streptomycin	  
resistance	  plasmid	  pGB2.	  Drinking	  water	  containing	  5	  g/L	  streptomycin	  was	  provided	  to	  both	  groups	  until	  
day	  10.	  Colonisation	  was	  monitored	  by	  faecal	  shedding	  (A)	  and	  live-­‐imaging	  luminescence	  (B).	  Each	  group	  
of	  mice	   consisted	   of	   5	   animals,	  with	   2	  mice	   from	  each	   group	   culled	   at	   day	   3,	   and	   the	   remaining	   3	  mice	  
culled	  at	  day	  14.	  Data	  points	  shown	  are	  the	  average	  of	  each	  group,	  and	  standard	  deviation	  from	  the	  mean	  
displayed	  as	  error	  bars.	  
	  
Along	   with	   colonisation	   by	   faecal	   shedding	   and	   live	   imaging,	   luminal	   and	   adhered	  
bacterial	  counts	  in	  the	  intestine	  of	  mice	  infected	  with	  pGB2-­‐transformed	  TUV93-­‐0	  and	  OI-­‐
148A	  was	  assessed.	  Two	  mice	  from	  each	  group	  were	  culled	  7	  days	  after	  infection,	  and	  the	  
remaining	   three	  mice	   in	  each	  group	  culled	  14	  days	  after	   infection.	   Similarly	   to	   the	   rpsL	  
mutants,	  both	  strains	  were	  detected	  in	  all	  areas	  of	  the	  intestine	  with	  the	  concentration	  of	  
bacteria	  slightly	  higher	   in	  the	  caecum	  and	  large	  intestine	  than	  in	  the	  small	   intestine.	  No	  
significant	   difference	   in	   numbers	   of	   bacteria	   in	   either	   the	   lumen	   or	   tissue	   between	  
TUV93-­‐0	  and	  OI-­‐148A	  was	  observed	  at	  any	  time	  point	  (Figure	  9-­‐5).	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A	   Lumen	  (day	  7)	  	   	   	   B	   Tissue	  (day	  7)	  
	  
C	   Lumen	  (day	  14)	   	   	   D	   Tissue	  (day	  14)	  
	  
Figure	   9-­‐5:	   Intestinal	   bacterial	   recovery	   of	   TUV93-­‐0	   and	   OI-­‐148A.	   Lumen	   (A,	   C,)	   and	   tissue	   (B,	   D,)	  
colonisation	  of	  the	  small	  bowel,	  caecum	  and	  large	  bowel	  of	  mice	  infected	  with	   lux-­‐marked	  TUV93-­‐0	  (dark	  
blue)	  or	  OI-­‐148A	  (light	  blue),	  both	  transformed	  with	  the	  streptomycin	  resistance	  pGB2	  plasmid.	  Two	  mice	  
from	  each	  group	  were	  culled	  7	  days	  after	  infection	  (A,	  B),	  and	  the	  remaining	  3	  mice	  in	  each	  group	  culled	  14	  
days	  after	   infection	   (C,	   D)	   for	   intestinal	   counts.	   Symbols	   represent	  bacterial	   counts	   from	  a	   single	  animal.	  
The	  average	  bacterial	  count	  of	  each	  group	  (long	  line)	  and	  standard	  deviation	  from	  the	  mean	  (short	  line)	  is	  
also	  indicated. 
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9.3	  Comparison	  of	  pET-­‐21b	  eaeH	  and	  yghJ	  to	  chromosomal	  sequences	  
	  
To	   determine	   the	  molecular	   size	   of	   the	   pET-­‐21b-­‐encoded	   EaeH	   and	   YghJ	   proteins,	   the	  
eaeH	   and	   yghJ	   genes	   carried	   by	   the	   pET-­‐21b-­‐EaeH	   and	   pET-­‐21b-­‐YghJ	   plasmids	   were	  
sequenced	   and	   compared	   to	   TUV93-­‐0	   eaeH	   and	   LF82	   yghJ.	   The	   Eurofins	   MWG	   T7	  
sequencing	  primer	  (AATACGACTCACTATAG)	  was	  initially	  used	  for	  sequencing	  both	  genes,	  
and	   further	   primers	   designed	   from	   the	   end	   of	   each	   ~1000	   bp	   sequenced	   region.	  
Comparison	   of	   the	   full-­‐length	   TUV93-­‐0	   eaeH	   and	   LF82	   yghJ	   revealed	   that	   the	   pET-­‐21b	  
genes	  were	  significantly	  truncated,	  with	  eaeH	  covering	  approximately	  1650	  bp	  (full	  length	  
eaeH	  =	  4254	  bp)	  from	  ~1780-­‐3430	  bp	  (Figure	  9-­‐3),	  and	  yghJ	  covering	  approximately	  2700	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pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ATGTCACGTTATAAAACAGGTCATAAACAACCACGATTTCGTTATTCAGTTCTGGCCCGC 60 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TGCGTGGCGTGGGCAAATATCTCTGTTCAGGTTCTTTTTCCACTCGCTGTCACCTTTACC 120 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CCAGTAATGGCGGCACGTGCGCAGCATGCGGTTCAGCCACGGTTGAGCATGGGAAATACT 180 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ACGGTAACTGCTGATAATAACGTGGAGAAAAATGTCGCGTCGTTTGCCGCAAATGCCGGG 240 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ACATTTTTAAGCAGTCAGCCAGATAGCGATGCGACACGTAATTTTATTACCGGAATGGCC 300 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ACCGCTAAAGCTAACCAGGAAATACAGGAGTGGCTCGGGAAATATGGTACAGCGCGCGTC 360 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    AAACTGAATGTCGATAAAGATTTCTCGCTGAAGGATTCTTCGCTGGAAATGCTTTATCCG 420 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ATTTATGATACGCCGACAAATATGTTGTTCACTCAGGGGGCAATACATCGTACAGACGAT 480 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CGTACTCAGTCAAATATTGGTTTTGGCTGGCGTCATTTTTCAGGAAATGACTGGATGGCG 540 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GGGGTGAACACCTTTATCGACCATGATTTATCCCGTAGTCATACCCGCATTGGTGTTGGT 600 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GCGGAATACTGGCGCGATTATCTGAAACTGAGCGCCAATGGTTATATTCGGGCTTCTGGC 660 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TGGAAAAAATCGCCGGATATTGAGGATTATCAGGAACGCCCGGCGAATGGTTGGGATATC 720 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CGCGCAGAGGGCTATTTACCTGCCTGGCCGCAGCTTGGCGCAAGCCTGATGTATGAACAG 780 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TATTATGGCGATGAAGTCGGGCTGTTTGGTAAAGATAAGCGCCAGAAAGACCCGCATGCT 840 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    ATTTCTGCCGAGGTGACCTATACGCCAGTGCCTCTTCTGACACTGAGCGCCGGGCATAAG 900 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CAGGGCAAGAGCGGTGAGAATGACACTCGCTTTGGCCTGGAAGTTAACTACCGAATTGGC 960 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GAACCTTTGGCGAAACAACTCGATACGGATAGCATTCGCGAGCGTCGGGTACTGGCAGGC 1020 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    AGCCGCTATGACCTGGTTGAGCGTAATAACAACATCGTTCTTGAGTACCGCAAATCTGAA 1080 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GTGATCCGTATTGCTCTGCCTGAGCGTATTGAAGGTAAGGGCGGTCAGACACTTTCCCTG 1140 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GGGCTTGTGGTCAGCAAAGCAACTCACGGACTGAAAAATGTGCAGTGGGAAGCGCCGTCA 1200 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TTACTGGCTGAAGGTGGCAAAATTACCGGTCAGGGTAGTCAGTGGCAAGTAACGCTCCCG 1260 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GCTTATCGTCCAGGCAAAGACAATTATTATGCGATTTCAGCAGTTGCCTACGATAACAAA 1320 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GGCAATACCTCAAAACGCGTGCAGACAGAGGTGGTCATTACCGGAGCTGGTATGAGCGCC 1380 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GATCGCACGGCGTTAACGCTTGACGGTCAGAGCCGTATTCAAATGCTTGCTAACGGTAAT 1440 
                                                                             
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    GAGCAAAAACCGCTGGTGCTGTCTCTGCGCGACGCCGAGGGCCAGCCAGTCACGGGCATG 1500 
                                                                             
 
pET-21b eaeH    ----------TCTAGAAT------------------------AATTTTGT------TTAA 
TUV93-0 eaeH    AAAGATCAGATCAAGACTGAACTAACTTTCAAACCGGCTGGAAATATTGTGACTCGTTCC 1560 
                          ** *** *                        *** ****      **   
 
pET-21b eaeH    CT---------------------------------------------------TTAAGAA 
TUV93-0 eaeH    CTGAAGGCCACTAAATCACAGGCAAAGCCAACACTGGGTGAGTTCACCGAAACTGAAGCA 1620 
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pET-21b eaeH    GG---------------------------------------------------------- 
TUV93-0 eaeH    GGGGTGTATCAGTCTGTCTTTACTACCGGAACGCAGTCAGGTGAGGCAACGATTACTGTT 1680 
                **                                                           
 
pET-21b eaeH    --------------------------------AGATATAC---------------ATATG 
TUV93-0 eaeH    AGCGTTGATGGCATGAGCAAAACCGTCACTGCAGAACTGCGGGCCACGATGATGGATGTG 1740 
                                                ***  * *               ** ** 
 
pET-21b eaeH    GCTAGC------------------------------------GTTGCTGATGGTCAGCAA 
TUV93-0 eaeH    GCAAACTCCACCCTGAGCGCTAACGAGCCGTCAGGTGACGTGGTTGCTGATGGTCAGCAA 1800 
                ** * *                                    ****************** 
 
pET-21b eaeH    GCCTATACGTTGACGTTGACAGCGGTGGACTCCGAGGGTAATCCGGTGACGGGAGAAGCC 
TUV93-0 eaeH    GCCTATACGTTGACGTTGACTGCGGTGGACTCCGAGGGTAATCCGGTGACGGGAGAAGCC 1860 
                ******************** *************************************** 
 
pET-21b eaeH    AGCCGCCTGCGACTTGTTCCGCAAGACACTAATGGTGTAACCGTTGGTGCCATTTCGGAA 
TUV93-0 eaeH    AGCCGCTTGCGATTTGTTCCGCAAGACACTAATGGTGTAACCGTTGGTGCCATTTCGGAA 1920 
                ****** ***** *********************************************** 
 
pET-21b eaeH    ATAAAACCAGGGGTTTACAGCGCCACGGTTTCTTCGACCCGTGCCGGAAACGTTGTTGTG 
TUV93-0 eaeH    ATAAAACCAGGCGTTTACAGCGCCGCGGTTTCTTCGACCCGTGCCGGAAACGTTGTTGTG 1980 
                *********** ************ *********************************** 
 
pET-21b eaeH    CGTGCCTTCAGCGAGCAGTATCAGCTGGGCACATTACAACAAACGCTGAAGTTTGTTGCC 
TUV93-0 eaeH    CGTGCTTTCAGCGAGCAGTATCAGCTGGGCACATTACAACAAACGCTGAAGTTTGTTGCC 2040 
                ***** ****************************************************** 
 
pET-21b eaeH    GGGCCGCTTGATGCAGCACATTCGTCCATCACACTGAATCCTGATAAACCGGTGGTTGGC 
TUV93-0 eaeH    GGGCCGCTTGATGCAGCACATTCGTCCATCACCCTGAATCCTGATAAACCGGTGGTTGGG 2100 
                ******************************** **************************  
 
pET-21b eaeH    GGTACAGTTACGGCAATCTGGACGGCAAAAGATGCTAATGACAACCCTGTAACTGGCCTC 
TUV93-0 eaeH    GGGACAGTTACGGCAATCTGGACGGTAAAAGATGCCTATGACAACCCTGTGACCAGCCTC 2160 
                ** ********************** *********  ************* **  ***** 
 
pET-21b eaeH    AAGCCGGATGCACCGTCATTAGCGGGCGCAGCTGCTGCTGGTTCTACGGCATCAGGCTGG 
TUV93-0 eaeH    ACGCCGGAAGCGCCGTCATTAGCGGGTGCCGCTGCTGCTGGTTCTACGGCATCGGGCTGG 2220 
                * ****** ** ************** ** *********************** ****** 
 
pET-21b eaeH    ACGGATAATGGCGATGGGACCTGGACTGCGCAGATTTCTCTCGGCACTACGGCGGGTGAA 
TUV93-0 eaeH    ACAAATAATGGTGATGGGACGTGGACTGCGCAGATTACTCTCGGCTCTACGGCGGGTGAA 2280 
                **  ******* ******** *************** ******** ************** 
 
pET-21b eaeH    TTAGACGTTATGCCGAAGCTAAATGGGCAGGACGCGGCAGCAAATGCGGCAAAAGTAACC 
TUV93-0 eaeH    TTAGAAGTTATGCCGAAGCTAAATGGACAGAATGCGGCAGCAAATGCGGCAAAAGTAACC 2340 
                ***** ******************** *** * *************************** 
 
pET-21b eaeH    GTGGTGGCTGATGCATTATCTTCAAACCAGTCGAAAGTCTCTGTCGCAGAAGATCACGTA 
TUV93-0 eaeH    GTGGTGGCTGATGCGTTATCTTCAAACCAGTCGAAAGTCTCTGTCGCAGAAGATCACGTA 2400 
                ************** ********************************************* 
 
pET-21b eaeH    AAAGCCGGTGAAAGCACAACCGTAACGCTGGTGGCGAAAGATGCGCATGGCAACGCTATC 
TUV93-0 eaeH    AAAGCCGGCGAAAGCACAACCGTGACGCTGGTGGCGAAAGATGCGCATGGCAACGCTATC 2460 
                ******** ************** ************************************ 
 
pET-21b eaeH    AGTGGTCTTTCGTTGTCGGCAAGTTTGACGGGGACCGCCTCTGAAGGGGCGACCGTTTCC 
TUV93-0 eaeH    AGTGGTCTTGCGTTGTCGGCAAGTTTGACGGGGACCGCCTCTGAAGGGGCGACCGTTTCC 2520 
                ********* ************************************************** 
 
pET-21b eaeH    AGTTGGACCGAAAAAGGTGACGGTTCCTATGTTGCTACGTTAACTACAGGCGGAAAGACG 
TUV93-0 eaeH    AGTTGGACCGAAAAAGGTAACGGTTCCTATGTTGCTACGTTGACTACAGGTGGAAAGACG 2580 
                ****************** ********************** ******** ********* 
 
pET-21b eaeH    GGCGAGCTTCGTGTCATGCCGCTCTTCAACGGGCCAGCCTGCAGCCACCGAAGCCGCGCA 
TUV93-0 eaeH    GGCGAGCTTCGCGTCATGCCTCTCTTCAACGG-CCAGCCAGCAGCCACCGAAGCCGCGCA 2639 
                *********** ******** *********** ****** ******************** 
 
pET-21b eaeH    GCTGACTGTCATTGCCGGAGAGATGTCATCAGCGAACTCTACGCTTGTTGCGGACAATAAA 
TUV93-0 eaeH    GTTGACGGTCATTGCCGGAGAGATGTCATCAGCGAACTCTACGCTTGTTGCGGACAATAAG 2700 
                * **** *****************************************************                                              
 
pET-21b eaeH    GCTCCGACGGTTAAAACGACGACGGAACTCACCTTCACCATGAAGGATGCGTACGGGAAT 
TUV93-0 eaeH    GCTCCGACCGTCAAAACGACGACGGAACTCACCTTCACCGTGAAGGATGCGTACGGGAAC 2760 
                ******** ** *************************** *******************  
 
pET-21b eaeH    CCGGTCACCGGGCTGAAGCCAGATGCACCAGTGTTTAGTGGTGCCGCCAGCACGGGGAGT 
TUV93-0 eaeH    CCGGTCACCGGGCTGAAGCCAGATGCACCAGTGTTTAGCGGTGCCGCCAGCACGGGGAGT 2820 
                ************************************** ********************* 
 
pET-21b eaeH    GAGCGTCCTTCAGCCGGAAACTGGACAGAGAAAGGTAATGGGGTCTTCGTGTCGACTTTA 
TUV93-0 eaeH    GAGCGTCCTTCAGCAGGAAACTGGACAGAGAAAGGTAATGGGGTCTACGTGTCGACCTTA 2880 
                ************** ******************************* ********* *** 
 
pET-21b eaeH    ACGCTGGGATCTGCCGCGGGTCAGTTGTCTGTGATGCCGCGCGTGAACAGCCAAAATGCC 
TUV93-0 eaeH    ACGCTGGGATCTGCCGCGGGTCAGTTGTCTGTGATGCCGCGAGTGAACGGCCAAAATGCC 2940 
                ***************************************** ****** *********** 
 
pET-21b eaeH    GTTGCTCAGCCACTGGTGCTGAATGTTGCAGGTGACGCATCTAAGGCTGAGATGCGTGAT 
TUV93-0 eaeH    GTTGCTCAGCCACTGGTGCTGAACGTTGCAGGTGACGCATCTAAGGCTGAGATTCGTGAT 3000 
                *********************** ***************************** ****** 
 
pET-21b eaeH    ATGACAGTGAAGGTTAATAACCAACTGGCTAATGGACAGTCTGCTAACCAGATAACCCTG 
TUV93-0 eaeH    ATGACAGTGAAGGTTAATAACCAACTGGCTAATGGACAGTCTGCTAACCAGATAACCCTG 3060 
                ************************************************************ 
 
pET-21b eaeH    ACCGTTGTGGACAGCTATGGTAACCCGTTGCAGGGGCAGGAAGTTACGCTGACTTTACCA 
TUV93-0 eaeH    ACCGTTGTGGACACCTATGGTAACCCGTTGCAGGGGCAGGAAGTTACGCTGACTTTACCA 3120 
                ************* ********************************************** 
 
pET-21b eaeH    CCGTTGTGGACACCTATGGTAACCCGTTGCAGGGGCAGGAAGTTACGCTGACTTTACCGC 
TUV93-0 eaeH    CCGTTGTGGACACCTATGGTAACCCGTTGCAGGGGCAGGAAGTTACGCTGACTTTACCGC 3180 
                ************************************************************ 
 
pET-21b eaeH    CGTTGTCGACACCTATGGTAACCCGTTGCAGGGGCAGAAAGTTACGCTGACTTTACCGCA 
TUV93-0 eaeH    CGTTGTGGACACCTATGGTAACCCGTTGCAGGGGCAGGAAGTTACGCTGACTTTACCGCA 3240 
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pET-21b eaeH    GGGTGTGACCAGCAAGACGCGGAATACAGTAACAACTAATGCTGCAGGTATAGCGGACAT 
TUV93-0 eaeH    GGGTGTGACCAGCAAGACGGGGAATACAGTAACAACTAATGCGGCAGGTAAAGCGGACAT 3300 
                ******************* ********************** ******* ********* 
 
pET-21b eaeH    TGAGCTTATGTCAACGGTTGCGGGAGAACACAATATTTCCGCTTCGGTGAATGGTGCTCA 
TUV93-0 eaeH    TGAGCTTATGTCAACGGTTGCGGGAGAACACAATATTTCCGCTTCGGTGAATGGTGCTCA 3360 
                ************************************************************ 
 
pET-21b eaeH    GAAGACGGTCACGGTGAAATTCAACGCGGATGCCAGCACCGGTCAGGCAAACCTGCTGGT 
TUV93-0 eaeH    GAAGACGGTCACGGTTAAATTCAACGCGGATGCCAGCACCGGTCAGGCAAACCTGCAGGT 3420 
                *************** ****************************************:*** 
 
pET-21b eaeH    AGACGCCTCTGCTCAAA--GTGA--------AATTATGCA-------------------- 
TUV93-0 eaeH    AGACGCCGCTGCTCAAAAAGTGGCAAACGGCAAAGATGCCTTTACGCTGACGGCGAACGT 3480 
                ******* *********  ***         **  ****  
 
pET-21b eaeH    ------------------------------------------------------------  
TUV93-0 eaeH    TGAGGATAAAAATGGTAACCCTGTTCCAGGGAGCCTGGTGACCTTTAATCTGCCCCGGGG 3540 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TGTCAAGCCGCTTACAGGCGATAATGTCTGGGTGAAAGCCAACGATGAGGGGAAAGCAGA 3600 
                 
 
pET-21b eaeH    ------------------------------------------------------------   
TUV93-0 eaeH    GTTGCAGGTGGTTTCAGTGACTGCCGGAACGTATGAGATCACGGCATCGGCAGGGAATAG 3660 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CCAGCCTTCGAATACGCAGACTATAACGTTTGTAGCCGATAAGGCTACCGCAACCGTCTC 3720 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CGGTATTGAGGTGATTGGCAACTATGCACTGGCGGACGGCAATGCCAAACAGACGTATAA 3780 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CAGCCCGGCAAATTTAGTTCTGACTCCCAATGGGACGGCGAAAACTAATGAGCAAGGACA 3840 
                 
 
pET-21b eaeH    ------------------------------------------------------------   
TUV93-0 eaeH    GGCTATTTTCACCGCCACGACCACTGTCGCAGCGAAATATACACTCACGGCGAAAGTGAG 3900 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TCAGGCCGACGGTCAGGAATCGACGAAAACTGCCGAATCTAAATTCGTCGCGGATGATAC 3960 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    AAATGCAGTACTCACCGCATCATCTGATGTGACTTCTCTGGTGGCGGATGGGATATCGAC 4020 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TGCGAAGCTGGAGGTGACACTGATGTCGGCAAATAACCCCGTTGGGGGGAATATGTGGGT 4080 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    CGACATTAAGACGCCAGAAGGGGTGACGGAGAAGGATTATCAGTTCCTGCCGTCGAAAAA 4140 
                 
 
pET-21b eaeH    ------------------------------------------------------------ 
TUV93-0 eaeH    TGACCATTTCGTGAGCGGAAAAATCACGCGTACATTTAGTACCAGCAAGCCTGGTGTCTA 4200 
                 
 
pET-21b eaeH    --------------------------------------------------------      
TUV93-0 eaeH    TACGTTCACATTTAACGCCCTGACGTATGGCGGGTACGAAGGAGGCGATGAACTAA     4254 
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pET-21b yghJ    AGAATAATTTTGTTTAACTTTAAGAAGGAGATATACAT----------------------  
LF82 yghJ       ATGAATAAGAAATTTAAATATAAGAAATCGCTTTTAGCGGCTATTTTAAGCGCAACCCTG 60 
                *  *  *     ***** * ******   * * *                        
 
pET-21b yghJ    -------------ATG-----------------------GATACGCCGTCTGTAGATTCT  
LF82 yghJ       TTAGCCGGTTGTGATGGTGGTGGTTCAGGATCGTCCTCCGATACGCCGTCTGTAGATTCT 120 
                             ***                       ********************* 
 
pET-21b yghJ    GGATCAGGGACTTTGCCGGAAGTGAAACCCGATCCAACACCAACCCCGGAGCCGACACCT  
LF82 yghJ       GGATCAGGGACTTTGCCGGAAGTGAAACCCGATCCAACACCAACCCCGGAGCCGACACCT 180 
                ************************************************************ 
 
pET-21b yghJ    GAGCCGACGCCGGACCCAGAACCTACGCCGGATCCAACGCCTGATCCTGAGCCGACACCA  
LF82 yghJ       GAGCCGACGCCGGACCCAGAACCTACGCCGGATCCAACACCTGATCCTGAGCCGACACCA 240 
                ************************************** ********************* 
 
pET-21b yghJ    GAACCGGAGCCAGAACCTGTTCCTACGAAAACGGGTTATCTGACCCTGGGCGGAAGCCAG  
LF82 yghJ       GAACCGGAGCCAGAACCTGTTCCTACGAAAACGGGTTATCTGACCCTGGGCGGAAGCCAG 300 
                ************************************************************ 
 
pET-21b yghJ    CGGGTAACTGGTGCTACCTGTAATGGTGAATCCAGCGATGGCTTTACCTTTACGCCAGGC  
LF82 yghJ       CGGGTAACTGGTGCTACCTGTAATGGTGAATCCAGCGATGGCTTTACCTTTACGCCAGGC 360 
                ************************************************************ 
 
pET-21b yghJ    AATACCGTGAGTTGTGTGGTGGGCAGTACGACCATTGCAACATTCAACACCCAGTCAGAA  
LF82 yghJ       AATACCGTGAGTTGTGTGGTGGGCAGTACGACCATTGCAACATTCAACACCCAGTCAGAA 420 
                ************************************************************ 
 
pET-21b yghJ    GCTGCGCGTAGCCTGCGTGCGGTTGACAAAGTGTCGTTTAGCCTGGAGGACGCGCAGGAG  
LF82 yghJ       GCTGCGCGTAGCCTGCGTGCGGTTGACAAAGTGTCGTTTAGCCTGGAGGACGCGCAGGAG 480 
                ************************************************************ 
 
pET-21b yghJ    CTGGCGAATTCTGAAAATAAGAAAACCAACGCCATCTCTCTGGTGACGTCCAGCGACAGT  
LF82 yghJ       CTGGCGAATTCTGAAAATAAGAAAACCAACGCCATCTCTCTGGTGACGTCCAGCGACAGT 540 
                ************************************************************ 
 
pET-21b yghJ    TGCCCCGCAGATGCAGAACAGCTTTGTCTTACTTTCTCGTCAGTGGTTGATCGCGCGCGA  
LF82 yghJ       TGCCCCGCAGATGCAGAACAGCTTTGTCTTACTTTCTCGTCAGTGGTTGATCGCGCGCGA 600 
                ************************************************************ 
 
pET-21b yghJ    TTTGAAAAACTGTATAAGCAAATTGATCTGGCAACAGACAATTTCAGCAAGCTGGTCAAT  
LF82 yghJ       TTTGAAAAACTGTATAAGCAAATTGATCTGGCAACAGACAATTTCAGCAAGCTGGTCAAT 660 
                ************************************************************ 
 
pET-21b yghJ    GAAGAGGTGGAAAACAATGCTGCGACTGATAAAGCGCCGTCCACCCATACCTCAACGGTA  
LF82 yghJ       GAAGAGGTGGAAAACAATGCTGCGACTGATAAAGCGCCGTCCACCCATACCTCAACGGTA 720 
                ************************************************************ 
 
pET-21b yghJ    GTGCCAGTCACGACAGAGGGAACAAAACCGGATCTGAACGCGTCCTTCGTGTCGGCTAAC  
LF82 yghJ       GTGCCAGTCACGACAGAGGGAACAAAACCGGATCTGAACGCGTCCTTCGTGTCGGCTAAC 780 
                ************************************************************ 
 
pET-21b yghJ    GCGGAACAGTTTTATCAGTATCAACCCACTGAAATCATTCTTTCCGAAAGCCAACTGGTG  
LF82 yghJ       GCGGAACAGTTTTATCAGTATCAACCCACTGAAATCATTCTTTCCGAAGGCCAACTGGTG 840 
                ************************************************ *********** 
 
pET-21b yghJ    GATAGCCTGGGGAACGGTGTTGCTGGCGTTGACTACTACACCAATTCAG-CCGTGGCGTA  
LF82 yghJ       GATAGCCTGGGGAACGGTGTTGCTGGCGTTGACTACTACACCAATTCAGGCCGTGGCGTA 900 
                ************************************************* ********** 
 
pET-21b yghJ    ACTGACGAAAACGGTAAATTTTCCTTTAGCTGGGGCGAAACCATCTCCTTTGGTATCGAT  
LF82 yghJ       ACTGACGAAAACGGTAAATTCTCCTTTAGCTGGGGCGAAACCATCTCCTTTGGTATCGAT 960 
                ******************** *************************************** 
 
pET-21b yghJ    ACCTTTGAACT------AGTACGTGGCAT-AAGTCGACCATTGCGCTGACTGAATTGGGT  
LF82 yghJ       ACCTTTGAACTGGGCTCAGTACGTGGCAATAAGTCGACCATTGCGCTGACTGAATTGGGT 1020 
                ***********     ***********  ******************************                                              
 
pET-21b yghJ    GATGAAGTTCGCGGGGCAAATATCGATCAGCTCATTCATCGTTATTCGACGACTGGTCAA  
LF82 yghJ       GATGAAGTTCGCGGGGCAAATATCGATCAGCTCATTCATCGTTATTCGACGACTGGTCAA 1080 
                ************************************************************ 
 
pET-21b yghJ    AATAATACTCGTGTTGTTCCGGACGATGTACGCAAGGTCTTTGCCGAATATCCCAACGTG  
LF82 yghJ       AATAATACTCGTGTTGTTCCGGACGATGTACGCAAGGTCTTTGCCGAATATCCCAACGTG 1140 
                ************************************************************ 
 
pET-21b yghJ    ATCAACGAGATAATCAATCTTTCGTTATCCAACGGTGCGACGCTGGATGAAGGCGATCAA  
LF82 yghJ       ATCAACGAGATAATCAATCTCTCGTTATCCAATGGTGCGACGCTGGATGAAGGCGATCAA 1200 
                ******************** *********** *************************** 
 
pET-21b yghJ    AACGTTGTGCTGCCTAACGAATTTATCGAGCAGTTTAAGACGGGTCAGGCCAAAGAGATC  
LF82 yghJ       AATGTTGTGCTGCCTAACGAATTTATCGAGCAGTTTAAGACGGGTCAGGCCAAAGAGATC 1260 
                ** ********************************************************* 
 
pET-21b yghJ    GATACCGCGATTTGTGCGAAAACCGACGGTTGTAACGAGGCTCGCTGGTTCTCGCTGACA  
LF82 yghJ       GATACCGCGATTTGTGCGAAAACCGACGGTTGTAACGAGGCTCGCTGGTTCTCGCTGACA 1320 
                ************************************************************ 
 
pET-21b yghJ    ACGCGCAATGTTAATGACGGCCAGATTCAGGGCGTTATTAACAAGCTGTGGGGCGTGGAT  
LF82 yghJ       ACGCGCAATGTTAATGACGGCCAGATTCAGGGCGTTATTAACAAGCTGTGGGGCGTGGAT 1380 
                ************************************************************ 
 
pET-21b yghJ    ACGAACTATCAGTCTGTCAGCAAGTTCCACGTCTTCCATGACTCTACCAACTTCTATGGC  
LF82 yghJ       ACGAACTATCAGTCTGTCAGCAAGTTCCACGTCTTCCATGACTCTACCAACTTCTATGGC 1440 
                ************************************************************ 
 
pET-21b yghJ    AGCACCGGTAACGCGCGCGGTCAGGCGGTGGTAAATATCTCCAACTCGGCATTCCCGATT  
LF82 yghJ       AGCACCGGTAACGCGCGCGGTCAGGCGGTGGTAAATATCTCCAACTCGGCATTCCCGATT 1500 
                ************************************************************ 
 
pET-21b yghJ    CTGATGGCGCGTAATGATAAAAACTACTGGCTGGCGTTTGGCGAAAAACGCGCCTGGGAT  
LF82 yghJ       CTGATGGCGCGTAATGATAAAAACTACTGGCTGGCGTTTGGCGAAAAACGCGCCTGGGAT 1560 
                ************************************************************ 
 
pET-21b yghJ    AAAAATGAGCTGGCGTACATTACGGAAGCGCCTTCCATTGTGCAGCCAGAGAACGTTACG  
LF82 yghJ       AAAAATGAGCTGGCGTACATTACGGAAGCGCCTTCCATTGTGCAGCCAGAGAACGTTACG 1620 
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pET-21b yghJ    CGCGATACTGCGACTTTCAACCTGCCGTTTATTTCGCTGGGGCAAGTCGGTGAAGGCAAA  
LF82 yghJ       CGCGATACTGCGACTTTCAACCTGCCGTTTATTTCGCTGGGGCAAGTCGGTGAAGGCAAA 1680 
                ************************************************************ 
 
pET-21b yghJ     
LF82 yghJ       CTGATGGTTATCGGTAACCCGCACTACAACAGCATCCTGCGTTGCCCGAACGGTTACAGT 1740 
                ************************************************************ 
 
pET-21b yghJ    TGGGGCGGTGGTGTTAATAGTAAAGGTGAGTGTACGCTCGGCGGTGATTCTGATGACATG  
LF82 yghJ       TGGGGCGGTGGTGTTAATAGTAAAGGTGAGTGTACGCTCAGCGGTGATTCTGATGACATG 1800 
                *************************************** ******************** 
 
pET-21b yghJ    AAGCACTTTATGCAGAACGTACTGCGCTACTTGTCAAATGACATCTGGCAGCCAAATACC  
LF82 yghJ       AAGCACTTTATGCAGAACGTCCTGCGCTACTTGTCAAATGACATCTGGCAGCCAAATACC 1860 
                ******************** ***************************************            
 
pET-21b yghJ    AAGAGCATCATGACTGTCGGCACCAACCTGGAGAACGTTTATTTCAAAAAAGCGGGCGAG 
LF82 yghJ       AAGAGCATCATGACTGTCGGCACCAACCTGGAGAACGTTTATTTCAAAAAAGCGGGCCAG 1920 
                ********************************************************* **            
                                                               
 
pET-21b yghJ    GTAGTGGGAAATAGTGCACCATTTGCTTTCCATGAGGATTTCAATGGTATCACAGTTAAA 
LF82 yghJ       GTATTGGGAAATAGTGCACCATTTGCTTTCCATGAGGATTTCACTGGTATCACGGTTAAA 1980 
                *** *************************************** ********* ******            
                                                                             
pET-21b yghJ    CAGTTGACCAGCTATGGCGATCTGAATCCGGAAGAGATTCCGTTGCTGATCCTCAACGGC 
LF82 yghJ       CAGTTGACCAGCTATGGCGATCTGAATCCGGAAGAGATTCCGTTGCTGATCCTCAACGGC 2040 
                ************************************************************                                                                               
 
pET-21b yghJ    TTTGAATATGTGACTCAGTGGTCTCGCGATCCCTATGCTGTGCCTCTGCGTGCAGATACC 
LF82 yghJ       TTTGAATATGTGACTCAGTGGTCTGGCGATCCCTATGCTGTGCCTCTGCGTGCAGATACC 2100 
                ************************ ***********************************                                                                               
 
pET-21b yghJ    AGCAAACCGAAGCTGACTCAGCAGGATGTGACCGATCTGATCGCTTATCTGAACAAAGGT 
LF82 yghJ       AGCAAACCGAAGCTGACTCAGCAGGATGTGACCGATCTGATCGCTTATCTGAACAAAGGT 2160 
                ************************************************************                                                                               
 
pET-21b yghJ    GGCTCGGTGCTGATCATGGAAAACGTGATGAGCCATCTTAAGGAAGAGAGCGCGTCCAGT 
LF82 yghJ       GGCTCGGTGCTGATCATGGAAAACGTGATGAGCAATCTTAAGGAAGAGAGCGCGTCCAGT 2220 
                ********************************* **************************                                                                               
 
pET-21b yghJ    TTTGTGGGTCTGCTGGATGCCGCGGATCTGACAATGGCTCTGAACAAATCGGTGGTGAAC 
LF82 yghJ       TTTGTGCGTCTGCTGGATGCCGCGGGTCTGTCAATGGCTCTGAACAAATCGGTGGTGAAC 2280 
                ****** ****************** **** *****************************                                                                               
 
pET21b yghJ     AACGATCCGCAAGGGTATCCGGATCGCGTTCGTCAGCGTCGCGCGACTGGCATTTGGGTT 
LF82 yghJ       AACGATCCGCAAGGGTATCCGGATCGCGTTCGTCAGCGTCGCGCGACTGGCATTTGGGTT 2340 
                ************************************************************                                                                               
 
pET21b yghJ     TATGAACGTTATCCTGCTGCAGACGGCGCGGAACCGCCGTACACCATCGACCCAAATACA 
LF82 yghJ       TATGAACGTTATCCTGCTGCAGACGGCGCGCAACCGCCGTACACCATCGACCCAAATACA 2400 
                ****************************** *****************************                                                                               
 
pET21b yghJ     GGGGAAGTGACCTGGAAATACCAGCAAGACAACAAGCCTGATGACAAGCCGAAACTGGAA 
LF82 yghJ       GGGGAAGTGACCTGGAAATACCAGCAAGACAACAAGCCTGATGACAAGCCGAAACTGGAA 2460 
                ************************************************************                                                                               
 
pET21b yghJ     GTTGCGAGCGGGCAGGAGAAAGTTGAGGGCAAACAGGTAACGCGTTATGCCTTTATTGAT 
LF82 yghJ       GTTGCGAGCTGGCAGGAGGAAGTTGAGGGCAAACAGGTAACGCGTTATGCCTTTATTGAT 2520 
                ********* ******** *****************************************                                                                               
 
pET21b yghJ     GAAGCGGAATACACAACAGAAGAATCTCTGGAAGCGGCAAAGGCAAAAATCTGTGAGAAG 
LF82 yghJ       GAAGCGGAATACACAACAGAAGAATCTCTGGAAGCGGCAAAGGCAAAAATCTTTGAGAAG 2580 
                **************************************************** *******                                                                               
 
pET21b yghJ     TTTCCTGGGTTACAGGAGTGTAAGGACTCGACTTACCATTACGAGATTAACTGTTTGGAG 
LF82 yghJ       TTTCCTGGGTTACAGGAGTGTAAGGACTCGACTTACCATTACGAGATTAACTGTTTGGAG 2640 
                ************************************************************                                                                               
 
pET21b yghJ     CGCCGCCCAGGCCCGGATGTTCCGGTAACAGGTGGCATGTATGTTCCGCGCTATACGCAA 
LF82 yghJ       CGCCGCCCAGGCACGGATGTTCCGGTAACAGGTGGCATGTATGTTCCGCGCTATACGCAA 2700 
                ************ ***********************************************                                                                               
 
pET21b yghJ     CTGAATCTTGACGCCGACACCGCGAAAGCGATAGTGCAGGCGGCGGATTTTGGCACCAAC 
LF82 yghJ       CTGAATCTTGACGCCGACACCGCGAAAGCGATGGTGCAGGCGGCGGATTTAGGCACCAAC 2760 
                ******************************** ***************** *********                                                                               
 
pET21b yghJ     ATTCGGCGCCTGTATCAGCTTGAGGTTT-----CGTTCCGA------------------- 
LF82 yghJ       ATTCAGCGCCTGTATCAGCATGAGCTTTATTTCCGTACCAAAGGCAGTAAGGTGAGCGTA 2820 
                **** ************** **** ***     *** ** *  
                                                                       
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CTGAACAGTGTTGATCTGGAACGTCTGTACCAGAACATGTCGGTCTGGCTGTGGAACGAT 2880 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       ACGAAATATCGTTACGAAGAGGGCAAGGAAGATGAGCTGGGCTTTAAAACGTTCACCGAG 2940 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       TTCCTGAACTGCTACGCCAATGATGCCTATGCAGGCGGCACCAAGTGCTCCGCAGATCTG 3000 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AAAAAATCGCTGGTCGATAACAACATGATCTACGGTGACGGTAGCAGCAAAGCGGGCATG 3060 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       ATGAACCCAAGCTATCCGCTCAACTATATGGAAAAACCGCTGACGCGTCTGATGCTGGGC 3120 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CGTTCCTGGTGGGATCTGAACATTAAGGTTGATGTGGAGAAGTACCCTGGAGCGGTATCT 3180 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GTAGGGGGAGAAGAGGTTACTGAAACCATCAGCCTGTACTCGAATCCGACCAAATGGTTT 3240 
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pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GCAGGTAACATGCAGTCAACTGGCCTGTGGGCACCGGCTCAGAAAGAGGTCACCATTAAG 3300 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       TCCAATGCGAACGTTCCTGTGACCGTCACCGTGGCGCTGGCTGACGACCTGACCGGACGT 3360 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GAGAAGCATGAAGTTGCGCTGAACCGTCCGCCAAGAGTGACTAAAACGTACTCTCTGGAC 3420 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GCTAGCGGTACGGTGAAGTTCAAGGTGCCTTACGGTGGCCTGATTTATATCAAGGGCAAT 3480 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AGCTCTACCAATGAATCTGCCAGCTTCACCTTTACTGGCGTGGTAAAAGCACCGTTCTAT 3540 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AAAGACGGCGCATGGAAAAACGATCTGAACTCTCCTGCCCCGCTGGGCGAACTGGAGTCT 3600 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GCGTCGTTCGTCTATACCACACCGAAGAAGAACCTGAATGCCAGCAATTACACGGGCGGA 3660 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CTGGATCAATTCGCTAAAGATCTGGATACCTTTGCCAGCTCGATGAATGATTTCTACGGT 3720 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CGTAATGATGAAGACGGTAAGCACCGGATGTTTACCTATAAAAACTTGACGGGCCACAAG 3780 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CATCGTTTCACAAACGATGTGCAGATCTCCATCGGTGATGCGCACTCTGGTTATCCGGTA 3840 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       ATGAACAGCAGCTTCTCGACGAACAGCACCACGCTGCCGACGACGCCGCTGAACGACTGG 3900 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       CTGATTTGGCACGAAGTCGGTCATAACGCTGCAGAAACACCGCTGAACGTACCGGGTGCA 3960 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       ACTGAAGTGGCGAACAACGTGCTGGCGCTGTACATGCAGGATCGCTATCTCGGCAAGATG 4020 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AACCGTGTCGCTGACGACATTACCGTCGCGCCGGAATATCTGGAGGAGAGCAACGGTCAG 4080 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GCATGGGCGCGCGGCGGTGCGGGTGACCGTCTGCTGATGTACGCGCAGCTGAAAGAGTGG 4140 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GCAGAGAAAAACTTTGATATCAAACAGTGGTATCCAGAAGGTGACCTGCCTAAGTTCTAC 4200 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AGCGATCGTAAAGGGATGAAGGGCTGGAACCTGTTCCAGTTGATGCACCGTAAAGCGCGC 4260 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       GGCGATGATGTCAGCAATGACAAGTTTGGCGGCAGAAATTACTGTGCTGAGTCAAACGGT 4320 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AACGCTGCTGACACGCTGATGCTGTGTGCATCCTGGGTCGCTCAGGCGGATCTTTCGGAA 4380 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       TTCTTTAAGAAATGGAATCCGGGCGCAAATGCTTACCAGCTTCCGGGGGCAAGTGAGATG 4440 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AGCTTCGAAGGCGGAGTGAGCCAGTCGGCTTACAACACGCTCGCGTCGCTCAAGCTGCCG 4500 
                                                                             
 
pET21b yghJ     ------------------------------------------------------------ 
LF82 yghJ       AAACCGGAACAGGGGCCGGAAACCATTAACAAGGTTACCGAGCATAAGATGTCTGCCGAG 4560 
                                                                             
 
pET21b yghJ     --- 
LF82 yghJ       TAA 4563 
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